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I 
 
Resumo 
 
O cancro é uma das causas de morte mais comuns. Nos Estados Unidos, uma em 
cada quatro mortes é devida ao cancro. A Organização Mundial de Saúde prevê que em 
2030, 30 milhões de mortes serão devidas a cancro. Estes dados remetem para a urgência 
na pesquisa de novas moléculas capazes de melhorar o tratamento e prevenção da doença 
oncológica.  
 
Os triterpenóides representam um grupo de compostos abundante e diversificado, 
que pode ser encontrado em plantas, frutas e vegetais. As plantas medicinais contendo 
triterpenóides tem constituído ao longo dos séculos uma base para a medicina tradicional 
no tratamento de diversas doenças. Triterpenóides como o ácido ursólico, o ácido 
oleanólico, a betulina, o ácido betulínico, o ácido maslínico e o ácido glicirretínico, foram 
isolados de extratos de plantas, demonstrando ter várias actividades biológicas, incluindo 
a anti-tumoral. O potencial interesse em derivados de triterpenóides extraídos de plantas 
com actividade anti-tumoral está bem patente no crescente número de publicações nesse 
domínio científico. Uma análise das publicações enquadrando os triterpenóides com 
actividade anti-tumoral revelou um aumento exponencial no número de artigos e patentes 
na referida área científica. Estes factos têm impulsionado a comunidade científica para a 
síntese de novos derivados triterpénicos com melhorada actividade anti-tumoral.  
 
Com o objectivo de melhorar a actividade anti-tumoral dos ácidos ursólico e 
oleanólico, novos derivados semissintéticos heterocíclicos (compostos 2.18-2.58 e 3.15-
3.50) e fluorados (compostos 2.59-2.82 e 3.51-3.58) foram sintetizados e caracterizados 
através de técnicas de espectrometria de massa, espectroscopia de infravermelhos e 
ressonância magnética nuclear, e por fim avaliados através do uso de MTT para a 
inhibição do crescimento de linhas celulares tumorais e para os mecanismos de acção 
relevantes para a actividade anti-tumoral. A actividade antiproliferativa dos compostos 
estudados na linha tumoral do pâncreas AsPC-1 foi usada para estabelecer a relação 
estrutura-actividade entre os compostos.  
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Todos os 61 novos compostos derivados do ácido ursólico, compostos 2.18-2.82, 
demonstraram uma boa actividade antiproliferativa nas células tumorais pancreáticas 
AsPC-1, vários dos novos compostos apresentaram melhor actividade antiproliferativa do 
que o ácido ursólico 2.1, e algums apresentaram mesmo um IC50 inferior a 1 μM. Os 
compostos com resultados mais promissores foram também avaliados para a sua 
actividade antiproliferativa em linhas celulares tumorais de mama, fígado, pulmão, e 
próstata. O derivado heterocíclico 2.57 revelou ser o mais activo neste grupo, tendo sido 
usado para avaliar o mecanismo de acção responsável pelos efeitos antiproliferativos nas 
células AsPC-1: este composto, induz o aumento dos níveis de p53 o que leva ao 
aumento dos níveis de NOXA e p21
waf1
, conduzindo à activação das caspases 9 e 3 
induzindo a apotose nas células AsPC-1 tratadas. O composto fluorado 2.72 revelou ser o 
mais activo a inibir de forma efectiva o crescimento da linha celular tumoral pancreática 
através da inibição do ciclo celular na fase G1 a 1 μM e aumento dos níveis de p21waf1 e 
indução da apoptose a 8 μM, com aumento dos níveis de NOXA e diminuição dos níveis 
de c-FLIP.  
 
Os 42 novos derivados do ácido oleanólico 3.15-3.17 e 3.19-3.58 e o composto 3.18, 
já descrito, apresentaram uma actividade antiproliferativa superior ao ácido oleanólico 
3.1 nas células AsPC-1. Os compostos 3.27, 3.39 e 3.49, que apresentaram os valores de 
IC50 mais baixos nas células tumorais AsPC-1, viram a sua actividade antiproliferativa 
estudada em linhas celulares tumorais de mama, próstata, fígado e pulmão. Os estudos 
revelaram que os compostos têm boa actividade antiproliferativa, com IC50 mais baixos 
que 5 μM. Os compostos 3.27 e 3.39 induziram apoptose nas células AsPC-1, quando 
estas foram tratadas durante 24 h a uma concentração de 1.5 μM. 
 
Os novos compostos sintetizados derivados dos ácidos ursólico e oleanólico e 
avaliados na sua actividade antiproliferativa representam um novo grupo de moléculas 
com potencialidade para o tratamento de tumores sólidos malignos. 
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Abstract 
 
Cancer is one of the most common causes of death. In the United States alone, one in 
four deaths is the consequence of cancer. The World Health Organization (WHO) 
estimates that 30 million deaths will be related to cancer in the year 2030. These data 
demonstrate that research aimed at the identification of new molecules that can improve 
the treatment and prevention of cancer is urgent. 
 
Triterpenoids are a large and diverse group of compounds that can be found in 
medicinal plants, fruits and vegetables. Medicinal plants containing triterpenoids have 
been used for centuries in traditional medicine for the treatment of various diseases. 
Triterpenoids, such as ursolic acid, oleanolic acid, betulin, betulinic acid, maslinic acid, 
and glycyrrhetinic acid purified from plant extracts, have diverse biological activities, 
including antitumor activity. The potential interest of plant-derived triterpenoids as 
antineoplastic agents is reflected in the large number of scientific papers appearing in the 
field. Analysis of the publications concerning antineoplastic triterpenoids abstracted in 
available the online databases over the past few years revealed an exponential increase in 
the number of papers and patents in this area of research. These facts prompted the 
scientific community to pursue the synthesis of new, improved derivatives of the 
triterpenoids available. 
 
With the aim of improving the antitumor activity of ursolic and oleanolic acids, a 
series of new heterocyclic (compounds 2.18-2.58 and 3.15-3.50) and fluorine 
(compounds 2.59-2.82 and 3.51-3.58) derivatives were synthesized, fully characterized 
using MS, IR and NMR techniques and evaluated for their antiproliferative activity via an 
MTT assay, as well as for their mechanisms of antitumor action. The antiproliferative 
activity against the AsPC-1 pancreatic cancer cell line was used to establish the structure 
activity relationship (SAR) between compounds. 
 
The new 61 ursolic acid derivatives 2.18-2.82 showed a good antiproliferative 
activity against AsPC-1 cells, several of the newly synthesized compounds were more 
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active than that of ursolic acid 2.1 and some presented IC50s lower than 1 μM. The most 
promising compounds were evaluated further for their antiproliferative activity in breast, 
hepatic, lung and prostate cancer cell lines. The best heterocyclic derivative, compound 
2.57, was evaluated for its mechanisms of action in AsPC-1 cells: it induced the 
upregulation of p53, leading to the upregulation of NOXA and p21
waf1
, these events 
culminated with the upregulation of caspases 9 and 3, thus inducing apoptosis in AsPC-1 
cells. The fluorine derivative 2.72 exhibited the most effective inhibitory activity against 
pancreatic cancer cell growth, as it arrested the cell cycle at the G1 phase at 1 µM and 
upregulated p21
waf1
 and induced apoptosis at 8 M, with the upregulation of NOXA and 
the downregulation of c-FLIP. 
 
The new 42 oleanane derivatives 3.15-3.17 and 3.19-3.58 and the already described 
derivative 3.18 had better antiproliferative profile than oleanolic acid 3.1 against AsPC-1 
cancer cells. Compounds 3.27, 3.39 and 3.49, which had the lowest IC50s in AsPC-1 
cancer cells, were studied further for their antiproliferative activity in breast, prostate, 
liver and lung cancer cell lines. It was found that these compounds also had an excellent 
antiproliferative activity, with IC50s lower than 5 μM. Compounds 3.27 and 3.39 induced 
apoptosis in AsPC-1 cells treated for 24 h at a concentration of 1.5 μM. 
 
The novel ursane- and oleanane-type triterpenoids synthesized and evaluated for 
their antiproliferative activity represent a new group of valuable molecules for the 
treatment of solid cancers. 
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Thesis organization 
 
This dissertation is divided in five chapters. The first section comprehends a general 
introduction, the second and third sections relate all the experimental work developed, the 
results, the discussion and experimental procedures and the last two chapters are 
dedicated to the concluding remarks and the supporting references used in this work. 
 
The first chapter of this thesis presents the state-of-the-art relative to medicinal 
chemistry and natural products, focusing on the therapeutic potential of natural products, 
particularly of ursolic and oleanolic acids. The chemotherapeutic properties of ursolic and 
oleanolic acids are described. This chapter also focuses on the reported derivatives of 
ursolic and oleanolic acids and their antitumor activities. 
 
The second chapter is devoted to the synthesis and biological evaluation of ursolic 
acid intermediates, heterocyclic and fluorine derivatives. The synthesis of intermediates 
is described, as well as the experimental procedures used in that synthesis. The 
subsections dedicated to the heterocyclic and fluorine derivatives are composed of a 
general introduction describing the state-of-the-art related to the topic, chemical results 
and discussion with selected aspects of the structural elucidation of the new compounds, 
and biological results and discussion with establishment of the SAR findings and 
mechanisms of action, the subsections end with conclusions. The experimental 
procedures are described in the end of the chapter. 
 
The third chapter of this work comprises the synthesis and evaluation of new 
oleanolic acid derivatives and has been divided in two major subsections: the synthesis of 
intermediates and the synthesis and evaluation of new oleanolic derivatives. The 
synthesis of new olenane-type compounds is described and some details regarding the 
structural elucidation and biological evaluation of the antiproliferative activity of 
compounds are provided. This chapter ends with conclusions and experimental 
procedures. 
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Chapter 4 states the major findings and conclusions of this work. The last chapter 
provides the supporting references used in this dissertation. 
 
The nomenclature of natural products and related compounds followed the guidelines 
established by the IUPAC-IUB Joint Commission on Biochemical Nomenclature, as 
published by P. M. Giles Jr in Pure & Applied Chemistry, 1999, 71, 587-643, and 
reviewed by H. A. Favre in Pure & Applied Chemistry, 2004, 76, 1283-1292. However, 
some compounds have been designated using their trivial name. Reference indexation 
was made following the guidelines of the American Chemical Society: Style Guide. 
Several databases were used for bibliographic research; however, the ISI Web of 
Knowledge (Thompson Reuters) was preferred. SciFinder tools to search the CAS 
database were used to check the novelty of the compounds obtained in this work. 
 
In Chapters 1-3, ursane- and oleanane-type substrates and products were numbered 
sequentially. Compound numbering includes the chapter number. 
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1.1. Cancer 
 
Cancer is a complex group of diseases characterized by the unregulated growth and 
spread of abnormal cells. The abnormal cells result from a series of missteps in the 
genome that lead to anomalies in the control of cell fate. The genomic alterations can be 
due to external factors or internal failures that were not duly corrected. Malignant tumors 
result from the spread of abnormal cells to adjacent tissues. They can invade other tissues 
and form new colonies, called metastases.
1, 2
 
In the year 2007, cancer was the second cause of death worldwide.
3
 In Europe, it is 
expected that, in 2015, 23% of the deaths will be due to cancer among the population 
older than 65 years.
4
  
 
 
 
Figure 1.1.1. Estimated new cases of the three major cancers in women and men in Europe in 
2006. 
 
The incidence of cancer in women and men is different regarding the type of cancer. 
Breast and prostate cancers have greate incidence in women and men, respectively 
(Figures 1.1.1 and 1.1.2).
3, 4
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Figure 1.1.2. Estimated cancer-related death incidence for women and men in Europe in 2007. 
 
Cancer-related death is changing with modifications in the social and economic 
behavior of the populations. In 2011, in the USA, deaths by cancer will most likely be 
primarily due to lung and bronchus cancer, in both men and women.
5
  
 
1.1.1. Biology of cancer 
 
Normal cells evolve to the neoplastic state progressively, in a multistep process, 
acquiring a series of successive hallmark capacities that allow them to become 
tumorigenic and, finally, malignant (Figure 1.1.3). Tumors are complex tissues composed 
of different cell types, with a very singular microenvironment.
6-8
 
One of the first hallmarks acquired by cancer cells is the ability to auto-sustain a 
proliferative signaling output that allows proliferation for an undetermined amount of 
time without dependence on exogenous growth stimulation and avoiding the negative 
feedback mechanisms that attenuate proliferation and evade growth suppressors. 
Programmed cell death (apoptosis, autophagy or necrosis) is a mechanism via which 
organisms control the number of cells in a population. Cancer cells acquire the ability to 
resiste cell death via several mechanisms. In addition to programmed cell death, cancer 
cells have the ability to avoid destruction by the immune system. Changes in telomeres, 
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telomerases, DNA polymerases and in the entire machinery that controls and regulates 
DNA replication, genetic instability and mutated DNA are also hallmarks of cancer 
cells.
6, 8
 
 
 
 
Figure 1.1.3. Cancer hallmarks. Adapted from the literature.
6
 
 
After a certain stage, cancer cells start to require additional nutrients and oxygen, 
which the normal vascularization of the tissue does not provide. Cancer cells have the 
ability to induce angiogenesis, i.e., the creation of new blood vessels, producing a series 
of angiogenic and inflammatory factors, which enhance tumorigenesis. One of the last 
stages in tumor progression is the invasion of surrounding tissues and metastasis to other 
parts of the organism.
6, 7, 9
 
 
Cancer is a complex group of diseases and, with the evolution of knwoledge in 
biology, biochemistry and genomics, more layers of complexity are expected. Treatment 
and chemoprevention are far from the ideal solution for this disease and additional, 
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improved drugs targeting known and recently discovered proteins and genes are still 
needed. 
1.1.1.1.  Targeting the cell cycle in cancer treatment 
 
The cell cycle is an ubiquitous and complex process that is involved in the growth 
and proliferation of cells, organism development, in the regulation of DNA damage repair 
and in diseases such as cancer. The cell cycle involves numerous regulatory proteins that 
direct the cell through a specific sequence of events culminating in mitosis, with 
production of two daughter cells.
10
 
The cell cycle is a sequence of four stages: the G1, S, G2 and M phases. The 
duplication of the genetic material of the cell occurs in the S phase and the physical 
separation of the cellular material for the two new cells and mitosis occur in the M phase. 
The G1 and G2 phases are gaps for the control and preparation of the subsequent 
phases.
10
 The progression of the cell cycle is closely regulated by cyclins and cyclin-
dependent kinases (CDKs).
11
 The binding of a CDK to the correspondent cyclin induces 
conformational changes, leading to the exposure of the active site on the CDK. CDKs are 
constitutively expressed in the cell; after adequate stimulation, such as DNA damage, 
CDK inhibitors (CdkIs; p16
inka4
, p15
INK4B
, p18
INK4C
, p19
INK4D
, p21
Cip1
, p27
Kip1
 and 
p57
Kip2
) interact with CDKs and change their conformation, creating an inactive form 
(Figure 1.1.4).
1, 2
  
Cyclin D, the first cyclin to be expressed, allows entrance into the G1 phase of the 
cell cycle.
12
 Synthesis of cyclin D is stimulated by integrins, nutrients, G coupled-
proteins and tyrosine kinase receptors. Cell cycle progression is accompanied by the 
synthesis of cyclins E, A and B, in that order. After a complete cell cycle, cells can 
undergo a new cell cycle or enter the G0 phase, which is a quiescent state.  
The restriction point (R point) represents a mark for the progression of the cell cycle 
from the G1 phase to the S phase and is controlled by the nuclear Rb protein. This protein 
regulates the activity of the E2F family of transcription factors, which is critical for the 
expression of the genes that are necessary for the entrance of cells into the S phase. 
CyclinD/CDK4/6 phosphorylates the Rb protein. This form is further phosphorylated by 
the cyclinE/CDK2 complex, producing an Rb-hyperphosphorylated form, which releases 
the E2F transcription factor (Figure 1.1.4)
1, 2, 13
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Figure 1.1.4. Cell cycle progression and regulation. 
 
During cell cycle progression several checkpoints impose control and ensure that the 
cell cycle is properly completed. The checkpoints at the end of the G1 and S phases do 
not allow cell cycle progression if the DNA is damaged. At the end of the G2 phase, the 
cell cycle can be blocked if DNA replication is not completed. The M phase also has a 
control checkpoint: the cell cycle does not progress if the chromatids do not assemble in 
the correct form at the mitotic spindle. 
 
In normal cells, DNA damage triggers a series of responses that culminate in cell 
cycle arrest or induction of cell death. Each type of DNA damage involves a different set 
of cellular machinery components, which are tightly regulated. Cancer cells are able to 
elude several cell cycle checkpoints and complete a cell division successfully.
11, 12, 14
  
Cancer cells often have mutated genes that encode cell cycle regulators, overexpress 
cyclins and CDKs or delete and inhibit the expression of CdkI.
13, 15
 Tumor cells have the 
ability to overcome the G2 and M phase checkpoints, generating cells with more 
mutations than the parental cells, increasing tumorigenesis.
13  
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Targeting components of the cell cycle is an option in the treatment of cancer.
13, 14
 
 
1.1.1.2.  Targeting apoptosis in cancer treatment 
 
Programmed cell death controls morphogenesis and cell population, eliminates 
damaged cells and maintains homeostasis.
16
 Programmed cell death can be achieved by 
apoptosis, autophagy or necrosis. Apoptosis is morphologically distinct from the other 
types of cell death, presenting cell shrinkage, cytoplasmic condensation, nuclear 
fragmentation, cytoplasmic membrane blebbing and formation of apoptotic bodies. In 
addition it is restrict to one cell without an inflammatory process.
17-22
  
Apoptosis can be initiated by two major pathways: the extrinsic pathway, which 
culminates in the activation of caspase 8, and the intrinsic pathway, with the activation of 
caspase 9 (Figure 1.1.5). Recently, other pathways for the activation of apoptosis were 
described: the granzyme B pathway, which is a caspase-independent pathway, and the 
endoplasmic reticulum stress-induced pathway.
17, 22-24
  
The extrinsic pathway of apoptosis is activated at the cell surface when a specific 
ligand binds to its corresponding death receptor (DR); this leads to the oligomerization of 
the receptor and promotes the recruitment of adapter proteins, such as the Fas associated 
death domain protein (FADD). The adapter proteins connect to several pro-caspase 8 
molecules via the death effector domains (DED), forming the death-inducing signaling 
complex (DISC). Because of the high concentration of pro-caspase 8, the mutual 
activation of caspase 8 takes place, leading to the activation of downstream executioner 
caspases.
16, 21, 23-26
  
The intrinsic pathway of apoptosis is correlated to mitochondria. After an apoptotic 
stimulus, proapoptotic Bcl-2 members (Bax/Bak) alter the permeability of the 
mitochondrial membrane because of the interaction between BH3-only proteins, such as 
PUMA, NOXA and Bim, with anti-apoptotic proteins (Mcl-1, Bcl-2 and Bcl-xL). This 
alteration in permeability is due to the formation of permeability transition pore 
complexes, leading to changes in mitochondrial membrane potential, cytochrome c 
release and production of reactive oxygen species (ROS). The presence of cytochrome c 
in the cytosol allows the interaction between the caspase recruitment domain (CARD)- 
containing adapter protein Apaf-1, ATP, and pro-caspase 9, which results in the 
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formation of the apoptosome. Pro-caspase 9 is then activated and activates downstream 
executioner caspases.
16, 21, 22, 26, 27
  
 
 
 
Figure 1.1.5. Simplified apoptotic pathways in mammalian cells. 
 
The extrinsic and intrinsic pathways converge in the activation of the effector 
caspases, caspases 3, 6 and 7, leading to the cleavage of DNA, proteins and enzymes. The 
extrinsic and intrinsic pathways exhibit cross talk once caspase 8 has activated Bid via 
the formation of truncated Bid, tBid. This BH3-only protein translocates from the cytosol 
to mitochondria, thus activating the intrinsic apoptotic pathway.
22, 25, 28
  
Apoptosis is a highly regulated mechanism; thus, several inhibitory and regulatory 
mechanisms are present in cells. FADD-like interleukin-1β converting enzyme (FLICE) 
inhibitory proteins (FLIPs) are caspase 8 homologues that compete for the binding of 
DED regions in the DISC complex, leading to the inhibition of this complex and 
inhibition of apoptosis.
18, 22
 The intrinsic pathway can be inhibited by a family of 
inhibitors of apoptosis (IAPs), the best-known of which is XIAP. XIAP has the ability to 
inhibit both initiator (caspase 9) and effector caspases. Smac is released from 
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mitochondria simultaneously with cytochrome c and has the ability to inhibit the activity 
of XIAP.
16, 22, 23, 26
 
The extrinsic and intrinsic apoptotic pathways are regulated by proteins such as p53, 
the nuclear factor κB (NFκB), the ubiquitin proteasome system and the PI3K/Akt 
pathway. p53 is a regulator of gene transcription, controlling genes that are important for 
the cell cycle, DNA repair and apoptosis. NFκB regulates a large series of genes involved 
in apoptosis, tumorigenesis and inflammation. The ubiquitin/proteasome system is 
responsible for the degradation of the intracellular proteins and regulates cell growth and 
apoptosis. The PI3K/Akt pathway controls many signaling pathways that are important 
for cell survival, proliferation, mobility and tissue neovascularization.
21, 23, 25
 
 
Defects in the apoptosis mechanism play an important role in tumor pathogenesis, as 
they allow the survival of neoplastic cells beyond their normal life span, subvert the need 
for exogenous survival factors, provide protection from hypoxia and oxidative stress as 
the tumor mass expands and allow the accumulation of genetic alterations that deregulate 
cell proliferation, interfere with differentiation, promote angiogenesis and increase cell 
mobility and invasiveness during tumor progression.
23, 29
 Several genes that encode 
components of the apoptotic machinery are directly targeted by genetic lesions on cancer 
cells, leading to the overexpression of proapoptotic proteins, such as Bcl-2, XIAP and 
FLIP, and the downregulation of anti-apoptotic proteins, such as DR, Bax and Bad.
28, 30
 
Most of the cancer therapeutic drugs promote cancer cell apoptosis. The targeting of 
the apoptotic pathway is also responsible for the side effects of these drugs. Mutations in 
apoptotic programs can lead to chemoresistance to cancer therapy.
17, 20, 22
 
 
1.2. Natural products in medicinal chemistry  
 
Natural products have been the source of medicines for mankind for thousands of 
years. The first written records of the use of plants as a source of medicine date from 
2600 BC in Mesopotamia. Quinine was the first isolated natural compound to be 
commercialized by Caventou.
31
 According to the WHO, the primary health care of 80% 
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of the world’s population is based on traditional medicinal treatments derived from 
natural sources.
32-34
 
In modern pharmaceutical research on new drugs, natural sources (such as plants and 
microorganisms) have been explored to identify novel lead compounds. From the 
pharmaceutical entities approved worldwide between 1981 and 2006, 5.7% were natural 
products and 27.6% were natural-product derived molecules, whereas from 2005 to 2010, 
seven natural products and 12 natural product derivatives were approved for use in 
clinical practice (Figure 1.2.1).
35-39
 
 
 
 
Figure 1.2.1. Sources of small molecules in clinical use for 1981-2006. S) Totally synthetic 
molecule; ND) natural product derived molecule; N) natural product; S*) from total 
synthesis, but the pharmacophore is from a natural product. Adapted from the literature.
37
 
 
Natural products have been major sources of lead compounds in the discovery of 
new drugs for the treatment of infectious diseases, lipid disorders, neurological diseases, 
cardiovascular and metabolic diseases, immunological, inflammatory and related 
diseases, and oncologic diseases (Table 1.2.1).
40-44
 
Despite promising data, pharmaceutical companies have invested less in the 
discovery and research at natural products over the last decade, which can be explained 
by the development of combinatorial chemistry.
34, 45, 46
 Natural products can also present 
difficulties regarding access and supply, which discourage pursuit of research into this 
S ND N S* 
49,60% 
27,60% 
5,70% 
17,10% 
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type of compounds by pharmaceutical companies.
47
 Another factor that may have 
contributed to the lack of interest of pharmaceutical companies in natural products was 
the introduction of high-throughput screening assays for several defined molecular 
targets. There are few libraries of natural products, or the existent libraries compile 
mixtures of compounds with different activities and concentrations. These obstacles to 
the screening and research of natural products are being solved with the introduction of 
better separation techniques, such as high-pressure liquid chromatography (HPLC) 
coupled with mass spectrometry (MS) and improved and more potent nuclear magnetic 
resonance (NMR) techniques.
43, 45, 47-54
 
 
Table 1.2.1. Some examples of natural products and natural product derivatives currently in 
clinical use. 
Entry Disease area Generic name (Trade name) 
Lead 
compound 
Year 
1 Antibacterial Doripenem (Finibax/Doribax
®
) Thienamycin 2005 
2 Antiparasitic Fumagillin (Flisint
®
) Fumagillin 2005 
3 Oncology Romidepsin (Istodax
®
) Romidepsin 2009 
4 Alzheimer’s disease Galantamine (Reminyl
®
) Galantamine 2002 
5 Immunosuppression 
Mycophenolate sodium 
(Myfortic
®
) 
Mycophenolic 
acid 
2003 
6 Dyslipidemia Rosuvastatin (Crestor
®
) Mevastatin 2003 
7 Pain Capsaicin (Istodax
®
) Capsaicin 2009 
8 Diabetes Exenatide(Byetta
®
) Exenatide 2006 
 
Natural products are derived from the phenomenon of biodiversity in which the 
interactions between organisms and their environment formulate diverse complex 
chemical entities.
34, 35
 Natural products typically have more stereogenic centres and more 
architectural complexity (aromatic rings, complex ring systems, and higher degree of 
molecule saturation) than do synthetic molecules fashioned by medicinal chemists.
36, 55
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Natural products contain relatively more carbon, hydrogen and oxygen, and less nitrogen 
and other elements than do synthetic medicinal agents.
49
 Natural products often have a 
molecular masses greater than 500 da and high polarity (greater water solubility).
44
 Most 
classical small molecules obtained from nature are secondary metabolites-products from 
conditional pathways that are turned on in a particular context or situation, making them 
more likely to hit a molecular target.
36
 
Despite all this knowledge only, 10% of the world’s biodiversity has been explored 
for possible new biologically active natural compounds. New sources of natural products 
are now being explored, such as marine microorganisms and small organisms.
36, 48, 51, 53, 
54, 56
 
 
1.2.1. Natural products and treatment of cancer 
 
Natural products represented around 50% of the entire pool of drugs between 2003-
2005 in clinical use for the treatment of cancer.
38, 39
 Novel natural compounds with 
diverse structures that were isolated isolated from plant sources have been considered as 
prototypes, leads or heads of series, and structural modifications have provided 
extraordinary therapeutic possibilities to compounds. In 2007, more than 30 compounds 
of natural origin were in different phases of clinical study for the treatment of various 
types of cancer.
57
 
Secondary metabolites are directly involved in the regulation of the growth of 
organisms; therefore, many serve as templates for the modulation of tumor 
development.
58
 Cancers are highly dependent on oncogene activation for the maintenance 
of their malignant phenotype. Multitarget agents and combination therapies may be 
required to prevent salvage or escape mechanisms and to enhance the efficacy of the 
therapy in cancer treatment. The promiscuous character of natural products has been 
associated with dirty drugs, in contrast to high-affinity single-target drugs; however in the 
face of the new knowledge on cancer mechanisms, the ability of natural compounds to hit 
several targets can be advantageous in cancer treatment.
58
 
Currently, several natural products are in clinical use for cancer treatment; the most 
common can be divided into five major classes: vinca alkaloids, epipodophyllotoxins, 
taxanes, camptothecins and photosensitizers. Nevertheless, a series of new compounds 
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with different chemical structures and targets are being explored.
58, 59
 From these groups 
several derivatives were synthesized with the aim of improving the activity and reducing 
the side effects of the original products.  
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Figure 1.2.2. Representation of some vinca alkaloids. 
 
Vinka alkaloids are isolated from Catharanthus roseus. Vinblastine and vincristine 
were the first plant constituents to be used as antineoplastic agents, in the 1950s. Vinka 
alkaloids inhibit the growth of cancer cells, preventing mitosis by disrupting microtubules 
and consequently dissolving cell mitotic spindles. Cancer cells treated with vinka 
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alkaloids exhibit arrest in the M phase and finally undergo apoptosis. From the alkaloids 
isolated initially, several derivatives were synthesized (vindesine, vinorelbine and 
vinflunine) that are currently in clinical use (Figure 1.2.2).
31, 55, 57, 60
 
Podophyllin was isolated from the roots of several species of Podophyllum. The 
antimitotic properties of podophyllin were only discovered in 1940-50.
32
 The initial 
research revealed a high toxicity for this compound, which led to the production of 
several derivatives. Teniposide, etoposide and etopophos are three saponin epimers of 
podophyllotoxin (Figure 1.2.3)
57, 61
 that inhibit irreversibly the DNA-topoisomerase II 
complexes at the G2 phase of cell cycle and eventually lead to apoptosis.
32, 55
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Figure 1.2.3. Representation of podophyllotoxin and some derivatives. 
 
Paclitaxel is a taxane diterpene first isolated from Taxus brevifolia but is also found 
in other species of Taxus. It was first reported by Wall and coworkers in 1971, but was 
discarded because of its high toxicity. This compound was rescued later based on it 
different mode of action and was introduced in the USA for the treatment of refractory 
ovarian cancer in 1992. Paclitaxel and docetaxel, a semisynthetic analogue, stabilize the 
mitotic apparatus by enhancing the rate and speed of microtubule assembly, resulting in 
arrest of the cell cycle in the M phase and culminating in cell death. The use of paclitaxel 
and docetaxel is restricted by their low oral bioavaibility, P-glycoprotein (Pgp)-mediated 
multidrug drug resistance (MDR) and toxicity. Based on SAR studies, several 
semisynthetic derivatives were generated, ortataxel being one of the most promising of 
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these derivatives as it presents better bioavailability and better activity against a variety of 
drug-resistant cancers compared with the parent compound (Figure 1.2.4).
31, 57
 
 
N
H
O
O
OH
O
H3COCO O
OH
HO
OCOCH3
O
O
O
Paclitaxel
O N
H
O
O
OH
O
HO O
OH
HO
OCOCH3
O
O
O
Docetaxel
O N
H
O
O
OH
O
H3COCO O
OH
HO
OCOCH3
O
O
O
Ortataxel
H
H
H
 
 
Figure 1.2.4. Representation of naturally occurring paclitaxel and its semisynthetic 
derivatives. 
 
Camptothecin is a quinoline alkaloid discovered in Camptotheca acuminata. This 
compound presents solubility and toxicity problems and was never used in clinical trials. 
Camptothecin has a different mode of action when compared with taxanes: it inhibits 
topoisomerase I by stabilizing intermediate complexes produced during DNA synthesis. 
The semisynthetic derivatives topotecan and irinotecan were prepared to overcome these 
problems associated to the use of camptothecin (Figure 1.2.5).
57, 61
 
Photodynamic therapy is a promising new cancer treatment approach that was first 
described in 1903 by Von Tappeiner and Jesionek. Photosensitizing compounds have a 
low cytotoxicity in the dark however, when subjected to radiation, produce highly 
reactive and toxic species. Porphyrins are the most extensively used group of 
sensitizer/tumor-selective compounds. Photofrin was the first sensitizer to be used in 
clinical settings; hypericin has been studied in recent years as a naturally occurring 
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photosensitizer that exhibits high affinity for tumors by triggering necrosis or apoptosis, 
depending on the level of oxidative stress produced (Figure 1.2.6).
31
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Figure 1.2.5. Representation of quinine alkaloids. 
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Figure 1.2.6. Representation of the porphyrins currently used in clinical setting as 
chemosensitizers. 
 
Preventing disease is highly preferable to treatment. Chemoprevention was defined 
by Sporn M. B. and collaborators as a strategy for cancer control via the administration or 
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ingestion of synthetic or natural compounds that act to retard or suppress the process of 
carcinogenesis.
62, 63
 These compounds can be classified as blocking or suppressing agents 
depending on the stage of carcinogenesis at which they act. 
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Figure 1.2.7. Chemopreventive drugs currently in clinical use. 
 
The FDA has approved tamoxifen for the prevention of breast cancer and celecoxib 
for the prevention of colon cancer in patients with family history of polyposis (Figure 
1.2.7). Curcumin and resveratrol are the most promising natural compounds for 
chemoprevention and also increase the sensitivity of cancer cells to traditional 
chemotherapeutic agents (Figure 1.2.8).
31, 55, 64-66
 Curcumin inhibits the action of several 
carcinogens, induces apoptosis and has antiangiogenic effects in cancer cells.
67, 68
 
Resveratrol inhibits several steps of carcinogenesis in vitro and in vivo via several 
mechanisms.
69
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Figure 1.2.8. Natural products with chemopreventive activity in clinical studies. 
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1.3. Terpenoids 
 
Natural products are characterized by structural diversity, which is mainly due to the 
initial formation of building blocks with the arrangement of diverse carbon-carbon bonds, 
carbocations and electrophilic additions. Terpenoids are a diverse family of secondary 
plant metabolites that are minor but ubiquitous components of the human diet and are 
considered relatively nontoxic.  
 
1.3.1. General dispositions 
 
Terpenes have their primary origin in the condensation of a unit of isopentenylallyl 
diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). Until 1990, the IPP and 
DMAPP building blocks of terpene were assigned to the mevalonate pathway; however, 
isotope experiments revealed a coexistent pathway called the non-mevalonate pathway. 
These two pathways coexist and metabolites from both pathways can be mutually 
exchanged.
70, 71
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Figure 1.3.1. Simplified scheme of the origin of the diverse biosynthetic plant terpene classes. 
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Despite the knowledge of the synthetic pathway involved in the synthesis of 
terpenes, these compounds are traditionally known as derivatives of isoprene, a five-
carbon acyclic chain (C5H8). Based on the number of building blocks, terpenes are 
commonly classified as monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), 
triterpenes (C30) and tetraterpenes (C40) (Figure 1.3.1). 
 
1.3.2. Biosynthetic diversity of triterpenoids 
 
Triterpenes are a diverse group of natural products derived from squalene or related 
acyclic 30-carbon precursors. As a general mechanism, these precursors can be activated 
by a cationic attack and, via a cascade of cation–olefin cyclizations, generate a cyclic 
carbocation that can rearrange and cyclize further. These reactions are catalyzed by a 
group of enzymes generally know as triterpene synthases, which can be classified as 
squalene cyclases and oxidosqualene cyclases.
72-75
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Figure 1.3.2. Simplified scheme of the origin of some triterpenoids. 
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Oxidosqualene is probably the precursor of most 3β-OH-triterpenoids; however, 
squalene cyclization followed by oxidation of the hydroxyl group at C3 is also plausible. 
Oxidosqualene is the percursor for β-amyrin, α-amyrin, lupeol and dammarenediol 
(Figure 1.3.2). β-Amyrin gives origin to oleanane triterpenoids, α-amyrin to ursane type 
triterpenoids and lupeol to lupane triterpenoids.
72
 From a biological point of view, the 
most important triterpenoid structures are oleanane, ursane, lupane and dammarane-
euphane triterpenoids.
76
  
 
1.3.3. Ursolic acid 
 
Ursolic acid (3β-hydroxy-urs-12-en-28-oic acid) and analogues (Figure 1.3.3) are 
present in several plants, vegetables and fruits, (Table 1.3.1) in the free form or 
conjugated with glycosides.
77, 78
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Figure 1.3.3. Ursolic acid and naturally occurring analogues. 
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Table 1.3.1. Some sources of ursolic acid in Nature. 
Entry Specie Activity Ref. 
1 D. dendo Antimicrobial 
79
 
2 Quinchamalium majus Antitubercular 
80
 
3 Rosmarinus officinalis Tripanocidal 
81
 
4 Gardenia saxatilis Antiplasmodial 
82
 
5 Pourouma guianensis Antileishmanial 
83
 
6 Geum japonicum Anti-HIV 
84
 
7 Actinidia arguta Lipolytic 
85
 
8 Lycopus lucidus Antiatherosclerotic 
86
 
9 Origanum majorana Anti-alzheimer 
87, 88
 
10 Eucalyptus tereticornis Hepatoprotector 
89
 
11 Nepeta sibthorpii Analgesic 
90
 
12 Salvia officinalis 
Anti-inflammatory and 
antimicrobial 
91, 92
 
13 Perilla frutescens 
Anti-inflammatory and 
antitumor 
93
 
14 Prunella vulgaris 
Anti-inflammatory and 
antiallergic 
94
 
15 Plantago major Anti-inflammatory 
95
 
16 Ugni molinae Anti-inflammatory 
96
 
17 Cussonia bancoensis 
Anti-inflammatory and anti-
nociceptive 
97
 
18 Vaccinium macrocarpon Anti-inflammatory 
98
 
19 Calluna vulgaris Antitumor 
99
 
20 Prunus mume Antitumor 
100
 
 
Ursolic acid has several biological activities, such as antibacterial, antiprotozoal, 
anti-HIV, antiosteoporotic, cardioprotector, antiobesity, antiatherosclerotic, antidiabetic, 
immunomodulator, analgesic, hepatoprotector, anti-inflammatory and anticarcinogenic.  
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1.3.3.1.  General activities 
 
Resistant bacterial infections are a common problem in hospitals and 
immunosuppressed individuals. Ursolic acid has been tested in several strains of bacteria 
(Table 1.3.2).  
 
Table 1.3.2. Minimum inhibitory concentration (MIC) of ursolic acid for several bacterial 
species. 
a) Isoniazid; b) Rifampin; c) Ampicillin; d) Amoxicillin; e) Oxacillin; f) Vancomycin; g) 
Ticarcilin.  
 
Entry Bacteria 
MIC (µg/mL) 
Ref. 
Ursolic acid Reference antibiotic 
1 M. tuberculosis H37Ra 50 0.06
a
 
101
 
2 M. tuberculosis H37Rv 31 0.03
b
 
80
 
3 E. faecium FN-1 4 128
c
 
92
 
4 E. faecium BM4147 4 32
c
 
92
 
5 E. faecalis FA2-2 4 4
c
 
92
 
6 E. faecalis NCTC 12201 4 4
c
 
92
 
7 S. aureus OM481 8 64
c
 
92
 
8 S. aureus OM584 8 64
c
 
92
 
9 S. pneumonia R6 8 0.06
c
 
92
 
10 E. coli K12 >128 n.t. 
92
 
11 P. aeruginosa PAO1 >128 n.t 
92
 
12 S. marcescens NUSM8905 >128 n.t 
92
 
13 E. coli ATCC 25922 >256 4
d
 
102
 
14 S. aureus ATCC 25923 8 <1
e
 
102
 
15 S. aureus ATCC 29213 8 <1
e
 
102
 
16 E. faecalis ATCC 29212 4 <1
f
 
102
 
17 P. aeroginosa ATCC 27858 256 16
g
 
102
 
18 Penicillinase-producing E. coli >256 >256
d
 
102
 
19 MRSA (mecA gene) >256 256
e
 
102
 
20 E. faecium (vanB gene) >256 64
f
 
102
 
21 E. faecalis (vanA gene) >256 256
g
 
102
 
22 P. aeruginosa  >256 64
g
 
102
 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
24 
 
Biofilm formation in bacterial infections is a common cause of the reoccurrence of 
symptoms and treatment failure. Bacterial cells involved in a biofilm, a polysaccharide 
matrix, often have lower metabolism and oxygen consumption, which renders them 
resistante to antibiotics. Ursolic acid is a biofilm formation inhibitor.
79
 
 
Protazoan parasites affect 3 billion people worldwide, with malaria and 
trypanosomatid parasites causing the greatest morbidity.
103
 Ursolic acid was shown to 
suppress parasitemia in mice infected with Plasmodium berghei and was also reported to 
reduce the in vitro proliferation of P. falciparum 3D7, W2 and K1 strains.
82, 104-106
 
Leishmaniasis is an insect-borne protozoan infection for there is no effective vaccine. 
Ursolic acid can inhibit the growth of two species of Leishmania in the form of 
promastigotes or amastigotes (Table 1.3.3) because of the activation of nitric oxide (NO) 
intermediates by macrophages.
83, 107
  
 
Table 1.3.3. In vitro determination of the IC50 (μM) of ursolic acid for several strains of 
leishmania. 
Entry Species IC50 (µM) Ref. 
1 L. amazonensis promastigotes 20 
83
 
2 L. infantum promastigotes >25 
83
 
3 L. amazonensis promastigotes 11 
107
 
4 L. amazonensis amastigotes 24 
107
 
 
Betulinic acid has been the triterpenoid most used for the study of anti-HIV 
activity.
108, 109
 Ursolic acid was found to have anti-HIV activity, with a low therapeutic 
index because of its toxicity (TI = 3.3).
110
 This triterpenoid acts via inhibitory effects on 
HIV reverse transcriptase (RT; 28% inhibition at 100 μM), inhibition of the dimerization 
of RT
84, 111
 and inhibition of the gp120-CD4 interaction, which is required for the entry of 
the virus into lymphocytes.
112, 113
  
 
Osteoporosis is the most common consequence of the imbalance between bone 
resorption by osteoclasts and bone formation by osteoblasts.
114, 115
 An in vitro study 
showed that ursolic acid stimulated osteoblast differentiation and mineralization through 
the activation of mitogen-activated protein (MAP)-kinases (JNK and p38) and 
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transcription factors (NF-κB and AP-1), with a mechanism of action that is different from 
that of the drugs currently used.
116, 117
  
 
Cardio-related diseases are the number one cause of death worldwide.
118
 The 
administration of ursolic acid to a Dahl salt-sensitive, insulin-resistant rat model of 
hypertension prevented the development of severe hypertension via antihyperlipidemic, 
antioxidant, diuretic, salturetic and natriuretic effects.
119
 Treatment of arrhythmic Wistar 
rats with ursolic acid has vasodepressor and bradycardic effects that can be attributed to a 
β-blocker activity and inhibition of a Na+/H+ exchanger.120 In two different rat models of 
heart injury, ursolic acid exhibited antioxidative activity, protecting the heart from further 
damage by decreasing the lipid peroxidation and increasing the activity ROS scavenging 
activities;
121, 122
 these effects were also verified in isolated mitochondria.
123
 Treatment of 
rats with isoproterenol-induced myocardial infarction with ursolic acid prevents the 
increase of the activity of creatine kinase-MB, lipid peroxidase markers, DNA 
fragmentation and several markers of apoptosis in plasma and heart tissues; and the 
decrease of the activity of enzymatic antioxidants.
124
 
 
Obesity is a global health problem and a risk factor for the development of metabolic 
disorders, dislipidemia, atherosclerosis and type 2 diabetes.
125, 126
 Ursolic acid decreases 
the levels of triacylglycerol in the plasma via the inhibition of pancreatic lipase (IC50 
15.83 µM) and by stimulating lipolysis in adipocytes.
85, 127
 Ursolic acid has the ability to 
reduce the levels of plasma total cholesterol, free fatty acids and triglycerides in diabetic 
mice.
128
 Fatty acid synthase (FAS) is a key enzyme in the synthesis of long-chain fatty 
acids, which are a target in the treatment of obesity; ursolic acid inhibits FAS with an 
IC50 of 6.0 µg/mL by changing the conformation of the enzyme.
129
 Ursolic acid has the 
ability to activate the peroxisome proliferator-activated receptor (PPAR)-α in Hep G2 
cells, leading to a reduction in the cellular content of triglycerides and cholesterol by 
increasing fatty acid uptake and oxidation and by inhibiting fatty acid synthesis.
130
  
 
Atherosclerosis is considered a chronic inflammatory disease.
131, 132
 Vascular smooth 
muscle cells (VSMCs) treated with ursolic acid exhibit inhibition of chemotaxis, 
reduction in the expression of the proliferative cell nuclear antigen (PCNA) and a 
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disorganization of β-tubulin.133 C-reactive protein (CRP) is an acute response protein that 
acts as a direct regulator of the development of atherosclerosis.
134-136
 Ursolic acid 
decreases the synthesis of CRP, leading to the reduction of the vascular cell adhesion 
molecule 1 (VCAM-1) and of the low-density lipoprotein receptor-1 (LOX-1) in the 
endothelium.
137
  
 
Diabetes and diabetic complications are responsible for a significant amount of 
hospital admissions and expenses in health care.
138
 The antidiabetic and glycative-
reducing stress activity of ursolic acid are well documented. Ursolic acid has an insulin-
sensitizing effect in vitro
139, 140
 and in vivo.
128, 141, 142
 In diabetic mice, the supplement of 
the diet with ursolic acid leads to improvement of glucose plasma levels, lower 
intolerance to glucose, increases sensitivity to insulin, improvement of the immune 
response by stimulating T-cell activation;
141
 reduction of the activities of aldose reductase 
(AR) and sorbitol dehydrogenase (SDH), leading to the reduction of oxidative stress, and 
augmentation of the activity of glucokinase and glycogen content in the liver.
128
 Ursolic 
acid also reduces the activities of AR and SDH in the polyol pathway in the kidney, 
contributing to the decrease and prevention of glycation, which is associated with renal 
diseases.
142
  
Diabetes increases the risk of developing mild cognitive impairment, which is 
usually associated with brain inflammation and insulin resistance.
143-145
 Mice on a high-
fat diet (HFD) ultimately develop type 2 diabetes with a pronounced insulin resistance in 
the hippocampus, culminating in cognitive impairment. Ursolic acid reverses the 
cognitive impairment via the inhibition of endoplasmic reticulum stress, inhibition of the 
NF-κB (IκB) kinase (IKK)-β/NF-κB-mediated inflammatory signaling pathway, and 
activation of the PI3K/Akt/mTOR pathway in the mouse hippocampus.
146
 
 
Alzheimer’s disease (AD) is characterized by selective neuronal loss and 
neurofibrillary and extracellular deposits of insoluble amyloid protein.
147
 Oxidative stress 
contributes to the formation of amyloid plaques, which can be a source of oxidative 
species by themselves. An in vitro study showed that ursolic acid inhibits the formation 
of ROS from amyloid plaques, thus improving cell viability by decreasing 
neurotoxicity.
87
 The decrease in choline acetyltransferase (ChAT) and 
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acetylcholinesterase (AChE) activity is correlated with dementia.
148
 Ursolic acid inhibits 
AChE in a dose-dependent and competitive/non competitive way.
88
  
 
Mice treated with ursolic acid exhibited an increase in bone marrow cellularity and 
α-esterase-positive cells. The same mice treated simultaneously with an antigen and 
ursolic acid show an increase in specific antibody titre and in the number of plaque-
forming cells in the spleen. These effects contribute to the immunomodulator effect of 
ursolic acid.
149
  
 
Ursolic acid presents some analgesic effects in mice. It increased the response time 
in the hot plate test and produced some results in the aceptic acid-induced writhing test 
assay,
90, 97
 which were reversed by naloxone, suggesting an involvement of opioid 
receptors in this process.
90
  
 
Ursolic acid is known being hepatoprotective against several toxins.
89, 150-152
 In 
isolated rat hepatocytes, incubation with ethanol increases the levels of aspartase 
aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (AP), 
which are markers of hepatic function, and decreases cell viability; co-treatment of cells 
with ursolic acid leads to preservation of cell viability and reversal of the induction of 
AST, ALT and AP.
89
 These effects were also observed in an in vivo assay.
150
 Toxins, 
such as galactosamine, thioacetamide and carbon tetrachloride, are used to induce liver 
injuries in animal models. Pretreatment with ursolic acid grants a protection against the 
alterations of several biochemical markers of liver damage.
152
 Metallothionein (MT) 
enzymes are liver enzymes that are required for the homeostasis of essential metals.
153
 
Ursolic acid induces the hepatic expression of MT in murine hepatic cells via the 
induction of the tumor necrosis factor (TNF)-α and interleukin (IL)-6.154  
Liver fibrosis is a consequence of chronic liver damage and is caused by xenobiotic 
damage, viral infection and certain genetic diseases.
155
 The induction of cell death in 
hepatic stellate cells (HSCs) can lead to the recovery from established experimental 
fibrosis.
156
 In culture activated HSCs, ursolic acid induces apoptosis through the 
activation of the NF-κB and Akt pathways, which leads to mitochondrial permeability 
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and activation of downstream caspases. Treatment of Wistar rats with liver fibrosis with 
one single injection of ursolic acid led to the reversal of the induced liver fibrosis.
157, 158
  
 
Anti-inflammatory effects of ursolic acid were detected in in vitro cell culture 
systems and in vivo experiments. In vitro experiments have shown that the anti-
inflammatory activity of ursolic acid is due to its ability to repress the activity of several 
pro-inflammatory enzymes, such as lipoxygenase,
99, 159, 160
 cyclooxygenase-2 (COX-2, an 
inductive cyclooxygenase with an IC50 value of 130 μM),
95, 161
 matrix metalloproteinase-
9 (MMP-9, by stimulating the nuclear translocation of glucocorticoid receptor), 
162, 163
 
and inducible nitric oxide synthase (iNOS, with an IC50 of 17 μM in RAW 264.7 cells).
94, 
164, 165
 Ursolic acid reportedly attenuates the effect of NF-κB; however, contradicting 
results have been published. You et al reported an induction of iNO and TNF-α via NF-
κB activation, implying that the effects of this triterpenoid are dependent on the 
biological status of macrophages.
166, 167
 
Adhesion molecules, such as endothelial (E)-selectin, VCAM-1 and intercellular 
adhesion molecule (ICAM)-1, are expressed on the surface of endothelial cells at an early 
stage of inflammation. Expression of E-selectin is induced by NF-κB activation. 
Pretreatment of human umbilical vein endothelial cells (HUVECs) with ursolic acid 
reduced the expression E-selectin, in parallel to the inhibition of the NF-κB signaling 
pathway.
168
 RAW264.7 mouse macrophages treated with ursolic acid exhibit a decrease 
in intracellular migration inhibitory factor (MIF), which occurs through extracellular 
signal-regulated kinase 2 (ERK2) activation.
169
  
Mucus in the airway epithelium plays a pivotal role in defensive mechanisms against 
airborne chemicals, particles and microorganisms. Ursolic acid regulates mucin secretion 
by acting directly on the airway mucin-secreting cells.
170
  
In vivo studies of the use of ursolic acid as an anti-inflammatory agent were 
performed in mice, with inflammation induced by 12-O-tetradecanoylphorbol-13-acetate 
(TPA), croton oil (in the mice ear), and dimethylbenz[α]anthracene (DMBA). Ursolic 
acid (ID50 0.1 mg/ear) had a better effect than indomethacin (ID50 0.3 mg/ear), but its 
effect was not better than that of hydrocortisone (ID50 0.03 mg/ear) on a TPA model.
93
 
Ursolic acid reduced the oedema in mouse ears treated with croton oil, by 84% (ID50 0.14 
μM/cm2), which is an effect that is two-fold more potent than that of indomethacin (ID50 
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0.26 μM/cm2).91 Mouse skin treated with DMBA exhibits an increase in the mRNA levels 
of TNF-α, COX-1 and iNOS; the application of ursolic acid decreased these levels by 
several fold.
171
  
Some signaling pathways of the inflammatory process are closely related with the 
promotion, progression and invasion of cancer.
1, 9, 163, 165, 171
  
 
1.3.3.2.  Antitumor activity 
 
Cancer treatment and/or prevention should target tumor microenvironment, 
promotion, progression, angiogenesis, invasion and metastasis, as well as the immune 
response and chronic inflammation. Natural compounds supply a vast range of options 
for cancer treatment and prevention. Ursolic acid can target several steps of cancer 
development, thus representing a promising tool for the treatment and chemoprevention 
of cancer.
77, 172-178
 
 
Table 1.3.4. IC50 (µM) for ursolic acid in oral, stomach and esophageal cancer cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Oral carcinoma 
1 HSC-2 63.4 MTT 24 
179
 
2 HSG 105.1 MTT 24 
179
 
3 KB 8.2 Methylene blue 72 
180
 
4 Ca9-22 12.9 MTT - 
181
 
Stomach carcinoma 
5 HGT 20.0 MTT 24 
99
 
6 
BCG-823 
117.6 SRB 48 
182
 
7 >10 MTT 96 
183
 
8 66.38 MTT 24 
184
 
9 >10 MTT 72 
185
 
10 22.96 MTT 24-72 
186
 
11 NUGC-3 30.0 MTT 48 
112
 
Esophageal carcinoma 
12 YES-2 10-25 WST-8 48 
100
 
13 Eca-109 40.0 MTT 48 
187
 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
30 
 
Stomach and esophageal cancers are responsible for 2.4% of new cases of cancer in 
the USA.
3, 5
 Ursolic acid has demonstrated antiproliferative activity against several oral, 
stomach and esophageal cancer cells (Table 1.3.4). Ursolic acid is a well known inhibitor 
of inflammation. Its activity against stomach cancer HGT cells is based on its activity as 
an inhibitor of 15-lipoxygenase, an important inflammatory enzyme (Table 1.3.4, entry 
5).
99
 
DNA polymerase and DNA topoisomerase are enzymes that are critical for DNA 
replication, repair and recombination and are ideal targets for anticancer agents. Ursolic 
acid inhibits DNA polymerases α and β with an IC50 of 38 and 42 µM, respectively, and 
topoisomerase II with an IC50 of 150 µM, inhibiting the growth of NUGC-3 stomach 
cancer cells via cell cycle arrest at the S phase (Table 1.3.4, entry 11).
112
  
The combination of ursolic acid with 5-fluorouracil has synergistic effects in 
esophageal cancer cells, because these two compounds target and arrest the cell cycle in 
two different phases.
100
 The combination of ursolic acid with 5-fluorouracil exhibits 
adjuvant antiproliferative effects in Eca-109 cells, as it induces cell cycle arrest at the G1 
phase through the increase in p27
kip1
 and apoptosis, with a decrease in the ratio of Bcl-
2:Bax. Similar results were obtained in an in vivo mouse model of esophageal cancer 
treated with ursolic acid.
187, 188
 
 
The incidence of colorectal cancer is increasing, mainly because of modifications in 
eating habits.
3
 In an in vivo model of the formation of aberrant crypt foci (ACF) induced 
by azoxymethane, which is a model of colorectal cancer, ursolic acid had a 
chemopreventive effect on the initiation phase of the formation of ACF, which was 
correlated with the increase of neutral shingomyelinase, an enzyme that is downregulated 
in cancer cells.
189
 Ursolic acid reduced the formation of ACF induced by 1,2-dimethyl-
hydrazine.
190
 
Ursolic acid is active against several colorectal cancer cell lines (Table 1.3.5). In HT-
29 cells, ursolic acid induces apoptosis through the activation of caspases 8 and 9, as a 
consequence of the increase in the levels of DNA-histone complexes
191
 and in the activity 
of alkaline sphingomyelinase.
192
 Shan et al reported that HT-29 cells treated with ursolic 
acid undergo apoptosis via suppression of the phosphorylation of the epidermal growth 
factor receptor (EGFR), downregulation of ERK1/2, p38 MAP kinase and JNK and 
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increase in the expression of Bcl-2 and Bcl-xL, with consequent activation of caspases 9 
and 3.
193
  
Several pathways are altered in colorectal cancer. COX-2, an inducible enzyme that 
is present in 90% of colorectal cancers, plays an essential role in tumorigenesis and 
chemoresistance.
194, 195
 HCT15 cells overexpress COX-2, which is in contrast with 
HCT116 cells, which do not express this enzyme, rendering HCT116 cells more sensitive 
to treatment with ursolic acid. In HT-29 cells with ursolic acid-induced apoptosis, COX-2 
was overexpressed via the activation of the p38 MAP kinase pathway as a mechanism of 
apoptosis resistance.
196
  
 
Table 1.3.5. IC50 (µM) for ursolic acid in colorectal cancer cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
1 
HT-29 
30.0 Crystal violet 3 
197
 
2 20.0-40 WST-1 24 
191
 
3 26.0/20.0/18.0 MTT 24/48/72 
193
 
4 4.7 Methylene blue 72 
180
 
5 26.31 MTT 24-72 
186
 
6 25.0 Trypan blue 48 
196
 
7 
HCT15 
30.0 MTT 72 
198
 
8 2.5-4 MTT 48 
199
 
9 10.7 SRB 48 
200
 
10 7.2 - - 
201
 
11 17.5 SRB 48 
202
 
12 9.6 - 48 
203
 
13 CO115 5-10 MTT 48 
199
 
14 
Caco-2 
>50 MTT 48 
204
 
15 34.4 MTS 96 
205
 
16 SW480 20 MTT 72 
206
 
17 SW620 38 MTT 72 
206
 
 
The TNF-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, 
as it binds to DR4 and DR5 and induces apoptosis; however, resistance to TRAIL is often 
seen in cancer.
207
 HCT116 cells are moderately sensitive to ursolic acid and TRAIL; 
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nevertheless, pretreatment with ursolic acid before treatment with TRAIL enhances the 
cytotoxicity of the latter. Ursolic acid enhances the protein levels of DR4 and DR5 in 
HCT116 and HT-29 colorectal cancer cells, which is accompanied by a decrease in the 
expression of Bcl-xL, survivin and XIAP; these results were confirmed in an in vivo 
model.
208
 Treatment of SW480 colorectal cancer cells sensitive to TRAIL with ursolic 
acid induces apoptosis via the downregulation of Bcl-xL, Bcl-2 and survivin.
206
 
The HCT15 and CO115 colorectal cancer cell lines have mutations in KRAS and 
BRAF, respectively. Ursolic acid inhibits the growth of HCT15
198, 199, 209
 and CO115
199, 
209
 cells in a time- and concentration-dependent manner, with inhibition of PI3K activity 
and decrease in the levels of p-Akt in CO115 cells.
199, 209
 Ursolic acid enhances 
synergistically the apoptotic effects of 5-fluorouracil in HCT15 cells, with an increase in 
autophagosomes and a decrease in mutant p53 and phosphor-mammalian target of 
rapamycin (p-mTOR).
210
 DNA damage is one of the causes of induction of 
tumorigenesis. Oxygen peroxide (H2O2) can induce DNA damage; ursolic acid protects 
Caco-2 cells from H2O2 damage by increasing incision activity for DNA repair.
204
 
 
Hepatocellular carcinoma is one of the most deadly cancers, with poor 
chemotherapeutic options.
3, 211
 Treatment of different hepatic cancer cell lines with low 
doses of ursolic acid (Table 1.3.6, entries 8, 16, 17 and 19) induces apoptosis through an 
increase in DNA fragmentation and in the activity of caspases 3 and 8, decrease in 
membrane potential and in the activity of Na
+
-K
+
-ATPase, and suppression of vascular 
endothelial growth factor (VEGF) and ICAM-1 which are two molecules that are 
important for angiogenesis and invasion in cancer.
212
 Caspase activation and DNA 
fragmentation were observed by others in Hep G2 cells.
213-215
 The induction of apoptosis 
and of the cell cycle arrest by ursolic acid in Hep G2 cells is due to the downregulation of 
the PI3K/Akt pathway, with consequent downregulation of survivin
213
 and upregulation 
of p53, leading to the downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and 
p21
waf1 213, 214
 and inhibition of topoisomerase I and replication protein A.
214
 Pretreatment 
with ursolic acid has chemoprotective effects in Hep G2 cells treated with t-butyl 
hydroperoxide, via DNA repair.
216
 
MDR is one of the main causes of failure of chemotherapeutic drugs. The expression 
of Pgp, which encodes a membrane transporter, is associated with MDR. Doxorubicin is 
1. Introduction 
33 
 
one of the main combinational therapeutic options for the treatment of hepatic cancer, 
although its application is limited because of drug resistance induced by Pgp.
217
 
Doxorubicin resistant Hep G2 cells (R-Hep G2) (Table 1.3.6, entries 12 and 13) are 
sensitive to ursolic acid treatment. These results were confirmed in vivo in xenographic 
nude mice.
218, 219
 Ursolic acid can circumvent the effects of Pgp, as it is not a substrate of 
this pump.
218
 Ursolic acid induces apoptosis in R-Hep G2 cells through the activation of 
the extrinsic and intrinsic death pathways, with increase in the levels of the ligand of the 
Fas death receptor (FasL) and tBid and increase in apoptosis inducing factor (AIF).
218, 219
  
 
Table 1.3.6. IC50 (μM) for ursolic acid in several hepatic cancer cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
1 
Hep G2 
21.10 MTT - 
220
 
2 53.42 MTT 24-72 
186
 
3 68.82 MTT 24 
184
 
4 37.0 MTT 48 
218
 
5 33.96 MTT 48 
219
 
6 31.54/26.65 MTT 48/72 
213
 
7 20-30 MTT 48 
214
 
8 4-8 MTT - 
212
 
9 30-40 MTT 72 
216
 
10 20 Trypan Blue 72 
215
 
11 87.4 MTS 96 
205, 221
 
12 
R-Hep G2 
20.0 MTT 48 
218
 
13 21.3 MTT 48 
219
 
14 Bel-7402 98.5 SRB 48 
182
 
15 SMMC-7721 45.72 MTT 24 
222
 
16 Hep3B 4-8 MTT - 
212
 
17 
HuH7 
>8 MTT - 
212
 
18 75 MTT 24 
223
 
19 HA22T 8.0 MTT - 
212
 
 
Ursolic acid induces apoptosis in a dose-dependent way in the SMMC-7721 and 
HuH7 cell lines (Table 1.3.6, entries 15, 17 and 18), with induction of Bax and 
downregulation of Bcl-2.
222, 223
 In SMMC-7721 cells, ursolic acid induces p53, thus 
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modifying the expression of GDF15, SOD2, ATF3 and fos.
222
 HuH7 cells treated with 
ursolic acid exhibit a downregulation of NF-κB, leading to the downregulation of 
XIAP.
223
 
Diethylnitrosamine (DEN) is known as a chemical carcinogenic agent that is present 
mainly in tobacco smoke. Hepatocarcinogenesis induced by DEN in mices and promoted 
by phenobarbital is characterized by high levels of lipid peroxidation and carbonyl 
proteins. Oral administration of ursolic acid reduces the levels of lipid peroxidation and 
protein carbonyls, restoring membrane integrity.
224
  
 
Cancers of the uterine cervix, uterine corpus and ovaries are responsible for 5% of all 
cancers diagnosed in women, with a death incidence of 4.9%.
3, 5
 Ursolic acid is active 
against cervical cancer cells, inducing cell death (Table 1.3.7, entries 1-4). Cervix cancer 
HeLa cells treated with ursolic acid exhibit accumulation in the sub-G1 phase (apoptosis) 
as a result of the activation of caspase 8. Calpain and CDK5 are also upregulated by 
ursolic acid in HeLa cells and may play an important role in apoptosis induction.
225
 
Mutations of the tumor suppressor PTEN are found in 30-50% of all human 
endometrial cancers. PTEN blocks G1 cell cycle progression, induces apoptosis and 
regulates the PI3K/Akt cell survival pathways.
226, 227
 Exposure of SNG-II and HEC108 
endometrial cancer cells to ursolic acid reduce the levels of p-Akt, PI3K and downstream 
targets, MAP kinase and p-P44/42, inducing apoptosis.
228
 
Ursolic acid inhibits the proliferation of CAOV3 ovary cancer cells, with an IC50 
higher than 40 µM (Table 1.3.7, entry 9). ERK plays an important role in cell growth, 
development, division, death and malignant transformation. Ursolic acid decreases ERK 
and its phosphorylation in CAOV3 cells and inhibits MAP kinase phosphatase (MKP)-1, 
an enzyme that regulates the expression of ERK via its degradation. Ursolic acid also 
increases the levels of Bax and decreases the levels of Bcl-2 in CAOV3 cells, inducing 
apoptosis.
229
 
 
Breast cancer is the number one cause of death by cancer in women.
3-5, 230
 Ursolic 
acid has chemopreventive effects in mammary carcinoma.
231
 Ursolic acid prevents the 
induction of COX-2 and the synthesis of prostaglandin E2 in human mammary epithelial 
cells treated with phorbol 12-myristate-13-acetate, by activating ERK1/2, JNK and p38 
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MAP kinase.
161
 Ursolic acid was uneffective in the inhibition of the mammary 
tumorigenesis induced by DMBA in rats.
232
  
 
Table 1.3.7. IC50 (µM) for ursolic acid in uterine cervix, ovary and breast carcinoma cell 
lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Cervix carcinoma 
1 
HeLa 
>10 MTT 72 
185
 
2 108.0 SRB 48 
182
 
3 33.12 MTT 24 
184
 
4 UISO 7.0 - - 
201
 
Ovary carcinoma 
5 
SKOV3 
>10 MTT 72 
185
 
6 >10 MTT 96 
183
 
7 7.9 - 48 
203
 
8 9.6 SRB 48 
200
 
9 CAOV3 >40 MTT 48 
229
 
10 OVCAR-5 7.0 - - 
201
 
11 A2780 20.8 - - 
233
 
Breast carcinoma 
12 MCF-7/wt 30 MTT 72 
206
 
13 MCF-7/ADR 40 MTT 72 
206
 
14 BT-20 48 MTT 48 
234
 
15 
MCF-7 
53 MTT 48 
235
 
16 178.0 MTT 72 
236
 
17 10.3 MTT 72 
237
 
18 18.2 MTS 96 
205, 221
 
19 17.5 SRB 48 
202
 
20 
MDA-MB-231 
3.3 MTT 72 
237
 
21 40 MTT 24/48 
238
 
22 25-50 SRB 24 
239
 
 
Breast cancer is known to be influenced by several hormones, more specifically, 
estrogen and progesterone. Aromatase plays an importante role in the production of 
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estrogen. Triterpenoids, such as ursolic acid, have a structure that is similar to that of 
steroids, rendering them good leading molecules for hormonal-related therapy.
240
 Ursolic 
acid is an inhibitor of aromatase, with an IC50 of 32 µM.
241
  
Ursolic acid inhibits the proliferative activity of MCF-7 cells (Table 1.3.7, entries 15-
19) via the induction of the intrinsic mitochondrial apoptotic pathway, with poly ADP-
ribose polymerase (PARP) cleavage and downregulation of Bcl-2 proteins. In these cells 
ursolic acid was shown to modulate glucocorticoid receptor content.
235
  
Treatment of the highly metastatic MDA-MB-231 cancer cells with ursolic acid leads 
to a decrease in cell viability (Table 1.3.7, entries 20-21). Ursolic acid induces apoptosis 
through both intrinsic and extrinsic pathways, with downregulation of Bcl-2, upregulation 
of Bax, release of cytochrome c, decrease of mitochondrial membrane potential and 
induction of the Fas receptor.
238
 Ursolic acid has the ability to inhibit the migration and 
invasion of MDA-MB-231 cells via the inhibition of the Akt/mTOR and NF-κB signaling 
pathways, which results in the inhibition of MMP-2 and the urokinase-type plasminogen 
activator (uPA).
239
 
 
Prostate cancer is the leading cause of cancer-related death in men.
3-5
 In the initial 
stages of prostate cancer, cells are dependent of androgens for growth, but progression to 
an androgen-independent growth can occur, leading to the most lethal phenotypes of the 
disease.
242
  
The androgen-sensitive cells LNCaP undergo apoptosis when treated with ursolic 
acid (Table 1.3.8, entries 6-8).
243-245
 In the LNCaP and LNCaP-AI (androgen insensitive) 
cell lines, ursolic acid has the ability to disturb the ratio of Bcl-2:Bax, inducing apoptosis 
through the intrinsic pathway.
243, 244
 The decrease in Bcl-2 is due to its phosphorylation 
and consequent degradation by the activation of a JNK-mediated pathway.
244
 LNCaP 
cells treated with ursolic acid present a decrease in the phosphorylation of IKK, thus 
preventing the activation of NF-κB, a decrease in the phosphorylation of signal 
transducer and activator of transcription (STAT) 3 (which is related to the decrease of IL-
6) and a decrease in p-Akt, culminating in apoptosis.
245
 
Ursolic acid can inhibit the proliferation of hormone refractory prostate cancer cells 
PC-3 (Table 1.3.8, entries 10-13).
243, 246, 247
 PC-3 cells treated with ursolic acid exhibit a 
decrease in Bcl-2, which is related to the activation of the JNK pathway.
243, 246
 Treatment 
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of PC-3 cells with ursolic acid leads to the inhibition of the Akt pathway, subsequently 
increasing the expression of FasL, inducting the extrinsic apoptotic pathway, reducing 
MMP-9 expression and inhibiting invasion to adjacent tissues.
246
 The reduction of p-Akt 
through the disruption of the mTOR pathway is correlated with the induction of 
autophagy in PC-3 cells treated with ursolic acid. The activation of autophagy is 
correlated with G1 cell cycle arrest, with upregulation of p21
waf1
 and p27 and 
downregulation of cyclins D1 and D3 and CDK4.
247
 
 
Table 1.3.8. IC50 (µM) for ursolic acid in prostate carcinoma cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
1 
DU145 
>100 MTT 24 
234
 
2 25-50 MTT 72 
245
 
3 >50 MTT 24 
248
 
4 20-30 MTT 24 
247
 
5 50 MTT 72 
249
 
6 
LNCaP 
20-25 MTT 72 
245
 
7 15.7 MTT 48 
243
 
8 20-50 MTT 48 
244
 
9 LNCaP-AI 20-50 MTT 48 
244
 
10 
PC-3 
>40 MTT 24 
247
 
11 40-80 MTT 72 
246
 
12 32.6 MTT 48 
243
 
13 30.5 SRB 48 
202
 
14 
RC-
58T/h/SA#4 
10-20 SRB 72 
250
 
 
Ursolic acid inhibits growth in the DU145 prostate cancer cell lines, which is an 
androgen-independent cell line (Table 1.3.8, entries 1-5). DU145 cells treated with 
ursolic acid undergo apoptosis via the downregulation of Bcl-2, due to the activation of 
the JNK signaling pathway, which induces phosphorylation of Bcl-2 and its consequent 
degradation.
249
 DU145 cells treated with ursolic acid exhibit a decrease in the 
phosphorylation of IKK, which impairs the activation of NF-κB; there is also a decrease 
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in p-STAT 3. The downregulation of the NF-κB and STAT 3 pathways was also observed 
in a xenograft mouse model of DU145 prostate cancer cells.
245
 
CXCR4 and CXCL12 are chemokine receptors that are involved in tumor 
proliferation, invasion and metastasis. Ursolic acid has the ability to reduce the mRNA 
expression of these receptors in DU145 and PC-3 prostate cancer cells. This 
downregulation is enabled by the suppression of NF-κB. In a transgenic model of prostate 
cancer, ursolic acid also decreased the expression of CXCR4, which correlated with the 
decrease of metastasis to the lung, liver and gastro-intestinal tract.
248
 
Ursolic acid induced apoptosis in a primary cell line of prostate cancer, RC-
58T/h/SA#4, through activation of caspases 8 and 9, with a decrease in Bcl-2 levels.
250
 
 
Lung cancer is one of the deadliest cancers, representing 27% of the deaths by cancer 
worldwide.
3-5
 Ursolic acid can induce cell cycle arrest, inhibit proliferation and inhibit 
invasion and migration in A549 human non-small lung cancer cells (Table 1.3.9, entries 
1-6).
251, 252
 Ursolic acid induces cell cycle arrest at the G1 phase and apoptosis in A549 
lung cancer cells because of the increase in p21
waf1
 expression in a p53-dependent 
manner, decrease in cyclins and CDKs, increase in the expression of IκB-α (leading to a 
decrease in the expression of NF-κB), increase in the apoptotic proteins Bax and FasL 
and decrease in the anti-apoptotic proteins Bcl-2 and Bcl-xL.
251
 Alterations in NF-κB 
expression were also observed in H1299 and ASTC-a-1 lung cancer cells.
165, 253
  
Ursolic acid treatment can prevent the invasion and migration of A549, H3255 and 
Calu-6 lung cancer cells through a decrease in the production of VEGF and transforming 
growth factor (TGF)-β1 and suppression of the expression of ICAM-1, fibronectin and 
MMP-9 and -2.
252
 Suppression of MMP-9 is observed in H1299 lung cancer cells.
165
 
H460 lung cancer cells treated with ursolic acid exhibit an increase in the expression of 
the MMP-1, -2, -3, -9 and -10 genes, which is correlated with the induction of 
apoptosis.
254
 
Ursolic acid sensitizes ASTC-a-1 cells to paclitaxel and cisplatin, reducing the need 
of high doses of these two chemotherapeutic drugs. The combination of paclitaxel or 
cisplatin with ursolic acid induces apoptosis through the activation of the intrinsic 
pathway, via overexpression of tBid and activation of the Fas/FasL–caspase 8 pathway; 
inhibition of NF-κB was also observed.253 
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Skin cancer is one of the most common types of cancer and is responsible for nearly 
half of the diagnosted cancers in the Caucasian population.
3, 5
 Melanoma is the deadliest 
of the skin cancers, once it affects deeper layers of the skin, and has the ability to spread 
to other tissues.
255
 Ursolic acid is well known to inhibit TPA-induced skin tumorigenesis 
in mice,
171, 256-258
 with increased levels of mRNA expression for COX-1, COX-2, and 
TNF-α.171  
 
Table 1.3.9. IC50 (µM) for ursolic acid in lung and skin cancer cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Lung carcinoma 
1 
A549 
4-8 MTT 48 
252
 
2 40 XTT 48 
251
 
3 9.4 SRB 48 
200
 
4 42.5 MTT 72 
237
 
5 >100 MTT 24 
234
 
6 9.2 - 48 
203
 
7 H3255 8-16 MTT 48 
252
 
8 Calu-6 8-16 MTT 48 
252
 
9 H460 10 Trypan Blue 24 
254
 
Skin carcinoma 
10 B16 2F2 4.8 - 72 
259
 
11 
B16 F0 
10-12.5 Trypan Blue 48 
260
 
12 10 SRB 48 
200
 
13 B16 F10 50 MTT 24 
261
 
14 B16 10 MTT 96 
262
 
15 M4Beu 12.5-15.0 Trypan Blue 48 
263
 
16 A431 50 MTT 48 
264
 
17 A375 8.0 Microscopy 72 
265
 
18 SK-MEL-2 10.8 SRB 48 
200
 
19 SK-MEL-3 10.1 - 48 
203
 
 
Treatment of mouse melanoma B16 cells with ursolic acid induces an increase in the 
number of cells at the G1 phase of the cell cycle, and increased concentrations of the 
triterpenoid induce apoptosis (Table 1.3.9, entry 14).
262
 Ursolic acid induces apoptosis in 
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B16 F10 cells, with induction of the p53 gene and downregulation of Bcl-2 through the 
inhibition of NF-κB.261 In M4Beu cancer cells, ursolic acid treatment induces apoptosis 
with activation of caspase 3 through the intrinsic mitochondrial pathway, with a decrease 
in Bcl-2 levels and increase in Bax levels.
263, 266
 Activation of caspase 3 with induction of 
apoptosis are observed in A431
264
 and HaCaT
266, 267
 cancer cells treated with ursolic acid. 
Ursolic acid has the ability to inhibit reverse transcriptase in A371cancer melanoma cells, 
with consequent induction of apoptosis and differentiation.
265
  
Melanoma is well known to being resistant to chemotherapeutic drugs. Ursolic acid 
can overcome this feature by inducing apoptosis in B16 F0 melanoma chemoresistant 
cells via the repression of tyrosinase-related protein (TRP)-2, an enzyme that is involved 
in melanogenesis (Table 1.3.9, entries 11 and 12).
260, 268
  
Several proteases, such as urokinase and cathepsins, play an important role in the 
invasion and metastasis of cancers.
269
 Ursolic acid is an inhibitor of the activity of 
urokinase (IC50 12 μM) and cathepsin (IC50 10 μM); the inhibition of these two enzymes 
is associated with the reduction of the number of lung metastasis in mice bearing B16 
melanoma cancer.
270
  
Ursolic acid increases the cell mediated immune response against B16 F10 metastic 
tumors in mice via activation of natural-killer cell activity and increase in antibody-
dependent cell-mediated cytotoxity and antibody-dependent complement-mediated 
cytotoxicity.
271
 
 
Leukemia, a blood cancer, is responsible for 2.8% of the new cases of cancer 
diagnosed every year.
3, 5
 Treatment of different leukemia cell lines with ursolic acid has 
antiproliferative effects (Table 1.3.10, entries 1-16). The induction of apoptosis by ursolic 
acid in HL60 cancer cells is associated with increased levels of intracellular Ca
2+ 272
 and 
with induction of the inhibitory effects of c-AMP.
273
 In a more recent study, ursolic acid 
was shown to induce HL60 monocytic differentiation through the activation of the ERK 
pathway.
274
 Its ability to induce cell death was observed in the MDR cancer cells, 
HL60/ADR and K562/ADR, although this required higher doses of ursolic acid (Table 
1.3.10, entries 8 and 16).
206
 In K562 cancer cells, ursolic acid induces apoptosis through 
the downregulation of Bcl-xL and upregulation of p-JNK.
275
 In KBM-5 cancer cells, 
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ursolic acid inhibits NF-κB-DNA binding, deregulating this pathway; it also suppress the 
TNF-mediated induction of cyclin D1, COX-2 and MMP-9.
165
  
In L1210, K562 and HL60 leukemia cells treated with oxygen peroxide, ursolic acid 
pretreatment inhibits DNA damage, via the impairment of the generation of ROS 
species.
276
 The combination of ursolic acid and doxorubicin results in an antagonistic 
effect, decreasing the apoptotic effects of doxorubicin in L1210 and HL60 cells and its 
differentiation effects in K562 cancer cells. The antagonistic effects of ursolic acid are 
likely due to its antioxidant properties by modulating glutathione (GSH) metabolism.
277
  
 
Table 1.3.10. IC50 (µM) for ursolic acid in leukemia and lymphoma cancer cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Leukemia 
1 
HL60 
32.6 NBT 120 
274
 
2 5-10 MTT - 
272
 
3 10.9 Trypan Blue 24 
277
 
4 17.0
a
 TB exclusion 24 
276
 
5 157.6 
Twentyman  
and 
Luscombe 
48 
182
 
6 29.0 MTT 72 
206
 
7 19.0 MTT - 
181
 
8 HL60/ADR 32.0 MTT 72 
206
 
9 
L1210 
14.6 Trypan Blue 24 
277
 
10 12.0
a
 TB exclusion 24 
276
 
11 8.8 XTT 48 
278
 
12 
K562 
17.0
a
 TB exclusion 24 
276
 
13 33.0 MTT 72 
206
 
14 17.2 SRB 48 
202
 
15 38.9 XTT 72 
279
 
16 K562/ADR 43.0 MTT 72 
206
 
Lymphoma 
17 P3HR1 5.5 XTT 72 
279
 
a) Value for IC80 
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Ursolic acid has the ability to suppress the activation of STAT 3, which is 
constitutively activated in multiple myeloma, by suppressing its nuclear translocation and 
DNA-binding activity, leading to the downregulation of cyclin D1, survivin, Bcl-2, Bcl-
xL and Mcl-1. Ursolic acid also potentiates the effects of the proteasome inhibitor 
bortezomib and of the TNF inhibitor thalidomide, which are used currently in the 
treatment of multiple myeloma.
280
  
 
C6 glioma cells treated with ursolic acid have less invasive potential. Ursolic acid 
inhibits directly the interaction of ZIP/p65 with protein kinase C (PKC)-ζ, which leads to 
the blockage of the NF-κB-dependent pathway induced by IL-1β or TNF-α. This 
sequence of events permits the decrease in activity and levels of expression of MMP-9, 
which is a key enzyme for the invasion of C6 glioma cells.
281
 The downregulation of 
MMP-9 was observed in HT1080 fribrosarcoma cells.
162, 163
  
 
Table 1.3.11. IC50 (µM) for ursolic acid in several cancer cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Glioma 
1 
U87 
>100 MTT 24 
234
 
2 9.0 Microscopy 72 
265
 
3 C6 48.0 MTT 24 
281
 
Neuroblastoma 
4 U251 15.1 SRB 48 
202
 
5 
XF498 
10.7 SRB 48 
200
 
6 9.9 - 48 
203
 
7 SH-SY5Y 54.6 MTT 24 
184
 
Pancreatic carcinoma 
8 AsPC-1 >100 MTT 24 
234
 
Bladder carcinoma 
9 NTUB1 29.4 MTT 72 
282
 
Thyroid carcinoma 
10 ARO 7.0 Microscopy 72 
265
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Ursolic acid inhibits the differentiation of U87 glioblastoma cells and ARO thyroid 
carcinoma cells through the inhibition of endogenous reverse transcriptase (Table 1.3.11, 
entries 1, 2 and 10).
265
  
 
Angiogenesis consists in the formation of new capillaries from pre-existing vessels 
and is essential for tumor progression. Angiogenesis comprises several steps, which 
include the stimulation of endothelial cells by growth factors (such as VEGF), the release 
of proteolytic enzymes (such as MMPs), the subsequent degradation of the extracellular 
matrix (ECM) followed by invasion through ECM, migration and proliferation of 
endothelial cells and, finally, the formation of new capillary tubes.
283
 Ursolic acid inhibits 
endothelial cell proliferation with an IC50 of 5 µM and has inhibitory effects on the 
angiogenic process in chorioallantoic membranes of the chick embryo, with an ID50 of 10 
nmol/egg.
284, 285
  
High concentrations of ursolic acid promote angiogenesis through the formation of 
capillary-network-like structures with activation of the PI3K-Akt pathway in HUVECs 
cultured in serum-free medium. These effects, however, were not observed in HUVECs 
treated with low concentrations of ursolic acid and were contradictory with those 
obtained with HUVECs cultured in medium supplemented with serum.
286
 These 
observations suggest that the effects of ursolic acid on the angiogenic process are 
dependent on the concentrations and cell culture medium used.  
The antiangiogenic effects of ursolic acid were specifically observed in mice bearing 
melanoma B16 F10 cells, with decrease in the levels of VEGF, MMP-2, MMP-9 and 
NO;
287
 in colorectal cancer cells, in a dose-dependent manner;
288
 and in hepatoma cell 
lines, with decrease of the mRNA expression of the hypoxia-inducible transcription 
factor (HIF)-1α, VEGF, IL-8 and uPA and in the production of ROS and NO.289  
 
Chemotherapy and radiotherapy often produce detrimental side effects. Ursolic acid 
has no proven cytotoxic effects in vitro (Table 1.3.12 and references cited therein) and in 
in vivo models.
77, 133, 234
 Ursolic acid reduces the mutagenicity of doxorubicin in mice,
290
 
enhances hematopoietic recovery after radiation treatment of sarcoma in mice
291
 and 
reduces lipid oxidation and DNA damage after UVB radiation in human lymphocytes.
292
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Table 1.3.12. Cytotoxic effects of ursolic acid in nontumoral cell lines, represented as 
IC50 (μM).  
Entry Cell line Cell type IC50 (µM) Assay Time (h) Ref. 
1 L-02 Liver >8 MTT - 
212
 
2 HFLF Lung fibroblast 21.28 MTT 24 
184
 
3 GES-1 Gastric epithelium 93.83 MTT 48 
186
 
4 HSF Gingival fibroblasts 54.7 MTT 24 
179
 
5 MEF Fibroblast >50 MTT 24 
248
 
6 WI38 Fibroblast 160.0 Microscopy 72 
265
 
 
The proven effects of ursolic acid in several targets of cancer cells and its effects in 
animal models render this triterpenoid a potential lead for use in the chemoprevention and 
chemotherapeutic treatment of cancer.  
 
1.3.3.3.  Semisynthetic derivatives with antitumor activity 
 
Ursolic acid has been modified with the aim of improving the pre-existent antitumor 
activity. The main sites of modification were located at carbons C2, C3, C11 and C28 of 
the ursane backbone, generating several derivatives.  
 
Ursolic acid was first investigated for its anti-inflammatory properties, which are 
related with its ability to inhibit NO production and COX activation.
159, 164
 The induction 
of NO synthase is also observed in cancer, with production of high levels of NO in 
cancerous cells. Honda et al synthesized a series of new ursolic acid derivatives that can 
inhibit the production of NO in mouse macrophages. Most of the synthetic derivatives 
presented better activity compared with that of ursolic acid, as ursolic acid is toxic above 
10 μM and is inactive below 10 μM in mouse macrophages (Table 1.3.13).293-295 
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Table 1.3.13. IC50 (µM) of ursolic acid derivatives for the inhibition of the production of NO in 
mouse macrophages. 
C28
H
HA
C
 
Entry Compd Ring A Ring C C28 IC50 (µM) 
1 1.1 
O
 
O
 
COOH  5.1 
2 1.2 
O
 
 
COOH  17.6 
3 1.3 
O
 
O
 
COOMe  8.9 
4 1.4 
O
NC
 
O
 
COOMe  0.1 
5 1.5 
O
NC
 
O
 
COOH  0.8 
6 1.6 
O
NC
 
 
COOMe  5.1 
7 1.7 
O
NC
 
 
COOH  6.2 
8 Ursolic acid - - - Toxic 
 
Kwon et al synthesized a series of new ursane derivatives, 1.8-1.15 (Figure 1.3.4) 
that can inhibit the synthesis and production of NO in RAW247 cells, with better activity 
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than that of the parental compound, ursolic acid. Compound 1.14 at 20 µM was the best 
compound identified, with an NO inhibition of 93.7%.
296
 
 
R1O
H
O
OR2
H
R1 = CH3 R2 = H
R2 = CH3R1 = H
R1 = CH3 R2 = CH3
R2 = HR1 = Ac
R1 = CH3OCH2CO R2 = H
R1 = (CH3)2NCO R2 = H
NR1 = H R2 =
N
O
R1 = R2 = H
1.8
1.9
1.10
1.11
1.12
1.13
1.14
1.15
 
 
Figure 1.3.4. Schematic representation of compounds 1.8-1.15. 
 
High concentrations of NO can be cytotoxic, induce apoptosis in tumor cells, prevent 
metastasization and assist macrophage killing tumor cells.
297, 298
 NO can be generated by 
synthetic NO-donors, such as furoxan, nitrate and diazeniumdiolate.
299, 300
 A series of 
furoxan NO-donating derivatives of ursolic acid (at carbon C3), derivatives 1.16-1.21, 
were synthesized and evaluated for their cytotoxic activity against Hep G2 cancer cells 
(Table 1.3.14, entries 1-6). Compounds 1.16-1.19 and 1.21 have been proven to be more 
active than ursolic acid (Table 1.3.14, entry 7) and 5-fluorouracil (Table 1.3.14, entry 8) 
in the inhibition of Hep G2 cell growth.
220
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Table 1.3.14. IC50 (μM) of the ursolic acid derivatives 1.16-1.21 and 5-
fluorouracil in Hep G2 cancer cells. 
O
H
O
OH
H
R2
O
O
O
R1
N
O
N
PhO2S
O  
Entry Compd R1 R2 IC50 (µM) 
1 1.16 O(CH2)2  O(CH2)2  3.20 
2 1.17 O(CH2)3  O(CH2)2  10.74 
3 1.18 O(CH2)2(CH3)CH  O(CH2)2  5.42 
4 1.19 O(CH2)4  O(CH2)2  4.93 
5 1.20 O(CH2)4  
 
51.36 
6 1.21 O(CH2)2(CH3)CH  
 
9.76 
7 Ursolic acid - - 21.10 
8 5-Fluorouracil - - 15.96 
 
The cytotoxic activity of triterpenoids seems to be strongly correlated with their 
hidrophilicity. Compounds 1.22-1.26 (Figure 1.3.5), which are highly polar quaternary 
salts of ursolic acid, were prepared and evaluated for their cytotoxic activity against CEM 
T-lymphoblastic leukemia cells. Compound 1.24 was the best compound identified with 
an IC50 of 4.1 µM.
301
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HO
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O
O
H
Br
HO
H
O
O
H
N
Br
HO
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O
O
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O
O
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O
O
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N
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1.24 1.25
1.26  
 
Figure 1.3.5. Schematic representation of compounds 1.22-1.26. 
 
AcO
H
O
NHR1COOCH3
H
R1 = CH(CH2OH)
R1 = CH(CH2C6H4-p-OH)
R1 = CH2
1.27
1.28
1.29
AcO
H
O
NHR1OCOCH3
H
R1 = (CH2)2
R1 =  CH(CH3)CH2
R1 = C6H4(o-CH2)
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H
O
NHR1COOH
H
R1 = CH(CH(CH3)C2H5)1.33
 
 
Figure 1.3.6. Schematic representation of compounds 1.27-1.33. 
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Esterification at carbon C3 and the introduction of an amino group at carbon C28 in 
the ursolic acid backbone allowed the synthesis of compounds 1.27-1.33 (Figure 1.3.6), 
which exhibited good cytotoxic activity in ovary SKOV3 and stomach BGC-823 cancer 
cell lines (Table 1.3.15). Compound 1.31 was the best compound identified.
183
  
 
Table 1.3.15. IC50 (µM) for compounds 1.27-1.33 in ovary SKOV3 
and stomach BGC-823 cancer cell lines.  
Entry Compd 
IC50 (µM) 
SKOV3 BGC-823 
1 1.27 - >10 
2 1.28 - >10 
3 1.29 - >10 
4 1.30 6.1 >10 
5 1.31 2.2 8.3 
6 1.32 >10 >10 
7 1.33 >10 - 
 
Table 1.3.16. IC50 (µM ) for compounds 1.6, 1.34 and 1.35 in bladder and pancreatic cancer cell 
lines.  
Entry Compd Ring A 
IC50 (µM) 
253JB-V KU7 PANC-1 PANC-28 
1 1.6 
O
NC
 
0.17 0.30 0.53 0.97 
2 1.34 
O
I
 
4.9 6.02 6.91 13.49 
3 1.35 O
F3C
 
0.17 0.47 0.65 1.13 
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Modifications at carbon C2 of the ursane triterpenoid originated compounds 1.4-1.7 
(Table 1.3.13, entries 4-7), which were the most active against NO production in 
macrophages. With the aim of studying the effects of different substituents at carbon C2, 
compounds 1.6, 1.34 and 1.35 were evaluated against two bladder (KU7 and 253JB-V) 
and two pancreatic (PANC-1 and PANC-28) cancer cell lines. Compound 1.6 was the 
best compound tested (Table 1.3.16, entry 1).
302
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R1 = CH2CH(OH)CH2OH
R1 = CH3
R1 = CH2CH3
R1 = CH2CH2CH3
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Figure 1.3.7. Schematic representation of esters 1.36-1.55 of ursolic acid. 
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A series of ursane esters, compounds 1.36-1.55 (Figure 1.3.7), were prepared from 
ursolic acid and evaluated for their cytotoxic activity in several cells lines (Table 
1.3.17).
182, 184, 186, 282
  
 
Table 1.3.17. IC50 (µM) for compounds 1.36-1.55 in colon (HT-29), liver (Hep G2), stomach 
(BGC-823), bladder (NTUB1), neuroblastoma (SH-SY5Y) and cervix (HeLa) cancer cell lines, 
and in two nontumorigenic cell lines (HELF and GES-1). 
Entry Compd 
Cell line 
HT-29 Hep G2 BGC-823 NTUB1 SH-SY5Y HeLa HELF GES-1 
1 1.36 - 44.23 20.51 - - - - 154.3 
2 1.37 - - 54.1 37.13 - 51.8 - - 
3 1.38 - 70.77 69.32 13.45 66.28 29.18 81.92 - 
4 1.39 - 89.11 79.68 18.28 92.52 48.03 >100 - 
5 1.40 - - - 7.97 - - - - 
6 1.41  >100 >100 15.64 >100 63.24 >100  
7 1.42 - - - 27.79 - - - - 
8 1.43 - - - 26.16 - - - - 
9 1.44 - - - 10.93 - - - - 
10 1.45 - - - 19.53 - - - - 
11 1.46 - - - >30 - - - - 
12 1.47 - 79.58 84.24 - 71.07 36.21 68.06 - 
13 1.48 - 87.44 98.28 - 89.57 69.39 82.56 - 
14 1.49 - >100 >100 - >100 >100 >100 - 
15 1.50 - - 100.0 14.27 - 50.0 - - 
16 1.51 - >100 >100 - >100 >100 >100 - 
17 1.52 - >100 >100 - >100 >100 >100 - 
18 1.53 - >100 >100 - >100 >100 >100 - 
19 1.54 18.43 27.46 15.66 - - - - 155.4 
20 1.55 23.56 29.83 17.22 - - - - 137.2 
 
The exposure of the bladder cancer cell line NTUB1 to 40 µM of compound 1.40 for 
24 h increased the production of ROS. This increase in ROS was accompanied by an 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
52 
 
increase in the number of cells in the G1 phase and in apoptosis induction.
282
 BGC-823 
stomach cancer cells treated with compound 1.54 showed an accumulation of cells in the 
sub-G1 phase, upregulation of caspase 3 and downregulation of Bcl-2 and survivin, 
leading to the induction of the intrinsic apoptotic pathway. Compound 1.54 was tested in 
a mouse model, in which it led to a reduction in tumor growth with low toxicity to the 
hosts.
186
  
The cytotoxicity of compounds 1.56-1.77, which are C28 amide derivatives of 
ursolic acid (Figures 1.3.8-1.3.10), was tested against several cancer cell lines and 
nontumorigenic cell lines (Table 1.3.18).
184, 185
  
 
HO
H
O
R1
H
R1 = NHCH(CH2OH)COOH1.56
R1 = NHCH(CH2C6H4-p-OH)COOH1.57
R1 = NHCH2CH2OH1.58
R1 = N(CH2CH2OH)21.59
R1 =1.60 N N
OH
R1 =1.61 N N
O
OH
N
OH
R1 =1.62
R1 = NHCH(CH2OH)COOCH31.63
R1 = NHCH(CH2C6H4-p-OH)COOCH31.64
R1 = NHCH2CH2OH1.65
R1 = N(CH2CH2OH)21.66
R1 =1.67 N N
OH
R1 =1.68 N N
O
OH
N
OH
R1 =1.69
R1 =1.70 F
F
NHCH2
R1 =1.71 N ONH(H2C)2CH2
AcO
H
O
R1
H
 
 
Figure 1.3.8. Schematic representation of ursolic acid amide derivatives 1.56-1.71. 
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Compound 1.66 induced apoptosis and cell cycle arrest at the S phase in Hep G2 
cancer cells in a time- and dose-dependent manner, with increase in the activity of 
caspase 3. Compared with the control group, an anti-tumor effect as observed in 
Kunming mice treated with compound 1.66.
184
 
 
AcO
H
O
R1
H
O
R1 = NHC6H51.72
R1 = NHCH(CH3)CH2OH1.73  
 
Figure 1.3.9. Schematic representation of ursolic acid amide derivatives 1.72 and 1.73 which 
have an α,β unsaturated ketone in ring C. 
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O
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Figure 1.3.10. Schematic representation of ursolic acid amide derivatives 1.74-1.77. 
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Table 1.3.18. IC50 (µM) for compounds 1.56-1.77 in ovary (SKOV3), liver (Hep G2), 
stomach (BGC-823), neuroblastoma (SH-SY5Y) and cervix (HeLa) cancer cell lines, and 
in a nontumorigenic cell line (HELF). 
Entry Compd 
Cell lines 
SKOV3 Hep G2 BGC-823 SH-SY5Y HeLa HELF 
1 1.56 - 83.03 79.30 72.21 41.65 60.33 
2 1.57 - >100 >100 >100 >100 >100 
3 1.58 - 82.36 78.26 65.01 32.33 52.75 
4 1.59 - 35.66 39.27 21.38 14.36 36.92 
5 1.60 - >100 98.26 >100 52.33 32.75 
6 1.61 - 36.71 35.04 30.28 23.78 28.06 
7 1.62 - >100 >100 >100 67.29 >100 
8 1.63 - 35.36 29.01 37.18 20.61 22.34 
9 1.64 - >100 82.95 >100 66.67 35.81 
10 1.65 - 46.62 48.47 49.41 16.27 27.82 
11 1.66 - 20.25 15.52 13.24 10.87 38.06 
12 1.67 - 20.46 13.86 11.70 7.24 31.04 
13 1.68 - 15.26 12.83 9.51 6.28 38.92 
14 1.69 - 59.38 51.34 40.12 12.43 30.02 
15 1.70 >10 - >10 - >10 - 
16 1.71 7.40 - 4.46 - 2.71 - 
17 1.72 >10 - >10 - >10 - 
18 1.73 >10 - >10 - >10 - 
19 1.74 - - 5.63 - >10 - 
20 1.75 >10 - >10 - >10 - 
21 1.76 >10 - >10 - >10 - 
22 1.77 >10 - >10 - >10 - 
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Compounds 1.78-1.83, with modifications at carbon C3 (Figure 1.3.11), have diverse 
cytotoxic activities (Table 1.3.19).
197, 282
 Compound 1.82 was the most active in 
inhibiting the growth of bladder cancer cells.
282
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H
O
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R1 = COCH2CH2(CH3)21.81
R1 = COCH2CH2COOH1.82
R1 =1.83
N
COCHCH
 
 
Figure 1.3.11. Schematic representation of derivatives of ursolic acid.  
 
Table 1.3.19. IC50 (µM) for compounds 1.78-1.83 in bladder 
(NTUB1) and colorectal (HT-29) tumor cancer cells. 
Entry Compd 
Cell line 
NTUB1 HT-29 
1 1.78 >30 - 
2 1.79 >30 - 
3 1.80 11.94 - 
4 1.81 30.98 - 
5 1.82 8.65 - 
6 1.83 - 45 
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Some researchers have synthesized a series of new ursolic acid derivatives with an 
open and modified ring A (Figure 1.3.12). The cytotoxicity of compounds 1.85-1.87 and 
1.91 was tested against NRP.152 prostate cells. Compounds 1.85 and 1.86 had an IC50 
greater than 5.0 µM and compounds 1.87 and 1.91 had an IC50 of 2.4 µM and 0.3 µM, 
respectively.
303
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Figure 1.3.12. Schematic representation of ursolic acid derivatives with an open ring A. 
 
The cytotoxicity of compounds 1.84 and 1.88-1.90 (Figure 1.3.12) was tested against 
NTBU1 bladder cancer cells. Compounds 1.84 and 1.88 presented an IC50 greater than 30 
µM and compounds 1.89 and 1.90 presented an IC50 of 25.49 and 15.63 µM, respectively. 
Compound 1.89 induced apoptosis and cell cycle arrest at the G2/M phase through the 
increase of ROS production.
282
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Aromatase is a key enzyme for the development of breast and prostate hormone-
dependent cancers. Ursolic acid inhibits this enzyme (IC50 32 µM). Compounds 1.86 
(Figure 1.3.12) and 1.92-1.96 (Figure 1.3.13) were tested for the inhibition of aromatase, 
which revealed an IC50 around 500 µM for these compounds.
241
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Figure 1.3.13. Schematic representation of compounds 1.92-1.96. 
 
The combination of ursolic acid with oxaliplatin (compound 1.97), a 
chemotherapeutic drug in clinical use, exhibited cytotoxic activity against HT-29 cancer 
cells (Figure 1.3.14).
304
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Figure 1.3.14. Schematic representation of compound 1.97 and oxaliplatin 1.98. 
 
1.3.4. Oleanolic acid 
 
Oleanolic acid is a pentacyclic triterpenoid that can be found in the form of free acid 
or aglycones in various medicinal plants and fruits.
77, 175
 Oleanane triterpenoids are a 
wide group that is present in nature and includes oleanolic acid (3β-hydroxy-olean-12-en-
28-oic acid), maslinic acid (2α,3β-dihydroxyolean-12-en-28-oic acid), morolic acid (3β-
hydroxyolean-18-en-28-oic acid), moronic acid (3-oxoolean-18-en-28-oic acid) and 
others (Figure 1.3.15). 
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Figure 1.3.15. Oleanolic acid and some of its natural analogues. 
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Oleanolic acid was first considered inactive; however, in the past two decades it 
attracted interest because of its pharmacological effects combined with a low toxicity.
173, 
305
 Oleanolic acid has demonstrated antibacterial, antiparasitic, antiosteoporotic, 
antifertility, antihypertensive, antihyperlipidemic, diuretic, antidiabetic, 
immunomodalator, anti-inflammatory, inhibitory of complement pathway, 
antinociceptive, gastroprotective, hepatoprotective and anti-HIV activities.  
 
1.3.4.1.  General activities 
 
Nosocomial infections, which are caused by resistant or multiple-resistant bacteria, 
are a serious public health problem. Oleanolic acid has demonstrated activity against 
some bacteria that are responsible for these infections (Table 1.3.20).
92, 102, 306
 
Tuberculosis is responsible for a high number of deaths. Oleanolic acid was tested against 
Mycobacterium tuberculosis H37Ra and M. tuberculosis H37Rv and exhibited a MIC of 50 
µg/mL and 30 µg/mL, respectively.
80, 101
 Oleanolic acid was also active against 
Streptococcus mutans (MIC 625 µg/mL) and Porphyromonas gingivalis (MIC 488 
µg/mL), two strains that are responsible for caries and periodontal disease.
307
 
Leishmaniasis affects millions of people worldwide and its treatment is based in 
pentavalent antimonials, which are toxic and prone to drug resistance.
83
 Oleanolic acid 
has the ability to inhibit the promastigote and amastigote growth of Leishmania amazonis 
with an IC50 of 10 µg/mL and 27 µg/mL, respectively, because of a direct effect on L. 
amazonis.
83
 The anti-parasitic activity of oleanolic acid against promastigotes of L. 
infantum and L. amazonensis was higher than 25 µg/mL.
107
  
Several diseases are transmitted by insects and are responsible for losses in cereal 
and vegetable cultures despite the current use of insecticides. Oleanolic acid has 
insecticidal and anti-feedant effects on Stiphilus oryzae insects.
308
 
 
The therapeutic approach for the treatment of HIV includes nucleoside analogue HIV 
RT inhibitors, non-nucleoside RT inhibitors and protease inhibitors. Oleanolic acid 
inhibits HIV replication with an EC50 of 3.7 µM and a therapeutic index (IC50/EC50) of 
12.8.
110, 309, 310
 The anti-HIV activity of oleanolic acid is due to its activity as an inhibitor 
of HIV protease.
111, 311
 Oleanolic acid was also shown to have inhibitory activity (with 
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and IC50 of 56.5 µM) on the hepatitis C viral protease, which is an important enzyme for 
the maturation of the virus and for the progression of hepatitis C.
312, 313
 
 
Table 1.3.20. Values of MIC (μg/mL) for oleanolic acid against several strains of 
bacteria. 
a) Amoxicillin; b) Oxacillin; c) Vancomycin; d) Ticarcillin; e) Ampicillin. 
 
Osteoporosis is a disease that is characterized by low bone mineral density and 
structural deterioration of bone tissue.
116
 The anti-osteoporotic effect of oleanolic acid is 
Entry Bacteria 
MIC (µg/mL) 
Ref. Oleanolic 
acid 
Reference 
antibiotic 
1 E.coli ATCC 25922 >256/95 4
a
/- 
102, 306
 
2 S.aureus ATCC 25923 8/95 <1
b
/- 
102, 306
 
3 S.aureus ATCC 29213 8/>95 <1
b
/- 
102, 306
 
4 E.fecalis ATCC 29212 4 <1
c
 
102
 
5 P.aeruginosa ATCC 27853 256 16
d
 
102
 
6 Penicillinase-producing E.coli >256 >256
a
 
102
 
7 MRSA (mecA gene) >256 256
b
 
102
 
8 E.faecium (vanB gene) >256 64
c
 
102
 
9 E.fecalis (vanA gene) >256 256
c
 
102
 
10 
P.aeruginosa  
(overexpression of efflux pumps) 
>256 64
d
 
102
 
11 E.faecium FN-1 8 128
e
 
92
 
12 E.faecium BM4147 8 32
e
 
92
 
13 E.faecalis NCTC 12201 8 4
e
 
92
 
14 E.faecalis FA2-2 8 4
e
 
92
 
15 S.pneumoniae R6 16 0.06
e
 
92
 
16 S.aureus OM481 16 64
e
 
92
 
17 S. aureus OM584 16 64
e
 
92
 
18 E.coli K12 >128 - 
92
 
19 P.aeruginosa PAO1 >128 - 
92
 
20 S.marcescens NUSM8905 >128 - 
92
 
21 Salmonella typhimurium 65 - 
306
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related with its inhibitory capacity regarding the formation of osteoclast-like 
multinucleated cells (OCLs), with a 27.6% inhibition relative to the control.
314
 
 
The anti-fertility activity of oleanolic acid was evaluated in male albino rats. Its 
administration for 60 days decreased the fertilizing capacity of the animals via the arrest 
of spermatogenesis, without significant side effects.
315
 
 
The gastroprotective effects of oleanolic acid were tested in five induced gastric 
ulceration mouse models (Table 1.3.21).
316-318
  
 
Table 1.3.21. Protective effects of oleanolic acid in five models of gastric ulceration 
in the mouse. 
a) Ranitidine; b) Omeprazol.  
 
The lesions caused by acetic acid were analyzed histologically, which showed that 
oleanolic acid leads to the regeneration of the lesions and produces an increase in gastric 
mucosal thickness.
317
 The gastroprotective activity of oleanolic acid can be due to its 
ability to accelerate cell proliferation in MRC-5 fibroblasts and to increase the content of 
prostaglandins.
319
 
Entry 
Ulceration 
model 
Control Oleanolic acid 
Ref. Dose 
(mg/kg) 
Ulceration 
index (mm
2
) 
Dose 
(mg/kg) 
Ulceration 
index (mm
2
) 
1 Aspirin 50
a
 35.8 50 40.7 
316
 
2 
Ethanol 
50
b
 60.0 50 86.2 
318
 
3 20
b
 40.6 50 60.6 
316
 
4 Indometacin 20
b
 0.3 50 14.0 
318
 
5 Acetic acid 50
a
 6.9 50 17.8 
317
 
6 
Pylorus 
ligature 
50
a
 50.2 50 62.0 
316
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Oleanolic acid has cardiovascular protective and regulatory effects in in vitro and in 
vivo models. An in vitro study showed that oleanolic acid was able to improve the 
balance of vasodilator/anti-aggregant vs. vasoconstrictor/prothrombotic eicosanoids in 
human coronary smooth muscle cells (SMCs) via the activation of the MAPK/Erk kinase 
(MEK) 1/2 and p38 MAPK pathways, leading to an increase in the activity of COX-2, 
which results in an increase in prostaglandin I2 release.
320
  
Oleanolic acid prevents the development of severe hypertension through a potent 
diuretic-natriuretic-saluretic activity, the decrease in heart rate, an anti-hyperlipidemic 
effect, an antioxidant effect via increase of glutathione peroxidase (GPx) and superoxide 
dismutase activities and hypoglycemic activity in Dahl salt-sensitive rats.
119
 Oleanolic 
acid also displays dose-dependent vasodepressor and an anti-dysrhythmic effects.
120
 
Oleanolic acid exhibits a moderate diuretic effect compared with furosemide, which is a 
diuretic used clinically for the treatment of hypertension.
321
 Oleanolic acid induces 
arterial vasorelaxation through a calcium-independent pathway, with activation of the 
PI3K/Akt pathway, which leads to the phosphorylation of endothelial NO synthase and 
production of NO.
322
  
Oxygen-derived free radicals are involved in the pathogenesis of myocardial 
ischemia-reperfusion (I-R) injury.
323
 Pretreatment of rats with oleanolic acid conferred 
cardioprotection against I-R injury through the increase of GSH status in mitochondria 
and stimulation of the synthesis and regeneration of GSH and α-tocopherol.324 
 
Atherosclerosis remains the main cause of cardiovascular diseases. Oxidative stress 
is a characteristic of atherosclerosis and is responsible for the migration, proliferation and 
apoptosis of VSMCs. Treatment of VSMCs with oleanolic acid led to the upregulation of 
hemo oxygenase-1 through the activation of the Nrf2 pathway via the PI3K/Akt and ERK 
pathways.
325
 Apoliprotein E knockout (ApoE
–/–
) mice treated with oleanolic acid exhibit 
a decrease in plaque formation.
326, 327
 
 
Type 2 diabetes is associated with disorders of glucose metabolism. An ideal 
antidiabetic agent should be able to lower blood glucose in both the fed and fast states.
328
 
Several enzymes are involved in the regulation of glucose blood levels. Glycogen 
phosphorylase is the enzyme that is responsible for glycogen breakdown, to produce 
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energy.
329
 Oleanolic acid is a natural inhibitor of glycogen phosphorylase (IC50 14 
µM).
328-330
 Tyrosine phosphatase 1B is involved in the process of dephosphorylation of 
the insulin receptor; as it regulates the insulin pathway, oleanolic acid is a competitive 
inhibitor of this enzyme, with an IC50 of 3.4 µM.
331
 α-Glucosidase hydrolyses the 
cleavage of glucose from disaccharides and oligosaccharides; the inhibition of this 
enzyme delays carbohydrate digestion, causing a reduction in the postprandial rise in 
blood glucose. Oleanolic acid inhibits this enzyme with an IC50 of 11.2 µM.
332
 
Oleanolic acid can reduce the levels of blood glucose in alloxan- and streptozotocin-
induced diabetes in animal models.
333-335
 The antiglicative effects of oleanolic acid in 
streptozototocin-induced diabetic mice are accompanied by a beneficial effect on kidney 
function.
142, 336
 Diabetic streptozotocin-induced mice transplanted with Balb/c islets for 
the treatment of diabetes and treated simultaneously with oleanolic acid have a faster 
improvement of glucose levels and a decrease in pro-inflammatory cytokines, thus 
delaying the immune responses against the islets.
337
 
 
Obesity is a gobal concern as it can increase the predisposition to several diseases.
125, 
126
 Oleanolic acid treatment in high-fat fed mice decreased the levels of serum glucose, 
insulin, cholesterol and triglycerides and the accumulation of visceral fat.
338, 339
 The 
reduction in the accumulation of visceral fat can be due to the decrease of ghrelin, a 
hormone that is secreted in the stomach and has apetite-stimulating activity, and the 
increase in leptin secretion, a hormone that suppresses food intake.
338
 Oleanolic acid is an 
agonist of TGR5 and, when stimulated, leads to an increase in energy expenditure, thus 
preventing the development of insulin resistance and the accumulation of visceral fat.
339
 
 
Ischemic stroke can result from a transient or permanent reduction in cerebral blood 
flow.
340, 341
 Oleanolic acid protects neuronal cells from induced death by oxygen peroxide 
via a reduction in the intracellular levels of Ca
2+
 and ROS, thus having a neuroprotector 
effect.
342
 In a mouse model, oleanolic acid reduced cerebral ischemic damage as it 
reduced the infarcted area and the cerebral edema, prolonging the survival time of the 
animals. In vitro studies have demonstrated that oleanolic acid reduces the oxidative 
damage induced by treatment with oxygen peroxide in PC12 cells.
343
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Multiple sclerosis is an autoimmune/inflammatory degenerative disease of the central 
nervous system (CNS).
344
 Oleanolic acid is able to ameliorate the neurological signs of 
multiple sclerosis by inhibiting the action of the inflammatory and humoral components 
of the disease in an experimental allergic encephalomyelitis mouse model.
345
  
Oleanolic acid has the capacity to modulate the immune system. Its administration to 
Balb/c mice increased the total number of white blood cells, bone marrow cells and α-
esterase cells, as well as the production of specific antibodies and the percentage of 
plaque-forming cells in the spleen and inhibited the delayed-type hypersensitive reaction 
by 88%.
149
 The transcription factor “nuclear factor of activated T cells” (NFAT) is 
excessively activated in immunopathological reactions, including autoimmune 
diseases.
346
 
346
 Oleanolic acid has the ability to inhibit NFAT with an IC50 greater than 50 
µM.
347
 
 
The antinociceptive effect of oleanolic acid was evaluated in acute nociception 
induced by intraplantar injection of capsaicin and intracolonic injection of mustard oil in 
mice. Oleanolic acid exerts it antinociceptive action through an opioid mechanism 
involving NO production and activation of ATP-gated K
+ 
channels.
348, 349
 
 
Oleanolic acid protects against the hepatotoxicity of carbon tetrachloride in mice, in 
a dose-dependent manner.
350-352
 Oleanolic acid pretreatment induces an increase in ALT 
levels and in GSH regeneration capacity.
353
 It also decreases the levels of lactic 
dehydrogenase, cytochrome P450 2E1-dependent p-nitrophenol hydroxylation, aniline 
hydroxylation 
354
 and γ-glutamyltransferase, while maintaining the levels of glutathione 
redutase, catalase, superoxide dismutase, glutathione S-transferase and GPx.
355
 
Pretreatment of rats and mice with oleanolic acid decreases serum transaminase, 
aminopyrine N-demethylase and aniline hydroxylase.
355
 Hepatic MT is responsible for 
the acute response to hepatotoxicants and is increased during the pretreatment with 
oleanolic acid in mouse models.
351, 352
  
Oleanolic acid has protective effects on the hepatotoxicity caused by acetaminophen, 
bromobenzene, thioacetamide, furosemide, phalloidin, colchicines, D-galactosamine, 
endotoxin and cadmium.
350, 352
 Pretreatment with oleanolic acid in a mouse model with 
hepatotoxicity induced by acetaminophen leads to a decrease in the liver injury.
356
 
1. Introduction 
65 
 
Oleanolic acid treatment facilitates Nrf2 accumulation, which contributes to the 
hepatoprotection against acetaminophen, carbon tetrachloride, cadmium and 
bromobenzene.
352, 357
 
Cadmium liver injury is reduced in mice pretreated with oleanolic acid, with 
decreased levels of ALT and SDH and increased levels of MT.
352, 358
 In a model of 
toxicity induced by t-butyl hydroperoxide in QZG human liver cells, oleanolic acid 
decreases toxicity through the activation of the JNK and ERK pathways.
359
 Mice treated 
with oleanolic acid and 1-chloro-2,4-dinitrobenzene presented modification in several 
enzymes related with liver function.
360
 
 
The anti-inflammatory activity of oleanolic acid was determined using in vitro and in 
vivo assays. Oleanolic acid has inhibitory effects on TPA-induced inflammation in the ear 
of mice. This effect was also observed in carrageenan, 12-deoxyphorbol-13-phenylacetate 
and dextran rat models.
93, 305, 361-363
 Inflammation is mediated by several enzymes; 
oleanolic acid has the capacity to inhibit COX-1 and COX-2, which are enzymes that are 
related with inflammatory states, at 295 and 380 µM, respectively.
95
 Secretory 
phospholipase A2 (sPA2) is a main enzyme in the mediation of inflammation; oleanolic 
acid inhibits sPA2 with an IC50 from 3.08 to 7.78 µM.
364
  
High mobility group box protein 1 (HMGB1) is a potent pro-inflammatory 
mediator.
365
 In HUVECs, oleanolic acid inhibits the lipopolysaccharide-mediated 
HMGB1 release and the HMGB1-mediated vascular permeabilization through the 
inhibition of CAM expression and reduction in monocyte adhesion and migration.
366
  
The classical pathway of the complement system is part of the inflammatory process. 
Oleanolic acid has the capacity to inhibit the complement pathway with an IC50 of 72.3 
µM.
367, 368
 C3-convertase is one of the enzymes involved in the classical complement 
pathway; oleanolic acid inhibits this enzyme at 219 µM.
369
  
 
1.3.4.2.  Antitumor activity 
 
The main studied activities of oleanolic acid are its antitumoral and chemopreventive 
activities. Because of them, oleanolic acid has been described in pharmaceutical 
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preparations for the treatment of nonlymphatic leukemia and is recommended in Japan 
for use in skin cancer therapy.
370
  
 
Oral and esophageal cancers represent 3.5% of the estimated new cases of cancer in 
2011.
5
 Oleanolic acid is cytotoxic against oral and esophageal cancers (Table 1.3.22, 
entries 1-3). Co-treatment of YES-2 cancer cells with oleanolic acid and 5-fluorouracil or 
cisplatin has additive or antagonist effects, respectively.
100
 
 
Hepatocellular carcinoma lacks chemotherapeutic options; thus, the demand for new 
chemotherapeutic drugs is a reality. Oleanolic acid has cytotoxic activity in several 
hepatocarcinoma cell lines (Table 1.3.22, entries 4-10). Oleanolic acid has been proven to 
induce the activation of caspases 8 and 3 in Hep G2, Hep3B, Huh7 and HA22T cells,
212, 
215, 223
 with a consequent increase in the number of cells in the G1 phase of the cell 
cycle,
215
 loss of mitochondrial membrane potential,
212
 downregulation of XIAP and Bcl-2 
and upregulation of Bax.
223
 
 
Colorectal cancer is the third most common cancer in both men and women.
5
 
Chemoprevention has the aim of blocking, inhibiting or reversing some aspects of 
carcinogenesis. ACF induced by azoxymethane are considered as preneoplasic lesions 
and biomarkers of colon cancer. Oleanolic acid has the ability to reduce the incidence of 
azoxymethane-induced ACF in F344 rats.
371, 372
 The reduction of the incidence of ACF 
by oleanolic acid was correlated with the inhibition of COX-2 and iNOS
371
 and a 
decrease of cells in the S phase.
372
 Oleanolic acid has the ability to reduce the incidence 
of 1,2-dimethyl-hydrazine-induced ACF in rats.
190
 
Oleanolic acid has demonstrated cytotoxic activity in vitro against colorectal cancer 
cells (Table 1.3.22, entries 11-15). In HT-29 cancer cells, oleanolic acid induces 
apoptosis, with the activation of the intrinsic pathway through the production of ROS.
373, 
374
 The induction of cell death by oleanolic acid is observed in HCT15 colorectal cancer 
cells, with a decrease of cells in the S phase and an increase of cells in the G0/G1 
phase.
198
 
AKR1B10 is an aldo-keto reductase that is overexpressed in several carcinomas and, 
when silenced in xenograph mouse models, leads to a reduction in the growth of the 
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tumor.
375, 376
 It has been suggested that the AKR1B10 enzyme is involved in the 
development of mitomycin C resistance in human colorectal cancers.
377
 Oleanolic acid 
inhibits AKR1B10 with an IC50 of 0.09 μM by binding to the substrate site of the enzyme 
in a selective manner.
378
 
 
Table 1.3.22. IC50 (µM) for oleanolic acid in oral, esophageal, liver and colorectal 
carcinomas cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Oral carcinoma 
1 HSC-2 285.0 MTT 24 
179
 
2 HSG 503.6 MTT 24 
179
 
Esophageal carcinoma 
3 YES-2 100-125 WST-8 48 
100
 
Liver carcinoma 
4 
HuH7 
100 MTT 24 
223
 
5 >8 MTT 48 
212
 
6 
Hep G2 
17.5 MTT 72 
237
 
7 70 Trypan Blue 72 
215
 
8 4-8 MTT 48 
212
 
9 H22T 4-8 MTT 48 
212
 
10 Hep3B >8 MTT 48 
212
 
Colorectal carcinoma 
11 
HT-29 
26.6 Sytox-Green 72 
374
 
12 160 Sytox-Green 72 
373
 
13 
HCT15 
26.5 - 48 
203
 
14 60 MTT 72 
198
 
15 
HT-29 
mitomycin  
C-resistant 
180 Tryptan Blue 96 
378
 
 
Breast cancer is the most common cancer in women and is responsible for the 
greatest number of cancer-related deaths.
4, 5
 Oleanolic acid can induce cell death in breast 
cancer cells lines (Table 1.3.23, entries 3-10), including breast cancer multi-drug resistant 
cells (Table 1.3.23, entries 8 and 9). Oleanolic acid induction of cell death in MCF-7 
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breast cancer cells is related with the inhibition of cell cycle progression at the G0/G1 
checkpoint, with inhibition of DNA replication.
379
 
 
Table 1.3.23. IC50 (µM) for oleanolic acid in ovary and breast carcinoma cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Ovary carcinoma 
1 SK-OV-3 27.2 - 48 
203
 
2 A2780 23.4 - - 
233
 
Breast carcinoma 
3 
MCF-7 
28 MTT 72 
206
 
4 >100 XTT 24 
379
 
5 263 MTT 72 
236
 
6 213 MTT 72 
380
 
7 5.38 MTT - 
381
 
8 
MCF-7/ADR 
44 MTT 72 
206
 
9 37.02 MTT - 
381
 
10 MDA-MB-231 >50 SRB 24 
239
 
 
Breast cancer cells without expression of estrogen and prostagen receptors and 
amplified expression of HER2 are less differentiated, more aggressive and do not respond 
to the available therapies. Oleanolic acid has the ability to target specifically and 
effectively estrogen-receptor-negative breast cancer cells. In MCF-7, Hs578T and MDA-
MB-231 cells, oleanolic acid disrupts the cholesterol synthetic pathway, interfering with 
the lipid rafts and leading to the decrease in the activity of mTOR complex 1 and mTOR 
complex 2, thus inhibiting the Akt pathway.
382
  
 
The cytototoxic effects of oleanolic acid treatment in MG63 and Saos-2 
osteosarcoma cells (Table 1.3.24, entries 1 and 2) are due to the downregulation of 
mTOR complex 1 and mTOR complex 2, with cell cycle arrest at the G1 phase and 
downregulation of cyclin D1.
383
 
 
Lung cancer is the number one cause of cancer-related deaths; therefore, new 
chemotherapeutic agents are needed for this disease.
5
 Oleanolic acid has cytotoxic effects 
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against non-small lung cancer cells (Table 1.3.24, entries 4-8). SPC-A-1 cells treated with 
oleanolic acid present a decrease in the levels of Bcl-2 and an increase in the levels of 
Bax and Bad proteins, with induction of apoptosis.
384
 Lung cancer is characterized by the 
presence of MDR proteins that contribute to the poor outcome of this cancer.
385, 386
 
Oleanolic acid induces apoptosis in A549 and H460 lung cancer cells, overcoming the 
natural MDR in these cell lines. Oleanolic acid leads to the downregulation of survivin 
and VEGF and to the upregulation of Bax, but does not inhibit the proteins that are 
responsible for drug resistance.
387
 
 
Table 1.3.24. IC50 (µM) for oleanolic acid in osteosarcoma, lung and skin cancer cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Osteosarcoma 
1 MG63 75 MTT 72 
383
 
2 Saos-2 50 MTT 72 
383
 
3 LM-8 >100 MTT 48 
388
 
Lung carcinoma 
4 
A549 
35.9 - 48 
203
 
5 >100 MTT 48 
389
 
6 88-100 MTT 48 
387
 
7 SPC-A-1 16-32 MTT 48 
384
 
8 H460 55-88 MTT 48 
387
 
Skin carcinoma 
9 SK-MEL-3 40.5 - 48 
203
 
10 B16 F10 >100 MTT 48 
390
 
11 B16 2F2 3.1 - 72 
259
 
 
TPA is a well know skin tumor inducer in animal models. The topical application of 
TPA induces a series of proteins and genes related with tumor induction and promotion, 
such as ornithine decarboxylase (ODC), MT, c-fos and c-jun. Oleanolic acid prevents 
tumor induction by TPA in mice
257, 391, 392
 through the inhibition of the induction of ODC, 
MT and c-fos.
391
 Oleanolic acid also inhibited tumor growth in a xenograph mouse model 
of melanoma cancer 
393
 and reduced the development of lung metastasis in an in vivo 
model of melanoma cancer.
387
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Oleanolic acid has cytotoxic properties towards skin cancer cells (Table 1.3.24, 
entries 9-11). Oleanolic acid induces apoptosis in B16 F10 cells via the activation of p53 
and consequent upregulation of Bax, p21 and p27 and inhibition of the NF-κB-induced 
Bcl-2 pathway.
390
 
 
Table 1.3.25. IC50 (µM) for oleanolic acid in leukemia, lymphoma and neuroblastoma cancer 
cell lines. 
Entry Cell line IC50 (µM) Assay Time (h) Ref. 
Leukemia 
1 
K562 
33 MTT 72 
206
 
2 100
a
 TB 24 
276
 
3 K562/ADR 43 MTT 72 
206
 
4 
HL60 
30 MTT 72 
206
 
5 8.9 NBT 72 
394
 
6 70.6 Trypan blue 24 
277
 
7 40
a
 TB 24 
276
 
8 237.4 XTT 72 
279
 
9 HL60/ADR 32 MTT 72 
206
 
10 
L1210 
27.6 XTT 48 
278
 
11 32.3 Trypan blue 24 
277
 
12 8
a
 TB 24 
276
 
Lymphoma 
13 P3HR1 58.6 XTT 72 
279
 
14 U937 80.3 XTT 72 
279
 
Neuroblastoma  
15 XF498 >60 - 48 
203
 
16 1321N1 25 
[
3
H] thymidine 
uptake 
24 
395
 
a) Value for IC80 
 
Oleanolic acid induces cell death in leukemic and lymphatic cells, in a dose-
dependent manner (Table 1.3.25, entries1-14). Oleanolic acid can induce apoptosis and 
cell cycle arrest at the G2/M phase in L1210 leukemic cells, and G0/G1 cell cycle arrest 
in HL60 cancer cells with induction of apoptosis.
396
 The combination of oleanolic acid 
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and doxorubicin increases synergistically the effects on the differentiation of L120 and 
HL60 cells lines.
277
 The differentiation effects of oleanolic acid were observed in the M1 
leukemia cell line.
397
 Oleanolic acid induces an increase in apoptosis in the K562 cell line 
and in the Lucena 1 cell line, a vincristine-resistant cell line, overcoming the 
overexpression of the Pgp protein.
398
 Oleanolic acid inhibits the multidrug resistance 
protein (ABCC1), but has no effect on the Pgp protein.
399
 The cytotoxic effect of 
oleanolic acid in multi-drug resistant cell lines was verified in HL60/ADR and 
K562/ADR cancer cells (Table 1.3.25, entries 3 and 9).
206
  
 
Oleanolic acid has the ability to induce cytotoxicity and apoptosis in several 
neuroblastoma cells (Table 1.3.25, entries 15 and 16). The induction of apoptosis in 
1321N1 cancer cells by oleanolic acid is due to the generation of ROS, disruption of the 
mitochondrial membrane potential and cytoskeleton alterations.
395
 Oleanolic acid inhibits 
the proliferation of U373 human glioma cells through the inhibition of the activation of 
STAT 3.
400
 
 
Chemotherapeutic drugs that are DNA damaging agents are used currently in clinical 
practice. DNA polymerase β is a key enzyme involved in DNA repair and is responsible 
for some resistance to chemotherapeutic drugs that induce DNA damage.
401, 402
 Oleanolic 
acid is an inhibitor of DNA polymerase β in the presence or absence of bovine serum 
albumin (BSA), with an IC50 of 7.5 μM and 3.7 μM, respectively.
403, 404
 The activity of 
DNA polymerase β can be divided in lyase and polymerase activities, oleanolic acid can 
inhibit both of the two activities with IC50s of 26.25 μM and 24.98 μM, respectively.
389
  
DNA ligase is responsible for the joining of single-stranded breaks in double-
stranded DNA and is involved in DNA replication, repair and recombination.
405, 406
 
Oleanolic acid inhibits DNA ligase with an IC50 of 216 μM.
407
 
 
Oleanolic acid has antimutagenic activity in γ irradiation-, doxorubicin- and oxygen 
peroxide-induced toxicity in the mouse hematopoietic system and leukemic cells.
276, 290, 
291
 This antimutagenic effect of oleanolic acid is probably due to its antioxidant effect.
276, 
408
 Oleanolic acid can, therefore, be used as a chemopreventive agent, to reduce the 
severe side effects of common chemotherapeutic drugs.  
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Angiogenesis is the basis of solid tumor growth and dissemination and results from 
several steps, each one representing a potential target for antiangiogenic drugs. Oleanolic 
acid inhibits angiogenesis in a dose-dependent manner, as it has inhibitory effects on 
embryonic angiogenesis in chick embryo chorioallantoic membranes and on the 
proliferation of vascular endothelial cells.
284
 Angiogenesis is regulated by several factors, 
such as VEGF, IL-8, HIF-1α, ROS, NO, uPA and the basic fibroblast growth factor 
(bFGF). Hepatic cancer cells Hep3B, Huh7 and HA22T treated with lower concentrations 
of oleanolic exhibit suppression of the expression of HIF-1α, VEGF, IL-8 and uPA and 
lower levels of ROS and NO production, leading to a decrease in the invasion and 
migration potential of these cells.
289
 
 
1.3.4.3.  Semisynthetic derivatives with antitumor activity 
 
Several semisynthetic derivatives of oleanolic acid have been described. The 
chemical modifications made in the oleanane structure are located mainly at carbons C2, 
C3, C11, C12 and C28. 
Honda et al first synthesized a series of oleanolic acid derivatives (some are 
represented in Table 1.3.26) and evaluated their inhibitory action on the production of 
NO by mouse macrophages.
293-295, 409, 410
 NO is an important molecule in physiological 
and pathological processes. At low concentrations, it promotes tumor growth, as it 
mediates DNA repair, angiogenesis and stimulates prosurvival pathways; at higher 
concentrations, it promotes tumor death and regression, as it stimulates DNA damage and 
apoptosis.
411, 412
 
 
 
 
Table 1.3.26. IC50 (µM) of oleanolic acid derivatives for the inhibition of the production of 
NO in mouse macrophages. 
C28
H
HA
C
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Entry Compd Ring A Ring C C28 IC50 (µM) 
1 1.99 
HO
  
COOH  >40 
2 1.100 
O
  
COOH  37.1 
3 1.101 
O
 
 
COOH  5.6 
4 1.102 
O
 
O
 
COOH  3.3 
5 1.103 
O
 
O
 
COOH  1.4 
6 1.104 
O
NC
 
O
 
COOMe  0.2 
7 1.105 
NC
O
 
O
 
COOH  0.02 
8 1.106 
O
 
O
 
COOH  0.04 
9 1.107 
NC
O
 
O
 
COOH  0.0002 
10 1.108 
NC
O
 
O
 
COOMe  0.0001 
11 1.109 
HOOC
O
 
O
 
COOMe  0.0008 
12 1.110 
HOOC
O
 
O
 
COOH  0.2 
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From the first series of oleanolic acid derivatives evaluated, the following structure 
activity relationships were concluded: a) in ring A, a 1-en-3-one functionality combined 
with an electron-withdrawing group, such as the carbonyl or nitrile at C2, increases 
activity; b) in ring C, the 9-en-12-one functionality increases the activity of these 
compounds the most; c) the influence of the group at C28 is unclear, as only a free 
carbonyl and a methoxy groups were tested. 
To elucidate the influence of the substituent at carbon C28, a series of new 
compounds were synthesized, following the previous SAR conclusions and using 
compound 1.107 as an outline model (Table 1.3.27).
413
  
 
Table 1.3.27. IC50 (µM) of oleanolic acid derivatives for the inhibition of the production of NO 
in mouse macrophages. 
R1
O
H
H
R2
O
 
Entry Compd R1 R2 IC50 (nM) 
1 1.111 CN  CN  0.0035 
2 1.112 CN  COOH  1.68 
3 1.113 COOEt  CN  0.8 
4 1.114 COOEt  COOH  7.93 
5 1.115 CHO2CH2CH CH2  CN  1.33 
6 1.116 CO2(CH2)3CH3  CN  6.65 
7 1.117 
O2C  
CN  4.45 
8 1.118 CO2CH2Ph  CN  4.35 
9 1.119 CO2(CH2)7CH3  CN  60.4 
10 1.120 CO-D-Gluc(OAc)4  CN  0.07 
11 1.121 CO-D-Gluc  CN  10.1 
12 1.122 CONH2  CN  0.098 
13 1.123 CONHNH2  CN  0.26 
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14 1.124 CONHMe  CN  0.58 
15 1.125 CONH(CH2)2CH3  CN  1.5 
16 1.126 CONH(CH2)5CH3  CN  14.9 
17 1.127 CONHPh  CN  28.6 
18 1.128 CONHCH2Ph  CN  9.2 
19 1.129 CONMe2  CN  1.55 
20 1.130 CON(n-Pr)2  CN  32.9 
21 1.131 CON
 
CN  0.8 
22 1.132 CON
 
CN  0.95 
23 1.133 NCON
 
CN  1.0 
24 1.134 CON O
 
CN  2.4 
25 1.135 CON N
 
CN  0.014 
26 1.136 
CON
N  
CN  12.0 
 
Among the compounds synthesized, CDDO 1.107 (Table 1.3.26, entry 9), CDDO-
Me 1.108 (Table 1.3.26, entry 10), CDDO-CN 1.111 (Table 1.3.27, entry 1) and CDDO-
Im 1.135 (Table 1.3.27, entry 25) were the most studied.
172, 414, 415
 CDDO-Me 1.108 is 
currently in phase II of a clinical trial for the treatment of chronic renal inflammation in 
patients with type 2 diabetes.
416
 
Compound 1.100 was evaluated further in other cell lines (Table 1.3.28).
303, 417
 This 
compound presents a good in vitro cytotoxic acitivity. In vivo, it was specifically 
cytotoxic in a melanoma model; this effect was probably due to the induction of 
differentiation of melanoma cells through an increase in the production of melanin and by 
the inhibition of topoisomerase I.
417
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Table 1.3.28. IC50s (μM) for compound 1.100 in several cell lines. 
Entry Cell line Cell type IC50 (μM) 
1 Ketr-3 Human renal carcinoma 37.1 
2 B16 BL6 Highly metastic mouse melanoma 23.7 
3 KB Human mouth squamous carcinoma 14.3 
4 KB/V 
Viscristin- human mouth squamous 
carcinoma 
25.5 
5 HCT-8 
Human intestine ileocecal 
adenocarcinoma 
11.6 
6 PC-3M 
Human prostate carcinoma  
(highly metastic) 
42.8 
7 A549 Human lung carcinoma 6.1 
8 B3T3 Mouse fibroblast cells 39.3 
9 HELF Human embryonic lung fibroblast cells 37.7 
10 NRP.152 Mouse prostate >5 
 
With the aim of stimulating NO production in cancer cells, several derivatives of 
oleanolic acid were synthesized. The activity of compounds 1.137-1.154 (Figure 1.3.16) 
in preventing Fas-mediated apoptosis induction were evaluated in Hep G2 cells; however, 
only compounds 1.138 and 1.140-1.143 were effective. This activity is due to the 
production of small amounts of NO in a p53-independent manner.
418
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Figure 1.3.16. Schematic representation of compounds 1.137-1.154. 
 
The cytotoxic activity of compounds 1.155-1.163 (Figure 1.3.17) was evaluated in 
Hep G2, Hep3b, HeLa, PC-3, MCF-7 and HEK 293 cell lines. Only compounds 1.155-
1.159 and 1.162 presented cytotoxic activity against Hep G2 and Hep3b liver cancer 
cells.
419
 Compound 1.156 exhibited an IC50 of 1.37, 4.78 and 14.5 μM against Hep G2, 
SMMC-7721 and BEL-7402 hepatic carcinoma cell lines, respectively.
420
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O
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O
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O
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O
N
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O
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R= (CH2)2O(CH2)2O
R= (CH2)2NH
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1.158
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1.160
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O
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O
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N
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R= (CH2)4O
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Figure 1.3.17. Schematic representation of compounds 1.155-1.163.  
 
Compounds 1.155-1.159 and 1.162 promoted high levels of NO in hepatocellular 
carcinoma cells in vitro, in a selective manner. This increase in NO concentration is 
likely to be responsible for the cytotoxicity of these compounds. In a mouse model of 
hepatocellular carcinoma, treatment with compounds 1.156 and 1.162 led to a decrease in 
the volume of tumors.
419
  
Compound 1.156 presented some restrictions regarding in vivo administration. With 
the aim of facilitating the administration of compound 1.156, a galactosyl derivative, 
compound 1.64, was synthesized (Figure 1.3.18).
420
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Figure 1.3.18. Schematic representation of compound 1.164. 
 
Compound 1.164 had better solubility than compound 1.156 and was specific and 
strongly cytotoxic against hepatocellular carcinoma. Compound 1.164 presented an IC50 
of 2.13, 1.18 and 2.96 μM for Hep G2, SMMC-7721 and BEL-7402 cell lines, 
respectively. This compound also presented in vivo activity by reducing the volume of 
tumors in a mouse model of hepatocellular carcinoma.
420
  
N-aryl-N’-hydroxyguanidine-based oleanolic acid derivatives, compounds 1.165-
1.172, presented strong selective cytotoxic activity for SMMC-7721 cells, which was 
related with their ability to produce high amounts of NO (Figure 1.3.19).
421
  
 
O
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1.171
1.172  
 
Figure 1.3.19. Schematic representation of compounds 1.165-1.172. 
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Table 1.3.29. Cell viability of B16 cells treated with compounds 1.173-1.186 relative to the 
control (100% of cell viability). 
 
H
H
H
R2O
O
OR1
 
Entry Compd R1 R2 Cell viability (%) 
1 1.173 HNCH2COOH  H  87.2 
2 1.174 HNCH(CH3)COOH  H  82.6 
3 1.175 HNCH(CH(CH3)2)COOH  H  80.9 
4 1.176 
HNCH(CH(CH2CH3)CH3)COOH
 
H  81.0 
5 1.177 HNCH(CH2CH(CH3)2)COOH  H  81.4 
6 1.178 HNCH(CH2Ph)COOH  H  76.4 
7 1.179 
CHCOOHN
 
H  84.6 
8 1.180 HNCH2COOH  Ac  39.6 
9 1.181 HNCH(CH3)COOH  Ac  67.8 
10 1.182 HNCH(CH(CH3)2)COOH  Ac  80.5 
11 1.183 HNCH(CH(CH2CH3)CH3)COOH  Ac  77.5 
12 1.184 HNCH(CH2CH(CH3)2)COOH  Ac  73.0 
13 1.185 HNCH(CH2Ph)COOH  Ac  57.8 
14 1.186 
CHCOOHN
 
Ac  72.3 
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The cytotoxicity of a series of oleanolic acid derivatives conjugated with amino acids 
was evaluated in B16 mouse melanoma cells (Table 1.3.29). Among the compounds with 
an amino methyl esther and an acetoxy group at carbon C3 (compounds 1.180-1.186), 
compound 1.180 was the most active found.
393
 In vitro, compound 1.180 increased the 
number of cells in the G0/G1 phase and decreased the number of cells in the S phase, 
with a decrease in the levels of cyclin D1 and CDK4 and an increase in the levels of p15. 
Compound 1.180 had the ability to inhibit tumor growth in a mouse model, prolonging 
survival time.
393
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Figure 1.3.20. Schematic representation of compounds 1.187-1.191. 
 
Oleanolic acid is a hydrophobic compound. This property can hamper reaching the 
active concentrations needed to overcome this difficulty, a series of quaternary 
ammonium salts of oleanolic acid were synthesized (compounds 1.187-1.191, Figure 
1.3.20). The cytotoxic activity of these compounds was tested in CEM T-lymphoblastic 
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leukemia cells: compound 1.190 was the most active derivative found, with an IC50 of 
10.7 μM.301 
Compound 1.192 (Figure 1.3.21) was cytotoxic against MCF-7, MCF-7/ADR, 
CCRF-CEM, CCRF-VCR100 and MCF10A cell lines, with an IC50 of 4.53, 3.77, 1.69, 
1.56 and 18.36 μM, respectively. The normal cell line MCF10A was more resistant to this 
compound than were the tumor cell lines.
381
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Figure 1.3.21. Schematic representation of compounds 1.192-1.194. 
 
Compound 1.193 (Figure 1.3.21) inhibited the growth of HT-29 cells with an IC50 of 
40 μM, via the inhibition of COX-2 and iNOS, which resulted in apoptosis. In 
azoxymethane-induced ACF rats, treatment with compound 1.193 inhibited the formation 
of ACF by 48% at low concentrations.
371
 
A dextrose-oleanolic acid derivative, compound 1.194, was evaluated for its action in 
osteosarcoma cell lines. It inhibited cell proliferation and induced apoptosis in MG-63, 
U2-OS, HOS and LM-8 cells. This compound also inhibited tumor growth in the C3H 
and LM-8 mouse models of osteosarcoma tumors.
388
  
 
1. Introduction 
83 
 
H
O
OH
H
H
NC
H
O
OH
H
H
HO
O
H
O
OH
H
H
H
O
H
O
OH
H
H
H2N
1.195 1.196
1.197 1.198
 
 
Figure 1.3.22. Schematic representation of oleanolic acid derivatives 1.195-1.198 with an open 
ring A. 
 
A series of oleanolic acid derivatives with an open ring A (Figure 1.3.22) and indole-
fused rings in ring A (Figure 1.3.23) were synthesized. These compounds were evaluated 
for their ability to inhibit the growth of premalignant NRP.152 prostate cells.
303, 422
 
Among the series of open ring A derivatives, compound 1.198 was the more active, with 
an IC50 of 0.7 μM.
303
 The indole-fused ring derivatives of oleanolic acid 1.200 and 1.201 
were the only ones that exhibited some activity against NRP.152 cells (IC50 < 5 μM); the 
remaining compounds were considered inactive (IC50 > 5 μM).
422
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Figure 1.3.23. Schematic representation of oleanolic acid derivatives 1.199-1.205 with indole-
fused ring 
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1.4. General objectives of this thesis 
 
Cancer is the second leading cause of death worldwide, despite the progress in drug 
discovery. The layers of complexity in the biology of cancer and the drug resistance often 
found make the need for new chemotherapeutic drugs with different mechanisms of 
action a current reality.  
 
The recognization of natural triterpenoids, in particular ursane and oleanane type 
pentacyclic triterpenoids, as lead molecules for the design and synthesis of more efficient 
and effective antitumor derivatives propped us to the preparation of new ursolic and 
oleanolic acid derivatives, with better antiproliferative activity than the parental 
compounds. 
 
The introduction of fluorine and heteroaryl rings into the backbone structure of 
biological active molecules has proven to further improve the pre-existent biological 
activity. 
 
With the goal to obtain new pentacyclic triterpene derivatives two synthetic 
strategies were projected. The reaction of alcohols and carboxylic acids with N, N’-
carbonyldiazole type reagents was used aiming the preparation of carbamates, N-
acylimidazoles and N-alkylimidazoles. The reaction of ursane and oleanane type 
triterpenoids with electrophilic and nucleophilic fluorination reagents was made with the 
purpose to synthesize new fluorine derivatives.  
The structural elucidation of the new prepared compounds should be achieved 
through MS, IR and NMR techniques.  
 
The new semisynthetic compounds should be tested for at least one solid tumor 
cancer cell line, in order to stablish an IC50 and to define the structure relantionship 
activity correlation between the different compounds. Based on the SAR findings the best 
compounds should be tested for other cancer cell lines in order to further prove their 
antiproliferative activity.  
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The best compound of each series should be tested for basic mechanisms of 
antitumor activity through the use of FACS and western blot techniques, aiming the study 
of perturbations on the cell cycle and apoptosis. These techniques should shed some ligh 
in the mechanisms of action of the most active compounds found for each series. 
 
 
  
 
2.  
Ursolic acid derivatives: 
synthetic routes, 
structural elucidation, 
biological evaluation 
and SAR studies 
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2. Ursolic acid derivatives 
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A series of new 41 heterocyclic, 14 fluorine, and 6 fluorine-heterocyclic derivatives 
of ursolic acid 2.1 were synthesized and fully characterized using IR, MS and 1D and 2D 
NMR. All new compounds were tested for their antiproliferative activity against AsPC-1 
pancreatic cancer cells. 
The intermediates were synthesized based on the literature, with some procedural 
modifications. In addition, these compounds were characterized, and some were 
evaluated for their antiproliferative activity against AsPC-1 cancer cells. These 
intermediates served as starting material in synthetic routes to obtain new ursolic acid 
derivatives. 
The heterocyclic derivatives of ursolic acid 2.1 were obtained via the reaction of 
commercially available heterocyclic reagents. Most of the compounds tested exhibited 
better antiproliferative activity compared with ursolic acid 2.1 in AsPC-1 pancreatic 
cancer cells. The best compounds found were tested further for their antiproliferative 
activity in other pancreatic, breast, lung, prostate and hepatic cancer cell lines. Compound 
2.57 was the most active, inducing apoptosis in AsPC-1 cells. 
Ursolic acid fluorine derivatives were synthesized via the reaction of ursolic acid 2.1 
or intermediates with selectfluor or deoxofluor. These compounds were evaluated for 
their inhibitory action on the growth of AsPC-1 cells, and the most active were selected 
and evaluated further for their antiproliferative activity in other cell lines. The most active 
compound, fluorolactone 2.72, induced cell cycle arrest at low concentrations and 
apoptosis at higher concentrations. 
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2.1. Intermediates synthesis 
 
Scheme 2.1.1.
a
 Synthesis of derivatives 2.2-2.9.  
HO
H
O
OH
H
R1
H
O
R2
H
R1 = 
R2 = OH
O
R1 = 
R2 = OH
OAc
R1 = 
R2 = OH
O
O COOH
R1 = 
R2 = OH
OCOCF3
2.1............................................. 2.2
b
c
d
a
R1 = 
R2 = OMe
OH
e
R1
H
O
R2
H
O
.......................... 2.7
.......................... 2.8
.......................... 2.10
f
f
f
R1 = 
R2 = OH
OCOCF3
R1 = 
R2 = OH
O
R1 = 
R2 = OH
OAc
2.1............................................. 2.3
2.1............................................. 2.4
2.1............................................. 2.5
2.1............................................. 2.6
 
 
a
Reagents: (a) Trifluoroacetic anhydride, DMAP, THF, r.t.; (b) Jones reagent, acetone, ice; (c) 
Acetic anhydride, DMAP, THF, r.t.; (d) Phthalic anhydride, DMAP, pyridine, 115 ºC; (e) CH3I, 
K2CO3, DMF, N2, r.t.; (f) KMnO4, Fe2(SO4)3.nH2O, t-BuOH, H2O, CH2Cl2. 
 
Conventionally, anhydrides are obtained via the reaction of the substrate with the 
adequate anhydride in pyridine in the presence of 4-(-dimethylamino-)-pyridine (DMAP, 
catalyst).
309, 423
 To avoid the use of pyridine as a solvent in these reactions, some 
researchers started to use tetrahydrofuran (THF) in the preparation of the anhydride 
derivative, with good yields.
183
 Anhydrides 2.2 and 2.4 were prepared in good yields 
from ursolic acid 2.1 using trifluoroacetic anhydride and acetic anhydride, respectively 
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(Scheme 2.1.1). Ursolic acid phthalate 2.5 was prepared in reflux of pyridine and with an 
excess of reagents, to achieve the completion of the reaction (Scheme 2.1.1).
331, 424
  
The oxidation of the 3β-hydroxyl group of ursolic acid 2.1 was achieved via Jones 
oxidation (Schemes 2.1.1 and 2.1.2). Some authors have described the advantage of the 
presence of a carbonyl group in ring C of triterpenoids for their biological activity;
293
 
however, in ursolic acid 2.1, the presence of a methyl group at position C19 increases the 
steric hindrance around position C12, thus rendering the functionalization of ring C more 
difficult.
425
 The oxidative mixture of potassium permanganate and copper sulfate is 
described for the allylic oxidation of oleanolic acid, although this mixture allows not only 
the preparation of the allylic oxidation, but also the co-preparation of other products.
306
 
The reaction of compounds 2.2-2.4 and 2.10 with a mixture of potassium permanganate 
and iron sulfate (Fe2(SO4)3.nH2O) afforded 2.7-2.9 and 2.11 with a carbonyl group at C11 
(Schemes 2.1.1 and 2.1.2). This oxidative mixture is used for the preparation of epoxides 
in the case of unsaturated steroids;
426
 however, in the case of ursane triterpenoids, the 
reaction afforded α,β-unsaturated ketones in ring C, with yields greater than 80%. 
 
Scheme 2.1.2.
a 
Synthesis of derivatives 2.10-2.13. 
O
H
O
OMe
H
O
H
O
OMe
H
O
O
H
O
OMe
H
O
HO
O
H
O
OMe
H
HO
a
b
c
c
2.6
2.10
2.11 2.12
2.13
 
 
a
Reagents: (a) Jones reagent, acetone, ice; (b) KMnO4, Fe2(SO4)3.nH2O, t-BuOH, H2O, CH2Cl2; 
(c) Ethyl formate, benzene, NaOMe, r.t. 
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The methylation of the free acid in ursolic acid 2.1 is commonly achieved using 
diazomethane.
427
 Lee et al described the methylation of carboxylic acid in triterpenoids 
using a mixture of potassium carbonate and methyl iodide in dry DMF, with quantitative 
yields (Schemes 2.1.1 and 2.1.3).
428, 429
 The reaction of compounds 2.3, 2.10 and 2.11 
with ethyl formate and sodium methoxide allows the preparation of derivatives with an 
unsaturated exocyclic double bond in ring A (Schemes 2.1.2 and 2.1.4).
330, 430, 431
 The 
reaction of compound 2.16 with hydroxylamine leads to the obtention of the pyrazol 
ursane derivative 2.17 (Scheme 2.1.4).
295
  
 
Scheme 2.1.3.
a
 Synthesis of derivatives 2.14 and 2.15. 
HO
H
O
OH
H
O
HO
H
O
OMe
H
Oa b
2.9
2.14 2.15
 
 
a
Reagents: (a) KOH, MeOH, reflux; (b) CH3I, K2CO3, DMF, N2, r.t. 
 
The compounds synthesized were characterized using IR, MS and 1D NMR. Ursane 
compounds are characterized by the presence of the H12 proton signal at around δ 5.23 
ppm. Compounds 2.2, 2.4, 2.5, 2.7 and 2.9 exhibited a signal in the 
1
H NMR spectrum at 
a δ around 4.7 ppm, corresponding to proton H3 (Figure 2.1.1). The carbonyl carbon of 
the anhydride moiety was present at a δ around 170 ppm in the 13C NMR spectrum; 
however, in the presence of a trifluoroacetoxy group, this signal became lower and 
presented as a doublet at δ 157.36 ppm, with a coupling constant of 47 Hz (Figure 2.1.2). 
The presence of the α,β-unsaturated carbonyl group in ring C was confirmed by the 
presence of a band at around 1660 cm
–1
 in the IR spectra (which is characteristic of the 
carbonyl group of the α,β-unsaturated ketone), by the presence of the signal for proton 
H12 at approximately δ 5.6 ppm in the 1H NMR spectrum (which is slightly higher than 
that observed for compounds without the carbonyl group at C11), and by the presence of 
an extra δ signal for a carbonyl group in the 13C NMR spectrum. In compounds with a 
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carbonyl group at C11, the δ values for carbons C12 and C13 in the 13C NMR spectrum 
were higher than those observed for compounds without the carbonyl group in ring C. 
 
Scheme 2.1.4.
a
 Synthesis of derivatives 2.16 and 2.17. 
O
H
O
OH
H
HO
H
O
OH
HN
O
a b
2.3
2.16 2.17
 
 
a
Reagents: (a) Ethyl formate, benzene, NaOMe, r.t.; (b) NH2OH.HCl, H2O, EtOH, reflux.  
 
The methylation of the carboxylic acid of ursolic acid 2.1 could be tracked based on 
the decrease in the δ signal of carbon C28 in the 13C NMR spectrum, because the 
methylation of this group led to a decrease in the signal of around 8 ppm. 
 
 
Figure 2.1.1. 
1
H NMR spectrum of compound 2.2. 
 
In compounds 2.12, 2.13 and 2.16, the signal at around δ 7.8 ppm corresponded to 
the proton of the exocyclic double bond at C2 in the 
1
H NMR spectrum. In the 
13
C NMR 
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spectrum, the presence of this functionality was confirmed by the δ signal around 131 
ppm, and the signal for C2 appeared around a δ of 123 ppm. 
 
 
Figure 2.1.2. 
13
C NMR spectrum of compound 2.2. 
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2.2. Heterocyclic derivatives 
 
2.2.1. Introduction 
 
Heteroaryl groups are present in a variety of biologically active molecules, including 
several classes of derivatives, such as fungicides and anticancer agents.
432-436
 
In this section, the introduction of different heteroaryl groups into the ursolic acid 2.1 
backbone was achieved using the commercially available reagents 1,1’-
carbonyldiimidazole (CDI), 1,1’-carbonyl-di(1,2,4-triazole) (CDT) and 1,1’-
carbonylbis(2’methylimidazole) (CBMI) (Figure 2.2.1).  
 
O
N
N
N
N
O
N
N
N
N
N
N
CDTCDI
CBMI
O
N
N
N
N
 
 
Figure 2.2.1. Schematic representation of the reagents 1,1’-carbonyldiimidazole (CDI), 1,1’-
carbonyl-di(1,2,4-triazole) (CDT) and 1,1’-carbonylbis(2’methylimidazole) (CBMI). 
 
The introduction of a heterocyclic ring(s) in the structure of triterpenoids is a 
modification that has been performed in betulinic acid and betulin, affording several 
derivatives. Most of these new compounds presented better cytotoxic activity compared 
with that of the parental compounds.
433, 434, 437
 The introduction of the heterocyclic ring 
was made via the reaction of an alcohol, a carboxylic acid or an aldehyde with CDI, 
CBMI or CDT in reflux of THF under an inert atmosphere, affording N-
alklylimidazoles,
438-440
 imidazole carboxylic esthers (carbamates),
433, 434, 441
 or N-
acylimidazoles.
442
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Figure 2.2.2. Reaction mechanism of triterpenoids with CDI for the formation of carbamates. 
 
The formation of carbamates (Figure 2.2.2.), N-acylimidazoles or N-alkylimidazoles 
(Figure 2.2.3.) depends on the nature of the reactive group and on the reaction conditions 
used. Both products are achieved through nucleophilic attack of the alcohol on the 
carbonyl group of the heteroaryl reagent.
438, 440, 442
  
With the aim of improving the antitumor activity of ursolic acid 2.1 and 
intermediates, imidazole, methylimidazole or triazole rings were introduced in ursolic 
acid 2.1 and intermediates at different positions of the structure. 
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Figure 2.2.3. Reaction mechanism of CDI with triterpenoids for the formation of N-
alkylimidazoles (A) and N-acylimidazoles (B). 
 
2.2.2. Results and Discussion 
 
2.2.2.1. Chemistry 
 
2.2.2.1.1. Imidazole derivatives 
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The reaction of ursolic acid 2.1 and intermediates with CDI in THF under an inert 
atmosphere afforded N-acylimidazoles (Schemes 2.2.1 and 2.2.2), carbamates (Schemes 
2.2.1 and 2.2.2) and N-akylimidazoles (Scheme 2.2.3). 
 
Scheme 2.2.1.
a
 Synthesis of derivatives 2.18-2.23.
 
R1
H
O
R2
H
R1
H
O
R2
H
R1 = 
R2 = OH
OH
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R2 = OH
OH
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O N
N
O
N
N
...............................................
R1 = 
R2 = OH
OAC R1 = 
R2 =
OAc
N
N
R1 = 
R2 = OMe
OH R1 = 
R2 = OMe
O N
N
O
R1 = 
R2 = OH
O R1 = 
R2 = N
N
O
a
2.1
2.1
2.18
...............................................
...............................................
...............................................
...............................................
2.4
2.6
2.3
2.19
2.22
2.23
2.21
R1 = 
R2 = OH
OCOCF3 R1 = 
R2 =
OCOCF3
N
N
...............................................2.2 2.20
 
 
a
Reagents: (a) CDI, THF, N2, reflux.  
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Carbamates 2.18, 2.19, 2.23, 2.24 and 2.28 (Schemes 2.2.1 and 2.2.2) were 
characterized by the presence of a band in the IR at around 1750 cm
–1
, corresponding to 
the carbonyl group of the esther, a value that was higher than that obtained for carboxylic 
acids (1700 cm
–1
) or amides 2.20-2.22 and 2.25-2.27 (1726 cm
–1
) (Schemes 2.2.1 and 
2.2.2). The imidazole group did not stand in the IR spectra as an isolated band: C–N 
bands were present at around 1400 cm
–1
 and the unsaturated bonds of the ring were 
sometimes visualized as small bands, at around 3100 cm
–1
 (Figure 2.2.4).  
 
 
Figure 2.2.4. IR spectrum of compound 2.19. 
 
In the 
1
H NMR spectrum, N-alcylimidazole 2.21 presented three signals at δ 8.46, 
7.56 and 7.11 ppm that corresponded to the imidazole ring (Figure 2.2.5). In the 
13
C 
NMR spectrum, the imidazole ring signals corresponded to δ at 136.69, 117.79 and 
127.97 ppm (Figures 2.2.6 to 2.2.8). Proton H12 was detected as a triplet in the 
1
H NMR 
spectrum, with a signal at δ 5.25 ppm, the corresponded carbon (C12) has a δ signal at 
126.55 ppm. Proton H12 correlated with carbon C18, which allowed the identification of 
the signal at δ 54.22 ppm in the 13C NMR spectrum as corresponding to carbon C18 
(Figure 2.2.9). Protons of the C29 methyl group (δ 0.91 ppm) also correlated with carbon 
C18 and carbon C19 (δ 39.22 ppm). The identification of a methyl group at C29 allowed 
the identification of a signal at δ 1.00 ppm that corresponded to the methyl group at C30. 
The signals of the methyl groups at C29 and C30 were usually observed as doublets in 
the 
1
H NMR spectrum, as the protons in the methyl group were coupled with the geminal 
protons at C19 and C20, respectively. 
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Figure 2.2.5. 
1
H NMR spectrum of compound 2.21. 
 
 
Figure 2.2.6. 
13
C NMR spectrum of compound 2.21. 
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Figure 2.2.7. HMQC spectrum of compound 2.21. 
 
 
Figure 2.2.8. HMQC spectrum detail of compound 2.21, with incidence in the imidazole ring 
signals.  
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Figure 2.2.9. HMBC spectrum of compound 2.21. 
 
The signal at δ 136.88 ppm corresponded to carbon C13, as this signal was not 
present in the DETP spectrum of compound 2.21. The protons of the methyl group at C27 
(δ 1.10 ppm) correlated with carbon C13. The identification of the methyl group at C27 
allowed the attribution of the δ signals to carbons C8 (39.38 ppm), C9 (46.62 ppm) and 
C26 (16.73 ppm) in the 
13
C NMR spectrum. 
Carbon C3 of compound 2.21, with a signal at δ 217.61 ppm, correlated with the 
methyl groups at C23 and C24; however, because both groups were located at a geminal 
carbon (C4), it was not possible to identify these carbons specifically. In the 
1
H NMR 
spectrum, the δ signals at 1.06 and 1.03 ppm corresponded to the methyl groups at C23 or 
C24. 
The correlations observed on HMBC and HMQC permitted the identification of 
several 
13
C and 
1H NMR δ signals, which are presented in Table 2.2.1. 
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Table 2.2.1. NMR data for compound 2.21. 
28
3
O
2
1
4
23 24
5
6
7
8
26
14
27
15
16
17
22
21
20
30
19
29
18
H
13
12
11
9
10
25
O
N
H
N
 
Entry Position δ 1H NMR δ 13C NMR 
1 3 - 217.61 
2 4 - 47.38 
3 5 - 55.22 
4 7 - 32.29 
5 8 - 39.38 
6 9 - 46.62 
7 10 - 36.60 
8 12 5.25 (J= 7.32) 126.55 
9 13 - 136.88 
10 14 - 42.20 
11 15 - 27.72 
12 17 - 51.16 
13 18 - 54.22 
14 19 - 39.22 
15 20 - 38.62 
16 21 - 30.30 
17 25 1.02 15.17 
18 26 0.72 16.73 
19 27 1.10 23.50 
20 28 - 174.26 
21 29 0.91 (J= 6.46) 17.04 
22 30 1.00 (J= 6.32) - 
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Scheme 2.2.2.
a
 Synthesis of derivatives 2.24-2.28. 
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N
N
...............................................2.7 2.25
 
 
a
Reagents: (a) CDI, THF, N2, reflux. 
 
Compound 2.24, a carbamate at C3 with an N-alcylimidazole group located at C28, 
has two imidazole groups in its structure, which corresponded to five signals in the 
1
H 
NMR spectrum, as the signal at δ 7.05 ppm corresponded to two protons (Figure 2.2.10). 
On the 
13C NMR spectrum, the signals of the imidazole rings were observed at δ signal of 
136.95, 136.89, 130.48, 130.11, 117.25 and 116.98 ppm (Figure 2.2.11).  
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Figure 2.2.10. 
1
H NMR spectrum of compound 2.24. 
 
 
Figure 2.2.11. 
13
C NMR spectrum of compound 2.24. 
 
The carbamate group at C3 in compound 2.24 exhibited a signal at δ 85.91 ppm in 
the 
13
C NMR spectrum, which corresponded to carbon C3. Proton H3 in the 
1
H NMR 
spectrum appeared as a double doublet with a signal at δ 4.68 ppm. The carbonyl group 
appeared in the 
13C NMR spectrum as a signal at δ 148.47 ppm. Proton H12 was detected 
as a singlet at δ 5.66 ppm and was correlated with carbons C9 (61.17 ppm), C14 (43.75 
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ppm) and C18 (54.01 ppm), thus allowing their identification in the 
13
C NMR spectrum 
(Figure 2.2.12). Proton H18 (2.61 ppm) allowed the identification of the quaternary 
carbon C17 (50.61 ppm) and carbon C19 (38.33 ppm). The methyl group signals of 
carbons C29 (17.17 ppm) and C30 (20.78 ppm) appeared as doublets in the 
1
H NMR 
spectrum, with signals at δ 0.94 and δ 1.01 ppm, respectively.  
 
 
Figure 2.2.12. Detail of the HMBC spectrum of compound 2.24. The correlations between proton 
H12 and carbons C9, C14 and C18 are highlighted.  
 
In the 
1
H NMR spectrum of compound 2.24, the signal at δ 2.31 ppm was identified 
as proton H9, which allowed the attribution of δ signals at 198.84, 44.59 and 36.90 ppm 
to carbons C11, C8 and C10, respectively. The identification of carbon C10 allowed the 
attribution of the signal in the 
1
H NMR spectrum at δ 1.16 ppm to the methyl group at 
C25, and the signal at δ 16.30 ppm in the 13C NMR spectrum to C25. 
Some of the correlations discussed previously for compound 2.24 are presented in 
Figure 2.2.13. In addition, other correlations were observed and allowed the identification 
of other δ signals in the 13C NMR spectrum, as presented in experimental section 2.4.1. 
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Figure 2.2.13. Some HMBC correlations for compound 2.24. 
 
Compounds 2.20, 2.25 and 2.26 were also analyzed using 1D and 2D NMR. Some of 
the data obtained in the 
1
H NMR and 
13
C NMR analyses are presented in Table 2.2.2. 
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Table 2.2.2. Selected 
1
H and 
13
C NMR data from the backbone of compounds 2.20, 2.25 and 
2.26. 
Entry Position 
2.20 2.25 2.26 
δ H δ C δ H δ C δ H δ C 
1 1 - 38.05 - 38.54 - 39.76 
2 3 
4.67  
(J= 15.50) 
86.14 
4.68  
(J= 16.08) 
85.85 - 216.91 
3 4 - 37.88 - 38.18 - 47.69 
4 5 
0.82  
(J= 11.24) 
55.12 
0.77  
(J= 11.51) 
54.88 - 55.44 
5 7 - 32.62 - 32.74 - 32.33 
6 8 - 39.39  44.59 - 44.47 
7 9 1.51 47.33 2.30 61.15 2.37 60.68 
8 10 - 36.75 - 36.88 - 36.73 
9 11 - - - 198.91 - 198.55 
10 12 5.23 126.30 5.66 131.17 5.68 131.21 
11 13 - 137.01 - 161.29 - 161.40 
12 14 - 42.06 - 43.74 - 43.86 
13 15 - 27.70 - 28.19 - 28.29 
14 17 - 50.87 - 50.59 - 50.65 
15 18 
2.45  
(J= 11.03) 
54.10 
2.61  
(J= 11.10) 
53.99 
2.63  
(J= 10.67) 
54.06 
16 19 - 39.22 - 38.72 - - 
17 20 - 38.66 - 38.34 - 38.78 
18 21 - 30.35 - 30.08 - 38.37 
19 25 0.94 15.47 1.15 16.35 1.24 15.59 
20 26 0.68 16.70 0.86 18.43 0.89 18.36 
21 27 1.10 23.56 1.32 20.87 1.32 20.80 
22 28 - 174.70 - 173.79 - 173.82 
23 29 
0.91  
(J= 6.54) 
17.08 
0.93  
(J= 6.22) 
17.20 
0.93  
(J= 6.20) 
17.18 
24 30 
1.00  
(J= 6.15) 
21.02 
1.01  
(J= 6.09) 
20.82 - - 
25 OCO - 
157.34  
(J= 41.77) 
- 
157.31  
(J= 41.52) 
- - 
26 CF3 - 
114.62  
(J= 286.24) 
- 
114.60  
(J= 286.28) 
- - 
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Scheme 2.2.3 represents the synthesis of amines 2.29-2.31. These amines had an α,β 
unsaturated ketone in ring A, which was confirmed by the presence of a signal around δ 
7.8-7.7 ppm, corresponding to the proton in the exocyclic double bond at C2 in the 
1
H 
NMR spectrum. In the 
13
C NMR spectrum, the presence of this functionality was 
confirmed by the presence of a signal around δ 131 ppm, correspondent to the carbon of 
the exocyclic double bond at C2. The signal for carbon C2 appeared at around δ 123 ppm 
and the signal for C3 appeared at δ 200 ppm. The signals of the imidazole ring were 
similar to that described for compounds 2.21 and 2.24. 
 
Scheme 2.2.3.
a
 Synthesis of derivatives 2.29-2.31. 
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a
 
 
a
Reagents: (a) CDI, THF, N2, reflux. 
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2.2.2.1.2. Methylimidazole derivatives 
 
The synthesis of the ursolic acid methylimidazole derivatives 2.32-2.45 was achieved 
via the dissolution of the respective substrate in dry THF under an inert atmosphere and 
via the addition of CBMI. In some cases, the reaction proceeded slowly because CBMI is 
a bulky reagent and various substrates can present a slight sterical impairment for the 
reaction, affording lower yields. These reaction conditions allowed the synthesis of N-
acylimidazoles 2.34-2.36 and 2.39-2.41 (Schemes 2.2.4 and 2.2.5), N-alkylimidazoles 
2.43-2.45 (Scheme 2.2.6) and carbamates 2.32, 2.33, 2.37, 2.38 and 2.42 (Schemes 2.24 
and 2.2.5). 
Compound 2.34 has a trifluoroacetoxy moiety at carbon C3. In the IR spectrum, the 
C–F stretching vibration occurred at around 1100 cm–1, the stretching vibration for the 
carbonyl group of the anhydride appeared at around 1780 cm
–1
, whereas the carbonyl 
group of the amide was present at lower values (1710 cm
–1
) (Figure 2.2.14). 
 
 
 
Figure 2.2.14. IR spectrum of compound 2.34. 
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Scheme 2.2.4.
a
 Synthesis of derivatives 2.32-2.37. 
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N
 
 
a
Reagents: (a) CBMI, THF, N2, reflux. 
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Compounds 2.38-2.42 have an α,β unsaturated ketone in ring C of the ursane 
backbone. The stretching vibration of this carbonyl group occured at 1660 cm
–1
, which 
was a lower frequency than that of the anhydride carbonyl group (1780 cm
–1
) or the 
amide carbonyl group (1710 cm
–1
) (Figure 2.2.15). The IR spectra revealed the presence 
of weak signals at around 3120 cm
–1
 or higher; these signals were due to the C=C 
stretching vibration of the methylimidazole ring double bonds and the ∆12 bond. 
 
 
 
Figure 2.2.15. IR spectrum of compound 2.38. 
 
The introduction of the methylimidazole ring in the ursane backbone was confirmed 
by the analysis of the NMR spectra of the compounds prepared. The 
1
H NMR signals of 
the methylimidazole ring occurred as two singlets or doublets for the two protons, with δ 
signals higher than 6.80 ppm, whereas the methyl group appeared as a singlet at around δ 
2.5 ppm. The 
13
C NMR spectrum of these compounds was characterized by the presence 
of three additional δ signals greater than 116 ppm and a δ signal between 13 and 17 ppm, 
which corresponded to the methyl group of the methylimidazole ring. 
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Scheme 2.2.5.
a
 Synthesis of derivatives 2.38-2.42. 
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a
Reagents: (a) CBMI, THF, N2, reflux. 
 
Ursolic acid 2.1 has been well characterized using NMR techniques.
443
 Proton H12 is 
usually present as a triplet at around δ 5.23 ppm. Because of the presence of an α,β 
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unsaturated ketone in ring C, the signal of proton H12 in compound 2.42 appeared at δ 
5.61 ppm. Proton H3 in ursolic acid 2.1 was characterized previously.
443
 The presence of 
a carbamate at C3 in compound 2.42 resulted in a higher signal in the 
1
H NMR spectrum 
for proton H3 (δ 4.67 ppm), which appeared as a double doublet, similar to what was 
observed for ursolic acid 2.1 (Figure 2.2.16). In the 
13
C NMR spectrum, signals at δ 
163.09, 130.54 and 85.76 ppm correlated with carbons C13, C12 and C3, respectively 
(Figures 2.2.17 and 2.2.18). 
 
 
Figure 2.2.16. 
1
H NMR spectrum of compound 2.42. 
 
Proton H18 of compound 2.42 appeared as a doublet at δ 2.42 ppm in the 1H NMR 
spectrum and correlated with carbons C13, C14 and C12 in the HMBC spectrum, which 
were attributed to the δ signals observed at 163.09, 143.72 and 130.54 ppm, respectively. 
The singlet signal observed at δ 2.33 ppm was attributed to proton H9; the correlation of 
this proton with the δ signals at 199.44, 44.60 and 36.93 ppm in the HMBC spectrum 
allowed the identification of carbons C11, C8 and C10, respectively.  
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Figure 2.2.17. 
13
C NMR spectrum of compound 2.42. 
 
 
Figure 2.2.18. HMQC spectrum of compound 2.42, showing the correlations between protons 
and carbons of the methylimidazole ring (blue), C3 (red) and C12 (green). 
 
The δ signal at 1.17 ppm in the 1H NMR spectrum of compound 2.42 was identified 
as the methyl group at C25. This group correlated with carbons C9, C5 and C1, which 
were identified as the δ signals at 61.20, 55.01 and 38.64 ppm in the 13C NMR spectrum, 
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respectively. Proton H3 correlated with the carbonyl group of the carbamate, and the 
methyl group at C27 correlated with carbons C13 and C15. 
Other correlations were also observed in the HMBC spectrum of compound 2.42, 
allowing the attribution of several δ signals in the 1H and 13C NMR spectra. Some of the 
HMBC correlations are illustrated in Figure 2.2.19. 
 
O
O
OCH3
H
O
N
O
N
H3C
H
H
 
 
Figure 2.2.19. Selected HMBC correlations for compound 2.42. 
 
Amines 2.43-2.45 (Scheme 2.2.6) were fully characterized by NMR. These amines 
have an exocyclic double bond in ring A conjugated with a ketone at C3, affording an α,β 
unsaturated ketone in ring A. The α,β unsaturated ketone moiety was detected in the 1H 
NMR spectrum by the occurrence of a δ signal at 7.6-7.7 ppm, which corresponded to the 
proton on the exocyclic double bond. In the 
13
C NMR spectrum, the identification of this 
moiety in compound 2.44 was due to the occurrence of the δ signals at 206.63, 123.60 
and 130.38 ppm, which corresponded to carbons C3, C2 and the exocyclic double bond, 
respectively (Figures 2.2.20 and 2.2.21). 
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Scheme 2.2.6.
a
 Synthesis of derivatives 2.43-2.45. 
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N
N
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R2 = OMe
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O
N
N
...............................................
...............................................
...............................................
2.44
2.45
2.43
2.13
2.16
2.12
a
 
 
a
Reagents: (a) CBMI, THF, N2, reflux. 
 
The presence of the α,β unsaturated ketone in ring A of the ursane backbone allows 
the attribution of 
13C NMR δ signals to the methylimidazole ring due to the correlations 
between the exocyclic unsaturated double bond and the heterocyclic ring. In compound 
2.44, the proton observed at 7.66 ppm, which corresponded to the proton in the exocyclic 
unsaturated bond, correlated with carbon C5’ (118.19 ppm) of the heterocyclic ring. 
Carbon C2’ (147.31 ppm) was identified by the fact that it had a methyl group attached 
and was a quaternary carbon. Carbon C4’ (128.57 ppm) was identified by exclusion. 
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Other correlations in the ursane backbone were observed in the HMBC spectrum; the 
integration of this information with the data from HMQC, DEPT, 
13
C and 
1
H NMR 
specta led to the attribution of additional δ signals to several carbons and respective 
protons (Table 2.2.3).  
 
 
Figure 2.2.20. 
1
H NMR spectrum of compound 2.44. 
 
In compound 2.44, proton H12 appeared as a δ signal at 5.29 ppm and correlated 
with carbons C9, C14 and C18, with δ signals at 45.28, 42.21 and 53.01 ppm on the 13C 
NMR spectrum, respectively. The attribution of carbon C9 allowed the identification of 
carbon C8 as the δ signal at 39.38 ppm, and carbon C10 as the δ signal at 36.12 ppm on 
the 
13
C NMR spectrum (Figure 2.2.22). 
The doublet at δ 2.26 ppm in the 1H NMR spectrum of compound 2.44 was identified 
as proton H18, which correlated with carbon C17 (48.14 ppm) and carbon C19 (38.83 
ppm). Other correlations were found and allowed the identification of the majority of the 
signals in the 
13
C NMR spectrum of compound 2.44. The same procedure was used for 
compounds 2.43 and 2.45 (Table 2.2.3). 
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Figure 2.2.21. 
13
C NMR spectrum of compound 2.44. 
 
 
Figure 2.2.22. HMBC spectrum of compound 2.44. 
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Table 2.2.3. Selected 
1
H and 
13
C NMR data from the backbone of compounds 2.43-2.45. 
Entry Position 
2.43 2.44 2.45 
δ H δ C δ H δ C δ H δ C 
1 1 - 42.51 - 42.37 - 42.36 
2 2 - 122.98 - 123.60 - 123.07 
3 3 - 206.36 - 206.23 - 206.50 
4 4 - 45.39 - 45.31 - 45.20 
5 5 - 53.02 - 52.78 1.43 52.64 
6 7 - 31.65 - 32.01 - 31.78 
7 8 - 44.19 - 39.38 - 39.39 
8 9 2.45 58.90 - 45.28 - 45.15 
9 10 - 36.07 - 36.12 - 36.03 
10 11 - 198.71 - - - 35.43 
11 12 5.67 130.53 5.29 124.98 5.28 125.87 
12 13 - 163.99 - 138.45 - 137.37 
13 14 - 43.86 - 42.21 - 42.40 
14 15 - 28.47 - 27.97 - - 
15 17 - 47.64 - 48.14 - 51.84 
16 18 2.45 52.80 
2.26 
(J= 11.27) 
53.01 2.54 54.16 
17 19 - 38.59 - 38.83 - 39.55 
18 20 - 38.72 - 39.12 - 38.59 
19 21 - - - 30.63 - 30.42 
20 25 1.12 15.39 0.89 15.46 0.87 15.51 
21 26 0.94 18.26 0.79 16.62 0.77 16.90 
22 27 1.33 21.00 1.12 23.43 1.15 23.28 
23 28  177.11 - 177.92 - 176.52 
24 29 
0.89  
(J= 6.22) 
17.19 0.89 17.07 
0.95  
(J= 6.13) 
17.24 
25 30 
0.97  
(J= 6.28) 
20.94 
0.95 
(J= 5.85) 
21.11 
1.00 
(J= 6.13) 
21.07 
26 COCH3 3.61 51.87 3.60 51.45 - - 
27 C2CH 7.62 129.69 7.66 130.38 7.67 130.50 
28 C2’ - 147.23 - 147.31 - 147.39 
29 C2’’ - - - - - 149.35 
30 C4’ 7.32 128.38 7.01 128.57 7.00 128.68 
31 C5’ 6.99 118.24 7.16 118.19 7.16 118.11 
32 
C2’CH3 
imidazole 
2.49 13.66 2.47 13.68 2.47 13.75 
33 
C2’’CH3 
imidazole 
- - - - 2.54 17.93 
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2.2.2.1.3. Triazole derivatives 
 
The reaction of ursolic acid 2.1 and intermediates with CDT afforded carbamates 
2.46, 2.50, 2.51 and 2.55 (Schemes 2.2.7. and 2.2.8), N-acyltriazoles 2.47-2.49 and 2.52-
2.54 (Schemes 2.2.7 and 2.2.8) and N-alkyltriazoles 2.56-2.58 (Scheme 2.2.9).  
 
Scheme 2.2.7.
a
 Synthesis of derivatives 2.46-2.50. 
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a
Reagents: (a) CDT, THF, N2, reflux. 
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Figure 2.2.23. 
1
H NMR spectrum of compound 2.46. 
 
 
Figure 2.2.24. 
13
C NMR spectrum of compound 2.46. 
 
The presence of a triazole heterocyclic ring was confirmed in the 
1
H and 
13
C NMR 
spectra, because the protons of this ring had a δ signal higher than 8 ppm in the 1H NMR 
spectrum and the carbons had a δ signal higher than 145 ppm in the 13C NMR spectrum. 
For compound 2.46, with two triazole groups, the δ signals in the 1H NMR spectrum for 
the heterocyclic ring on the carbamate moiety were 8.06 and 8.77 ppm, and for the C28 
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amide moiety, they were 7.98 and 8.82 ppm. In the 
13C NMR spectrum, the δ signals 
were 153.57 and 145.29 ppm, and 152.21 and 145.29 ppm, respectively (Figures 2.2.23 
and 2.2.24).  
 
Scheme 2.2.8.
a
 Synthesis of derivatives 2.51-2.55. 
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a
Reagents: (a) CDT, THF, N2, reflux. 
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Table 2.2.4. Selected 
1
H and 
13
C NMR data from the backbone of 
compounds 2.46 and 2.54. 
Entry Position 
2.46 2.54 
δ H δ C δ H δ C 
1 1 - - - 38.80 
2 3 
4.79  
(J= 16.50) 
87.69 
4.49  
(J= 16.28) 
80.53 
3 4 - 38.17 - 37.97 
4 5 - 55.20 
0.75  
(J= 11.55) 
55.02 
5 7 - 32.67 - 32.86 
6 8 - 39.45 - 44.65 
7 9 - 47.40 2.31 61.34 
8 10 - 36.78 - 36.96 
9 11 - - - 199.33 
10 12 5.24 125.86 5.64 131.05 
11 13 - 137.60 - 161.72 
12 14 - 42.19 - 43.81 
13 15 - - - 28.60 
14 17 - 51.26 - 50.99 
15 18 - - - 53.97 
16 21 - - - 30.13 
17 25 0.97 15.49 1.12 16.33 
18 26 0.68 16.71 0.83 18.53 
19 27 1.11 23.56 1.32 20.89 
20 28 - 174.82 - 174.12 
21 29 
0.91 
(J= 6.35) 
17.03 
0.93 
(J= 6.36) 
17.14 
22 30 0.97 21.05 
1.00 
(J= 6.29) 
20.87 
23 OCO - 147.28 - 170.97 
24 OCOCH3 - - 2.03 21.27 
 
The presence of the N-acyltriazol, carbamate or N-alkyltriazole moieties was studied 
in a manner similar to that used for the imidazole and methylimidazole derivatives. Some 
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1
H and 
13C NMR δ signals attributed to compounds 2.46 and 2.54 are presented in Table 
2.2.4; these were attributed based on the analysis of the 1D and 2D NMR experiments. 
 
Scheme 2.2.9.
a
 Synthesis of derivatives 2.56-2.58. 
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a
Reagents: (a) CDT, THF, N2, reflux. 
 
The reaction of compounds 2.12, 2.13 and 2.16 with a vinyl alcohol at position C2 
afforded amines 2.56-2.58 with good yield (Scheme 2.2.9). The structural elucidation of 
the compounds was achieved via MS, IR and 1D and 2D NMR experiments, the results of 
which are described in experimental section 2.4.1. 
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2.2.2.2. Biological evaluation 
 
The antiproliferative activity of the new semisynthetic compounds was evaluated via 
the determination of the IC50 (μM) against AsPC-1 cells, a pancreatic cancer cell line, 
using a MTT assay. Overall, the new semisynthetic compounds exhibited better 
antiproliferative activity against this cell line compared with the intermediates and ursolic 
acid 2.1 (Tables 2.2.5 and 2.2.6). Compounds 2.33 and 2.47, in which the introduction of 
heterocyclic rings at positions C3 and C28 simultaneously resulted in the decrease of 
antiproliferative activity compared with ursolic acid 2.1, probably because of the volume 
of the substituents, which sterically impaired the interaction with the biological targets. 
Compounds 2.25, 2.28, 2.37 and 2.47 presented an IC50 higher than 30 μM. Compounds 
2.29-2.31, 2.43-2.45 and 2.56-2.58, with a heterocyclic ring conjugated with an α,β 
unsaturated ketone in ring A, exhibited the best antiproliferative activity in this cell line 
(Table 2.2.6). 
 
Table 2.2.5. The IC50 (µM) of ursolic acid intermediates in the inhibition of AsPC-1 cell 
growth. 
Compd AsPC-1 Compd AsPC-1 
2.1 12.6±0.03 2.9 33.5±0.05 
2.2 10.9±0.04 2.12 9.0±0.04 
2.3 24.5±0.1 2.13 7.2±0.02 
2.4 71.0±0.06 2.14 45.7±0.06 
2.6 17.7±0.06 2.15 34.2±0.04 
2.7 84.2±0.09 2.16 13.4±0.03 
2.8 54.9±0.03 - - 
AsPC-1 cells were treated with the indicated compounds at varying concentrations for 72 h. The 
antiproliferative effects were determined using a MTT assay and the IC50 was calculated. The 
results shown are means ± SE of three independent experiments. 
 
SAR based on the antiproliferative activity against AsPC-1 cell line for ursolic acid 
2.1 and compounds 2.12, 2.13, 2.16, 2.29-2.31, 2.43-2.45 and 2.56-2.58 is represented in 
Figure 2.2.25, once compounds with an α,β unsaturated ketone in ring A, represent the 
most active derivatives in these series. Herein compounds 2.29, 2.43, 2.44 and 2.57 have 
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the best antiproliferative activity against AsPC-1 cancer cells. The heterocyclic ring 
present at C2 position influences the antiproliferative activities, depending on the initial 
scaffold. Triazole substituent with an α,β unsaturated ketone in ring A appears to generate 
the most active compounds. Compound 2.57 is the most active compound. It is 7-fold 
more potent than ursolic acid 2.1, and 4-fold more potent than compound 2.13 (Figure 
2.2.25).  
 
Table 2.2.6. The IC50 (µM) of ursolic acid heterocyclic derivatives in the 
inhibition of AsPC-1 cell growth. 
Compd IC50 (μM) Compd IC50 (μM) Compd IC50 (μM) 
2.18 11.7±0.02 2.32 >100 - - 
2.19 13.2±0.07 2.33 53.8±0.3 2.46 50.4±0.04 
2.20 42.4±0.01 2.34 12.2±0.03 2.47 35.7±0.02 
2.21 15.2±0.03 2.35 19.6±0.02 2.48 19.2±0.07 
2.22 15.2±0.03 2.36 20.2±0.06 2.49 23.3±0.05 
2.23 8.0±0.04 2.37 40.3±0.05 2.50 28.4±0.02 
2.24 9.1±0.05 2.38 7.3±0.03 2.51 10.4±0.04 
2.25 48.3±0.1 2.39 26.1±0.02 2.52 12.9±0.02 
2.26 11.7±0.05 2.40 5.1±0.03 2.53 9.9±0.03 
2.27 13.9±0.04 2.41 15.3±0.06 2.54 10.2±0.02 
2.28 50.8±0.3 2.42 19.0±0.1 2.55 11.4±0.04 
2.29 2.3±0.02 2.43 2.1±0.01 2.56 8.1±0.02 
2.30 5.8±0.05 2.44 2.1±0.02 2.57 1.9±0.02 
2.31 5.1±0.02 2.45 11.3±0.02 2.58 3.9±0.04 
AsPC-1 cells were treated with the indicated compounds at varying concentrations for 
72 h. The antiproliferative effects were determined using a MTT assay and the IC50 was 
calculated. The results shown are means ± SE of three independent experiments. 
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Figure 2.2.25. Graphical representation of the SAR relationship between ursolic acid 2.1 and 
novel semisynthetic derivatives with modification at C2 of the ursane structure. Comparisons 
were based on the IC50 of compounds against the AsPC-1 cell line. Compound 2.57, which was 
the most active of these series, was 4-fold more active than the original intermediate 2.13 and 7-
fold more active than ursolic acid 2.1. Compound 2.43 was 4-fold more active than compound 
2.12 and 6-fold more active than ursolic acid 2.1. Compound 2.58 was 3-fold more active than 
compound 2.16 and ursolic acid 2.1. 
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Among compounds 2.29-2.31, 2.43-2.45 and 2.56-2.58, which were tested for 
antiproliferative activity in AsPC-1 cells, compounds 2.29, 2.30, 2.43, 2.44, 2.56 and 2.57 
were studied further in other pancreatic (PANC-1 and MIA PaCa 2), hepatic (Hep G2), 
breast (MCF-7), lung (A549) and prostate (PC-3) cancer cell lines (Table 2.2.7). 
Compound 2.57, an N-alkyltriazole, exhibited consistent antiproliferative activity in all 
the tested cell lines, with IC50 values ranging from 1.9 to 4.9 μM. The presence of the N-
alkyltriazole in ring A conjugated with an α,β unsaturated ketone afforded a greater 
Michael acceptor compared with compounds 2.30 and 2.44, allowing a better interaction 
with the biological target(s).
444
 The nature of the substituent at C2 in compounds with the 
same ursane backbone may be the reason for the differences observed in antiproliferative 
activity. 
 
Table 2.2.7. The IC50 (µM) of ursolic acid heterocyclic derivatives in the inhibition of the growth 
of pancreatic (PANC-1 and MIA PaCa 2), breast (MCF-7), prostate (PC-3), hepatic (Hep G2) and 
lung (A549) cancer cell lines. 
Compd PANC-1 MIA PaCa 2 Hep G2 MCF-7 A549 PC-3 
2.1 14.9±0.04 10.4±1.0 15.0±0.09 12.3±0.02 11.4±0.03 20.8±0.01 
2.29 18.2±0.06 24.3±0.03 27.6±0.05 9.4±0.05 12.2±0.08 12.9±0.05 
2.30 5.1±0.04 7.3±0.04 2.0±0.03 5.3±0.02 5.6±0.05 6.8±0.02 
2.43 14.4±0.04 8.3±0.02 8.5±0.06 3.5±0.05 18.7±0.03 5.7±0.02 
2.44 5.6±0.04 5.6±0.01 4.0±0.01 2.2±0.03 5.3±0.02 3.5±0.02 
2.56 12.1±0.2 7.8±0.03 7.9±0.03 12.5±0.06 12.9±0.02 9.5±0.03 
2.57 3.5±0.03 4.0±0.05 3.2±0.03 2.3±0.02 4.9±0.01 3.0±0.01 
PANC-1, MIA PaCa 2, MCF-7, PC-3, Hep G2 and A549 cells were treated with the indicated compounds 
at varying concentrations for 72 h. The antiproliferative effects were determined using an MTT assay and 
the IC50 was calculated. The results shown are means ± SE of three independent experiments. 
 
Pancreatic cancer AsPC-1 cells are the most susceptible to these compounds and 
compound 2.57 is the most active one. AsPC-1 cells were used to study the underlying 
antiproliferative mechanisms of compound 2.57. AsPC-1 cells were treated with 2-10 μM 
of compound 2.57 for 24 h.  
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Figure 2.2.26. Cell cycle arrest and apoptosis induction of compound 2.57 in AsPC-1 
cells. (A) Cell cycle analysis of AsPC-1 cells treated with compound 2.57. The results shown 
are means ± SE of three independent experiments. (B) Representative FACS analyses of cell 
cycle of AsPC-1 cells treated with compound 2.57 at the indicated concentrations for 24 h. 
The sub-G1 phase (apoptotic cells) of AsPC-1 cells was detected only in cells treated with 
compound 2.57 at 10 µM. The cell cycle was determined by FACS after staining with PI. 
 
Compound 2.57 induced cell cycle arrest at G1 phase at the concentration of 6 μM 
and the population of cells at sub-G1 phase was increased after treatment with compound 
2.57 at higher concentrations (Figure 2.2.26), implying that the antiproliferative effects of 
this compound are due to cell cycle arrest and induction of apoptosis. The levels of a few 
of cell cycle and apoptosis related proteins were determined (Figure 2.2.27). p21
waf1
 is a 
cell cycle regulator of G1 phase which is not expressed in pancreatic cancer cells.
445
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NOXA is a BH3 protein responsible for the regulation of anti-apoptotic protein Mcl-1. 
The levels of p21
waf1
 and NOXA were increased significantly in AsPC-1 cells treated 
with compound 2.57 at concentrations higher than 6 μM. Unlike other triterpenoid 
derivatives which decreased the levels of Mcl-1,
280
 compound 2.57 did not decrease the 
levels of Mcl-1. This result suggests that this compound has a new mechanism of action. 
The apoptosis induction may rely on the induction of NOXA which antagonize the 
function of Mcl-1 and then lead to apoptosis via activation of caspases 9 and 3. NOXA 
and p21
waf1
 are regulated by p53 and compound 2.57 increased the levels of p53 protein. 
The role of p53 in compound 2.57-mediated cell cycle arrest and apoptosis induction as 
well as the mechanism of compound 2.57 to increase p53 level need to be studied further. 
 
 
 
Figure 2.2.27. Compound 2.57 increased the levels of p21
waf1
, NOXA and p53 protein in AsPC-1 
cells. AsPC-1 cells were treated with compound 2.57 at the indicated concentrations for 24 h. The 
relative levels of indicated proteins were determined by Western blot analysis. GAPDH was used 
as a loading control. 
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2.2.3. Conclusions  
 
In summary, this section presented a series of new N-alkylimidazoles, N-
acylimidazoles and carbamate ursolic acid derivatives with the introduction of 
heterocyclic rings (imidazole, methylimidazole or triazole) at different positions of the 
ursane backbone. These new derivatives of ursolic acid 2.1 were fully characterized using 
NMR, MS and IR techniques. 
The new semisynthetic derivatives exhibited a good antiproliferative profile against 
AsPC-1 cells. Compounds 2.29-2.31, 2.43-2.45 and 2.56-2.58, which carried a 
heterocyclic ring in conjugation with an α,β unsaturated ketone in ring A of the ursane 
skeleton, were the most active in inhibiting AsPC-1 cell growth. Compound 2.57 yielded 
the best results in a series of cancer cell lines, targeting NOXA, p21
waf1
 and p53 in AsPC-
1 cells. 
These compounds represent a new group of ursane derivatives that are a good 
starting point for drug discovery in cancer. 
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2.3. Fluorolactones and fluorine derivatives 
2.3.1. Introduction 
 
Fluorine is the least abundant halide in natural compounds, as less than 20 natural 
compounds have it in their structure. This is because of its low abundance on the earth’s 
surface and because few living cells are able to metabolize it.
446, 447
 Until 1970, the 
presence of fluorine substituents in pharmaceutical compounds was less than 2%; 
currently, that percentage is around 20% and increasing.
448, 449
 This increase was possibly 
caused by the introduction of safer and more selective methods for fluorination reactions 
and of fluorinated agents that are compatible with ordinary laboratory equipment.
449
 
Fluorinated organic compounds can be obtained from nucleophilic, electrophilic and 
radical forms of fluorine reagents (Figure 2.3.1).
449-451
 Nucleophilic reagents, such as 
diethylaminosulfur trifluoride (DAST) and bis(2-methoxyethyl) aminosulfur trifluoride 
(Deoxofluor), are used to prepare mono and difluoroalklyl compounds from alcohols, 
ketones and aldehydes.
450, 452, 453
 Electrophilic reagents use an “F+”, usually in an N-F 
reagent, such as 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis 
(tetrafluoroborate) (Selectfluor) and N-fluorobenzenesulfonimide (Accufluor), to 
fluorinate the carboanion present in ketones, aldehydes, esters and heterocycles.
450, 452, 454
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Figure 2.3.1. Examples of nucleophilic (DAST and Deoxofluor) and electrophilic (Selectfluor 
and Accfluor) fluorine reagents. 
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Fluorinated compounds are very attractive, because a single fluorine atom located in 
a key position of a molecule can result in a profound pharmacological effect. Fluorine is a 
small and highly electronegative atom, and its presence in key positions of a biologically 
active molecule can improve metabolic and chemical stability, membrane permeability 
and binding affinity.
448, 455-457
 The C–F bond is one of the strongest chemical bonds and 
compounds with this functional group have a high thermal and oxidative stability, low 
polarity and a small surface tension, making them less likely to undergo enzymatic liver 
degradation, especially by the P450 cytochrome enzymes.
446, 449, 455, 456
 The presence of 
fluorine in bioactive molecules changes the basicity of nearby functional groups, thus 
changing the pKa of the molecule and having a strong effect on both the pharmocokinetic 
properties and binding affinity.
455
 Fluorine is oriented toward electropositive sites; thus, 
fluorophilic environments in peptides, interactions such as the C–F---H–N, C–F---C=O 
and C–F---H–C, have been identified.456  
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Figure 2.3.2. Some examples of fluorinated drugs used in medical settings. 
 
5-Fluorouracil, which was synthesized by Charles Heidelberger in 1957, was the first 
synthetic fluorinated compound used in clinical settings as an anticancer therapeutic 
agent.
448, 458, 459
 Synthetic and semisynthetic fluorinated compounds used in clinical 
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settings have a broad range of action, such as anti-inflammatory (fluoromethotrexate or 
celecoxib), antibacterial (fluoroquinolones), antidepressive (fluoxetine), anti-HIV 
(indinavir), anticolesterol (ezetimibe), antithrombotic (7,7-difluoro-thromboxane), 
noninvasive monitoring therapeutic (2-deoxy-2-fluor-D-glucosyl) and antitumorigenic 
(gemcitabine) (Figure 2.3.2).
455
  
Anticancer fluorinated compounds are very common in clinical practice and can be 
classified into different categories depending on their mechanism of action: thymidylate 
synthase inhibitor (5-fluorouracil), topoisomerase inhibitor (gemcitabine), multidrug 
efflux protein resistance inhibitor (zosuquidar), antiestrogenic (panomifene), protein 
kinase inhibitor (gefitinib) and antiandrogenic (flutamide) (Figure 2.3.3).
447
 
Fluorinated ursolic acid 2.1 derivatives were developed in an attempt to improve the 
antitumor activity of the parental compounds. 
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Figure 2.3.3. Anticancer fluorinated drugs. 
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2.3.2. Results and Discussion 
2.3.2.1. Chemistry 
2.3.2.1.1. Fluorolactones 
 
Selectfluor was used as the electrophilic fluorination reagent to introduce fluorine 
into ursolic acid 2.1 and derivatives. Selectfluor is a crystalline white solid and is stable at 
high temperatures. It is easy to work with this compound, as the byproducts are usually 
easily removed by an aqueous workup.
460, 461
 Several papers have described the reaction 
of alkenes with selectfluor, usually in the presence of a nucleophilic donor.
462-466
 The 
solvent, the temperature, and the nucleophilic donor can influence the efficiency and the 
outcome (number of isomers and byproducts) of this reaction. The optimal conditions for 
the performance of fluorination in several ursane-type substrates using selectfluor were 
achieved by using a mixture of two inert solvents, dioxane and nitromethane, at 80°C. 
The fluorination of ursane-type triterpenoids, if performed in a reaction medium 
without a nucleophilic donor, allows the synthesis of a fluorolactone. The free acid 
behaves as a nucleophilic donor, leading to loss of the proton and promotion of 
cyclization at carbon C13 in the ursane skeleton. This reaction is not possible in ursane-
type compounds in which the acid is protected; however, the free acid by itself does not 
react with selectfluor.
460
 
Compounds 2.59-2.63 were synthesized via the reaction of compounds 2.1, 2.3-2.5 
and 2.17 with selectfluor at 80ºC in a mixture of nitrometane and dioxane, affording a β-
fluorine at C12 and a 13,28-β-lactone, with yields above 36% (Schemes 2.3.1 and 2.3.2). 
The fluorination of compound 2.3 by selectfluor results in the formation of a 
fluorolactone, and in an additional fluorination at carbon C2, adjacent to the carbonyl 
group. Fluorination of positions adjacent to a carbonyl group are described in the 
literature, with the α isomer being the major product (Scheme 2.3.2). 454, 461, 465, 467 
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Scheme 2.3.1.
a
 Synthesis of derivatives 2.59-2.62. 
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a
Reagents: (a) Selectfluor, dioxane, nitromethane, 80 ºC. 
 
Scheme 2.3.2.
a
 Synthesis of derivative 2.63. 
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a
Reagents: (a) Selectfluor, dioxane, nitromethane, 80 ºC. 
 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
138 
 
The choice of performing fluorination before esterification and Jones oxidation in 
compounds 2.64-2.66 and 2.67, respectively, was based on the fact that some of these 
functionalities can also be fluorinated, giving a complex mixture of diverse fluorinated 
compounds (Scheme 2.3.3). Compounds 2.60 and 2.61 were fluorinated after 
esterification, as this synthetic route generates better yields. The new fluorolactones 
achieved are chemically stable and allow the performance of several post-fluorination 
modifications using acidic and basic conditions. 
 
Scheme 2.3.3.
a
 Synthesis of derivatives 2.64-2.67. 
O
H
O
OF
R1
O
R1 = CF3
R1 = CH2CH2CH3
 
R1=
HO
H
O
OF
O
H
O
OF
2.64
2.65
2.66
2.59
2.67
b
a
 
 
a
Reagents: (a) Anhydride, DMAP, THF, r.t.; (b) Jones reagent, acetone, ice. 
 
Honda et al first described the introduction of a cyano group at the C2 carbon of 
ursolic acid 2.1.
295
 Herein, we reproduced a similar reactional sequence for ursolic acid 
2.1, with the introduction of the fluorolactone as the last modification of the ursane 
backbone (Scheme 2.3.4). Despite the optimization of the process, this reaction yielded a 
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mixture of fluorolactone α- and β-isomers, among which compound 2.73, the β-isomer, 
was the major reaction product.  
 
Scheme 2.3.4.
a
 Synthesis of derivatives 2.72 and 2.73. 
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a
Reagents: (a) NH2OH.HCl, H2O, EtOH, reflux; (b) NaOMe, Et2O, MeOH, 0 ºC-r.t.; (c) DDQ, 
benzene, relux; (d) LiI, DMF, reflux; (e) Selectfluor, dioxane, nitromethane, 80 ºC.  
 
Previously, our group found that the introduction of heterocyclic rings into betulin 
and betulinic acid increased the cytotoxic activity of the parental compounds.
433, 434, 437
 
Ursolic acid 2.1 has several points in its structure that are accessible for these types of 
chemical modifications. The introduction of a heterocyclic ring in ursolic acid fluorine 
derivatives can be achieved, with good yields (Scheme 2.3.5). 
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Scheme 2.3.5.
a
 Synthesis of derivatives 2.74-2.80.
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a
Reagents: (a) Jones reagent, acetone, ice; (b) Ethyl formate, NaOMe, benzene, r.t.; (c) CDI or 
CBMI or CDT, THF, N2, reflux. 
 
The preparation of the new derivatives with fluorolactone and a heterocyclic ring 
(compounds 2.75-2.80) was achieved via the dissolution of the respective fluorolactone, 
compounds 2.59 or 2.74, in THF, heating until reflux under an inert atmosphere and by 
the addition of CDI, CBMI or CDT, to give imidazole, methylimidazole and triazole 
derivatives, respectively (Scheme 2.3.5). The reaction of alcohols with these reagents, 
CDI, CBMI and CDT, gave N-alklylimidazoles 
438, 440
 or imidazole carboxylic esthers 
(carbamates), 
433, 434, 441
 depending on the alcohol and reaction conditions used. 
Compound 2.59, with a secondary alcohol at position C3, afforded carbamates 2.75-2.77. 
Compound 2.74, with a vinyl alcohol at position C2, gave the N-alkylimidazoles 2.78-
2.80. 
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Full structural elucidation of the fluorolactones was achieved using IR, 1D and 2D 
NMR and MS. 
Usually, the band in IR corresponding to the C–F stretching vibration appeared 
between 1000-1400 cm
–1
, which in these compounds coincided with other bands, such as 
C–O and C–H (Figure 2.3.4). 
 
 
Figure 2.3.4. IR spectrum of compound 2.59. 
 
The nature of the isomers α and β was determined using 1D and 2D NMR and was 
confirmed via X-ray crystallography of compound 2.66. 
The geminal proton of the β-fluorine on carbon C12 gave a double triplet or a double 
quartet, with a δ signal at 5.0-4.8 ppm and a coupling constant around 62 Hz (Figure 
2.3.5). The α-isomer also gave a double triplet at δ 4.42-4.51 ppm, a signal that was 
slightly lower than that of the β-isomer, and a coupling constant around 67 Hz (Figure 
2.3.6), which was higher than that of the β-isomer, in the 1H NMR spectrum.468, 469 
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Figure 2.3.5. 
1
H NMR spectrum of compound 2.73. 
 
 
Figure 2.3.6. 
1
H NMR spectrum of compound 2.72. 
 
In the 
13C NMR spectrum of compounds bearing the β-fluorolactone modification, 
carbon C12 appeared as a doublet, with δ values between 88.5 and 89.6 ppm and a 
coupling constant around 180 Hz. Carbon C13 also appeared as a doublet, with values of 
δ 91.5-91.9 ppm with a lower coupling constant, around 14 Hz.469, 470 Carbons C18, C14, 
C11 and C9 on the ursane β-fluorolactone also have doublet δ signals in the 13C NMR 
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spectrum (Figure 2.3.7). In the 
13
C NMR spectrum, compound 2.72 presented some 
differences from compounds with a β-fluorolactone: carbon C12 appeared at higher 
values, a δ signal at 96 ppm, with a coupling constant of 189 Hz, and carbon C13 was 
present as a singlet at δ 90 ppm.469, 470 
 
 
Figure 2.3.7. 
13
C NMR of compound 2.73. 
 
The correlations in the HMBC and HMQC spectra of compound 2.73 allowed the 
indentification of several δ signals in the 1H and 13C NMR spectra (Figure 2.3.8). The 
modifications in ring A of this compound had been described previously, which permitted 
the identification of the δ signals for carbons C1, C2, C3 and CN.294 In the 1H NMR 
spectrum, compounds 2.72 and 2.73 presented a signal at δ 7.81 ppm, corresponding to 
proton H1. In the 
13
C NMR spectrum, this signal corresponded to a δ signal at 169.04 
ppm. Carbon C1 correlated with the methyl group at C25 and with proton H9; carbons 
C10 and C8 also correlated with proton H9. Carbons C13 and C17 correlated with proton 
H18, which allowed the identification of the δ signal observed at 52.61 ppm as C18 in the 
13
C NMR spectrum (Table 2.3.1).  
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Figure 2.3.8. HMBC of compound 2.73. 
 
NOESY experiments correlate protons that are close to each other in space, allowing 
the identification of protons with the same space orientation. In the fluorolactones 
synthesized, NOESY spectra allowed the identification of proton H12 as presenting an α 
configuration in compounds 2.59-2.71 and 2.73-2.80 (Figure 2.3.9). Proton H12 in 
NOESY spectra correlated with the methyl group at C27 and with proton H9, both of 
which exhibited an α configuration (Figure 2.3.10).  
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Figure 2.3.9. NOESY spectrum of compound 2.73. 
 
 
Figure 2.3.10. Detail of the NOESY spectrum of compound 2.73. Correlation of proton H12 with 
the methyl group at C27 (green) and correlation of proton H12 with proton H9 (red). 
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The configuration 12β-fluoro-13,28β-lactone was confirmed in the ORTEP of 
compound 2.66, which was crystallized in acetonitrile (Figure 2.3.11). 
 
 
 
Figure 2.3.11. ORTEP diagram of compound 2.66 (50% probability level, H atoms of arbitrary 
sizes).  
 
Fluorolactone 2.63, with one additional fluorine substituent at carbon C2, presented 
additional duplicated δ signals in the 1H and 13C NMR spectra. The analysis of the 1H, 
13C, DEPT, HMBC, HMQC and NOESY spectra permitted the identification of various δ 
signals in 
1
H and 
13
C NMR spectra (Table 2.3.1). 
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Table 2.3.1. Selected 
1
H and 
13
C NMR data from the backbone of 
compounds 2.63 and 2.73. 
Entry Position 
2.63 2.73 
δ H δ C δ H δ C 
1 1 
2.58 
(J= 26.25) 
47.23 
(J= 17.17) 
7.82 169.04 
2 2 
5.30 
(J= 66.18) 
89.05 
(J= 186.30) 
- 114.41 
3 3 - 209.63 - 197.70 
4 4 - 48.49 - 45.05 
5 5 - 56.41 - 52.71 
6 7 - 33.47 - - 
7 8 - 42.63 - 43.48 
8 9 - 
48.71 
(J= 48.71) 
- 
42.43  
(J= 9.85) 
9 10 - 
38.04 
(J= 9.40) 
- 40.40 
10 11 - 
25.72 
(J= 20.16) 
- - 
11 12 
4.88 
(J= 62.48) 
88.75 
(J= 186.09) 
4.94 
(J= 62.15) 
88.54 
(J= 183.62) 
12 13 - 
91.63 
(J= 14.40) 
- 
91.52 
(J= 14.49) 
13 14 - 
43.97 
(J= 2.97) 
- - 
14 15 - 27.60 - - 
15 17 - 45.13 - 
44.17 
(J= 2.72) 
16 18 - 
52.54 
(J= 3.34) 
- 
52..61 
(J= 3.16) 
17 25 1.23 17.48 1.20 27.69 
18 26 1.26 18.63 1.31 18.91 
19 27 1.19 17.16 
1.22 
(J= 3.13) 
17.00 
20 28 - 178.68 - 178.38 
21 29 - - 1.25 18.91 
22 30 - - 
0.98 
(J= 5.71) 
19.38 
23 CN - - - 114.70 
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Compounds 2.74-2.80 also exhibited the 12β-fluor-13,28β-lactone functionality, in 
which proton H12 was present in the 
1H NMR spectrum as a δ signal around 4.98 ppm. 
Moreover, in the 
13C NMR spectrum, the δ signals for carbons C12 and C13 appeared as 
doublets around 88 and 91 ppm, respectively. The proton of the exocyclic double bond at 
C2 of compounds 2.74 and 2.78-2.80 was observed on the 
1H NMR spectrum at δ signals 
between 8.62 and 7.66 ppm, depending on the substituent group present. The imidazole 
group on compounds 2.75 and 2.78 had three specific protons that appeared in the 
1
H 
NMR spectrum at a δ signal higher than 7 ppm. Compounds 2.76 and 2.79, with a 
methylimidazole group, had only two protons in the 
1H NMR spectrum, between δ 6.7 
and 7.4 ppm. The triazole group in compounds 2.77 and 2.80 was identified by the 
presence of two δ signals higher than 8 ppm. 
The HMBC, HMQC and NOESY spectra correlations allowed the identification of 
several δ signals (Figure 2.3.12). Table 2.3.2 presents some 1H and 13C NMR δ signals 
for compounds 2.75 and 2.79. 
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Figure 2.3.12. Some HMBC (black) and NOESY (red) correlations for compound 2.79. 
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Table 2.3.2. Selected 
1
H and 
13
C NMR data from the backbone of 
compounds 2.75 and 2.79. 
Entry Position 
2.75 2.79 
δ H δ C δ H δ C 
1 1 - - - 422.87 
2 2 - - - 123.05 
3 3 
4.68 
(J= 15.87) 
85.84 - 206.08 
4 4 - 38.19 - 45.16 
5 5 
0.86 
(J= 8.75) 
55.32 - 52.40 
6 8 - 42.54 - 42.21 
7 9 - 
49.06 
(J= 9.38) 
- 
47.08 
(J= 9.41) 
8 10 - 37.03 - 36.32 
9 12 
4.87 
(J= 62.65) 
89.49  
(J= 185.86) 
4.93 
(J= 62.33) 
89.33 
(J= 186.24) 
10 13 - 
91.80 
(J= 14.31) 
- 
91.74 
(J= 14.41) 
11 14 - 43.94 - 
44.06 
(J= 2.74) 
12 15 - 27.63 - - 
13 17 - 45.17 - 45.24 
14 18 - 
52.55 
(J= 3.34) 
- 
52.57 
(J= 3.34) 
15 19 - 38.40 - 38.57 
16 20 - 39.53 - 39.51 
17 25 0.98 19.39 0.90 16.41 
18 26 1.22 18.53 1.26 17.69 
19 27 1.21 17.21 1.24 16.48 
20 28 - 178.75 - 178.59 
21 29 
1.14 
(J= 6.20) 
16.50 1.16 16.48 
22 30 - - 0.97 19.36 
23 OCO - 148.46 - - 
24 C2CH - - 7.66 130.67 
25 C2’ - - - 147.37 
26 
CH3 
imidazole 
- - 2.48 13.66 
27 C4’ - - 7.16 117.97 
28 C5’ - - 7.03 128.76 
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2.3.2.1.2. Acyl fluorides 
 
Nucleophilic fluorination reactions using DAST or deoxofluor are methodologies 
that are widely used for the preparation of fluorinated organic compounds. Deoxofluor is 
thermally more stable than DAST and, in some cases, can have a better reactivity and 
selectivity.
471, 472
 Deoxofluor can easily convert alcohols to alkyl fluorides, aldehydes and 
ketones to gem-difluorides, and carboxylic acids to acid fluorides or trifluoromethyl 
derivatives.
453, 473, 474
  
Nucleophilic fluorination of lupane triterpenoids has been reported using DAST;
475
 
however, the reaction conditions require the use of extremely low temperatures. The use 
of deoxofluor as a nucleophilic reagent in ursane derivatives allowed the synthesis of acyl 
fluorides of the correspondent carboxylic acid, in good yields (Scheme 2.3.6).  
 
Scheme 2.3.6.
a
 Synthesis of derivatives 2.81 and 2.82.
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a
Reagents: (a) Deoxofluor, THF, ice.  
 
Acid halides have a carbonyl group with a stretching vibration near 1800 cm
–1
. 
Compounds 2.81 and 2.82 presented a stretching vibration around 1827 cm
–1
, 
corresponding to the carbonyl stretching vibration. The C–F stretching vibration was 
merged with other absorption regions of the ursane backbone (Figure 2.3.13).  
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Figure 2.3.13. IR spectrum of compound 2.81. 
 
On the 
1
H NMR spectrum, acyl fluorides with an ursane backbone presented a 
spectrum that was identical to that of the intermediate. On the 
13
C NMR spectrum, the 
only difference relative to the intermediate was the signal of the carbonyl group of the 
acyl haldide. In compounds 2.81 and 2.82, carbon C28 appears as a doublet with a δ 
signal of 167.06 ppm and a coupling constant of 376 Hz (Figure 2.3.14). 
 
 
Figure 2.3.14. 
13
C NMR spectrum of compound 2.82. 
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2.3.2.2. Biological evaluation 
 
The fluorolactone of ursolic acid 2.1, compound 2.59, exhibited a similar 
antiproliferative activity against AsPC-1 cells compared with ursolic acid 2.1. However, 
compounds 2.60 and 2.61, which have a fluorolactone moiety, showed increased 
antiproliferative activities compared with compounds 2.4 and 2.5, respectively (Figure 
2.3.15; Tables 2.3.3 and 2.3.4). Several additional modifications were performed at C3 of 
the ursane fluorolactone, to yield compounds 2.64-2.67 and 2.75-2.77. Oxidation of the 
hydroxyl function was reported to increase the biological activity of the triterpenoid 
compounds;
293
 however, compound 2.64 exhibited only a slight increase in the 
antiproliferative activity compared with compound 2.59. In addition, the introduction of a 
fluorine at C2, compound 2.63, did not increase the antiproliferative activity. Carbamates 
2.75 and 2.76 exhibited an increase of 2- and 3-fold in antiproliferative activity against 
AsPC-1 cancer cells compared with ursolic acid fluorolactone 2.59 (Table 2.3.4). 
Compounds 2.65 and 2.66 were prepared by esterification with butyric and benzoic 
anhydrides, respectively. This process generated some of the most active compounds, 
with 8- and 15-fold increase in antiproliferative activity compared with compound 2.59 
(Table 2.3.4).  
 
Table 2.3.3. The IC50 (µM) of ursolic acid intermediates in the inhibition of 
AsPC-1 cell growth. 
Entry Compd AsPC-1 
1 2.1 12.6±0.03 
2 2.3 24.5±0.12 
3 2.4 71.0±0.1 
4 2.5 42.3±0.02 
5 2.13 7.2±0.02 
6 2.70 2.0±0.1 
7 2.71 15.9±0.2 
AsPC-1 cells were treated with the indicated compounds at varying concentrations 
for 72 h. The antiproliferative effects were determined using a MTT assay and the 
IC50 was calculated. The results shown are means ± SE of three independent 
experiments. 
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Table 2.3.4. The IC50 (µM) of ursolic acid fluorolactone derivatives in the inhibition of 
AsPC-1 cell growth. 
H
O
OF
A
 
Entry Compd Ring A AsPC-1 
1 2.59 
HO
 
18.4±0.09 
2 2.60 
OH3C
O
 
13.4±0.10 
3 2.61 O
O
COOH  
18.0±0.06 
4 2.62 NO
 
10.9±0.02 
5 2.63 
O
F
 
14.1±0.15 
6 2.64 
OF3C
O
 
10.0±0.07 
7 2.65 
OH3CH2CH2C
O
 
2.2±0.1 
8 2.66 O
O
 
1.2±0.01 
9 2.67 
O
 
6.0±0.07 
10 2.75 
ON
O
N
 
9.5±0.1 
11 2.76 
ON
O
N
 
6.1±0.04 
12 2.77 ON
O
N
N  
26.6±0.12 
AsPC-1 cells were treated with the indicated compounds at varying concentrations for 72 h. The 
antiproliferative effects were determined using a MTT assay and the IC50 was calculated. The results shown 
are means ± SE of three independent experiments. 
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Table 2.3.5. The IC50 (µM) of ursolic acid fluorolactones in the inhibition of the growth of three 
pancreatic cancer cell lines.  
A H
O
OR
 
Entry Compd Ring A R AsPC-1 MIA PaCa 2 PANC-1 
1 2.72 
O
NC
 
F
 0.7±0.05 0.9±0.01 1.8±0.04 
2 2.73 
O
NC
 
F
 0.5±0.08 2.1±0.1 14.3±0.03 
3 2.74 O
HO
 
F
 11.0±0.05 ND ND 
4 2.78 
O
N
N
 
F
 1.1±0.02 6.0±0.03 4.6±0.03 
5 2.79 
O
N
N
 
F
 1.0±0.05 28.1±0.02 21.4±0.06 
6 2.80 O
N
N
N
 
F
 7.5±0.07 10.2±0.02 10.1±0.02 
AsPC-1, MIA PaCa 2 and PANC-1 cells were treated with the indicated compounds at varying 
concentrations for 72 h. The antiproliferative effects were determined using a MTT assay and the IC50 
was calculated. The results shown are means ± SE of three independent experiments. ND, not 
determined. 
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Figure 2.3.15. Structure activity relationships (SAR) among several synthetic 
derivatives of ursolic acid 2.1. The comparison was made based on their IC50s in the 
inhibition of AsPC-1 cell growth. Compound 2.60 was 5-fold more potent than compound 
2.4, and compound 2.61 was 2-fold more potent than compound 2.5. 
 
Previously, it was shown that the introduction of a cyano group at C2 and of a 
carbonyl group at C11 improved significantly the cytotoxicity of ursolic acid 2.1.
302
 We 
applied a similar chemical procedure at ring A, as described previously,
295
 and 
synthesized compounds 2.72 and 2.73 (Scheme 2.3.4). Compounds 2.72 and 2.73 were 
more effective than compounds 2.70 and 2.71 synthesized previously in the 
antiproliferative assay using AsPC-1 cells (Tables 2.3.3 and 2.3.5), as they exhibited an 
increase of 19-fold in antiproliferative activity compared with ursolic acid 2.1 (Figure 
2.3.16). The intermediates of compounds 2.72 and 2.73, compounds 2.70 and 2.71, were 
less active (Table 2.3.3, entries 5 and 6), suggesting that the addition of a fluorolactone 
contributes to the improvement of the antiproliferative activity of compounds 2.72 and 
2.73 (Table 2.3.5, entries 1 and 2). 
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Table 2.3.6. The IC50 (µM) of ursolic acid fluorolactones in the inhibition of the 
growth of breast (MCF-7), prostate (PC-3), hepatic (Hep G2) and lung (A549) cancer 
cell lines. 
Entry Compd MCF-7 PC-3 Hep G2 A549 
1 2.72 0.7±0.20 0.9±0.01 0.5±0.12 0.9±0.05 
2 2.73 2.2±0.11 2.0±0.03 3.0±0.11 10.0±0.05 
3 2.78 2.8±0.04 4.0±0.03 6.8±0.07 9.5±0.08 
4 2.80 7.0±0.05 5.6±0.02 10.6±0.14 16.2±0.03 
MCF-7, PC-3, Hep G2 and A549 cells were treated with the indicated compounds at varying 
concentrations for 72 h. The antiproliferative effects were determined using an MTT assay and 
the IC50 was calculated. The results shown are means ± SE of three independent experiments. 
 
Compound 2.74 was synthesized with the intent of exploring the effect of the 
introduction of different substituents at C2 of the fluorolactone structure, as it contains a 
vinyl alcohol at that position. The substitution of the alcohol group of compound 2.74 
with a heterocyclic ring, imidazole or methylimidazole, afforded compounds 2.78 and 
2.79, respectively, with improved antiproliferative effects in AsPC-1 cells, reaching an 
increase of 17-fold compared with compound 2.59 (Figure 2.3.16). Compounds 2.78 and 
2.79, N-alklylimidazoles, exhibited activities similar to those of 2.72 and 2.73 in the 
inhibition of AsPC-1 cell growth (Table 2.3.5). The antiproliferative effects of 
compounds 2.72, 2.73 and 2.78-2.80 were determined in two additional pancreatic cancer 
cell lines. MIA PaCa 2 and PANC-1 cells were less sensitive than AsPC-1 cells to these 
compounds, with higher IC50s (Table 2.3.5). 
The antiproliferative effects of compounds 2.72, 2.73, 2.78 and 2.80 were also tested 
against MCF-7, PC-3, Hep G2 and A549 cell lines. Among the compounds tested, 
compound 2.72 was the most active in all cell lines, with IC50s lower than 1 μM (Table 
2.3.6). 
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Figure 2.3.16. Structure activity relationships (SAR) among several synthetic derivatives of 
ursolic acid 2.1. The comparison was made based on their IC50s in the inhibition of AsPC-1 cell 
growth. Compound 2.71 was 5- fold more potent than ursolic acid 2.1. Compounds 2.72 and 2.73 
were 19-fold more potent than ursolic acid 2.1, 4-fold more potent than compound 2.71 and 26-
fold more potent than compound 2.59. Compounds 2.78 and 2.79 were 11-fold more potent than 
ursolic acid 2.1, 2-fold more potent than compound 2.71, and 17-fold more potent than compound 
2.59. Compound 2.66 was 11-fold more potent than ursolic acid 2.1 and 15-fold more potent than 
compound 2.59. Compound 2.65 was 6-fold more potent than ursolic acid 2.1 and 8-fold more 
potent than compound 2.59. 
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Figure 2.3.17. Cell cycle arrest and apoptosis induction by compound 2.72 in AsPC-1 cells. (A) 
Cell cycle analysis of AsPC-1 cells treated with compound 2.72. (B) Representative FACS 
analyses of G1 phase arrest in AsPC-1 cells treated with compound 2.72 at 1 µM for 24 h. (C) 
Representative FACS analyses of induction of sub-G1 phase (apoptotic cells) in AsPC-1 cells 
treated with compound 2.72 at 8 µM for 24 h. (D) Relative levels of apoptosis- and cycle-related 
proteins in AsPC-1 cells treated with a variety of concentrations of compound 2.72 for 24 h. The 
cell cycle was determined by FACS after staining with PI. The relative protein levels were 
determined by Western blot analysis. GAPDH was used as a loading control. 
 
The introduction of an electron-withdrawing group at C2 of the ursolic acid 2.1 
(compounds 2.72 and 2.73) amplified the antitumor activity of these compounds, 
allowing the nucleophilic attack by thiol or other nucleophiles at C1, which in turn 
acquired an increased electrophilic nature because of the substituent at C2.
414, 444
 The 
presence of a fluorolactone moiety may increase the ability of these compounds to 
interact with potential targets. Overall, the modification by introduction of a fluorolactone 
(compounds 2.72 and 2.73) instead of a methoxyl group at C28 improved the 
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antiproliferative activity of these compounds by more than 4-fold compared with that of 
compound 2.71 (with a cyano group at C2) and by more than 19-fold compared with that 
of ursolic acid 2.1 (without a cyano group at C2) in AsPC-1 cells (Figure 2.3.16). 
Fluoro acyl derivatives 2.81 and 2.82 had an IC50 of 11.8 and 33.4 μM, respectively, 
which represented an improvement of 0.5- and 2-fold relative to the intermediates 2.3 and 
2.4. These compounds did not exhibit an improvement in antiproliferative activity when 
compared with ursolic acid 2.1. 
Because compound 2.72 was the most active, it was selected to study the mechanism 
by which antiproliferative activity is mediated in AsPC-1 cells. As shown in Figure 
2.3.17 A-C, compound 2.72 arrested the cell cycle at the G1 phase at 1 μM and increased 
the population of cells in the sub-G1 phase at higher concentrations (8 μM). These data 
suggest that this compound has a dual effect: it arrests cell cycle progression and induces 
apoptosis. The effects of compound 2.72 were tested at the level of cell cycle-regulating 
and apoptosis-related proteins at concentrations of 1-8 μM. Compound 2.72 significantly 
increased the levels of p21
waf1
 at 1 μM, which correlated with cell cycle arrest in the G1 
phase (Figure 2.3.17 D). The observation that other proteins were not significantly 
regulated by compound 2.72 at 1 μM suggests that p21waf1 is a primary target of 
compound 2.72. Increased concentrations of compound 2.72 did not increase the levels of 
p21
waf1
 further, but decreased the levels of c-FLIP (Figure 2.3.17 D). Ursolic acid 2.1 has 
been shown to decrease the levels of c-FLIP as a mechanism to potentiate TRAIL-
induced apoptosis in the HCT116 human colon adenocarcinoma cell line.
208
 These data 
suggest that the downregulation of c-FLIP may lead to apoptotic effects. We observed 
evident apoptotic induction ability at 8 μM, which was not only correlated with the 
downregulation of c-FLIP, but also correlated with the upregulation of NOXA. NOXA is 
a BH3 protein that blocks the anti-apoptotic protein Mcl-1. Unlike other triterpenoid 
derivatives, compound 2.72 did not decrease the levels of Mcl-1, suggesting a different 
mechanism of action for this new compound.
280
 The upregulation of p21
waf1
 and NOXA 
and the downregulation of c-FLIP after treatment with compound 2.72 were also 
observed in MIA Paca 2 and PANC-1 cells (Figure 2.3.18). This data suggest that the 
p21
waf1
, NOXA and c-FLIP proteins are targets of these new fluorolactone derivatives. 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
160 
 
 
 
Figure 2.3.18. Relative levels of apoptosis- and cycle-related proteins in (A) MIA PaCa 
2 and (B) PANC-1 cells.  Cells were treated with compound 2.72 at 8 µM for 24 h. Relative 
protein levels were assessed by Western blot analysis. GAPDH was used as a loading 
control. 
 
2.3.3. Conclusions 
 
In conclusion, a new procedure for the preparation of fluorolactones and fluorine 
acyl derivatives of ursolic acid was achieved via the preparation of a novel panel of 
fluorine derivatives, compounds 2.59-2.82. Some of these compounds exhibited a better 
antiproliferative activity against AsPC-1 cells compared with ursolic acid 2.1. 
 
Compound 2.72 was the most active in inhibiting cancer cell growth, with IC50 
values lower than 1 μM. This compound arrested the cell cycle in the G1 phase and 
induced apoptosis with upregulation of NOXA and p21
waf1
 and downregulation of c-
FLIP. The mechanisms underlying the increase of NOXA and p21
waf1
 levels and the 
decrease of c-FLIP levels are worthy of further investigation. 
 
These results show that ursolic acid fluorolactone derivatives, such as compound 
2.72, are good starting points for drug discovery in cancer. 
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2.4. Experimental section 
2.4.1. Chemical 
 
IR spectra were recorded in JASCO FT/IR-420. 
1
H, 
13
C, DEPT-135, HMQC, 
HMBC, COESY and NOESY spectra were recorded in a Bruker Avance III 400 MHz 
spectrometer. The chemical shifts were recorded in δ (ppm) using the δ 7.26 of CHCl3 
(
1H NMR) and the δ 77.00 (13C NMR) as internal standards. Chemical shifts measures 
were given in ppm and coupling constants (J) in hertz (Hz). Low resolution mass 
spectrometry was obtained in a Finnigan Polaris QGC/MS Benchtop Ion Trap 
spectrometer with a direct insertion probe and the elemental analysis was obtained in an 
Analyzer Elemental Carlo Erba 1108 by chromatographic combustion. Melting points 
were determined using a BUCHI melting point B-540 apparatus and were uncorrected. 
For thin layer chromatography (TLC) analysis Kiesel gel 60HF254/kiesel gel 60G was 
used and FCC was performed using Kieselgel 60 (230-400 mesh, Merck). Ursolic acid 
2.1, CDI, CBMI, CDT, Selectfluor, Deoxofluor, DMAP, fluoroacetic anhydride, benzoic 
anhydride, butyric anhydride, acetic anhydride, phthalic anhydride, ethyl formate, 2,3-
dichloro-5,6-dicyanobenzoquinone (DDQ), sodium methoxide (NaOMe), lithium iodide, 
THF, dioxane, nitromethane, dimethylformamide (DMF) and benzene were purchased 
from Sigma Aldrich Co. The solvents used in the workups were purchase from VWR 
Portugal, and were of analytical grade. Potassium bicarbonate, sodium chloride, sodium 
bicarbonate, sodium sulfite, potassium permanganate, and hidroxylamine chlorhydrate 
were purchased from Merck Co. All the solvents used in the reactions were previously 
purified and dried according to the literature procedures. 
 
3β-Trifluoroacetoxy-urs-12-en-28-oic acid (2.2): To a stirred mixture of 2.1 (50 mg 
0.11 mmol) in THF (1 mL) at room temperature, was added DMAP (10% of the mass of 
2.1) and triflouroacetic anhydride (0.15 mL 1.1 mmol). After 30 minutes the reaction 
mixture was acidified with HCl 10% (40 mL) and the aqueous phase extracted with ether 
(3×25 mL). The organic phase was washed with NaHCO3 (3×25 mL) and water (3×25 
mL), dried over Na2SO4, filtered and evaporated to the dryness, to afford a solid (98%). mp 
176.1-177.8 ºC. IR (film CHCl3): 2975.6, 2940.9, 2878.2, 1778.1, 1690.3, 1462.7, 1412.6, 
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1386.6, 1371.1, 1357.6, 1316.2, 1280.5, 1256.4, 1224.6 cm
-1
. 
1
H NMR (400 MHz CDCl3): 
δ 5.22 (1H t J=6.84), 4.68 (1H dd J=15.98), 1.08 (3H s), 0.98 (3H s), 0.94 (3H d J=6.23), 
0.90 (3H s), 0.85 (3H d J=6.45), 0.77 (3H s).
 13
C NMR (100 MHz CDCl3): δ 184.23, 
157.36 (J=41.80), 137.98, 125.50, 114.66 (J=286.19), 86.22, 55.14, 52.42, 47.95, 47.42, 
41.87, 39.45, 38.98, 38.79, 38.05, 37.93, 36.86, 36.66, 32.72, 30.55, 27.94, 27.86, 23.96, 
23.59, 23.24, 23.11, 21.15, 18.05, 17.03, 16.97, 16.41, 15.48. EI-MS m/z: 550.56 (1) M
-2
, 
247.53 (26), 202.56 (55), 188.65 (20), 132.83 (100), 118.82 (26), 106.76 (14), 104.78 (23), 
94.74 (11), 92.69 (13), 90.73 (20), 78.62 (11). Anal. Calcd for C32H47F3O4 C 69.54, H 
8.57, found C 69.92, H 8.52. 
 
3-Oxours-12-en-28-oic acid (2.3): 2.3 was prepared according to the literature,
241
 
from 2.1 (100 mg 0.218 mmol) to give a solid (99%). mp 281.5-286.8 ºC. IR (film 
CHCl3): 2972.7, 2929.3, 2872.4, 1690.3, 1457.9, 1385.6, 1316.2, 1276.7, 1255.4, 1235.2, 
1214.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.26 (1H t), 1.08 (3H s), 1.08 (3H s), 1.05 
(3H s), 1.02 (3H s), 0.95 (3H s), 0.87 (3H s), 0.82 (3H s).
 13
C NMR (100 MHz CDCl3): δ 
217.89 (C3), 183.92 (C28), 137.98 (C13), 125.53 (C12). EI-MS m/z: 455.3 (2) M
+1
, 
249.3 (20), 248.3 (100), 219.4 (22), 205.5 (20), 204.5 (22), 203.5 (55), 134.3 (22), 133.3 
(44). Anal. Calcd for C30H46O3 C 79.25, H 10.20, found C 78.98, H 10.34. 
 
3β-Acetoxy-urs-12-en-28-oic acid (2.4): Preparation of 2.4 was made according to 
previously described method from 2.1 (100 mg 0.218 mmol),
183
 providing a solid (92%): 
mp 287.4-290.8 ºC. IR (film CHCl3): 2926.5, 1735.6, 1691.3, 1460.8 cm
-1
. 
1
H NMR (400 
MHz CDCl3): δ 5.21 (1H t J=6.54), 4.47 (1H dd J=15.99), 2.16 (1H d J=11.51), 2.02 (3H 
s), 1.05 (3H s), 0.94 (3H s), 0.84 (6H s), 0.83 (3H s), 0.74 (3H s). 
13
C NMR (100 MHz 
CDCl3): δ 183.84 (C28), 171.03 (OCOCH3), 137.92 (C13), 125.71 (C12), 80.92 (C3). EI-
MS m/z: 497.82 (1) M
+
, 437.89 (23), 93.76 (37), 91.78 (50), 89.79 (100), 81.87 (22), 
79.88 (83), 77.9 (73), 75.89 (34), 67.87 (23), 65.86 (62). Anal. Calcd for C32H50O4: C 
77.06, H 10.10, found C 77.46, H 10.05.  
 
3β-Phthaloxy-urs-12-en-28-oic-acid (2.5): To a stirred mixture of 2.1 (200 mg 0.44 
mmol) in pyridine (5 mL) at 115ºC, was added DMAP (53.77 mg 1 mmol) and phthalic 
anhydride (651.73 mg 0.25 mmol). After 23.5 hours the reaction mixture was diluted with 
2. Ursolic acid derivatives 
163 
 
ice (50 mL) and the aqueous phase extracted with chloroform (3×40 mL).  The organic 
phase was washed with water (3×40 mL), dried over Na2SO4, filtered and evaporated to 
the dryness, to afford a solid (90%). mp 198.3-205.1 ºC. IR (film CHCl3): 3064.3, 2926.5, 
1716.3, 1691.3, 1457.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.89 (1H d J=6.92), 7.72 (1H 
d J=6.85), 7.59 (2H m J=26.69), 5.24 (1H s H12), 4.75 (1H dd J=14.88 H3), 1.09 (3H s), 
0.94 (6H s), 0.93 (3H s), 0.88 (3H s), 0.85 (3H s), 0.78 (3H s). 
13
C NMR (100 MHz 
CDCl3): δ 183.93 (C28), 171.62 (OCOC), 167.93 (COOH), 137.95 (C13), 131.59, 
131.53, 131.02, 130.65, 129.61, 128.83, 125.68 (C12), 82.902 (C3). EI-MS m/z: 604.97 
(1) M
+
, 247.72 (52), 202.77 (50), 188.87 (20), 148.90 (27), 133.19 (100), 118.96 (24), 
105.10 (30), 90.94 (23). Anal. Calcd for C38H52O6.H2O: C 73.28, H 8.74, found C 73.68, 
H 8.52.  
 
Methyl 3β-hydroxy-urs-12-en-28-oate (2.6): 2.6 was prepared according to the 
literature
429, 434
 from 2.1 (45.6 mg 0.1 mmol) to give a solid (93%). mp 170.7-172.0 ºC. 
IR (film CHCl3): 3434.6, 2926.5, 1718.3, 1645.9, 1457.0 cm
-1
.
 1
H NMR (400 MHz 
CDCl3): δ 5.23 (1H t J=7.32 H12), 3.59 (3H s COOCH3), 3.20 (1H dd J=15.83 H3), 1.07 
(3H s), 0.98 (3H s), 0.93 (3H s), 0.91 (3H s), 0.85 (3H d J=6.48), 0.77 (3H s), 0.73 (3H 
s). 
13
C NMR (100 MHz CDCl3): δ 178.05 (C28), 138.12 (C13), 125.55 (C12), 79.03 
(C3). EI-MS m/z: 471.04 (7) M
+1
, 261.99 (53), 207.08 (21), 203.07 (89), 202.15 (20), 
189.19 (28), 134.11 (38), 133.21 (100), 119.13 (26), 91.22 (21). Anal. Calcd for 
C31H50O3.0.25 hexane: C 79.30, H 10.95, found C 79.68, H 11.31.  
 
3β-Trifluoroacetoxy-11-oxours-12-en-28-oic acid (2.7): To a stirred solution of 2.2 
(1.3 g 2.35 mmol) in dichloromethane (25 mL) at room temperature was added a mixture 
of KMnO4 (4.7 g) and Fe2(SO4)3.nH2O (2.35 g), previous reduced to fine powder, water 
(0.235 mL) and t-butanol (1.1 mL). After 27 hours the reaction mixture was diluted with 
ether (60 mL) and mixed for 30 minutes. The resulting mixture was filtred through a 
celite plate, which is washed with ether (200 ml). The resulting organic phase was 
washed with NaHCO3 (2×75 mL) and water (2×75 mL), dried over Na2SO4, filtered and 
evaporated to the dryness, to afford a slight yellow powder (82%). mp 270.0-271.9 ºC. IR 
(film CHCl3): 2875.3, 1780.0, 1691.3, 1657.5, 1460.8, 1384.6, 1217.8, 1167.7 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 5.60 (1H s H12), 4.68 (1H d J=11.38), 2.87 (1H d J=13.61), 
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2.38 (1H d J=11.51), 2.31 (1H s), 1.29 (3H s), 1.15 (3H s), 0.97 (3H s), 0.96 (3H s), 0.90 
(12H s).
 13
C NMR (100 MHz CDCl3): δ 199.71, 183.05, 163.10, 157.56 (J=7.02), 130.63, 
114.63 (J=285.80), 85.86, 61.16, 54.86, 52.42, 47.47, 44.64, 43.66, 38.53, 38.23, 38.21, 
38.07, 36.94, 35.96, 32.75, 31.10, 30.18, 28.33, 27.86, 23.52, 23.07, 21.05, 20.90, 19.08, 
17.13, 16.99, 16.35, 16.30. EI-MS m/z: 567.18 (18) M
+
, 303.04 (24), 262 (26), 257.07 
(32), 234.04 (40), 189.02 (63), 175.08 (27), 161.06 (69), 159.09 (24), 133.07 (27), 119.06 
(100), 107.06 (29), 105.05 (49), 95.05 (29), 93.03 (29), 91.04 (64), 79.01 (41), 76.99 
(29), 66.98 (32).  
 
3,11-Dioxours-12-en-28-oic acid (2.8): 2.8 was prepared according to the same 
method as for 2.7, starting with 2.3 (100 mg 0.22 mmol). After 23.5 hours the workup is 
executed to afford a white powder (71%). mp 285.8-300.4 
o
C. IR (film CHCl3): 2945.7, 
2873.4, 1700.9, 1691.3, 1661.4, 1460.8, 1385.6, 1312.3, 1276.7, 1255.4, 1231.3, 1212.0 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.62 (1H s), 1.30 (3H s), 1.24 (3H s), 1.08 (3H s), 
1.02 (3H s), 0.97 (3H d J=6.14), 0.94 (3H s), 0.86 (3H d J=6.25).
 13
C NMR (100 MHz 
CDCl3): δ 217.11 (C3), 199.26 (C11), 182.65 (C28), 163.12 (C13), 130.66 (C12), 60.67, 
55.31, 52.49, 47.66, 47.48, 44.50, 43.79, 39.70, 38.55, 38.52, 36.72, 35.97, 34.14, 32.34, 
30.21, 28.42, 26.44, 23.59, 21.32, 20.99, 20.91, 18.92, 18.65, 16.99, 15.57. EI-MS m/z: 
469.13 (14) M
+
, 303.04 (49), 262.08 (37), 257.13 (66), 134.04 (56), 190.09 (31), 189.06 
(84), 175.14 (33), 161.13 (100), 119.19 (79), 105.14 (43), 95.19 (34), 91.04 (45), 79.11 
(40), 67.07 (34), 55.04 (32).  
 
3β-Acetoxy-11-oxours-12-en-28-oic acid (2.9): Compound 2.9 was prepared using 
the same method as for the preparation of 2.7, starting with 2.4 (1.3 g 2.61 mmol). After 
25 hours the workup is executed to afford a white powder (83%). mp 315.7-318.1 ºC. IR 
(film CHCl3): 2941.9, 2873.4, 1725.0, 1690.3, 1661.4, 1459.9, 1367.3, 1318.1, 1252.5, 
1214.0, 1167.7, 1141.7 cm
-1
. EI-MS m/z: 513.30 (15) M
+
, 303.1 (73), 262.09 (63), 
257.17 (68), 134.19 (80), 189.27 (100), 175.3 (63), 174.33 (63), 162.29 (46), 161.28 (99), 
120.08 (47), 119.21 (87), 105.28 (53), 91.17 (45), 79.27 (45).  
 
Methyl 3-oxours-12-en-28-oate (2.10): 2.10 was prepared according to the 
literature,
241
 from 2.6 (2.69 g 5.7 mmol) to give a solid (93%). mp 196.3-197.2 ºC. IR 
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(film CHCl3): 2946.7, 2872.5, 1725.0, 1704.8, 1456.0, 1384.6, 1309.4, 1271.8, 1230.4, 
1198.5, 1143.6, 1111.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.26 (1H s), 3.61 (3H s), 
1.08 (6H s), 1.04 (6H s), 0.94 (3H d J=5.73), 0.86 (3H d J=6.33), 0.79 (3H s).
 13
C NMR 
(100 MHz CDCl3): δ 217.70 (C3), 177.99 (C28), 138.29 (C13), 125.33 (C12). EI-MS 
m/z: 470.48 (27) M
+
, 469.47 (94), 264.09 (51), 262.48 (100), 248.92 (16), 205.74 (18), 
204.63 (19), 203.81 (25), 203.2 (16), 202.52 (26), 201.52 (23), 200.44 (18), 189.08 (16), 
134.34 (25), 133.12 (64), 131.3 (16). 
 
Methyl 3,11-dioxours-12-en-28-oate (2.11): 2.11 was prepared using the same 
method as for the preparation of 2.7, starting with 2.10 (100 mg 0.22 mmol). After 23 
hours the workup is executed to afford a white powder (97%). mp 128.5-130.7 ºC. IR 
(film CHCl3): 2948.6, 2872.5, 1725.0, 1704.8, 1660.4, 1457.0, 1386.6, 1273.8 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 5.63 (1H s), 3.60 (3H s), 1.29 (3H s), 1.24 (3H s), 1.08 (3H 
s), 1.04 (3H s), 0.96 (3H d J=6.53), 0.93 (3H s), 0.86 (3H d J=5.82).
 13
C NMR (100 MHz 
CDCl3): δ 217.12 (C3), 199.06 (C11), 177.13 (C28), 163.26 (C13), 130.55 (C12). EI-MS 
m/z: 483.38 (28) M
+
, 482.35 (28), 467.36 (37), 454.38 (27), 317.32 (99), 276.37 (34), 
258.45 (31), 257.4 (100), 248.49 (60), 233.5 (38), 190.47 (34), 189.42 (78), 162.45 (41), 
161.36 (58), 119.33 (46). 
 
Methyl 2-hydroxymethylene-3,11-dioxours-12-en-28-oate (2.12): Preparation of 
2.12 was made according to previously described method
330, 431
 from 2.11 (947.7 mg 1.96 
mmol) to give a solid (98%). mp 134.7-138.1 ºC. IR (film CHCl3): 3436.5, 2949.6, 
2870.5, 1726.0, 1656.6, 1588.1, 1457.0, 1387.5, 1320.0, 1272.8 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 14.86 (1H s), 8.62 (1H s), 5.67 (1H s), 3.62 (3H s), 3.45 (1H d J=14.76), 2.45 
(1H d J=11.19), 1.31 (3H s), 1.19 (3H s), 1.13 (3H s), 1.11 (3H s), 0.97 (6H d J=8.98), 
0.88 (3H d J=6.40).
 13
C NMR (100 MHz CDCl3): δ 199.20 (C3), 189.57 (C11), 188.82 
(C2CH), 177.15 (C28), 163.48 (C13), 130.68 (C12), 105.79 (C2). EI-MS m/z: 510.28 
(11) M
+
, 495.32 (18), 317.15 (52), 258.17 (20), 257.14 (100), 189.16 (22), 187.19 (22), 
175.18 (16), 173.19 (18), 161.18 (96), 135.2 (25), 119.2 (25), 105.18 (18), 91.15 (21). 
Anal. Calcd for C32H46O5.0.5H2O C 73.95, H 9.12, found C 74.1, H 9.52. 
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Methyl 2-hydroxymethylene-3-oxours-12-en-28-oate (2.13): 2.13 was prepared 
using the same method as for the preparation of 2.12, starting with 2.10 (100 1g 
2.2mmol). After 1 hours the workup is executed to afford a solid (97%). mp 127.9-131.7 
ºC. IR (film CHCl3): 3441.3, 2924.5, 2872.5, 1725.0, 1634.4, 1586.2, 1456.0, 1377.9, 
1307.5, 1271.8, 1229.4, 1200.5, 1143.6 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 14.90 (1H s), 
8.57 (1H s), 5.30 (1H s), 3.61 (3H s), 1.19 (3H s), 1.11 (3H s), 1.09 (3H s), 0.94 (3H d 
J=5.98), 0.91 (3H s), 0.87 (3H d J=6.39), 0.81 (3H s).
 13
C NMR (100 MHz CDCl3): δ 
190.84 (C3), 188.17 (C2CH), 178.00 (C28), 138.23 (C13), 125.35 (C12), 105.79 (C2). 
EI-MS m/z: 497.40 (30) M
+
, 263.63 (40), 262.47 (99), 233.44 (52), 204.71 (31), 203.41 
(95), 189.41 (45), 187.33 (25), 134.35 (48), 133.23 (100), 119.23 (27). Anal. Calcd for 
C32H48O4.0.25H2O C 76.68, H 9.75, found C 76.63, H 10.20 
 
3β-Hydroxy-11-oxours-12-en-28-oic acid (2.14): 2.14 was prepared according to 
the literature,
367
 from 2.9 (1.12 g 2.01 mmol) to give a solid (79%). mp 236.7-238.6 ºC. 
IR (film CHCl3): 3421.1, 2930.3, 2866.7, 1687.4, 1655.6, 1457.0, 1386.6, 1038.5 cm
-1
. 
EI-MS m/z: 471.30 (10) M
+
, 303.09 (48), 262.06 (48), 257.10 (66), 234.09 (54), 189.09 
(81), 175.14 (67), 161.13 (100), 119.15 (91), 107.13 (42), 105.14 (56), 91.13 (61), 79.09 
(44).  
 
Methyl 3-hydroxy-11-oxours-12-en-28-oate (2.15): 2.15 was prepared using the 
same method as for the preparation of 2.6, starting with 2.14 (794.1mg 1.7mmol). After 3 
hours the workup is executed to afford a solid (98%). mp 128.2-130.2 ºC. IR (film 
CHCl3): 3482.8, 2947.7, 2870.5, 1725.0, 1654.6, 1457.0, 1386.6, 1386.6, 1201.4 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 5.59 (1H s), 3.59 (3H s), 3.21 (1H dd J=16.35), 2.77 (1H dt 
J=20.56), 1.28 (3H s), 1.10 (3H s), 0.97 (3H s), 0.95 (3H d J=6.28), 0.89 (3H s), 0.85 (3H 
d J=6.47), 0.78 (3H s).
 13
C NMR (100 MHz CDCl3): δ 199.92 (C11), 177.19 (C28), 
162.89 (C13), 130.61 (C12), 78.78 (C3). EI-MS m/z: 484.51 (36) M
+
, 174.43 (26), 
160.46 (55), 134.54 (35), 132.56 (36), 120.58 (31), 118.6 (100), 106.58 (38), 104.59 (51), 
94.55 (39), 92.53 (29), 90.54 (46), 78.47 (26).  
 
2-Hydroxymethylene-3-oxours-12-en-28-oic acid (2.16): 2.16 was prepared using 
the same method as for the preparation of 2.12, starting with 2.3 (500mg 1.1mmol). After 
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72 hours the workup is executed to afford a solid (96%): mp 148.0-150.4 ºC. IR (film 
CHCl3): 3440.4, 2925.5, 2872.5, 1694.2, 1640.2, 1580.4, 1456.0, 1379.8, 1314.3, 1234.2 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 14.89 (1H s), 8.58 (1H s), 5.29 (1H s), 1.18 (3H s), 
1.09 (3H s), 1.08 (3H s), 0.95 (3H d J=5.93), 0.91 (3H), 0.86 (3H t J=12.40), 0.82 (3H s).
 
13
C NMR (100 MHz CDCl3): δ 190.60 (C3), 188.43 (C2CH), 184.01 (C28), 137.94 
(C13), 125.56 (C12), 105.72 (C2). EI-MS m/z: 482.57 (7) M
+
, 202.50 (25), 172.57 (12), 
146.63 (13), 144.66 (13), 133.72 (12), 132.72 (100), 130.76 (13), 120.70 (13), 118.75 
(29), 116.72 (11), 106.69 (17), 104.71 (28), 94.65 (14), 92.62 (28). Anal. Calcd for 
C31H46O4.0.25 H2O C 76.42, H 9.62, found C 76.18, H 10.02. 
 
Isoxazolo[4,5-b]urs-12-en-28-oic acid (2.17): Preparation of 2.17 was made 
according to previously described method,
295
 from 2.16 (250 mg 0.52 mmol) to give a 
solid (98%): mp 172.8-175.0 ºC IR (film CHCl3): 2970.8, 2925.5, 2870.5, 1694.2, 
1456.8, 1382.7, 1275.7 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.98 (1H s), 5.30 (1H s), 
1.30 (3H s), 1.18 (3H s), 1.10 (3H s), 0.95 (3H s), 0.87 (3H d J=6.11), 0.85 (3H s), 0.83 
(3H s). 
13
C NMR (100 MHz CDCl3): δ 183.92 (C28), 173.03, 150.16 (C2CH), 137.96 
(C13), 125.49 (C12), 108.84, 53.49, 52.60, 48.03, 46.05, 42.08, 39.53, 39.07, 38.79, 
38.63, 36.65, 35.58, 34.69, 32.19, 30.59, 28.83, 28.01, 24.04, 23.46, 23.27, 21.32, 21.12, 
18.78, 16.95, 16.76, 15.43. EI-MS m/z: 479.75 (7) M
+
, 202.52 (40), 132.82 (100), 118.77 
(24), 106.74 (25), 94.70 (11), 90.69 (27).  
 
3β-(1H-Imidazol-1-carbonyloxy)-urs-12-en-28-oic (2.18) and 28-(1H-imidazol-1-
yl)-28-oxours-12-en-3β-yl-1H-imidazole-1-carboxylate (2.19): To a stirred solution of 
2.1 (300 mg 0.66 mmol) in THF (4 mL), under N2 atmosphere, at 70 ºC, was added CDI 
(321.1 mg 1.98 mmol). After 5 hours the reaction mixture was diluted with water (60 
mL), the aqueous phase was extracted with ethyl acetate (3×50 mL). The resulting 
organic phases were washed with NaCl 10% (3×50 mL), dried over Na2SO4, filtered and 
evaporated to the dryness, to afford a yellow residue. The residue was subjected to flash 
column chromatography [hexanes-ethyl acetate from (65:35) to (55:45)], to afford 2.18 
(7%) and 2.19 (76%). 2.18: mp 295.8-297.4 ºC IR (film CHCl3): 3133.8, 2926.5, 2875.3, 
1803.1, 1758.8, 1467.6, 1388.5, 1318.1, 1287.3, 1239.0. 
1
H NMR (400 MHz CDCl3): δ 
8.14 (1H s), 7.42 (1H s), 7.08 (1H s), 5.32 (1H s), 4.71 (1H dd J=16.19), 1.25 (3H s), 1.11 
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(3H s), 0.98 (9H s), 0.88 (3H d J=5.97), 0.85 (3H s). EI-MS m/z: 550.97 (2) M
+
, 202.93 
(55.86), 189.96 (53.8), 188.96 (100), 186.98 (54.53), 132.91 (54.26). 2.19: mp 228.7-
231.3 ºC. IR (film CHCl3): 3128.0, 2927.4, 2872.5, 1756.8, 1719.2, 1468.5, 1388.5, 
1318.1, 1287.3 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.23 (1H s), 8.12 (1H s), 7.52 (1H s), 
7.39 (1H s), 7.05 (1H s), 7.03 (1H s), 5.23 (1H s), 4.67 (1H dd J=16.12), 1.10 (3H s), 0.99 
(3H d J=6.17), 0.95 (3H s), 0.94 (6H s), 0.91 (3H d J=6.31), 0.68 (3H s).
 13
C NMR (100 
MHz CDCl3): δ 174.65, 148.48, 137.02, 137.00, 136.94, 130.48, 129.55, 126.33, 117.44, 
116.98, 86.17, 55.19, 54.11, 50.88, 47.33, 42.07, 39.40, 39.21, 38.65, 38.01, 36.75, 35.53, 
32.63, 30.34, 28.13, 27.70, 24.97, 23.56, 23.37, 23.26, 20.99, 19.38, 17.99, 17.06, 16.83, 
16.70, 15.45. EI-MS m/z: 600.93 (14) M
+
, 203.03 (68), 201.99 (40), 189.04 (59), 1887.05 
(55), 147.05 (56), 145.06 (48), 133.03 (81), 131.03 (45), 121.03 (46), 119.04 (85), 109.06 
(43), 107.02 (77), 105.02 (100). Anal. Calcd for C37H52N4O3 C 73.96, H 8.72, N 9.32, 
found C 74.25, H 9.03, N 9.27.  
 
3β-Trifluoroacetoxy-urs-12-en-28-yl-1H-imidazole-1-carboxylate (2.20): 2.20 
was prepared using the same method as for 2.18, using 2.2 (300 mg 0.54 mmol) as a 
starting material and CDI (175.12 mg 1.08 mmol). The workup was performed after 7 
hours. The solid was subjected to flash column chromatography [hexanes-ethyl acetate 
from (75:25) to (65:35)], to afford 2.20 (84%). mp 187.9-192.9 ºC. IR (film CHCl3): 
3128.0, 2951.5, 2875.3, 1778.1, 1720.2, 1466.6, 1382.7, 1279.5, 1222.7, 1165.8 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 8.24 (1H s), 7.52 (1H s), 7.04 (1H s), 5.23 (1H s H12), 4.67 
(1H dd J=15.50 H3), 2.45 (1H d J=11.03 H18), 1.51 (1H s H5), 1.10 (3H s C27), 1.00 
(3H d J=6.15 C30), 0.94 (3H s C25), 0.91 (3H d J=6.54 C29), 0.89 (6H s C23 and C24), 
0.82 (1H d J= 11.24 H5), 0.68 (3H s C26).
 13
C NMR (100 MHz CDCl3): δ 174.70 (C28), 
157.34 (OCOCF3 J=41.77), 137.05 (Cimidazole), 137.01 (C13), 129.63 (Cimidazole), 
126.30 (C12), 117.45 (Cimidazole), 114.62 (CF3 J=286.24), 86.14 (C3), 55.12 (C5), 
54.10 (C18), 50.87 (C17), 47.33 (C9), 42.06 (C14), 39.39 (C8), 39.22 (C19), 38.66 
(C20), 38.05 (C1), 37.88 (C4), 36.75 (C10), 35.54, 32.62 (C7), 30.35 (C21), 27.83 (C23 
or C24), 27.70 (C15), 24.97, 23.56 (C27), 23.25, 23.05, 21.02 (C30), 17.97, 17.08 (C29), 
16.70 (C26), 16.41 (C23 or C24), 15.47 (C25). EI-MS m/z: 602.94 (8) M
+
, 302.95 (99), 
203.03 (84), 189.04 (60), 175.07 (59), 133.09 (62), 119.10 (61), 107.09 (63), 105.11 (65), 
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95.14 (63), 91.15 (67), 79.09 (55), 69.04 (100). Anal. Calcd for C35H49F3N2O3 C 69.74, H 
8.19, N 4.65, found C 69.91, H 8.52, N 4.58. 
 
3-Oxours-12-en-28-yl-1H-imidazole-1-carboxylate (2.21): 2.21 was prepared using 
the same method as for 2.18, using 2.3 (300 mg 0.6 mmol) as a starting material and CDI 
(194.58 mg 1.2 mmol). The workup was performed after 18.5 hours. The solid was 
subjected to flash column chromatography [hexanes-ethyl acetate from (70:30) to 
(60:40)], to afford 2.21 (84%). mp 141.0-147.3 ºC. IR (film CHCl3): 3128.0, 2927.4, 
1703.8, 1459.0, 1381.8, 1362.5, 1277.6, 1225.5, 1204.3 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.46 (1H s), 7.56 (1H s), 7.11 (1H s), 5.25 (1H t J=7.32 H12), 1.10 (3H s C27), 
1.06 (3H s C23 or C24), 1.03 (3H s C23 or C24), 1.02 (3H s C25), 1.00 (3H d J=6.32 
C30), 0.91 (3H d J=6.46 C29), 0.72 (3H s C26).
 13
C NMR (100 MHz CDCl3): δ 217.61 
(C3), 174.26 (C28), 136.88 (C13), 136.69 (Cimidazole), 127.97 (Cimidazole), 126.55 
(C12), 117.79 (Cimidazole), 55.23 (C5), 54.22 (C18), 51.16 (C17), 47.38 (C4), 46.62 
(C9), 42.20 (C14), 39.38 (C8), 39.26, 39.22 (C19), 38.62 (C20), 36.60 (C10), 35.48, 
34.11, 32.29 (C7), 30.30 (C21), 27.72 (C15), 26.41 (C23 or C24), 24.95, 23.50 (C27), 
23.41, 21.45, 20.97, 19.33, 17.04 (C29), 16.73 (C26), 15.17 (C25). EI-MS m/z: 504.99 
(11) M
+
, 205 (44), 201.01 (77), 175.06 (40), 133.04 (54), 119.04 (48), 107.03 (52), 
105.04 (51), 95.04 (51), 91.03 (51), 79 (43), 68.97 (100). Anal. Calcd for C33H48N2O2 C 
78.53, H 9.59, N 5.55, found C 78.93, H 9.89, N 5.67. 
 
3β-Acetoxy-urs-12-en-28-yl-1H-imidazole-1-carboxylate (2.22): 2.22 was 
prepared using the same method as for 2.18, using 2.4 (300 mg 0.60 mmol) as a starting 
material and CDI (194.58 mg 1.2 mmol). The workup was performed after 10 hours. The 
solid was subjected to flash column chromatography [hexanes-ethyl acetate from (75:25) 
to (70:30)], to afford 2.22 (88%). mp 204.0-207.5 ºC. IR (film CHCl3): 3151.1, 2927.4, 
2873.4, 1725.0, 1466.6, 1368.3, 1275.7, 1246.8, 1205.3, 1101.2 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.22 (1H s), 7.51 (1H s), 7.01 (1H s), 5.20 (1H s), 4.46 (1H t J=15.70), 2.43 
(1H d J=11.03), 2.02 (3H s), 1.07 (3H s), 0.98 (3H d J=6.17), 0.90 (6H s), 0.82 (3H s), 
0.81 (3H s), 0.65 (3H s). 
13
C NMR (100 MHz CDCl3): δ 174.67, 170.88, 137.02, 136.92, 
129.57, 126.48, 117.41, 80.74, 55.22, 54.10, 50.86, 47.33, 42.03, 39.39, 39.19, 38.64, 
38.23, 37.57, 36.75, 35.54, 32.68, 30.33, 27.97, 27.68, 24.98, 23.52, 23.44, 23.24, 21.22, 
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20.98, 18.01, 17.06, 16.69, 16.63, 15.44. EI-MS m/z: 548.91 (14) M
+
, 248.95 (30), 
203.01 (45), 189.06 (55), 187.09 (22), 147.1 (23), 133.11 (36), 119.12 (32), 107.12 (34), 
105.15 (34), 95.16 (29), 91.15 (33), 79.14 (32), 69.15 (100). Anal. Calcd for C35H52N2O3 
C 76.60, H 9.55, N 5.10, found C 76.38, H 9.74, N 5.09. 
 
Methyl 3β-(1H-imidazole-1-carbonyloxy)-urs-12-en-28-oate (2.23): 2.23 was 
prepared using the same method as for 2.18, using 2.6 (300 mg 0.64 mmol) as a starting 
material and CDI (207.552 mg 1.28 mmol). The workup was performed after 4 hours. 
The solid was subjected to flash column chromatography [hexanes-ethyl acetate from 
(75:25) to (70:30)], to afford 2.23 (90%). mp 119.0-125.1 
o
C. IR (film CHCl3): 3133.8, 
2947.7, 2872.5, 1757.8, 1724.1, 1469.5, 1388.5, 1319.1, 1288.2, 1240.0, 1199.5 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 8.13 (1H s), 7.41 (1H s), 7.07 (1H s), 5.25 (1H s), 4.70 (1H 
dd J=16.32), 3.61 (3H s), 2.24 (1H d J=11.24), 1.09 (3H s), 0.99 (3H s), 0.97 (3H s), 0.97 
(3H s), 0.94 (3H d J=5.77), 0.86 (3H d J=6.39), 0.76 (3H s).
 13
C NMR (100 MHz 
CDCl3): δ 178.01, 148.48, 138.26, 136.96, 130.42, 125.27, 117.05, 86.39, 55.25, 52.84, 
51.44, 48.06, 47.47, 42.00, 39.49, 39.03, 38.85, 38.13, 38.08, 36.84, 36.60, 32.82, 30.62, 
28.20, 28.00, 24.18, 23.58, 23.45, 23.29, 21.16, 18.16, 17.04, 16.89 (2C), 15.46. EI-MS 
m/z: 564.92 (3) M
+
, 261.99 (40), 202.97 (80), 189.03 (32), 133.01 (100), 119.02 (30), 
107.02 (15), 105.02 (23), 94.99 (21), 90.99 (24), 78.96 (19), 68.93 (75), 66.95 (14). Anal. 
Calcd for C35H52N2O4 C 74.43, H 9.28, N 4.96, found C 74.06, H 9.60, N 4.86. 
 
28-(1H-Imidazol-1-yl)-11,28-dioxours-12-en-3β-yl-1H-imidazole-1-carboxylate 
(2.24): 2.24 was prepared using the same method as for 2.18, using 2.14 (290 mg 0.62 
mmol) as a starting material and CDI (301.60 mg 1.86 mmol). The workup was 
performed after 8 hours. The workup was performed after 4 hours. The solid was 
subjected to flash column chromatography [hexanes-ethyl acetate from (60:40) to 
(35:65)], to afford 2.24 (44%). mp 167.5-173.1 ºC. IR (film CHCl3): 3135.7, 2971.8, 
2872.5, 1754.9, 1718.3, 1656.6, 1469.5, 1388.5, 1322.0, 1286.3, 1241.0, 1209.2 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 8.25 (1H s), 8.10 (1H s), 7.52 (1H s), 7.39 (1H s), 7.05 (2H 
s), 5.66 (1H s H12), 4.68 (1H dd J=14.76 H3), 2.88 (1H d J=13.33 H1), 2.61 (1H t 
J=9.88 H18), 2.31 (1H s H9) 1.32 (3H s C27), 1.16 (3H s C25), 1.01 (3H d J=5.79 C30), 
0.94 (9H s C23 or C24 and C29), 0.86 (3H s C26), 0.83 (1H s H5).
 13
C NMR (100 MHz 
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CDCl3): δ 198.84 (C11), 173.77 (C28), 161.19 (C13), 148.47 (OCO), 136.95 
(Cimidazole), 136.89 (Cimidazole), 131.19 (C12), 130.48 (Cimidazole), 130.11 
(Cimidazole), 117.25 (Cimidazole), 116.98 (Cimidazole), 85.91 (C3), 61.17 (C9), 54.99 
(C5), 54.01 (C18), 50.61 (C17), 44.59 (C8), 43.75 (C14), 38.72 (C20), 38.60 (C1), 38.33 
(2C C4 and C29), 36.90 (C10), 34.82, 32.77 (C7), 30.08 (C21), 28.21 (C15), 28.11 (C23 
or C24), 24.47, 23.38, 20.88 (C27), 20.78 (C30), 18.46 (C26), 17.17 (2C C29), 16.79 
(C23 or C24), 16.30 (C25). EI-MS m/z: 615.00 (2) M
+
, 217.06 (38.), 189.06 (80), 175.12 
(29), 147.11 (45), 119.13 (28), 107.1 (21), 105.09 (27), 95.08 (28), 91.11 (35), 79.07 
(20), 69.02 (100). Anal. Calcd for C37H50N4O4.0.5hexane.0.5EtOAc C 71.86, H 8.76, N 
7.98 found C 71.72, H 9.16, N 8.1.  
 
3β-Trifluoroacetoxy-11-oxours-12-en-28-yl-1H-imidazol-1-carboxylate (2.25): 
2.25 was prepared using the same method as for 2.18, using 2.7 (300 mg 0.53 mmol) as a 
starting material and CDI (171.88 mg 1.06 mmol). The workup was performed after 2 
hours. The solid was subjected to flash column chromatography [hexanes-ethyl acetate 
from (70:30) to (60:40)], to afford 2.25 (57%). mp 129.6-134.5 ºC. IR (film CHCl3): 
3138.6, 2928.4, 2874.4, 1777.1, 1719.2, 1657.5, 1466.6, 1384.6, 1365.4, 1380.5, 1259.3, 
1213.0, 1167.7, 1139.7 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.26 (1H s), 7.53 (1H s), 
7.06 (1H s), 5.66 (1H s H12), 4.68 (1H dd J=16.08 H3), 2.87 (1H d J=13.68 H1), 2.61 
(1H d J=11.10 H18), 2.30 (1H s H9), 1.32 (3H s C27), 1.15 (3H s C25), 1.01 (3H d 
J=6.09 C30), 0.93 (3H d J=6.22 C29), 0.90 (3H s C23 or C24), 0.88 (3H s C23 or C24), 
0.86 (3H s C26), 0.77 (1H d J=11.51 H5).
 13
C NMR (100 MHz CDCl3): δ 198.91 (C11), 
173.79 (C28), 161.29 (C13), 157.31 (OCOCF3 J=41.52), 136.88 (Cimidazole), 131.17 
(C12), 130.11 (Cimidazole), 117.26 (Cimidazole), 114.60 (CF3 J=286.29), 85.85 (C3), 
61.15 (C9), 54.88 (C9), 53.99 (C18), 50.59 (C17), 44.59 (C8), 43.74 (C14), 38.72 (C19), 
38.54 (C1), 38.34 (C20), 38.18 (C4), 36.88 (C10), 34.82, 32.74 (C7), 30.08 (C21), 28.19 
(C15), 27.82 (C23 or C24), 24.46, 23.04, 20.87 (C30), 20.82 (C27), 18.43 (C26), 17.20 
(C29), 17.13, 16.37 (C23 or C24), 16.35 (C25). EI-MS m/z: 616.94 (6) M
+
, 199.00 (25), 
188.97 (100), 175.03 (24), 147.03 (52), 119.04 (28), 105.03 (25), 95.03 (29), 91.02 (24), 
68.96 (34).  
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3,11-Dioxours-12-en-28-yl-1H-imidazole-1-carboxylate (2.26): 2.26 was prepared 
using the same method as for 2.18, using 2.8 (300 mg 0.64 mmol) as a starting material 
and CDI (207.55 mg 1.28 mmol). The workup was performed after 4.5 hours. The solid 
was subjected to flash column chromatography [hexanes-ethyl acetate from (65:35) to 
(50:50)], to afford 2.26 (52%). mp 211.9-218.8 ºC. IR (film CHCl3): 3133.8, 2927.4, 
2871.5, 1703.8, 1658.5, 1460.8, 1386.6, 1364.4, 1278.6, 1224.6, 1208.2 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 8.27 (1H s Himidazole), 7.53 (1H s Himidazole), 7.06 (1H s 
Himidazole), 5.68 (1H s H12), 1.32 (3H s C27), 1.24 (3H s C25), 1.06 (3H s C23 or 
C24), 1.02 (6H d J=7.81 C23 or C24 or C30), 0.93 (3H d J=6.20 C29), 0.89 (3H s C26).
 
13
C NMR (100 MHz CDCl3): δ 216.91 (C3), 198.55 (C11), 173.82 (C28), 161.40 (C13), 
136.89 (Cimidazole), 131.21 (C12), 130.14 (Cimidazole), 117.28 (Cimidazole), 60.68 
(C9), 55.44 (C5), 54.06 (C18), 50.65 (C17), 47.69 (C4), 44.47 (C8), 43.86 (C14), 39.76 
(C1), 38.78 (C20), 38.37 (C21), 36.73 (C10), 34.86, 34.14, 32.33 (C7), 30.11, 28.29 
(C15), 26.34 (C23 or C24), 24.50, 21.36 (C23 or C24 or C30), 20.87 (C23 or C24 or 
C30), 20.80 (C27), 18.61, 18.36 (C26), 17.18 (C29), 15.57 (C25). EI-MS m/z: 519.00 (5) 
M
+
, 216.98 (29), 188.98 (100), 147.03 (62), 133.05 (22), 119.03 (33), 107.03 (23), 105.02 
(32), 95.02 (43), 91.01 (37), 81.01 (30), 79.00 (25), 68.96 (55), 66.97 (33), 54.95 (26). 
Anal. Calcd for C33H46N2O3.0.5EtOAc C 74.70, H 8.95, N 4.98, found C 74.76, H 9.35, 
N 4.84.  
 
3β-Acetoxy-11-oxours-12-en-28-yl-1H-imidazole-1-carboxylate (2.27): 2.27 was 
prepared using the same method as for 2.18, using 2.9 (290 mg 0.57 mmol) as a starting 
material and CDI (184.85 mg 1.14 mmol). The workup was performed after 2.5 hours. 
The solid was subjected to flash column chromatography [hexanes-ethyl acetate from 
(65:35) to (55:45)], to afford 2.27 (56%). mp 145.7-152.4 ºC. IR (film CHCl3): 3139.5, 
2969.8, 1872.5, 1721.2, 1656.6, 1465.6, 1365.4, 1245.8, 1208.2 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.28 (1H s Himidazole), 7.52 (1H s Himidazole), 7.05 (1H s Himidazole), 5.64 
(1H s H12), 4.48 (1H dd J=15.98 H3), 2.77 (1H d J=13.55), 2.60 (1H d J=11.11), 2.02 
(3H s OCOCH3), 1.30 (3H s), 1.12 (3H s), 1.01 (3H d J=6.17), 0.92 (3H d J=6.24), 0.84 
(9H s).
 13
C NMR (100 MHz CDCl3): δ 199.15, 173.78, 170.94, 161.02, 136.87, 131.24, 
130.04, 117.27, 80.48, 61.28, 55.00, 53.99, 50.60, 44.61, 43.71, 38.78, 38.69, 38.34, 
37.94, 36.94, 34.84, 32.83, 30.08, 28.17, 27.98, 24.47, 23.47, 21.24, 20.84, 20.80, 18.44, 
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17.19 (2C), 16.62, 16.33. EI-MS m/z: 563.00 (14) M
+
, 217.02 (73), 189.04 (100), 175.05 
(78), 161.05 (33), 147.06 (74), 133.07 (34), 119.07 (52), 107.06 (33), 105.06 (53), 95.06 
(54), 91.06 (49), 79.03 (32), 68.99 (78). Anal. Calcd for C35H50N2O4 C 74.70, H 8.95, N 
4.98, found C 74.30, H 9.35, N 4.58.  
 
Methyl 3β-(1H-imidazole-1-carbonyloxy)-11-oxours-12-en-28-oate (2.28): 2.28 
was prepared using the same method as for 2.18, using 2.15 (270 mg 0.56 mmol) as a 
starting material and CDI (181.6 mg 1.12 mmol). The workup was performed after 6 
hours. The solid was subjected to flash column chromatography [hexanes-ethyl acetate 
from (70:30) to (60:40)], to afford 2.28 (62%). mp 158.0-164.0 ºC. IR (film CHCl3): 
3133.8, 2949.6, 2872.5, 1757.8, 1726.9, 1660.4, 1457.0, 1387.5, 1321.0, 1287.3, 1240.0 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.14 (1H s), 7.41 (1H s), 7.07 (1H s), 5.61 (1H s), 
4.70 (1H dd J= 16.47), 3.60 (3H s), 2.89 (1H d J=13.70), 2.42 (1H d J=11.23), 1.30 (3H 
s), 1.17 (3H s), 0.97 (9H s), 0.92 (3H s), 0.87 (3H d J=6.41).
 13
C NMR (100 MHz 
CDCl3): δ 199.42, 177.14, 163.10, 148.41, 136.91, 130.54, 130.26, 117.06, 86.12, 61.20, 
54.98, 52.69, 51.84, 47.62, 44.60, 43.72, 38.57 (3C), 38.36, 36.91, 35.91, 32.83, 30.25, 
28.35, 28.18, 23.87, 23.42, 21.04, 20.95, 18.81, 17.27, 17.08, 16.86, 16.20. EI-MS m/z: 
578.95 (11) M
+
, 2447.99 (49), 188.98 (78), 174.04 (38), 161.06 (46), 119.08 (100), 
107.08 (44), 105.09 (51), 95.08 (38), 93.07 (31), 91.09 (58), 79.06 (41), 69.02 (97). Anal. 
Calcd for C35H50N2O5 C 72.63, H 8.71, N 4.84 found C 72.3, H 9.1, N 7.05.  
 
Methyl 2-(1H-imidazol-1-yl)-methylene-3,11-dioxours-12-en-28-oate (2.29): 2.29 
was prepared using the same method as for 2.18, using 2.12 (300 mg 0.59 mmol) as a 
starting material and CDI (191.34 mg 1.18 mmol). The workup was performed after 5.5 
hours. The solid was subjected to flash column chromatography [hexanes-ethyl acetate 
from (65:35) to (50:50)], to afford 2.29 (56%). mp 137.3-141.0 ºC. IR (film CHCl3): 
3116.4, 2949.6, 1866.7, 1725.0, 1686.4, 1652.7, 1613.2, 1517.7, 1486.9, 1383.7, 1302.7, 
1272.8, 1212.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.84 (1H s), 7.65 (1H s), 7.35 (1H s), 
7.14 (1H s), 5.68 (1H s), 4.16 (1H d J=16.47), 3.61 (3H s), 2.46 (2H s), 2.25 (1H d 
J=16.45), 1.33 (3H s), 1.18 (3H s), 1.12 (6H s), 0.97 (3H d J=6.23), 0.94 (3H s), 0.90 (3H 
d J=6.33).
 13
C NMR (100 MHz CDCl3): δ 206.25, 198.67, 177.11, 164.05, 138.85, 
130.51, 130.26, 130.11, 122.70, 119.21, 58.91, 52.85, 52.79, 51.86, 47.63, 45.28, 44.15, 
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43.85, 43.17, 38.72, 38.58, 35.97, 35.88, 31.59, 30.24, 29.71, 28.45, 23.81, 22.34, 20.97, 
20.93, 19.45, 18.19, 17.17, 15.44. EI-MS m/z: 561.20 (24) M
+
, 229.01 (30), 216.99 (32), 
215.98 (100), 201.08 (48), 188.10 (42), 174.13 (42), 105.14 (21), 91.17 (27), 69.13 (36). 
Anal. Calcd for C35H48N2O4.0.25H2O C 74.37, H 8.65, N 4.96, found C 74.29, H 9.05, N 
4.83.  
 
Methyl 2-(1H-imidazol-1-yl)-methylene-3-oxours-12-en-28-oate (2.30): 2.30 was 
prepared using the same method as for 2.18, using 2.13 (300 mg 0.60 mmol) as a starting 
material and CDI (194.58 mg 1.2 mmol). The workup was performed after 4 hours. The 
solid was subjected to flash column chromatography [hexanes-ethyl acetate from (80:20) 
to (60:40)], to afford 2.30 (63%). mp 134.0-137.5 ºC. IR (film CHCl3): 3116.4, 2948.6, 
2872.5, 1774.2, 1722.1, 1685.5, 1607.3, 1519.6, 1457.0, 1380.8, 1306.5, 1225.5 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 7.81 (1H s), 7.70 (1H s), 7.23 (1H s), 7.16 (1H s), 5.30 (1H 
s), 3.60 (3H s), 2.89 (1H d J=15.97), 1.17 (3H s), 1.12 (6H s), 0.95 (3H d J=5.90), 0.89 
(6H s), 0.80 (3H s).
 13
C NMR (100 MHz CDCl3): δ 206.58, 177.93, 138.46 (2C), 130.70, 
130.41, 124.94, 123.08, 119.41, 53.03, 52.62, 51.45, 48.16, 45.31, 45.18, 43.14, 42.23, 
39.36, 39.15, 38.84, 36.55, 36.01, 31.98, 30.65, 29.76, 27.96, 24.18, 23.59, 23.41, 22.42, 
21.11, 20.25, 17.07, 16.57, 15.59. EI-MS m/z: 546.13 (35) M
+
, 285.07 (48), 202.97 (56), 
187.04 (22), 133.02 (100), 119.03 (33), 105.02 (29), 91.00 (31), 78.97 (21), 68.94 (36). 
Anal. Calcd for C35H50N2O3.0.5H2O.0.5EtOAc C 74.09, H 9.24, N 4.67, found C 74.36, 
H 9.54, N 4.63.  
 
28-(1H-Imidazol-1-yl)-3,28-dioxours-12-en-2-(1H-imidazol-1-yl)-methylene 
(2.31): 2.31 was prepared using the same method as for 2.18, using 2.16 (323 mg 0.67 
mmol) as a starting material and CDI (326 mg 2.06 mmol). The workup was performed 
after 5 hours. The solid was subjected to flash column chromatography [hexanes-ethyl 
acetate from (45:55) to (20:80)], to afford 2.31 (46%). mp 281.7-285.0 ºC. IR (film 
CHCl3): 3116.4, 2967.0, 2924.5, 2870.5, 1719.2, 1685.5, 1606.4, 1486.9, 1381.8, 1303.6, 
1224.6 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.22 (1H s), 7.78 (1H s), 7.68 (1H s), 7.51 
(1H s), 7.21 (1H s), 7.14 (3H s), 7.02 (1H s), 5.27 (1H s), 2.86 (1H d J=15.90), 2.48 (1H 
d J=11.04), 1.13 (6H s), 1.09 (3H s), 0.99 (3H d J=5.78), 0.95 (3H d J=5.85), 0.86 (3H s), 
0.71 (3H s).
 13
C NMR (100 MHz CDCl3): δ 206.40, 174.59, 138.37, 137.15, 136.95, 
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130.76, 130.42, 129.61, 125.94, 122.67, 119.36, 117.37, 54.21, 52.42, 50.89, 45.09, 
45.05, 43.06, 42.25, 39.26, 39.20, 38.57, 35.87, 35.42, 31.73, 30.32, 29.67, 27.61, 24.88, 
23.51, 23.35, 22.33, 20.94, 20.03, 17.08, 16.36, 15.55. EI-MS m/z: 582.97 (7) M
+
, 488.19 
(35), 487.18 (100), 486.13 (27), 297.10 (31), 145.10 (30), 133.09 (39), 131.11 (32), 
119.10 (46), 117.11 (32), 107.11 (41), 105.11 (56), 95.11 (33), 91.14 (64), 79.10 (48), 
69.08 (73). Anal. Calcd for C37H50N4O2.0.5EtOAc C 74.72, H 8.68, N 8.94, found C 
74.93, H 9.08, N 9.16. 
 
3β-(2´Methyl-1H-imidazol-1-carbonyloxy)-urs-12-en-28-oic (2.32): To a stirred 
solution of 2.1 (300 mg 0.66 mmol) in THF (4 mL), under N2 atmosphere, at 70 ºC, was 
added CBMI (376.6 mg 1.98mmol). After 26 hours the reaction mixture was diluted with 
water (60 mL), the aqueous phase was extracted with ethyl acetate (3×50 mL). The 
resulting organic phases were washed with NaCl 10% (3×50 mL), dried over Na2SO4, 
filtered and evaporated to the dryness, to afford a yellow residue. The residue was 
subjected to flash column chromatography [hexanes-ethyl acetate from (60:40) to 
(25:75)], to afford 2.32 (18%). mp 287.5-291.6 ºC IR (film CHCl3): 3162.7, 3122.2, 
2928.4, 2872.5, 1803.1, 1753.0, 1550.5, 1510.0, 1457.0, 1395.3, 1373.1, 1321.0, 1294.0, 
1214.0. 
1
H NMR (400 MHz CDCl3): δ 7.34 (1H s), 6.86 (1H s), 5.32 (1H s), 4.67 (1H dd 
J=15.97), 2.65 (3H s), 2.21 (1H d J=11.08), 1.11 (3H s), 0.98 (6H s), 0.97 (6H s), 0.88 
(3H d J=5.98), 0.85 (3H s). EI-MS m/z: 564.87 (1) M+, 393.08 (45), 202.98 (63), 189.94 
(61), 188.97 (100), 187.04 (77), 175.03 (44), 159.01 (57), 133 (70), 118.97 (61), 105 
(50), 94.96 (41).  
 
28-(2’-Methyl-1H-imidazol-1-yl)-28-oxours-12-en-3β-yl-2’-methyl-1H-
imidazole-1-carboxylate (2.33): 2.33 was prepared using the same method as for 2.32, 
using 2.1 (300 mg 0.66 mmol) as a starting material and CBMI (627.69 mg 3.3 mmol). 
The workup was performed after 24 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (55:45) to (30:70)], to afford 2.33 (84%). 
mp 253.4-256.5 ºC. IR (film CHCl3): 3162.7, 3119.3, 2928.4, 2872.5, 1753.0, 1719.2, 
1509.0, 1457.0, 1391.4, 1294.0, 1246.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.54 (1H s), 
7.33 (1H d J=0.92), 6.87 (1H s), 6.85 (1H s), 5.24 (1H s), 4.66 (1H dd J=16.27), 2.64 (3H 
s), 2.56 (3H s), 1.12 (3H s), 1.00 (3H d J=6.28), 0.96 (6H s), 0.95 (3H s), 0.92 (3H d 
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J=6.33), 0.74 (3H s).
 13
C NMR (100 MHz CDCl3): δ 176.63, 149.45, 149.39, 147.85, 
137.22, 127.75, 127.27, 126.24, 118.0, 117.36, 85.87, 55.26, 54.05, 51.83, 47.39, 42.23, 
39.56, 39.51, 38.65, 38.21, 37.98, 36.82, 35.54, 32.65, 30.45, 28.19, 27.78, 24.87, 23.46 
(2C), 23.28, 21.10, 18.06, 17.86, 17.26, 17.19, 17.04, 16.89, 15.51. EI-MS m/z: 628.91 
(6) M
+
, 202.96 (13), 190.98 (10), 188.97 (13), 186.98 (11), 132.98 (11), 126.93 (18), 
119.00 (15), 108.99 (12), 106.99 (12), 105.02 (15), 95.01 (15), 91.01 (14), 83.00 (100), 
81.01 (17). 
 
3β-Trifluoroacetoxy-urs-12-en-28-yl-2’-methyl-1H-imidazole-1-carboxylate 
(2.34): 2.34 was prepared using the same method as for 2.32, using 2.2 (300 mg 0.54 
mmol) as a starting material and CBMI (205.43 mg 1.08 mmol). The workup was 
performed after 53 hours. The solid was subjected to flash column chromatography 
[hexanes-ethyl acetate from (75:25) to (65:35)], to afford 2.34 (68%). mp 235.5-237.6 ºC. 
IR (film CHCl3): 3122.2, 2928.4, 2872.5, 1779.0, 1718.3, 1509.0, 1457.0, 1384.6, 1268.9, 
1218.8, 1165.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.53 (1H s), 6.86 (1H s), 5.23 (1H s), 
4.67 (1H dd J=15.29), 2.55 (3H s), 1.10 (3H s), 0.99 (3H d J=6.17), 0.95 (3H s), 0.89 (9H 
s), 0.72 (3H s).
 13
C NMR (100 MHz CDCl3): δ 176.60, 157.34 (J=41.54), 149.37, 137.19, 
127.28, 126.15, 117.35, 114.62 (J=286.12), 86.13, 55.10, 54.00, 51.77, 47.35, 42.18, 
39.50, 39.47, 38.61, 38.06, 37.89, 36.75, 35.50, 32.59, 30.42, 27.84, 27.73, 24.81, 23.41, 
23.23, 23.04, 21.09, 17.98, 17.90, 17.19, 17.16, 16.41, 15.49. EI-MS m/z: 616.88 (23) 
M
+
, 506.97 (42), 302.91 (100), 203.04 (55), 189.03 (57), 175.07 (57), 119.09 (44), 107.11 
(44), 105.11 (44), 95.15 (57), 91.15 (45), 81.12 (40). Anal. Calcd for C36H51F3N2O3 C 
70.10, H 8.33, N 4.54, found C 69.91, H 8.73, N 4.64.  
 
3-Oxours-12-en-28-yl-2’-methyl-1H-imidazole-1-carboxylate (2.35): 2.35 was 
prepared using the same method as for 2.32, using 2.3 (300 mg 0.66 mmol) as a starting 
material and CBMI (251.1 mg 1.32 mmol). The workup was performed after 24 hours. 
The workup was performed after 53 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (65:35) to (50:50)], to afford 2.35 (36%). 
mp 196.0-199.7 ºC. IR (film CHCl3): 3735.4, 2927.4, 2872.5, 1703.8, 1508.1, 1457.9, 
1385.6, 1268.9, 1247.7 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.53 (1H s Himidazole), 6.87 
(1H s Himidazole), 5.24 (1H s H12), 2.56 (3H s CH3imidazole), 1.10 (3H s), 1.06 (3H s), 
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1.03 (3H s), 1.01 (3H s), 0.98 (3H d J=6.25), 0.90 (3H d J=6.32), 0.76 (3H s).
 13
C NMR 
(100 MHz CDCl3): δ 217.53, 176.55, 149.34, 137.20, 127.04, 126.25, 117.37, 55.24, 
54.08, 51.86, 47.37, 46.66, 42.30, 39.50 (2C), 39.28, 38.61, 36.60, 35.48, 34.10, 32.27, 
30.42, 27.74, 26.42, 24.83, 23.39, 23.36, 21.44, 21.06, 19.41, 17.76, 17.20, 17.13, 15.18. 
EI-MS m/z: 518.91 (13) M
+
, 408.98 (96), 244.96 (44), 204.95 (73), 203.00 (100), 89.02 
(50), 175.06 (58), 121.07 (44), 119.07 (42), 107.08 (42), 105.10 (40), 95.11 (48). Anal. 
Calcd for C34H50N2O2 C 78.72, H 9.71, N 5.40, found C 78.96, H 9.91, N 5.56. 
 
3β-Acetoxy-urs-12-en-28-yl-2’-methyl-1H-imidazole-1-carboxylate (2.36): 2.36 
was prepared using the same method as for 2.32, using 2.4 (300 mg 0.60 mmol) as a 
starting material and CBMI (228.25 mg 1.2 mmol). The workup was performed after 88 
hours. The solid was subjected to flash column chromatography [hexanes-ethyl acetate 
from (75:25) to (65:35)], to afford 2.36 (66%). mp 216.1-219.7 ºC. IR (film CHCl3): 
3180.0, 3116.4, 2926.5, 2872.5, 1720.2, 1509.0, 1457.9, 1366.3, 1245.8 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 7.53 (1H s), 6.86 (1H s), 5.22 (1H s), 4.47 (1H t J=14.86), 2.55 (3H 
s), 2.03 (3H s), 1.09 (3H s), 0.99 (3H d J=6.00), 0.92 (6H s), 0.84 (3H s), 0.83 (3H s), 
0.71 (3H s).
 13
C NMR (100 MHz CDCl3): δ 176.65, 170.96, 149.35, 137.13, 127.24, 
126.39, 117.35, 80.79, 55.25, 54.04, 51.83, 47.39, 42.19, 39.55, 39.49, 38.64, 38.29, 
37.64, 36.80, 35.55, 32.70, 30.45, 28.01, 27.75, 24.88, 23.49, 23.41, 23.26. 21.27, 21.09, 
18.06, 17.84, 17.25, 17.18, 16.67, 15.51. EI-MS m/z: 562.94 (20) M
+
, 248.94 (61), 
203.06 (47), 191.08 (25), 189.07 (100), 187.13 (28), 119.14 (38), 107.14 (36), 105.16 
(35), 95.19 (41), 91.18 (35), 81.15 (31), 79.14 (29). Anal. Calcd for C36H54N2O3 C 76.82, 
H 9.67, N 4.98, found C 77.04, H 9.34, N 5.03. 
 
Methyl 3β-(2’methyl-1H-imidazole-1-carbonyloxy)-urs-12-en-28-oate (2.37): 
2.37 was prepared using the same method as for 2.32, using 2.6 (300 mg 0.64 mmol) as a 
starting material and CBMI (243.5 mg 1.28 mmol). The workup was performed after 78 
hours. The solid was subjected to flash column chromatography [hexanes-ethyl acetate 
from (75:25) to (70:30)], to afford 2.37 (98%). mp 123.4-125.2 
o
C. IR (film CHCl3): 
3184.5, 3122.2, 2947.7, 2872.5, 1753.9, 1725.0, 1510.0, 1456.0, 1395.3, 1373.1, 1294.0, 
1199.5 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.34 (1H s), 6.85 (1H s), 5.25 (1H s), 4.67 
(1H dd J=16.32), 3.60 (3H s), 2.65 (3H s), 1.09 (3H s), 0.98 (3H s), 0.97 (3H s), 0.96 (3H 
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s), 0.94 (3H d J=5.88), 0.86 (3H d J=6.19), 0.76 (3H s).
 13
C NMR (100 MHz CDCl3): δ 
178.00, 149.41, 147.85, 138.24, 127.64, 125.28, 118.01, 86.02, 55.28, 52.84, 51.43, 
48.05, 47.46, 41.99, 39.48, 39.03, 38.84, 38.18, 37.99, 36.85, 36.60, 32.82, 30.62, 28.22, 
28.00, 24.18, 23.58, 23.51, 23.29, 21.16, 18.17, 17.06 (2C), 16.88 (2C), 15.45. EI-MS 
m/z: 578.96 (12) M
+
, 261.97 (32), 203 (67), 189.08 (32), 134.05 (21), 133.16 (100), 
127.11 (20), 119.14 (29), 107.12 (17), 105.15 (21), 95.19 (22), 91.19 (26), 83.28 (86), 
81.17 (23), 79.15 (19).  
 
28-(2’-Methyl-1H-imidazol-1-yl)-11,28-dioxours-12-en-3β-yl-2’-methyl-1H 
imidazole-1-carboxylate (2.38): 2.38 was prepared using the same method as for 2.32, 
using 2.14 (280 mg 0.595 mmol) as a starting material and CBMI (339.50 mg 1.785 
mmol). The workup was performed after 5.5 hours. The solid was subjected to flash 
column chromatography [hexanes-ethyl acetate from (55:45) to (25:75)], to afford 2.38 
(27%). mp 237.2-240.5 ºC. IR (film CHCl3): 3166.5, 3122.2, 2971.8, 2872.5, 1753.0, 
1717.3, 1659.5, 1549.5, 1511.0, 1457.0, 1391.4, 1324.9, 1294.0, 1248.7, 1215.9 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 7.52 (1H s), 7.32 (1H s), 6.89 (1H s), 6.84 (1H s), 5.66 (1H 
s), 4.66 (1H dd J=15.67), 2.87 (1H d J=13.45), 2.63 (3H s), 2.53 (3H s), 1.33 (3H s), 1.17 
(3H s), 1.01 (3H d J=6.00), 0.95 (6H s), 0.90 (3H s), 0.84 (3H d J=7.31).
 13
C NMR (100 
MHz CDCl3): δ 198.97, 175.43, 161.41, 149.69, 149.38, 147.83, 131.14, 127.88, 127.64, 
117.96, 116.94, 85.60, 61.16, 55.03, 54.21, 51.55, 44.65, 43.89, 38.94, 38.68, 38.35, 
38.27, 36.93, 34.68, 32.77, 30.11, 28.25, 28.16, 24.14, 23.46, 20.85, 20.79, 18.87, 18.17, 
17.29, 17.20, 17.00, 16.80, 16.33. EI-MS m/z: 643.21 (3) M
+
, 217.03 (27), 189.04 (100), 
175.15 (22), 161.14 (22), 147.08 (50), 133.09 (22), 119.07 (30), 107.07 (22), 105.06 (35), 
95.05 (31), 91.06 (37). Anal. Calcd for C39H54N4O4.0.5hexane.0.5EtOAc C 72.39, H 
8.97, N 7.67, found C 72.17, H 9.37, N 7.91.  
 
3β-Trifluoroacetoxy-11-oxours-12-en-28-yl-2’-methyl-1H-imidazole-1-
carboxylate (2.39): 2.39 was prepared using the same method as for 2.32, using 2.7 (300 
mg 0.53 mmol) as a starting material and CBMI (201.62 mg 1.06 mmol). The workup 
was performed after 7 hours. The solid was subjected to flash column chromatography 
[hexanes-ethyl acetate from (70:30) to (55:45)], to afford 2.39 (23%). mp 132.7-137.5 ºC. 
IR (film CHCl3): 3180.0, 3122.2, 2953.5, 2928.4, 2873.4, 1778.1, 1717.3, 1659.5, 1512.9, 
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1457.9, 1384.6, 1270.9, 1248.7, 1215.9, 1166.7 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.52 
(1H s), 6.90 (1H s), 5.66 (1H s), 4.68 (1H dd J=16.10), 2.87 (1H d J=13.68), 2.66 (1H d 
J=11.14), 2.53 (3H s), 1.32 (3H s), 1.15 (3H s), 1.01 (3H d J=6.18), 0.93 (3H d J=6.51), 
0.90 (3H s), 0.89 (3H s), 0.89 (3H s).
 13
C NMR (100 MHz CDCl3): δ 199.01, 175.41, 
161.51, 157.32 (J=41.41), 149.72, 131.10, 127.81, 116.98, 114.61 (J=285.97), 85.85, 
61.13, 54.88, 54.19, 51.53, 44.63, 43.86, 38.92, 38.54, 38.33, 38.18, 36.87, 34.64, 32.73, 
30.10, 28.22, 27.83, 24.09, 23.03, 20.88, 20.77, 18.83, 18.22, 17.30, 17.14, 16.38 (2C). 
EI-MS m/z: 630.94 (5) M
+
, 216.91 (27), 198.97 (21), 189.96 (16), 188.94 (100), 175.01 
(17), 147.03 (39), 119.05 (18), 105.04 (17), 95.04 (22), 91.03 (17), 83.02 (24), 81.01 
(20). Anal. Calcd for C36H49F3N2O4 C 68.55, H 7.83, N 4.44, found C 68.16, H 7.62, N 
4.26.  
 
3,11-Dioxours-12-en-28-yl-2’methyl-1H-imidazole-1-carboxylate (2.40): 2.40 was 
prepared using the same method as for 2.32 (300 mg 0.64 mmol), using 2.8 as a starting 
material and CBMI (243.47 mg 1.28 mmol). The workup was performed after 6 hours. 
The solid was subjected to flash column chromatography [hexanes-ethyl acetate from 
(65:35) to (50:50)], to afford 2.40 (34%). mp 279.4-285.3 ºC. IR (film CHCl3): 3182.9, 
3120.3, 2927.4, 1871.5, 1704.8, 1659.5, 1549.5, 1511.9, 1460.8, 1384.6, 1365.4, 1270.9, 
1248.7, 1232.3, 1215.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.53 (1H s), 6.91 (1H s), 
5.69 (1H s), 2.55 (3H s), 1.33 (3H s), 1.25 (3H s), 1.07 (3H s), 1.03 (3H s), 1.01 (3H d 
J=6.18), 0.92 (6H s).
 13
C NMR (100 MHz CDCl3): δ 216.94, 198.65, 175.42, 161.60, 
149.73, 131.14, 127.69, 116.99, 60.65, 55.43, 54.24, 51.60, 47.71, 44.52, 43.98, 39.75, 
38.98, 38.35, 36.72, 34.67, 34.15, 32.32, 30.11, 28.32, 26.33, 24.13, 21.38, 20.87, 20.76, 
18.76, 18.61, 18.13, 17.28, 15.61. EI-MS m/z: 532.95 (7) M
+
, 423.01 (12), 216.89 (18), 
190.96 (16), 189.96 (16), 188.96 (100), 173.09 (12), 147.10 (38), 119.09 (14), 105.10 
(12), 95.15 (23), 91.12 (13), 83.14 (24), 81.10 (14). Anal. Calcd for C34H48N2O3 C 76.65, 
H 9.08, N 5.26, found C 76.26, H 9.42, N 4.86.  
 
3β-Acetoxy-11-oxours-12-en-28-yl-2’-methyl-1H-imidazole-1-carboxylate (2.41): 
2.41 was prepared using the same method as for 2.32, using 2.9 (290 mg 0.57 mmol) as a 
starting material and CBMI (216.84 mg 1.14 mmol). The workup was performed after 7 
hours. The solid was subjected to flash column chromatography [hexanes-ethyl acetate 
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from (60:40) to (50:50)], to afford 2.41 (39%). mp 170.0-171.0 ºC. IR (film CHCl3): 
2950.6, 2872.5, 1722.1, 1656.6, 1458.9, 1365.4, 1247.7 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 7.52 (1H s Himidazole), 6.89 (1H s Himidazole), 5.65 (1H s H12), 4.48 (1H dd 
J=15.82 H3), 2.77 (1H d J=13.47), 2.65 (1H d J=10.98), 2.53 (3H s), 2.03 (3H s), 1.31 
(3H s), 1.13 (3H s), 1.00 (3H d J=6.19), 0.92 (3H d J=6.28), 0.88 (3H s), 0.84 (6H s).
 13
C 
NMR (100 MHz CDCl3): δ 199.26, 175.43, 170.97, 161.22, 149.70, 131.19, 127.72, 
116.99, 80.50, 61.28, 55.01, 54.18, 51.56, 44.68, 43.85, 38.91, 38.80, 38.34, 37.96, 36.95, 
34.69, 32.84, 30.11, 28.21, 28.00, 24.13, 23.48, 21.26, 20.87, 20.74, 18.86, 18.15, 17.30, 
17.19, 16.64, 16.36. EI-MS m/z: 577.02 (5) M
+
, 216.94 (31), 199.02 (12), 189.99 (17), 
188.97 (100), 176.05 (11), 175.04 (40), 173.07 (11), 161.06 (10), 147.07 (34), 133.07 
(10), 119.05 (13), 105.07 (12), 95.07 (17), 91.06 (10), 83.04 (20), 80.99 (14). Anal. Calcd 
for C36H52N2O4 C 74.96, H 9.09, N 4.86, found C 74.7, H 9.48, N 4.48.  
 
Methyl 3β-(2’-methyl-1H-imidazole-1-carbonyloxy)-11-oxours-12-en-28-oate 
(2.42): 2.42 was prepared using the same method as for 2.32, using 2.15 (270 mg 0.56 
mmol) as a starting material and CBMI (213.03 mg 1.12 mmol). The workup was 
performed after 21 hours. The solid was subjected to flash column chromatography 
[hexanes-ethyl acetate from (70:30) to (60:40)], to afford 2.42 (66%). mp 243.1-247.0 ºC. 
IR (film CHCl3): 3168.5, 3122.2, 2949.6, 2872.5, 1753.0, 1727.9, 1660.4, 1457.0, 1396.2, 
1324.9, 1294.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.33 (1H d J=0.85), 6.85 (1H s), 5.61 
(1H s H12), 4.67 (1H dd J=16.39 H3), 3.60 (3H s COOCH3), 2.88 (1H dt J=13.68), 2.65 
(3H s CH3 imidazole), 2.42 (1H d J=11.21 H18), 1.30 (3H s C27), 1.17 (3H s C25), 0.97 
(9H s C23, C24 and C30), 0.91 (3H s C26), 0.87 (3H d J=6.36 C29).
 13
C NMR (100 MHz 
CDCl3): δ 199.44 (C11), 177.14 (C28), 163.09 (C13), 149.34 (OCO), 147.87 (C2’), 
130.54 (C12), 127.48, 118.0, 85.76 (C3), 61.20 (C9), 55.01 (C5), 52.69 (C18), 51.83 
(COOCH3), 47.62 (C17), 44.60 (C8), 43.72 (C14), 38.64 (C1), 38.59 (C19 or C20), 38.56 
(C19 or C20), 38.28 (C4), 36.93 (C10), 35.91, 32.83 (C7), 30.25, 28.35 (C15), 28.20 
(C23 or C24 or C30), 23.87, 23.49, 21.04 (C27), 20.95 (C23 or C24 or C30), 18.81 
(C26), 17.28, 17.08 (C23 or C24 or C30), 17.02 (C29), 16.80 (CH3 imidazole), 16.19 
(C25). EI-MS m/z: 593.04 (6) M
+
, 467.14 (100), 407.15 (44), 217.02 (44), 189 (61), 
161.03 (51), 119.06 (61), 107.05 (42), 105.05 (43), 91.03 (41), 83.01 (53), 81.01 (43). 
Anal. Calcd for C36H52N2O5 C 72.94, H 8.84, N 4.73, found C 72.98, H 9.21, N 4.80.  
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Methyl 2-(2´-methyl-1H-imidazol-1-yl)-methylene-3,11-dioxours-12-en-28-oate 
(2.43): 2.43 was prepared using the same method as for 2.32, using 2.12 (300 mg 0.59 
mmol) as a starting material and CBMI (224.45 mg 1.18 mmol). The workup was 
performed after 5.5 hours. The solid was subjected to flash column chromatography 
[hexanes-ethyl acetate from (65:35) to (50:50)], to afford 2.43 (39%). mp 263.4-266.1 ºC. 
IR (film CHCl3): 3119.3, 2949.6, 2867.6, 1726.0, 1684.5, 1654.6, 1604.5, 1540.8, 1504.2, 
1456.0, 1410.7, 1382.7, 1320.0, 1273.8, 1244.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.62 
(1H s C2CH), 7.32 (1H s H4’), 6.99 (1H s H5’), 5.67 (1H s H12), 4.14 (1H d J=16.36 
H1), 3.61 (3H s COOMe), 2.49 (3H s CH3 imidazole), 2.45 (2H H18 and H9), 2.18 (1H d 
J=16.46 H1), 1.33 (3H s C27), 1.18 (3H s C23 or C24), 1.13 (3H s C23 or C24), 1.12 (3H 
s C25), 0.97 (3H d J=6.28 C30), 0.94 (3H s C26), 0.89 (3H d J=6.22 C29).
 13
C NMR 
(100 MHz CDCl3): δ 206.36 (C3), 198.71 (C11), 177.11 (C28), 163.99 (C13), 147.23 
(C2’), 130.53 (C12), 129.69 (C2CH), 128.38 (C4’), 122.98 (C2), 118.24 (C5’), 58.90 
(C9), 53.02 (C5), 52.80 (C18), 51.87 (COOMe), 47.64 (C17), 45.39 (C4), 44.19 (C8), 
43.86 (C14), 42.51 (C1), 38.72 (C20), 38.59 (C19), 36.07 (C10), 35.90, 31.65 (C7), 
30.25, 29.67 (C23 or C24), 28.47 (C15), 23.82, 22.47 (C23 or C24), 21.00 (C27), 20.94 
(C30), 19.44, 18.26 (C26), 17.19 (C29), 15.39 (C25), 13.66 (CH3 imidazole). EI-MS m/z: 
575.20 (17) M
+
, 243.01 (44), 231.00 (23), 229.98 (100), 229.07 (19), 215.1 (54), 202.11 
(36), 189.12 (18), 188.14 (50), 83.14 (25). Anal. Calcd for C36H50N2O4 C 75.22, H 8.77, 
N 4.87, found C 74.88, H 9.12, N 4.86.  
 
Methyl 2-(2’-methyl-1H-imidazol-1-yl)-methylene-3-oxours-12-en-28-oate 
(2.44): 2.44 was prepared using the same method as for 2.32, using 2.13 (300 mg 0.60 
mmol) as a starting material and CBMI (228.25 mg 1.2 mmol). The workup was 
performed after 7 hours. The solid was subjected to flash column chromatography 
[hexanes-ethyl acetate from (75:25) to (60:40)], to afford 2.44 (55%). mp 229.5-231.7 ºC. 
IR (film CHCl3): 2948.6, 2872.5, 1724.1, 1685.5, 1603.5, 1540.9, 1500.4, 1456.0, 1411.6, 
1274.7, 1242.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.66 (1H s C2CH), 7.16 (1H s C5’), 
7.01 (1H s C4’), 5.29 (1H s C12), 3.60 (3H s COOMe), 2.89 (1H d J=15.84 C1), 2.47 
(3H s CH3 imidazole), 2.26 (1H d J=11.27 C18), 2.17 (1H d J= 15.49 C1), 1.16 (3H s 
C23 or C24), 1.14 (3H s C23 or C24), 1.12 (3H s C27), 0.95 (3H d J=5.85 C30), 0.89 (6H 
s C29 and C25), 0.79 (3H s C26).
 13
C NMR (100 MHz CDCl3): δ 206.63 (C3), 177.92 
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(C28), 147.31 (C2’), 138.45 (C13), 130.38 (C2CH), 128.57 (C4’ imidazole), 124.98 
(C12), 123.60 (C2), 118.19 (C5’ imidazole), 53.01 (C18), 52.78 (C5), 51.45 (COOMe), 
48.14 (C17), 45.31 (C4), 45.28 (C9), 42.37 (C1), 42.21 (C14), 39.38 (C8), 39.12 (C20), 
38.83 (C19), 36.55, 36.12 (C10), 32.01 (C7), 30.63 (C21), 29.67 (C23 or C24), 27.97 
(C15), 24.17, 23.54, 23.43 (C27), 22.57 (C23 or C24), 21.11 (C30), 20.23, 17.07 (C29), 
16.62 (C26), 15.46 (C25), 13.68 (CH3 imidazole). EI-MS m/z: 561.17 (12) M
+
, 300.07 
(17), 299.06 (75), 297.08 (18), 243.06 (16), 203.03 (47), 134.01 (26), 133.15 (100), 131.1 
(16), 119.07 (26), 117.09 (16), 107.05 (16), 105.09 (23), 91.13 (29), 83.18 (39), 79.08 
(18). ). Anal. Calcd for C36H52N2O3 C 77.10, H 9.35, N 5.00, found C 76.70, H 9.56, N 
5.02.  
 
28-(2’-Methyl-1H-imidazol-1-yl)-3,28-dioxours-12-en-2-(2’-methyl-1H-imidazol-
1-yl)-methylene (2.45): 2.45 was prepared using the same method as for 2.32, using 2.16 
(300 mg 0.62 mmol) as a starting material and CBMI (353.79 mg 1.86 mmol). The 
workup was performed after 24.5 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (40:60) to (10:90)], to afford 2.45 (36%). 
mp 283.3-286.1 ºC. IR (film CHCl3): 3116.4, 2952.5, 2870.5, 1717.3, 1684.5, 1603.5, 
1540.9, 1411.6, 1383.7, 1247.7 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.67 (1H s C2CH), 
7.53 (1H s H4’’or H5’’), 7.16 (1H s H5’), 7.00 (1H s H4’), 6.87 (1H s H4’’ or H5’’), 5.28 
(1H s H12), 2.86 (1H d J=15.80 H1), 2.54 (4H s CH3 C2’’ and H18), 2.47 (3H s CH3 
C2’), 1.15 (6H s C27 or C23 or C24), 1.12 (3H s C23 or C24), 1.00 (3H d J=6.13 C30), 
0.95 (3H d J=6.13 C29), 0.87 (3H s C25), 0.77 (3H s C26).
 13
C NMR (100 MHz CDCl3): 
δ 206.50 (C3), 176.51 (C28), 149.35 (C2’’), 147.39 (C2’), 137.37 (C13), 130.50 (C2CH), 
128.68 (C4’), 127.37, 125.87 (C12), 123.07 (C2), 118.11 (C5’), 117.31, 54.16 (C18), 
52.64 (C5), 51.84 (C17), 45.20 (C4), 45.15 (C9), 42.40 (C14), 42.36 (C1), 39.55 (C19), 
39.39 (C8), 38.59 (C20), 36.03 (C10), 35.43 (C11), 31.78 (C7), 30.42 (C21), 29.66 (C3 
or C24), 27.72 (C15), 24.75, 23.49, 23.28 (C27), 22.52 (C23 or C24), 21.07 (C30), 20.08 
(C6), 17.93 (CH3 C2’’), 17.24 (C29), 16.90 (C26), 15.51 (C25), 13.75 (CH3 C2’). EI-MS 
m/z: 611.12 (5) M
+
, 502.17 (38), 501.20 (100), 311.14 (14), 197.16 (25), 119.11 (10), 
105.13 (11), 91.17 (12), 83.17 (14), 81.10 (9), 79.10 (8). Anal. Calcd for C39H54N4O2 C 
76.68, H 8.91, N 9.17, found C 76.28, H 9.31, N 8.89.  
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28-(4H-Triazol-4-yl)-28-oxo-urs-12-en-3β-yl-4H-triazole-4-carboxylate (2.46): 
To a stirred solution of 2.1 (300 mg 0.66 mmol) in THF (4 mL), under N2 atmosphere, at 
70 ºC, was added CDT (433.3 mg 2.64 mmol). After 6.5 hours the reaction mixture was 
diluted with water (60 mL), the aqueous phase was extracted with ethyl acetate (3×50 
mL). The resulting organic phases were washed with NaCl 10% (3×50 mL), dried over 
Na2SO4, filtered and evaporated to the dryness, to afford a yellow residue. The residue 
was subjected to flash column chromatography [hexanes-ethyl acetate from (70:30) to 
(65:35)], to afford 2.46 (62%). mp 143.7-150.1 ºC. IR (film CHCl3): 3133.8, 2951.5, 
2872.5, 1761.7, 1734.7, 1511.0, 1457.0, 1405.9, 1279.5, 1226.5 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.82 (1H s C3’’ or C5’’), 8.77 (1H s C3’ or C5’), 8.06 (1H s C3’ or C5’), 7.99 
(1H s C3’’ or C5’’), 5.24 (1H s H12), 4.79 (1H t J=16.50 H3), 1.11 (3H s C27), 0.99 (3H 
s C23 or C24), 0.97 (6H C30 and C23 or C24), 0.97 (3H s C25), 0.91 (3H d J=6.35 C29), 
0.68 (3H s C26).
 13
C NMR (100 MHz CDCl3): δ 174.82 (C28), 153.57 (C3’ or C5’), 
152.21 (C3’’ or C5’’), 147.28 (OCOC), 145.29 (2C), 137.60 (C13), 125.86 (C12), 87.69 
(C3), 55.20 (C5), 51.26 (C17), 47.40 (C9), 42.14 (C14), 39.45 (2C C8), 39.09 (C19 or 
C20), 38.51 (C19 or C20), 38.17 (C4), 38.14, 36.78 (C10), 34.39, 32.67 (C7), 30.42, 
28.13 (2C C23 or C24), 23.56 (2C C27), 23.40, 23.27, 21.05 (C30), 18.04, 17.03 (C29), 
16.81 (C23 or C24), 16.71 (C26), 15.49 (C25). EI-MS m/z: 602.64 (1) M
+
, 505.07 (71), 
392.15 (44), 202.02 (85), 190.00 (100), 189.04 (74), 145.10 (40), 132.05 (94), 119.09 
(51), 117.13 (73), 91.16 (46), 70.04 (44). 
 
3β-Trifluoroacetoxy-urs-12-en-28-yl-4H-triazole-4-carboxylate (2.47): 2.47 was 
prepared using the same method as for 2.46, using 2.2 (300 mg 0.54 mmol) as a starting 
material and CDT (265.89 mg 1.62 mmol). The workup was performed after 5 hours. The 
residue was subjected to flash column chromatography [hexanes-ethyl acetate from 
(85:15) to (80:20)], to afford 2.47 (34%). mp 189.6-191.0 ºC. IR (film CHCl3): 3142.4, 
2953.5, 2927.4, 2878.2, 1780.0, 1734.7, 1511.9, 1457.0, 1347.0, 1275.9, 1219.8, 1166.7 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.82 (1H s), 7.99 (1H s), 5.23 (1H s), 4.68 (1H dd 
J=15.51), 1.10 (3H s), 0.98 (3H d J=6.26), 0.94 (3H s), 0.91 (3H d J=6.84), 0.89 (6H s), 
0.67 (3H s).
 13
C NMR (100 MHz CDCl3): δ 174.82, 157.34 (J=41.64), 152.21, 145.29, 
137.58, 125.85, 114.63 (J=286.06), 86.16, 55.12, 52.91, 51.25, 47.38, 42.13, 39.42, 
39.08, 38.50, 38.06, 37.89, 36.76, 34.38, 32.65, 30.41, 28.12, 27.85, 23.55, 23.43, 23.25, 
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23.06, 21.05, 18.00, 17.02, 16.69, 16.42, 15.47. EI-MS m/z: 603.80 (1) M
+
, 505.97 (44), 
201.88 (95), 200.96 (41), 189.98 (100), 188.96 (80), 145.03 (40), 133.01 (43), 131.96 
(89), 131.10 (51), 119.05 (61), 117.03 (82), 105.06 (47), 91.00 (43). Anal. Calcd for 
C34H48F3N3O3 C 67.64, H 8.01, N 6.96, found C 67.61, H 8.87, N 6.98.  
 
3-Oxours-12-en-28-yl-4H-triazole-4-carboxylate (2.48): 2.48 was prepared using 
the same method as for 2.46, using 2.3 (200 mg 0.44 mmol) as a starting material and 
CDT (216.65 mg 1.32 mmol). The workup was performed after 5 hours. The residue was 
subjected to flash column chromatography [hexanes-ethyl acetate from (75:25) to 
(70:30)], to afford 2.48 (98%). mp 129.4-133.9 ºC. IR (film CHCl3): 3133.8, 2925.5, 
2870.5, 1733.7, 1703.8, 1510.0, 1457.0, 1384.6, 1348.0, 1275.7, 1181.1 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 8.82 (1H s Htriazole), 7.98 (1H s Htriazole), 5.24 (1H s H12), 1.10 
(3H s), 1.06 (3H s), 1.02 (3H s), 1.01 (3H s), 0.97 (3H d J=6.31), 0.90 (3H d J=6.37), 
0.71 (3H s).
 13
C NMR (100 MHz CDCl3): δ 217.58, 174.80, 152.20, 145.28, 137.60, 
125.92, 55.24, 53.0, 51.30, 47.36, 46.69, 42.25, 39.41, 39.27, 39.10, 38.49, 36.60, 34.37, 
34.11, 32.33, 30.42, 28.12, 26.44, 23.49, 23.44, 23.40, 21.44, 21.02, 19.44, 16.99, 16.69, 
15.17. EI-MS m/z: 505.84 (1) M
+
, 409.02 (38), 408.01 (100), 202.98 (18), 201.94 (47), 
201.01 (28), 190.00 (58), 189.02 (42), 145.09 (24), 133.04 (26), 132.03 (62), 131.05 (23), 
119.08 (32), 117.10 (48), 105.10 (23), 91.12 (24). Anal. Calcd for C32H47N3O2 C 76.00, 
H 9.37, N 8.31, found C 75.66, H 9.45, N 8.70.  
 
3β-Acetoxy-urs-12-en-28-yl-4H-triazole-1-carboxylate (2.49): 2.49 was prepared 
using the same method as for 2.46, using 2.4 (300 mg 0.60 mmol) as a starting material 
and CDT (295.43 mg 1.8 mmol). The workup was performed after 2 hours. The residue 
was subjected to flash column chromatography [hexanes-ethyl acetate from (85:15) to 
(80:20)], to afford 2.49 (94%). mp 124.0-128.8 ºC. IR (film CHCl3): 3139.5, 2950.6, 
2924.5, 2872.5, 1732.7, 1511.9, 1456.0, 1348.0, 1275.7, 1246.7, 1183.1 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 8.81 (1H s), 7.98 (1H s), 5.23 (1H s), 4.48 (1H t J=15.77), 2.04 (3H 
s), 1.10 (3H s), 0.98 (3H d J=6.29), 0.92 (6H s), 0.85 (3H s), 0.84 (3H s), 0.66 (3H s).
 13
C 
NMR (100 MHz CDCl3): δ 174.87, 170.99, 152.20, 145.30, 137.54, 126.09, 80.84, 55.28, 
52.96, 51.30, 47.43, 42.14, 39.47, 39.11, 38.54, 38.29, 37.66, 36.82, 34.44, 32.76, 30.45, 
28.15, 28.03, 23.56, 23.51 (2C), 23.29, 21.29, 21.06, 18.09, 17.05, 16.74, 16.69, 15.51. 
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EI-MS m/z: 548.86 (1) M
+
, 452.08 (23), 202.96 (32), 201.92 (100), 201.03 (25), 190.04 
(85), 189 (53), 188.05 (26), 145.02 (21), 133.05 (31), 131.93 (97), 119.02 (39), 117.04 
(53), 104.98 (28), 91.00 (30), 78.96 (22). Anal. Calcd for C34H51N3O3 C 74.28, H 9.35, N 
7.64, found C 74.56, H 9.21, N 8.00. 
 
Methyl 3β-(4H-triazole-1-carbonyloxy)-urs-12-en-28-oate (2.50): 2.50 was 
prepared using the same method as for 2.46, using 2.6 (300 mg 0.64 mmol) as a starting 
material and CDT (315.13 mg 1.92 mmol). The workup was performed after 2.5 hours. 
The residue was subjected to flash column chromatography [hexanes-ethyl acetate from 
(85:15) to (80:20)], to afford 2.50 (93%). mp 121.6-126.8 
o
C. IR (film CHCl3): 3133.8, 
2947.7, 2872.5, 1762.6, 1723.1, 1510.0, 1456.0, 1405.9, 1280.5, 1226.5, 1200.5, 1169.6 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.78 (1H s), 8.06 (1H s), 5.25 (1H s), 4.80 (1H t 
J=16.55), 3.60 (3H s), 1.08 (3H s), 1.00 (3H s), 0.99 (6H s), 0.94 (3H d J=5.77), 0.86 (3H 
d J=6.33), 0.76 (3H s).
 13
C NMR (100 MHz CDCl3): δ 177.99, 153.57, 147.29, 145.30, 
138.25, 125.23, 87.79, 55.23, 52.83, 51.43, 48.04, 47.47, 41.99, 39.47, 39.02, 38.83, 
38.19, 38.14, 36.83, 36.58, 32.81, 30.61, 28.17, 27.99, 24.16, 23.56, 23.44, 23.27, 21.15, 
18.15, 17.03, 16.87, 16.84, 15.46. EI-MS m/z: 565.68 (1) M
+
, 262.00 (66), 204.03 (18), 
202.94 (100), 201.95 (27), 190.01 (19), 89.01 (36), 133.05 (89), 119.08 (24), 105.05 (19), 
91.01 (21). 
 
28-(4H-Triazol-4-yl)-11,28-dioxours-12-en-3β-yl-4H-triazole-4-carboxylate 
(2.51): 2.51 was prepared using the same method as for 2.46, using 2.14 (262.8 mg 0.56 
mmol) as a starting material and CDT (459.56 mg 2.8 mmol). The workup was performed 
after 7 hours. The residue was subjected to flash column chromatography [hexanes-ethyl 
acetate from (70:30) to (60:40)], to afford 2.51 (76%). mp 162.1-165.4 ºC. IR (film 
CHCl3): 3137.6, 2955.4, 2874.4, 1763.6, 1733.7, 1658.5, 1512.9, 1457.0, 1405.9, 1362.5, 
1350.9, 1279.5, 1226.5 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.80 (1H s), 8.74 (1H s), 
8.02 (1H s), 7.97 (1H s), 5.61 (1H s), 4.76 (1H dd J=16.33 H3), 2.87 (1H d J=13.74), 
2.45 (1H d J=11.14), 1.30 (3H s), 1.13 (3H s), 0.96 (6H s), 0.93 (3H s), 0.89 (3H d 
J=6.31), 0.81 (3H s).
 13
C NMR (100 MHz CDCl3): δ 198.87, 174.00, 161.84, 153.45, 
152.56, 147.16, 145.27, 145.23, 130.84, 87.25, 61.09, 54.85, 53.01, 50.87, 44.50, 43.74, 
38.53, 38.50, 38.35, 38.20, 36.78, 33.59, 32.66, 30.01, 28.51, 28.02, 23.29, 22.83, 20.82, 
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20.76, 18.42, 17.10, 17.03, 16.67, 16.22. EI-MS m/z: 616.80 (1) M
+
, 406.00 (30), 256.96 
(100), 217.03 (88), 216.04 (65), 161.02 (33), 70.03 (42). Anal. Calcd for 
C35H48N6O4.0.5EtOAc C 67.25, H 7.93, N 12.72, found C 66.90, H 8.33, N 12.56.  
 
3β-Trifluoroacetoxy-11-oxours-12-en-28-yl-4H-triazole-4-carboxylate (2.52): 
2.52 was prepared using the same method as for 2.46, using 2.7 (300 mg 0.53 mmol) as a 
starting material and CDT (260.96 mg 1.59 mmol). The workup was performed after 2 
hours. The residue was subjected to flash column chromatography [hexanes-ethyl acetate 
from (80:20) to (75:25)], to afford 2.52 (51%). mp 127.3-132.4. IR (film CHCl3): 3139.5, 
2955.4, 2930.3, 2875.3, 1778.1, 1732.7, 1660.4, 1513.9, 1457.9, 1384.6, 1348.0, 1276.7, 
1214.0, 1166.7, 1139.7 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.84 (1H s), 8.01 (1H s), 
5.65 (1H s), 4.68 (1H dd J=16.35), 2.87 (1H d J=13.75), 2.49 (1H d J=12.63), 2.32 (1H 
s), 1.33 (3H s), 1.14 (3H s), 1.00 (3H d J=6.26), 0.93 (3H d J=6.37), 0.90 (3H s), 0.88 
(3H s), 0.84 (3H s).
 13
C NMR (100 MHz CDCl3): δ 199.07, 174.11, 161.98, 157.32 
(J=41.55), 152.65, 145.36, 130.95, 114.61 (J=286.26), 85.87, 61.19, 54.88, 53.10, 50.96, 
44.59, 43.82, 38.64, 38.53, 38.30, 38.19, 36.87, 33.68, 32.74, 30.11, 28.59, 27.84, 23.05, 
22.91, 20.90, 20.86, 18.50, 17.16, 17.13, 16.39, 16.33. EI-MS m/z: 617.84 (4) M
+
, 258.01 
(21), 257.02 (100), 255.18 (18), 217.08 (60), 216.08 (45), 176.15 (23), 161.16 (28), 
146.13 (24), 119.04 (17), 105.11 (18), 91.14 (21), 79.22 (17). Anal. Calcd for 
C34H46F3N3O4 C 66.11, H 7.51, N 6.80, found C 65.88, H 7.90, N 7.13.  
 
3,11-Dioxours-12-en-28-yl-4H-triazole-4-carboxylate (2.53): 2.53 was prepared 
using the same method as for 2.46, using 2.8 (300 mg 0.64 mmol) as a starting material 
and CDT (315.13 mg 1.92 mmol). The workup was performed after 4 hours. The residue 
was subjected to flash column chromatography [hexanes-ethyl acetate from (80:20) to 
(70:30)], to afford 2.53 (43%). mp 169.3-172.7 ºC. IR (film CHCl3): 3128.0, 2955.4, 
2872.5, 1732.7, 1702.8, 1659.5, 1513.9, 1458.9, 1385.6, 1349.9, 1275.7 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 8.84 (1H s), 8.01 (1H s), 5.67 (1H s), 1.33 (3H s), 1.23 (3H s), 1.06 
(3H s), 1.02 (3H s), 1.00 (3H d J=6.34), 0.92 (3H d J=6.38), 0.87 (3H s).
 13
C NMR (100 
MHz CDCl3): δ 216.98, 198.71, 174.14, 162.11, 152.65, 145.37, 130.97, 60.70, 55.41, 
53.13, 51.00, 47.69, 44.46, 43.92, 39.73, 38.69, 38.30, 36.70, 34.15, 33.71, 32.31, 30.12, 
28.67, 26.33, 22.94, 21.37, 20.89, 20.85, 18.62, 18.41, 17.10, 15.56. EI-MS m/z: 519.84 
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(8) M
+
, 421.97 (46), 407.03 (43), 256.99 (100), 217.04 (73), 216.04 (71), 161.11 (45), 
147.07 (32), 146.05 (42), 105.14 (31), 91.2 (39). Anal. Calcd for C32H45N3O3.0.5H2O C 
72.69, H 8.77, N 7.95, found C 73.08, H 8.85, N 7.61.  
 
3β-Acetoxy-11-oxours-12-en-28-yl-4H-triazole-4-carboxylate (2.54): 2.54 was 
prepared using the same method as for 2.46, using 2.9 (290 mg 0.57 mmol) as a starting 
material and CDT (280.66 mg 1.71 mmol). The workup was performed after 2 hours. The 
residue was subjected to flash column chromatography [hexanes-ethyl acetate from 
(80:20) to (75:25)], to afford 2.54 (46%). mp 151.8-156.5 ºC. IR (film CHCl3): 3133.8, 
2951.5, 2872.5, 1730.8, 1661.4, 1459.9, 1349.9, 1246.8 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.83 (1H s Htriazole), 8.00 (1H s Htriazole), 5.64 (1H s H12), 4.49 (1H dd 
J=16.28 H3), 2.79 (3H d J=2.77), 2.48 (1H d J=12.60), 2.31 (1H s H9), 2.03 (3H s CH3), 
1.32 (3H s C27), 1.12 (3H s C25), 1.00 (3H d J=6.29 C30), 0.93 (3H d J=6.36 C29), 0.84 
(6H s C23 or C24), 0.83 (3H s C26), 0.75 (1H d J=11.55 H5).
 13
C NMR (100 MHz 
CDCl3): δ 199.33 (C11), 174.12 (C28), 170.97 (OCOCH3), 161.72 (C13), 152.61 
(Ctriazole), 145.36 (Ctriazole), 131.05 (C12), 80.53 (C3), 61.34 (C9), 55.02 (C5), 53.10 
(C18), 50.99 (C17), 44.65 (C8), 43.81 (C14), 38.80 (C1), 38.65 (C19 or C20), 38.32 (C19 
or C20), 37.97 (C4), 36.96 (C10), 33.73, 32.86 (C7), 30.13 (C21), 28.60 (C15), 28.01 
(C23 or C24), 23.51, 22.96, 21.27 (OCOCH3), 20.89 (C27), 20.87 (C30), 18.53 (C26), 
17.22, 17.14 (C29), 16.66 (C23 or C24), 16.33 (C25). EI-MS m/z: 563.78 (4) M
+
, 465.94 
(16), 353.84 (21), 257.99 (23), 256.95 (100), 217.01 (60), 216.01 (49), 176.08 (19), 
175.08 (20), 174.06 (18), 161.08 (28), 159.10 (17), 147.05 (16), 146.03 (20), 91.12 (17). 
Anal. Calcd for C34H49N3O4 C 72.43, H 8.76, N 7.45, found C 72.2, H 9.16, N 7.05.  
 
Methyl 3β-(4H-triazole-4-carbonyloxy)-11-oxo-urs-12-en-28-oate (2.55): 2.55 
was prepared using the same method as for 2.46, using 2.15 (270 mg 0.56 mmol) as a 
starting material and CDT (275.74 mg 1.68 mmol). The workup was performed after 5 
hours. The residue was subjected to flash column chromatography [hexanes-ethyl acetate 
from (80:20) to (70:30)], to afford 2.55 (65%). mp 216.3-218.7 ºC. IR (film CHCl3): 
2179.0, 2949.6, 2872.5, 1762.6, 1726.0, 1656.6, 1457.9, 1405.9, 1280.5, 1225.5, 1202.4 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.77 (1H s), 8.06 (1H s), 5.61 (1H s), 4.81 (1H dd 
J=16.48), 3.60 (3H s), 2.91 (1H d J=13.67), 2.42 (1H d J=11.21), 1.30 (3H s), 1.18 (3H 
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s), 1.01 (3H s), 0.98 (3H s), 0.96 (3H d J=6.22), 0.91 (3H s), 0.87 (3H d J=6.39).
 13
C 
NMR (100 MHz CDCl3): δ 199.36, 177.12, 163.09, 153.54, 147.27, 145.29, 130.53, 
87.47, 61.19, 54.97, 52.70, 51.83, 47.62, 44.59, 43.72, 38.60 (2C), 38.56, 38.47, 36.91, 
35.91, 32.83, 30.25, 28.35, 28.16, 23.87, 23.42, 21.03, 20.94, 18.81, 17.27, 17.08, 16.80, 
16.21. EI-MS m/z: 580.13 (6) M
+
, 317.00 (91), 275.97 (53), 257.03 (95), 248.02 (82), 
189.06 (100), 175.13 (36), 174.12 (36), 161.14 (74), 119.16 (77), 105.15 (34), 91.16 (35). 
Anal. Calcd for C34H49N3O5 C 70.44, H 8.52, N 7.25, found C 70.48, H 8.25, N 6.87.  
 
Methyl 2-(4H-triazol-4-yl)-methylene-3,11-dioxours-12-en-28-oate (2.56): 2.56 
was prepared using the same method as for 2.46, using 2.12 (280 mg 0.55 mmol) as a 
starting material and CDT (180.54 mg 1.1 mmol). The workup was performed after 23.5 
hours. The residue was subjected to flash column chromatography [hexanes-ethyl acetate 
from (65:35) to (55:45)], to afford 2.56 (46%). mp 250.2-251.2 ºC. IR (film CHCl3): 
3122.2, 2949.6, 2869.6, 1725.0, 1688.4, 1654.6, 1617.0, 1508.1, 1457.0, 1383.7, 1275.7, 
1202.4 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.46 (1H s), 8.08 (1H s), 7.79 (1H s), 5.68 
(1H s), 4.39 (1H d J=17.42), 3.61 (3H s), 1.33 (3H s), 1.19 (3H s), 1.12 (6H s), 0.97 (3H 
d J=6.150), 0.94 (3H s), 0.91 (3H d J=6.26).
 13
C NMR (100 MHz CDCl3): δ 206.32, 
198.51, 177.13, 163.66, 152.49, 145.23, 130.61, 128.77, 125.27, 58.71, 53.01, 52.80, 
51.87, 47.66, 45.38, 44.19, 43.86, 43.56, 38.74, 38.61, 35.93, 35.81, 31.64, 30.27, 29.73, 
28.48, 23.85, 22.34, 20.97, 20.95, 19.50, 18.21, 17.19, 15.45. EI-MS m/z: 562.08 (12) 
M
+
, 317.91 (24), 316.93 (86), 285.03 (25), 258.03 (23), 256.97 (100), 217.01 (37), 216.04 
(28), 202.03 (14), 189.05 (19), 187.10 (23), 173.12 (21), 162.07 (20), 161.16 (91), 135.18 
(22), 119.16 (26). Anal. Calcd for C34H47N3O4.0.25EtOAc C 72.01, H 8.46, N 7.20, 
found C 71.72, H 8.85, N 6.88.  
 
Methyl 2-(4H-triazol-4-yl)-methylene-3-oxours-12-en-28-oate (2.57): 2.57 was 
prepared using the same method as for 2.46, using 2.13 (300 mg 0.60 mmol) as a starting 
material and CDT (295.43 mg 1.8 mmol). The workup was performed after 23 hours. The 
residue was subjected to flash column chromatography [hexanes-ethyl acetate from 
(80:20) to (70:30)], to afford 2.57 (40%). mp 202.1-206.3 ºC. IR (film CHCl3): 3116.4, 
2947.7, 1721.2, 1688.4, 1618.0, 1509.0, 1454.1, 1381.8, 1281.5, 1226.5 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 8.37 (1H s), 8.10 (1H s), 7.80 (1H s), 5.32 (1H s), 3.60 (3H s), 3.40 
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(1H d J=17.43), 1.18 (3H s), 1.13 (3H s), 1.12 (3H s), 0.95 (3H d J=5.92), 0.90 (6H s), 
0.80 (3H s).
 13
C NMR (100 MHz CDCl3): δ 207.06, 177.97, 152.82, 145.84, 138.26, 
128.35, 125.53, 125.26, 53.05, 52.80, 51.45, 48.17, 45.31, 45.07, 43.20, 42.22, 39.33, 
39.13, 38.86, 36.58, 35.79, 32.00, 30.65, 29.68, 27.98, 24.20, 23.59, 23.42, 22.49, 21.13, 
20.29, 17.08, 16.60, 15.67. EI-MS m/z: 584.05 (8) M
+
, 298.95 (25), 261.96 (44), 204.04 
(17), 203.05 (83), 202.08 (22), 189.12 (26), 187.13 (15), 134.05 (40), 133.13 (100), 
119.06 (24), 91.14 (17). Anal. Calcd for C34H49N3O3 C 74.55, H 9.02, N 7.67, found C 
74.15, H 9.42, N 7.62.  
 
28-(4H-Triazol-4-yl)-3,28-dioxours-12-en-2-(4H-triazol-4-yl)-methylene (2.58): 
2.58 was prepared using the same method as for 2.46, using 2.16 (300 mg 0.62 mmol) as 
a starting material and CDT (407 mg 2.48 mmol). The workup was performed after 7.5 
hours. The residue was subjected to flash column chromatography [hexanes-ethyl acetate 
from (80:20) to (70:30)], to afford 2.58 (21%). mp 245.5-251.1 ºC. IR (film CHCl3): 
3134.1, 2953.5, 2924.5, 2869.6, 1733.7, 1689.3, 1616.1, 1510.0, 1457.0, 1382.7, 1349.0, 
1276.7, 1222.7, 1184.1 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.82 (1H s), 8.37 (1H s), 
8.10 (1H s), 7.99 (1H s), 7.80 (1H s), 5.31 (1H s), 3.41 (1H d J=17.27), 1.25 (2H), 1.16 
(3H s), 1.15 (3H s), 1.11 (3H s), 0.99 (3H d J=6.26), 0.96 (3H d J=6.38), 0.88 (3H s), 
0.72 (3H s).
 13
C NMR (100 MHz CDCl3): δ 206.95, 174.81, 152.96, 152.24, 145.30, 
137.60, 137.03, 128.37, 125.92, 125.29, 52.75, 51.39, 45.28 (2C), 44.99, 43.18, 42.40, 
39.30, 39.21, 38.53, 35.74, 34.39, 31.87, 30.46, 29.66, 28.13, 23.59, 23.42 (2C), 22.48, 
21.02, 20.16, 17.08, 16.43, 15.68. EI-MS m/z: 584.94 (4) M
+
, 488.01 (31), 487.00 (70), 
202.01 (42), 190.07 (52), 189.09 (100), 187.13 (38), 133.03 (31), 132.03 (51), 119.05 
(45), 117.08 (48). Anal. Calcd for C35H48N6O2.0.5hexane.0.5EtOAc C 71.5, H 8.85, N 
12.51, found C 71.26, H 9.03, N 12.42.  
 
3β-Ol-12β-fluor-urs-13,28β-olide (2.59): To a stirred solution of ursolic acid 2.1 
(300 mg 0.66 mmol) in NO2Me (6 mL) and dioxane (4 mL) at 80ºC was added selectfluor 
(701.43 mg 1.98 mmol). After 24 hours the reaction mixture was diluted with water (60 
mL), the aqueous phase was extracted with ether (3×55 mL). The resulting organic 
phases were washed with NaCl 10% (3×60 mL), dried over Na2SO4, filtered and 
evaporated to the dryness, to afford a solid. The solid was subjected to flash column 
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chromatography [hexanes-ethyl acetate from (90:10) to (30:70)], to afford 2.59 (88%). 
mp 316.8-317.6 ºC. IR (film CHCl3): 3337.2, 2927.4, 2872.5, 1765.5, 1459.8 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 4.85 (1H dt J=62.84 H12), 3.19 (1H dd J=16.18 H3), 1.20 
(3H s), 1.19 (3H s), 1.13 (3H d J=6.26), 0.97 (6H s), 0.91 (3H s), 0.76 (3H s). 
13
C NMR 
(100 MHz CDCl3): δ 178.88 (C28), 91.97 (J=14.24 C13), 88.70 (J=185.75 C12), 78.68 
(C3), 55.32, 52.55 (J=3.58), 49.18 (J=9.078), 45.19, 43.90 (J=2.83), 42.53, 39.53, 39.03, 
38.84, 38.40, 37.12, 33.95, 31.34, 30.71, 27.92, 27.62, 27.22, 25.37 (J=19.72), 22.39, 
19.39, 18.50, 17.65, 17.22, 16.65, 16.46, 15.26. EI-MS m/z: 475.12 (8) M
+1
, 455.3 (93), 
246.24 (89), 207.32 (66), 189.36 (100), 187.37 (77), 119.22 (76). Anal. Calcd for 
C30H47FO3 C 75.91, H 9.98, found C 75.52, H 10.18. 
 
3β-Acetoxy-12β-fluor-urs-13,28β-olide (2.60): To a stirred solution of 2.4 (150 mg 
0.3 mmol) in NO2Me (3 mL) and dioxane (2 mL) at 80ºC was added selectfluor (318.8 
mg 0.9 mmol). The workup was performed according to the same method as for 2.59 
after 24 hours. The solid obtained was subjected to flash column chromatography 
[hexanes-ethyl acetate from (90:10) to (75:25)], to afford 2.60 (43%). mp 280.2-281.6 ºC. 
IR (film CHCl3): 2928.4, 1767.4, 1729.8, 1457.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 
4.86 (1H dt J=62.76 H12), 4.48 (1H dd J=16.35 H3), 2.05 (3H s), 1.25 (3H s), 1.21 (3H 
s), 1.20 (3H s), 1.14 (3H d J=6.26), 0.96 (3H d J=12.52), 0.85 (6H s). 
13
C NMR (100 
MHz CDCl3): δ 178.88 (C28), 170.98 (OCO), 91.93 (J=14.19 C13), 89.64 (J=185.74 
C12), 80.48 (C3), 55.42, 52.57 (J=3.39), 49.12 (J=9.22), 45.20, 43.91 (J=2.26), 42.56, 
39.55, 38.73, 38.42, 37.80, 37.06, 33.89, 31.36, 30.73, 27.89, 27.64, 25.42 (J=19.20), 
23.54, 22.41, 21.26, 19.42, 18.54, 17.56, 17.21, 16.74, 16.53, 16.41. EI-MS m/z: 516.91 
(5) M
+
, 497.04 (66), 190.12 (51), 189.14 (100), 187.19 (72), 119.13 (64), 107.11 (62), 
105.35 (55), 93.36 (55), 91.03 (57), 79.13 (67). Anal. Calcd for C32H49FO4 C 74.38, H 
9.56, found C 74.78, H 9.40. 
 
3β-Phthaloxy-12β-fluor-urs-13,28β-olide (2.61): To a stirred solution of 2.5 (304.8 
mg 0.5 mmol) in nitromethane (3 mL) and dioxane (2 mL) at 80ºC was added selectfluor 
(531.39 mg 1.5 mmol). The workup was performed according to the same method as for 
2.59 after 23 hours. The solid was subjected to flash column chromatography [hexanes-
ethyl acetate from (50:50) to (35:65)], to afford 2.61 (62%). mp 241.9-243.6 ºC. IR (film 
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CHCl3): 2929.3, 1770.3, 1723.1, 1457.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.89 (1H d 
J=6.92), 7.72 (1H d J=6.85), 7.59 (2H quintet J=26.69), 4.88 (1H dt J=62.80 H12), 4.76 
(1H dd J=16.04 H3), 1.21 (6H s), 1.15 (3H d J=6.24), 0.97 (6H d J=8.35), 0.93 (3H s), 
0.89 (3H s). 
13
C NMR (100 MHz CDCl3): δ 178.96 (C28), 171.75, 167.77, 133.35, 
131.99, 130.89, 130.27, 129.85, 128.94, 91.98 (J=14.25 C13), 89.62 (J=185.85 C12), 
82.59 (C3), 55.53, 52.58 (J=2.74), 49.09 (J=9.03), 45.21, 43.91 (J=2.56), 42.56, 39.55, 
38.75, 38.42, 38.05, 37.07, 33.88, 31.35, 30.72, 27.98, 27.64, 25.44 (J=19.48), 22.94, 
22.40, 19.42, 18.53, 17.54, 17.23, 16.68, 16.55 (2C). EI-MS m/z: 623.12 (2) M
+1
, 245.87 
(100), 201 (50), 188.96 (93), 187.02 (64), 148.95 (57), 118.96 (55). Anal. Calcd for 
C38H51FO6 C 73.28, H 8.25, found C 73.19, H 8.34. 
 
Methyl isoxazolo[4,5-b]-12β-fluor-13,28β-olide (2.62): To a stirred solution of 2.17 
(100 mg 0.21 mmol) in nitromethane (1.5 mL) and dioxane (1 mL) at 80ºC was added 
selectfluor (223.18 mg 0.63 mmol). The workup was performed according to the same 
method as for 2.59 after 25 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (70:30)], to afford 2.62 (38%). 
mp 292.6-293.9 ºC. IR (film CHCl3): 2929.3, 1875.3, 1771.3, 1458.9, 1388.5, 1277.6, 
1236.2 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.01 (1H s), 4.90 (1H dq J=62.36), 2.60 (1H 
d J=14.88), 1.31 (3H s), 1.27 (3H s), 1.23 (3H s), 1.21 (3H s), 1.15 (3H d J=6.09), 0.98 
(3H s), 0.91 (3H s). 
13
C NMR (100 MHz CDCl3): δ 178.75, 172.82, 150.14, 108.36, 
91.87 (J=14.17), 89.49 (J=186.44) 53.51, 52.58, 47.79 (J=9.41), 45.22, 42.45, 39.55, 
38.88, 38.57, 36.23, 34.90, 33.12, 31.32, 30.73, 29.66, 28.67, 27.72, 25.76 (J=19.60), 
22.38, 21.13, 19.39, 18.10, 17.99, 17.08, 16.70, 16.43. EI-MS m/z: 498.13 (12) M
+
, 
245.96 (97), 232.01 (56), 230.03 (57), 201.09 (94), 189.1 (51), 187.13 (100), 145.15 (51), 
120.04 (53), 119.14 (94), 107.1 (55), 105.13 (53), 91.2 (69), 79.14 (63). 
 
3-Oxo-2α,12β-difluor-urs-13,28β-olide (2.63): To a stirred solution of 2.3 (100 mg 
0.22 mmol) in nitromethane (3 mL) and dioxane (2 mL) at 80ºC was added selectfluor 
(233.8 mg 0.66 mmol). The workup was performed according to the same method as for 
2.59 after 24 hours. The solid was subjected to flash column chromatography [hexanes-
ethyl acetate from (80:20) to (65:35)], to afford 2.63 (36%). mp 347.3-348.8 ºC IR (film 
CHCl3): 2928.4, 2875.3, 1766.5, 1720.2, 1461.8, 1389.5, 1236.2 cm
-1
. 
1
H NMR (400 
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MHz CDCl3): δ 5.30 (1H dq J=66.18 H2), 4.88 (1H dq J=62.48 H12), 1.26 (3H s C26), 
1.23 (3H s C25), 1.19 (3H s C27), 1.15 (3H s C23 or C24), 1.13 (3H d J=6.41 C29), 1.09 
(3H s C23 or C24), 0.96 (3H d J=5.58 C30). 
13
C NMR (100 MHz CDCl3): δ 209.63 (C3), 
178.68 (C28), 91.63 (J=14.40 C13), 89.83 (J=30.850 C2), 87.98 (J=30.65 C12), 56.41 
(C5), 52.54 (J=3.34 C18), 48.71 (J=9.69 C9), 48.49 (C4), 47.23 (J=17.17 C1), 45.13 
(C17), 43.97 (J=2.97 C14), 42.63 (C8), 39.52 (C20), 38.36 (C19), 38.04 (J=9.69 C10), 
33.47 (C7), 31.29, 30.68, 27.60 (C15), 25.72 (J=20.16 C11), 24.81 (C23 or C24), 22.35, 
21.05 (C23 or C24), 19.40 (C30), 18.63 (C26), 18.42, 17.48 (C25), 17.16 (C27), 16.51 
(C29). EI-MS m/z: 490.84 (5) M
+
, 200.69 (70), 199.96 (52), 186.99 (81), 145.02 (52), 
133.03 (40), 131.03 (46), 119.04 (100), 107.04 (56), 105.05 (52), 93.03 (44), 91.04 (66), 
79.01 (59), 77 (37), 66.69 (41). 
 
3β-Trifluoroacetoxy-12β-fluor-urs-13,28β-olide (2.64): To a stirred mixture of 
2.59 (200 mg 0.42 mmol) in THF (5 mL) at room temperature, was added DMAP (10% 
of the mass of 2.59) and trifluoroacetic anhydride (0.58 mL 4.2 mmol). After 1 hour the 
reaction mixture was acidified with HCl 10% (50 mL) and the aqueous phase extracted 
with ether (3×40 mL). The organic phase is washed with NaHCO3 (3×40 mL) and water 
(3×40 mL), dried over Na2SO4, filtered and evaporated to the dryness, to afford a solid. 
The residue was subjected to flash column chromatography [hexanes-ethyl acetate from 
(95:5) to (75:25)], to afford 2.64 (31%). mp 280.2-282.2 ºC. IR (film CHCl3): 2953.5, 
2927.4, 2873.4, 1777.1, 1459.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 4.87 (1H dd J=62.64 
H12), 4.68 (1H dd J=16.16 H3), 1.26 (3H s), 1.23 (3H s), 1.21 (3H s), 1.15 (3H d 
J=6.19), 0.97 (3H s), 0.91 (3H s), 0.91 (3H s). 
13
C NMR (100 MHz CDCl3): δ 178.82 
(C28), 91.84 (J=14.52 C13), 89.53 (J=185.90 C12), 85.78 (C3), 55.30, 52.58, 49.10 
(J=9.24), 45.21, 43.95 (J=3.16), 42.58, 39.57, 38.57, 38.46, 38.09, 37.06, 33.85, 31.37, 
30.75, 29.70, 27.77, 27.68, 25.47 (J=19.59), 23.15, 22.41, 19.44, 18.56, 17.52, 17.24, 
16.75, 16.54, 16.19. EI-MS m/z: 570.84 (2) M
+
, 245.98 (54), 201.05 (65), 189.08 (71), 
187.1 (87), 145.16 (51), 119.16 (100), 107.15 (69), 105.15 (61), 93.16 (62), 91.23 (92), 
79.17 (81), 77.16 (53), 67.14 (54). Anal. Calcd for C31H43F4O4 C 67.35, H 8.12, found C 
67.74, H 8.46. 
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3β-Butyroxy-12β-fluor-urs-13,28β-olide (2.65): To a stirred mixture of 2.59 (200 
mg 0.42 mmol) in THF (5 mL) at room temperature, was added DMAP (10% of the mass 
of 2.59) and butyric anhydride (0.34 mL 2.1 mmol). The workup was performed 
according to the same method as for 2.64 after 1 hour. The solid obtained was subjected 
to a flash column chromatography [hexanes-ethyl acetate from (85:15) to (80:20)], to 
afford 2.65 (28%). mp 251.4-255 ºC. IR (film CHCl3): 2964.1, 2933.2, 2874.4, 1772.3, 
1729.8, 1458.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 4.86 (1H dt J=62.73 H12), 4.49 (1H 
dd J=16.28 H3), 1.21 (3H s), 1.20 (3H s), 1.14 (3H d J=6.22), 0.97 (3H s), 0.94 (6H d 
J=3.49), 0.85 (6H s). 
13
C NMR (100 MHz CDCl3): δ 178.87 (C28), 173.49 (OCO), 91.94 
(J=14.16 C13), 89.64 (J=185.88 C12), 80.13 (C3), 55.41, 52.56 (J=3.47), 49.10 (J=9.28), 
45.19, 43.90 (J=2.90), 42.55, 39.55, 38.71, 38.42, 37.83, 37.06, 36.69, 33.89, 31.36, 
30.73, 27.91, 27.64, 25.41 (J=19.09), 23.59, 22.41, 19.42, 18.59, 18.53, 17.55, 17.22, 
16.72, 16.53, 16.47, 13.70. EI-MS m/z: 544.25 (1) M
+
, 201.04 (43), 190.08 (53), 189.12 
(100), 187.14 (56), 120.01 (36), 119.11 (51), 93.18 (38), 91.2 (44), 79.35 (42). Anal. 
Calcd for C34H53FO4 C, 74.96, H 9.81, found C 75.36, H 9.70. 
 
3β-Benzoxy-12β-fluor-urs-13,28β-olide (2.66): To a stirred mixture of 2.59 (200 
mg 0.42 mmol) in THF (5 mL) at room temperature, was added DMAP (10% of the mass 
of 2.59) and benzoic anhydride (475.08 mg 2.1 mmol). The workup was performed 
according to the same method as for 2.64 after 8 hours. The solid obtained was subjected 
to a flash column chromatography [hexanes-ethyl acetate from (85:15) to (75:25)], to 
afford 2.66 (50%). mp 319.2-322.6 ºC. IR (film CHCl3): 3064.3, 2030.3, 2872.5, 1785.8, 
1715.4, 1599.7, 1452.1 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.04 (2H d J=7.53), 7.55 (1H 
t J=14.59), 7.44 (2H t J=15.16), 4.89 (1H dt J=62.70 H12), 4.73 (1H dd J=15.80 H3), 
1.24 (3H s), 1.22 (3H s), 1.16 (3H d J=6.18), 1.02 (3H s), 0.99 (6H d J=5.33), 0.94 (3H 
s). 
13
C NMR (100 MHz CDCl3): δ 178.88 (C28), 166.25 (OCO), 132.80, 130.78, 129.50 
(2C), 128.33 (2C), 91.95 (J=14.25 C13), 89.64 (J=185.93 C12), 81.09 (C3), 55.48, 52.58 
(J=3.33), 49.12 (J=9.08), 45.20, 43.93 (J=2.77), 42.58, 39.55, 38.74, 38.43, 38.20, 37.11, 
33.90, 31.36, 30.73, 28.06, 27.65, 25.45 (J=19.18), 23.61, 22.42, 19.43, 18.56, 17.58, 
17.24, 16.75, 16.71, 16.54. EI-MS m/z: 578.87 (1) M
+
, 245.90 (32), 201.97 (23), 201.01 
(25), 190.04 (35), 189.07 (60), 187.12 (33), 119.07 (29), 106.98 (27), 105.21 (100), 91.14 
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(22), 79.07 (21), 77.1 (49). Anal. Calcd for C37H51FO4 C, 76.78, H 8.88, found C 76.92, 
H 9.09. 
 
3-Oxo-12β-fluor-urs-13,28β-olide (2.67): 2.67 was prepared according to the 
literature
295
 from 2.59 (1.7755 g 3.74 mmol) to give a solid. The residue was subjected to 
flash column chromatography [hexanes-ethyl acetate from (80:20) to (65:35)], to afford 
2.67 (26%). mp 327.3-329.2 ºC. IR (film CHCl3): 2928.4, 1771.3, 1704.8, 1457.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 4.87 (1H dq J=62.47), 1.25 (3H s), 1.21 (3H s), 1.14 (3H d 
J=6.31), 1.08 (3H s), 1.04 (3H s), 1.02 (3H s), 0.96 (3H d J=5.56). 
13
C NMR (100 MHz 
CDCl3): δ 216.97 (C3), 178.75 (C28), 91.91 (J=14.27 C13), 89.49 (J=185.77 C12), 
54.83, 52.57, 48.48 (J=9.33), 47.28, 45.19, 44.02 (J=3.09), 42.40, 39.79, 39.55, 38.51, 
36.85, 33.89, 33.37, 31.33, 30.73, 27.64, 26.58, 25.75 (J=19.71), 22.39, 20.97, 19.40, 
18.99, 18.17, 17.09, 16.47, 16.42. EI-MS m/z: 473.03 (1) M
+
, 245.97 (67), 205.02 (65), 
210.03 (79), 187.03 (82), 163.04 (62), 119.03 (100), 107.02 (64), 105.03 (58), 91 (71), 
78.98 (75). Anal. Calcd for C30H45FO3.0.5 EtOAc C 74.38, H 9.56, found C 74.16, H 
9.61. 
 
Methyl isoxazolo[4,5-b]urs-12-en-28-oate (2.68): Preparation of 2.68 was made 
according to previously described method,
295
 from 2.13 (325.4 mg 0.655 mmol) to afford 
a solid (96%). mp 119.9-120.0 ºC. IR (film CHCl3): 2925.5, 2869.6, 1723.1, 1483.0, 
1457.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.97 (1H s), 5.30 (1H s H12), 3.61 (3H s), 
1.30 (3H s), 1.21 (3H s), 1.10 (3H s), 0.94 (3H d J=5.95), 0.89 (3H s), 0.87 (3H d 
J=6.52), 0.80 (3H s). 
13
C NMR (100 MHz CDCl3): δ 177.08 (C28), 173.03 (C3), 150.15 
(CHNO), 138.23 (C13), 125.25 (C12), 108.83 (C2). EI-MS m/z: 494.22 (14) M
+1
, 262.03 
(32), 203.09 (67), 189.07 (41), 133.13 (100), 119.15 (34), 105.17 (24), 91.16 (26).  
 
Methyl 2-cyano-3-hydroxy-urs-2,12-dien-28-oate (2.69): 2.69 was prepared 
according to the literature
295
 from 2.68 (257.6 mg 0.52 mmol) to give a solid (86%). mp 
136.4-140.3 ºC. IR (film CHCl3): 2947.7, 1869.6, 1719.2, 1457.9 cm
-1
. EI-MS m/z: 494.2 
(9) M
+1
, 262.0 (34), 249.1 (23), 203.02 (62), 189.05 (54), 133.1 (100), 119.13 (32), 
105.09 (22), 91.13 (27).  
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Methyl 2-cyano-3-oxours-1,12-dien-28-oate (2.70): Preparation of 2.70 was made 
according to previously described method,
295
 from 2.69 (195.4mg 0.396mmol) to afford a 
solid (88%). mp 134.7-137.5 ºC. IR (film CHCl3): 2947.7, 2872.5, 1721.2, 1685.5, 
1457.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.75 (1H s H1), 5.33 (1H s H12), 3.62 (3H s), 
1.22 (3H s), 1.20 (3H s), 1.14 (3H s), 1.10 (3H s), 0.95 (3H d J=5.87), 0.87 (3H d 
J=6.43), 0.85 (3H s). EI-MS m/z: 492.17 (7) M
+1
, 203.05 (35), 189.08 (58), 187.12 (20), 
133.11 (100), 119.13 (46), 117.13 (20), 105.13 (28), 91.11 (33). Anal. Calcd for 
C32H45NO3 C 78.17, H 9.22, N 2.85, found C 77.82, H 9.23, N 2.86. 
 
2-Cyano-3-oxours-1,12-dien-28-oic acid (2.71): 2.71 was prepared according to the 
literature
295
 from 2.70 (155.2 mg 0.316 mmol) to give a solid (64%). mp 213.7-217.6 ºC. 
IR (film CHCl3): 2926.5, 2870.5, 1652.2, 1609.3, 1456.0 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 7.76 (1H s), 5.32 (1H s), 1.22 (3H s), 1.20 (3H s), 1.12 (3H s), 1.11 (3H s), 
0.96 (3H d J=5.90), 0.88 (6H s). 
13
C NMR (100 MHz CDCl3): δ 198.02 (C3), 183.07 
(C28), 169.98 (C1), 138.87 (C13), 124.27 (C12), 114.91, 113.91. EI-MS m/z: 477.84 (1) 
M
+1
, 247.85 (64), 218.84 (25), 202.86 (70), 188.92 (27), 186.92 (22), 132.93 (100), 
118.94 (33), 104.95 (29), 90.91 (31). Anal. Calcd for C31H43NO3 C 77.95, H 9.07, N 
2.93, found C 77.89, H 9.47, N 2.94. 
 
2-Cyano-3-oxo-12α-fluor-urs-1-en-13,28β-olide (2.72) and 2-Cyano-3-oxo-12β-
fluor-urs-1-en-13,28β-olide (2.73): To a stirred solution of 2.71 (178.6 mg 0.38 mmol) 
in nitromethane (6 mL) and dioxane (4 mL) at 80ºC was added selectfluor (404.24 mg 
1.14 mmol). The workup was performed according to the same method has for 2.59 after 
2.5 hours. The obtained solid was subjected to flash column chromatography [hexanes-
ethyl acetate from (80:20) to (60:40)], to afford 2.73 (21%), and two mixture fractions. 
The mixture fractions were subjected to a new flash column chromatography [hexanes-
ethyl acetate from (75:25) to (60:40)], to afford 2.73 (16%) and a mixture fraction. The 
mixture fraction was subjected to a flash column chromatography [hexanes-ethyl acetate 
from (75:25) to (65:35)], to afford 2.72 (13%). 2.72: mp 264.9-268.6 ºC. IR (film 
CHCl3): 2926.5, 1740.4, 1685.5, 1457.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.81 (1H s 
H1), 4.51 (1H dt J=66.17 H12), 1.30 (3H d J=7.26), 1.25 (3H s), 1.22 (3H s), 1.20 (3H s), 
1.16 (3H s), 0.98 (6H t J=9.45). 
13
C NMR (100 MHz CDCl3): δ 197.72 (C3), 177.51 
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(C28), 168.79 (C1), 114.69, 114.61, 96.11 (J=189.19 C12), 90.38 (C13), 53.00, 45.264 
45.08 (J=9.305), 44.68, 43.46 (J=17.41), 42.35 (J=9.78), 41.04, 40.93, 39.04, 37.34, 
34.87, 31.67, 29.10, 27.396, 25.94 (J=25.20), 25.74, 22.73 (J=3.35), 21.81, 20.94, 20.49, 
20.34, 20.07, 19.46, 19.11. EI-MS m/z: 495.91 (4) M
+
, 123.06 (70), 122.04 (92), 121.06 
(45), 119.1 (48), 107.09 (100), 105.1 (46), 91.13 (60), 81.11 (57), 79.09 (66), 67.05 (46). 
Anal. Calcd for C31H42FNO3 C, 75.12, H 8.54, N 2.83, found C 74.77, H 8.94, N 2.94. 
2.73: mp 365.5-366.8 ºC. IR (film CHCl3): 2926.5, 1767.4, 1684.5, 1457.9 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 7.82 (1H s), 4.94 (1H dq J=62.15 H12), 1.31 (3H s C26), 1.25 (3H s 
C29), 1.22 (3H d J=3.13 C27), 1.20 (3H s C25), 1.15 (6H s C23 and C24), 0.98 (3H d 
J=5.71 C30). 
13
C NMR (100 MHz CDCl3): δ 197.70 (C3), 178.38 (C28), 169.04 (C1), 
114.70 (CN), 114.41 (C2), 91.52 (J=14.49 C13), 88.52 (J=187.42 C12), 52.71 (C5), 
52.61 (J=3.16 C18), 45.14, 45.05 (C4), 44.17 (J=2.72 C17), 43.48 (C8), 42.43 (J=9.85 
C9) 40.40 (C10), 39.53, 38.39, 33.06, 31.25, 30.67, 29.67, 27.69 (C25), 27.64, 25.64 
(J=20.53), 21.29, 19.38 (C30), 18.91 (C26 and C29), 18.25, 17.00 (C27), 16.53 (C23 or 
C24). EI-MS m/z: 496.15 (6) M
+1
, 189.11 (42), 187.17 (56), 163.2 (53), 119.2 (100), 
107.18 (51), 91.21 (53), 79.2 (49). Anal. Calcd for C31H42FNO3 C 75.12, H 8.54, N 2.83, 
found C 75.04, H 8,93, N 2.95. 
 
2-Hydroxymethylene-3-oxo-12β-fluor-urs-13,28β-olide (2.74): 2.74 was prepared 
according to the literature
295
 from 2.67 (154.5 mg 0.33 mmol) to give a solid. The solid 
was subjected to flash column chromatography [hexanes-ethyl acetate from (80:20) to 
(70:30)], to afford 2.74 (67%). IR (film CHCl3): 344.2, 2930.3, 1771.3, 1636.3, 1587.1, 
1457.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 14.89 (1H s), 8.62 (1H s), 4.89 (1H dq 
J=62.70 H12), 1.27 (3H s), 1.22 (3H s), 1.19 (3H s), 1.14 (3H d J=6.30), 1.11 (3H s), 
0.97 (3H d J=5.63), 0.92 (3H s). 
13
C NMR (100 MHz CDCl3): δ 189.87 (C3), 188.84 
(CHOH), 178.79 (C28), 105.21 (C2), 91.93 (J=14.19 C13), 89.50 (J=185.98 C12), 52.56 
(J=3.52), 51.98, 47.29 (J= 9.44), 45.21, 44.04 (J=2.83), 42.21, 40.18, 39.97, 39.52, 38.55, 
36.53, 33.06, 31.30, 30.72, 28.19, 27.61, 25.76 (J=19.43), 22.36, 20.55, 19.39, 18.77, 
17.99, 17.03, 16.41, 15.65. EI-MS m/z: 500.79 (2) M
+
, 245.72 (79), 232.77 (73), 200.8 
(68), 186.81 (100), 172.83 (60), 144.85 (56), 118.86 (82), 106.85 (67), 104.87 (58), 90.83 
(64), 78.8 (60). Anal. Calcd for C31H45FO4 C 74.36, H 9.06, found C 73.97, H 8.81.  
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3β-(1H-Imidazole-1-carbonyloxy)-12β-fluor-urs-13,28β-olide (2.75): To a stirred 
solution of 2.59 (300 mg 0.63 mmol) in THF (6.5 mL), under N2 atmosphere, at 70ºC, 
was added CDI (204.31 mg 1.26 mmol). The workup was performed according to the 
same method as for 2.18 after 3 hours. The residue was subjected to flash column 
chromatography [hexanes-ethyl acetate from (70:30) to (55:45)], to afford 2.75 (47%). 
mp 285.9-286.8 ºC. IR (film CHCl3): 3136.7, 2976.6, 2876.3, 1767.4, 1758.8, 1524.5, 
1470.5, 1395.3, 1319.1, 1288.2, 1240.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.13 (1H s), 
7.40 (1H s), 7.07 (1H s), 4.87 (1H dt J=45.82 H12), 4.68 (1H dd J=15.87 H3), 1.22 (3H s 
C26), 1.21 (3H s C27), 1.14 (3H d J=6.20 C29), 0.98 (3H s C25), 0.96 (9H s C23 or C24 
or C30), 0.86 (1H d J=8.75 H5). 
13
C NMR (100 MHz CDCl3): δ 178.15 (C28), 148.46 
(COO), 136.93 (Cimidazole), 130.48 (Cimidazole), 117.00 (Cimidazole), 91.80 (J=14.31 
C13), 89.49 (J=185.86 C12), 85.84 (C3), 55.32 (C5), 52.55 (J=3.34 C18), 49.06 (J=9.38 
C9), 45.17 (C17), 43.94 (C14), 42.54 (C7), 39.53 (C20), 38.57, 38.40 (C19), 38.19 (C4), 
37.03 (C10), 33.82 (C7), 31.33, 30.70, 28.02 (C23 or C24 or C30), 27.63 (C15), 25.44 
(J=19.38), 23.45, 22.38, 19.39 (C25), 18.53 (C26), 17.50, 17.21 (C27), 16.69 (C23 or 
C24 or C30), 16.58 (C23 or C24 or C30), 16.50 (C29). EI-MS m/z: 569.2 (8) M
+
, 189.2 
(89), 187.2 (62), 133.2 (64), 119.2 (100), 107.2 (75), 105.2 (78), 95.2 (75), 93.2 (62), 
91.2 (78), 79.15 (76). Anal. Calcd for C34H49FN2O4 C 71.80, H 8.68, N 4.93, found C 
72.06, H 8.58, N 4.96. 
 
3β-(2’Methyl-1H-imidazole-carbonyloxy)-12β-fluor-urs-13,28β-olide (2.76): To a 
stirred solution of 2.59 (300 mg 0.63 mmol) in THF (4 mL), under N2 atmosphere, at 
70ºC, was added CBMI (239.66 mg 1.26 mmol). The workup was performed according 
to the same method as for 2.32 after 8 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (70:30) to (50:50)], to afford 2.76 (49%). 
mp 293.1-293.6 ºC. IR (film CHCl3): 2933.2, 2878.2, 1769.4, 1758.8, 1457.9, 1395.3, 
1373.1, 1294.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.33 (1H s), 6.86 (1H s), 4.87 (1H dt 
J=45.78), 4.66 (1H dd J=15.70), 2.65 (3H s), 1.23 (3H s), 1.21 (3H s), 1.15 (3H d 
J=6.31), 0.98 (3H s), 0.96 (9H s). 
13
C NMR (100 MHz CDCl3): δ 178.768, 149.366, 
147.881, 127.636, 117.978, 91.83 (J=14.21), 89.51 (J=186.13), 85.54, 55.37, 52.60, 
52.56, 49.13, 49.04, 45.18, 43.96, 43.93, 42.56, 39.55, 38.64, 38.42, 38.14, 37.06, 33.84, 
31.35, 30.72, 28.05, 27.65, 25.56, 25.36, 23.53, 22.40, 19.40, 18.54, 17.53, 17.23, 16.80, 
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16.79, 16.70, 16.52. EI-MS m/z: 583.2 (6) M
+
, 190.1 (53), 189.1 (99), 187.2 (55), 147.1 
(57), 145.1 (48), 133.1 (65), 127.1 (54), 121.1 (60), 119.1 (100), 109.1 (74), 107.1 (84), 
105.1 (77), 95.1 (79), 93.1 (64), 91.1 (78). Anal. Calcd for C35H51FN2O4 C 72.13, H 8.82, 
N 4.81, found C 71.97, H 8.56, N 4.73. 
 
3β-(4H-Triazole-carbonyloxy)-12β-fluor-urs-13,28β-olide (2.77): To a stirred 
solution of 2.59 (300 mg 0.63 mmol) in THF (4 mL), under N2 atmosphere, at 70ºC, was 
added CDT (310.2 mg 1.89 mmol). The workup was performed according to the same 
method as for 2.46 after 7 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (65:35)], to afford 2.77 (36%). 
mp 256.1-256.4 ºC. IR (film CHCl3): 3133.8, 2933.2, 2872.5, 1771.3, 1510.0, 1457.9, 
1405.9, 1280.5, 1226.5, 1203.4 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.77 (1H s), 8.06 
(1H s), 4.86 (2H m J=71.41), 1.23 (3H s), 1.21 (3H s), 1.14 (3H d J=6.28), 1.00 (3H s), 
0.99 (3H s), 0.98 (3H s), 0.97 (3H s). 
13
C NMR (100 MHz CDCl3): δ 178.74, 153.60, 
147.29, 145.30, 91.79 (J=14.44), 89.48 (J=185.55), 87.23, 55.31, 52.56 (J=3.21), 49.07 
(J=9.11), 45.17, 43.94, 42.55, 39.54, 38.60, 38.41, 38.32, 37.04, 33.83, 31.33, 30.71, 
28.00, 27.64, 25.44 (J=19.43), 23.44, 22.38, 19.39, 18.53, 17.51, 17.20, 16.71, 16.52 
(2C). EI-MS m/z: 570.02 (1) M
+
, 246.07 (50), 201.16 (48), 189.2 (100), 187.22 (70), 
159.26 (54), 133.2 (56), 119.2 (74), 105.2 (45), 93.18 (47), 91.27 (66), 81.29 (47), 79.22 
(46), 70.3 (81).  
 
2-(1H-Imidazol-1-yl)-methylene-3-oxo-12β-fluor-urs-13,28β-olide (2.78): To a 
stirred solution of 2.74 (240 mg 0.48 mmol) in THF (3 mL), under N2 atmosphere, at 
70ºC, was added CDI (155.66 mg 0.96 mmol). The workup was performed according to 
the same method has for 2.18 after 4 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (50:50) to (30:70)], to afford 2.78 (63%). 
mp 316.4-321.2 ºC. IR (film CHCl3): 3114.5, 2929.3, 1771.3, 1685.5, 1609.3, 1518.7, 
1487.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.86 (1H s), 7.71 (1H s), 7.24 (1H s), 7.20 
(1H s), 4.96 (1H dq J=62.31 H12), 3.01 (1H d J=15.83), 2.30 (1H d J=15.76), 1.28 (3H 
s), 1.25 (3H s), 1.18 (6H s), 1.13 (3H s), 0.99 (3H s), 0.92 (3H s). 
13
C NMR (100 MHz 
CDCl3): δ 206.00 (C3), 178.65 (C28), 130.78, 130.02, 129.81, 123.30, 119.61, 91.81 
(J=14.26 C13), 89.25 (J=186.24 C12), 52.60 (J=2.99), 52.22, 46.95 (J=9.38), 45.19, 
2. Ursolic acid derivatives 
199 
 
44.09 (J=2.57), 43.63, 42.18, 39.53, 38.62, 36.27, 32.80, 31.30, 30.73, 29.53, 27.57, 
26.02 (J=19.68), 22.65, 22.34, 22.04, 19.62, 19.38, 17.65, 16.93, 16.51 (2C). EI-MS m/z: 
550.5 (8) M
+
, 297.1 (47), 285.09 (100), 187.01 (44), 132.97 (38), 118.97 (45), 104.94 
(50), 90.94 (46), 78.9 (47), 68.95 (79). Anal. Calcd for C34H47FN2O3 C 74.15, H 8.60, N 
5.09, found C 73.90, H 8.99, N 4.96. 
 
2-(2’-Methyl-1H-imidazol-1-yl)-methylene-3-oxo-12β-flour-urs-13,28β-olide 
(2.79): To a stirred solution of 2.74 (240 mg 0.48 mmol) in THF (3 mL), under N2 
atmosphere, at 70ºC, was added CBMI (182.6 mg 0.96 mmol). The workup was 
performed according to the same method as for 2.32 after 4.5 hours. The solid obtained 
was subjected to flash column chromatography [hexanes-ethyl acetate from (45:55) to 
(25:75)], to afford 2.79 (37%). mp 321.2-325.6 ºC. IR (film CHCl3): 3110.6, 2929.3, 
1770.3, 1684.5, 1603.5, 1539.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.66 (1H s C2CH), 
7.16 (1H s H4’), 7.03 (1H s H5’), 4.93 (1H dq J=62.33 H12), 2.97 (1H d J=15.83 H1), 
2.48 (3H s CH3 imidazole), 1.26 (3H s C26), 1.24 (3H s C27), 1.16 (6H s C23 or C24 or 
C29), 1.13 (3H s C23 or C24), 0.97 (3H s C30), 0.90 (3H s C25). 
13
C NMR (100 MHz 
CDCl3): δ 206.08 (C3), 178.59 (C28), 147.37 (C2’), 130.67 (C2CH), 128.76 (C5’), 
123.05 (C2), 117.97 (C4’), 91.74 (J=14.41 C13), 89.33 (J=186.24 C12), 52.57 (J=3.34 
C18), 52.40 (C5), 47.08 (J=9.41 C9), 45.24 (C17), 45.16 (C4), 44.06 (J=2.74 C14), 42.87 
(C1), 42.21 (C8), 39.51 (C20), 38.57 (C19), 36.32 (C10), 32.83, 31.27, 30.69, 29.45 (C23 
or C24), 27.56, 25.90 (J=19.64), 22.33, 22.15 (C23 or C24), 19.59, 19.36 (C30), 17.69 
(C26), 16.94 (C27), 16.48 (C29), 16.41 (C25), 13.66 (CH3 imidazole). EI-MS m/z: 
564.06 (10) M
+
, 300.09 (21), 299.06 (100), 189.96 (81), 187.06 (21), 119.03 (20), 107.01 
(22), 91 (22), 82.99 (38), 78.98 (20). Anal. Calcd for C35H49FN2O3 C, 74.43, H 8.74, F 
3.36, N 4.96, found C 74.54, H 8.88, N 5.14.  
 
2-(4H Triazol-4-yl)-methylene-3-oxo-12β-fluor-urs-13,28β-olide (2.80): To a 
stirred solution of 2.74 (250 mg 0.50 mmol) in THF (3 mL), under N2 atmosphere, at 
70ºC, was added CDT (246.2 mg 1.5 mmol). The workup was performed according to the 
same method as for 2.46 after 5 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (70:30) to (60:40)], to afford 2.80 (33%). 
mp 209.2-212.1 ºC. IR (film CHCl3): 2929.3, 2870.5, 1771.3, 1688.4, 1616.1, 1509.0, 
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1457.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.39 (1H s), 8.12 (1H s), 7.81 (1H s), 4.98 
(1H dq J=62.17), 3.59 (1H d J=17.43), 2.39 (1H d J=17.26), 1.27 (3H s), 1.24 (3H s), 
1.18 (6H s), 1.13 (3H s), 0.98 (3H s), 0.90 (3H s). 
13
C NMR (100 MHz CDCl3): δ 206.56 
(C3), 178.71 (C28), 153.03, 146.27, 128.29, 124.84, 91.92 (J=14.37 C13), 89.48 
(J=185.96 C12), 52.60 (J=3.51), 52.48, 46.80 (J=9.59), 45.28, 45.20, 44.11, 43.72, 42.15, 
39.54, 38.61, 35.98, 32.85, 31.31, 30.73, 29.45, 27.59, 25.92 (J=19.45), 22.36, 22.15, 
19.65, 19.39, 17.66, 16.94, 16.50 (2C). EI-MS m/z: 552.14 (6) M
+1
, 201.01 (57), 187.02 
(84), 173.04 (58), 145.04 (69), 133.04 (60), 119.04 (100), 107.03 (78), 105.04 (82), 91.02 
(96), 78.99 (80). Anal. Calcd for C33H46FN3O3.0.5hexane.0.5 EtOAc C 71.44, H 8.99, N 
6.58, found C 71.24, H 9.04, N 6.38. 
 
Fluor 3-oxours-12-en-28-oate (2.81): To a mixture of 2.3 (200 mg 0.44 mmol) and 
THF (4 mL) was added deoxofluor 50% dropwise (0.64 mL 1.76 mmol), in an ice bath. 
The temperature was allowed to rise up until the room temperature. After 2.5 hours, was 
added NaHCO3 dropwise (10 mL) to the reaction mixture. After being stirred for 30 
minutes, the mixture was extracted with ether (3×50 mL). The combined extract was 
washed with NaHCO3 (3×50mL) and water (3×50 mL), dried over Na2SO4, filtered and 
evaporated to the dryness, to afford a solid. The residue was subjected to flash column 
chromatography [hexanes-ethyl acetate from (95:5) to (90:10)], to afford 2.81 (84%). mp 
197.9-202.0 ºC. IR (film CHCl3): 2926.5, 2872.5, 1827.2, 1704.8, 1457.0, 1381.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.35 (1H s), 1.25 (3H s), 1.10 (3H s), 1.09 (3H s), 1.06 
(3H s), 1.05 (3H s), 0.96 (3H d J=6.02), 0.87 (3H d J=5.27). 
13
C NMR (100 MHz 
CDCl3): δ 217.64, 167.06 (J=376.60), 137.01, 126.56, 55.29, 52.87, 47.40, 46.71, 42.26, 
39.49, 39.36, 38.95, 38.66, 36.65, 35.23, 34.15, 32.58, 30.20, 29.68, 28.11, 26.52, 24.08, 
23.45, 23.29, 21.48, 20.96, 19.54, 17.00, 16.84, 15.26. EI-MS m/z: 456.99 (23) M
+
, 
409.11 (30), 250.05 (100), 222.15 (39), 221.12 (49), 205.18 (44), 204.18 (23), 203.21 
(52), 134.08 (34), 133.15 (67). 
 
Flour 3β-acetoxy-urs-12-en-28-oate (2.82): To a mixture of 2.4 (200 mg 0.4 mmol) 
and THF (4mL) was added deoxofluor 50% dropwise (0.6 mL 1.6 mmol), in an ice bath. 
The workup was performed according to the same method as for 2.81 after 1 hour. The 
solid was subjected to flash column chromatography [hexanes-ethyl aceate from (95:5) to 
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(90:10)], to afford 2.82 (98%). mp 242.7-245.7 ºC. IR (film CHCl3): 2928.4, 2878.2, 
1824.3, 1734.6, 1457.0, 1370.2, 1245.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.32 (1H s), 
4.49 (1H dd J=15.96), 2.04 (3H s), 1.09 (3H s), 0.96 (3H s), 0.95 (3H s), 0.88 (3H s), 0.86 
(3H s), 0.85 (3H s), 0.82 (3H s). 
13
C NMR (100 MHz CDCl3): δ 170.95, 167.05 
(J=376.37), 136.91, 126.68, 80.82, 55.29, 52.78, 48.82 (J=37.79), 47.41, 42.11, 39.50, 
38.90, 338.66, 38.33, 37.65, 36.82, 35.25, 32.97, 30.19, 28.09, 28.04, 24.08, 23.52, 23.33, 
23.29, 21.27, 20.97, 18.15, 16.99, 16.85, 16.70, 15.54. EI-MS m/z: 501.07 (2) M
+
, 249.91 
(100), 222.02 (37), 220.96 (48), 203.01 (55), 190.05 (73), 189.11 (80), 175.13 (32), 
147.15 (38), 133.14 (64), 119.14 (36), 105.26 (40).  
 
2.4.2. Biological activity assays 
 
1. Reagents. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
powder and dimethylsulfoxide (DMSO) were obtained from Sigma Aldrich Co (St. Luis, 
MO).  The compounds tested for biological activity were dissolved in DMSO for stock 
solutions, stored at -80ºC. The working solutions were prepared in medium. Antibodies to 
poly-(ADP-ribose)-polymerase (PARP) were obtained from Boehringer Mannheim 
(Mannheim-Waldhof, DE), to caspases 8 and p21
waf1
 from BD Biosciences (San Jose, 
CA), to c-FLIP from Alexis Biochemicals (Plymouth Meeting, PA), to Mcl-1 from Santa 
Cruz Biotechology Inc., (Santa Cruz, CA), to caspase 9, cleaved caspase 9, caspase 3, 
cleaved caspase 3 and Bcl-xL from Cell Signaling (Danvers, MA), to NOXA from 
Abcam (Cambridge, UK). 
 
2. Cell culture. Cancer cells AsPC-1, MIA PaCa 2, PANC-1, PC-3, Hep G2 and 
A549 cells were cultured in RPMI 1640 supplemented with 10% of FBS. MCF-7 cells 
were cultured in DMEM supplemented with 5% FBS and 1mg/mL insulin. 
 
3. Determination of cell growth inhibition. AsPC-1, MIA PaCa 2, PANC-1, MCF-
7, PC-3, Hep G2 and A549 cells were plated with 1.0×10
3
 cells/well in 96-well plates in 
100 μl medium. The tested compounds with variant concentrations in 100 μl were added 
24 h after seeding and the cells were continued to culture for 3 days. Fifty μl of MTT (0.5 
mg/ml) was added to each well and incubated for 4 h. Supernatant was removed and the 
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formazan precipitated was dissolved in DMSO (100 μl). The density of absorbance was 
measured at 570 nm on a multiple plate reader. Concentrations that inhibited cell growth 
by 50% (IC50) were determined by nonlinear regression with GraphPad Prism software 
version 5.0 (GraphPad Software, Inc., San Diego, CA). 
 
4. Cell cycle analysis. Cell cycle was assessed by flow cytometry using a 
fluorescence activated cell sorter (FACS). AsPC-1 cells were treated with diverse 
concentrations of compounds 2.57 and 2.72 for 24 h, and then fixed with ice-cold 70% 
ethanol at a density of 1 x 10
6
 cells/mL. The cells were treated with PI/RNase solution 
according to the manufactures protocol. DNA content was quantitated by a flow 
cytometry (Becton Dickinson, San Jose, CA) with an excitation wavelength of 488 nm 
and an emission wavelength of 625 nm.  
 
5. Western blot analysis. Protein extracts of cells treated with compounds 2.57 and 
2.72 at variant concentrations for 24 h were prepared with RIPA lysis buffer [50 mM 
Tris-HCl, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium 
deoxycholate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 100 μM leupeptin, and 2 
μg/mL aprotinin (pH 8.0)]. These protein extracts were separated on 8%, 10% or 12% 
SDS-polyacrylamide gel and transferred to nitrocellulose membranes. The membranes 
were stained with 0.2% Ponceau S red to assure equal protein loading and transfer. After 
blocking with 5% nonfat milk for 30 minutes, the membranes were incubated with a 
primary specific antibody over night at 4ºC. The membranes were then washed with 
TBS-tween 1% buffer for three times and incubated for 1.5 h with the appropriate 
secondary antibody in 1% non fat milk. After incubation the membranes were washed 
with TBS-tween 1% buffer. The immunocomplexes were visualized using enhanced 
chemiluminescence western blotting detection reagent (Amersahm Biosciences, England, 
UK).  
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biological evaluation 
and SAR studies 
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A panel of new oleanane derivatives with heterocyclic ring(s) and fluorine in several 
positions of the oleanane backbone was prepared and duly characterized using MS, IR 
and NMR. Hydroxy-lactones and 12-oxo derivatives were synthesized using novel 
methodologies with good yields. These intermediates and others served as starting 
materials for the synthesis of the new compounds.  
Heterocyclic derivatives were prepared via the reaction of the appropriate oleanane 
derivative or oleanolic acid 3.1 with commercially available reagents, such as CDI, 
CBMI and CDT. These modifications were performed mainly at carbons C2, C3, C12 
and C28. Deoxofluor and selectfluor were used as nucleophilic and electrophilic reagents, 
respectively, in the synthesis of new fluorine oleanane derivatives.  
The novel compounds synthesized were tested for their ability to inhibit the growth 
of AsPC-1 pancreatic cancer cell. Compounds 3.27, 3.39 and 3.49 were the most active, 
and were studied further for their antiproliferative activity in other solid tumor cells. In 
addition, these compounds were found to induce apoptosis in AsPC-1 cells.  
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3.1. Intermediates synthesis 
 
Most of the oleanolic acid intermediates have already been described and 
characterized, and some can be isolated from natural sources.
363, 476
 The reactions used to 
prepare the necessary oleanolic acid intermediates were performed according to 
previously described reactions for triterpenoids. The oxidation and acetylation of the 
secondary alcohol at C3 in oleanolic acid 3.1 were performed according to the literature, 
with good yields (Scheme 3.1.1).
183, 241
 Methylation of the carboxylic acid in oleanolic 
acid 3.1 was made via the reaction with methyl iodide, affording compound 3.4 with 
significant yields (Scheme 3.1.1).
428, 429, 434
  
 
Scheme 3.1.1.
a 
Synthesis of derivatives 3.2-3.4.
 
HO
H
O
OH
H
R1
H
O
R2
H
R1 = 
R2 = OH
O
R1 = 
R2 = OH
OAc
a
b
R1 = 
R2 = OMe
OH
c
................................................
................................................
................................................
3.1
3.1
3.1
3.2
3.3
3.4
 
 
a
Reagents: (a) Jones reagent, acetone, ice; (b) Acetic anhydride, DMAP, THF, r.t.; (c) CH3I, 
K2CO3, DMF, N2, r.t. 
 
Oleanolic δ-hydroxy-γ-lactones can be obtained from ∆12-oleananes by oxidative 
28,13β-lactonization. This reaction was performed under photochemical irradiation,477, 478 
with weak selectivity and low isolated yields. Alternatively, oxidation reagents such as 
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oxygen peroxide in acetic acid,
479
 the inorganic salt mixtures KMnO4/CuSO4,
306
 ozone
332, 
480, 481
 and m-chloroperoxybenzoic acid (m-CPBA)
482
, resulted in low yields and poor 
selectivity. Herein, the β-hydroxy-γ-lactones were obtained via m-CPBA oxidation, with 
high selectivity and yields higher than 90% (Scheme 3.1.2).
483
 The formation of the δ-
hydroxy-γ-lactones 3.5 and 3.6 occurs via the epoxidation of the parental compound (3.1 
or 3.2), followed by the nucleophilic attack of the 28-carbonyl group at C13 from the β-
face, with ring-opening of the 12α, 13α epoxide intermediate.484  
 
Scheme 3.1.2.
a 
Synthesis of derivatives 3.5 and 3.6. 
R1
H
O
OOH
R1 =
OH
R1 =
O
R1
H
O
OH
H
R1 =
OH
R1 =
O
3.1
3.2
3.5
3.6
a
H
 
 
a
Reagents: (a) m-CPBA 77%, CH3Cl, r.t. 
 
Oleanolic acid 3.1 is well characterized by NMR data, with the identification of 
proton H12 as a singlet at 5.49 ppm, and proton Hβ18 as a double doublet at 3.30 ppm.443 
The preparation of a δ-hydroxy-γ-lactone was confirmed in compound 3.5 by the absence 
of the characteristic δ signal for proton H12, which is present at 3.88 ppm in yhis 
compound. Proton H18 presents a signal at δ 2.04 ppm, this value is lower than in the 
substrate oleanolic acid 3.1, which may be explained by the magnetic anisotropy induced 
by the lactone moiety (Figure 3.1.1). The β configuration is illustrated by the ORTEP 
diagram in Figure 3.1.2.   
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Figure 3.1.1. 
1
H NMR sectrum of compound 3.5. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.2. ORTEP diagram of compound 3.5 (50% probability level, H atoms of arbitrary 
sizes). The asymmetric unit also contains a molecule of acetonitrile. 
 
In the past few years, bismuth(III) salts have emerged as convenient reagents for the 
development of a new chemical process for the synthesis of pharmaceutical interest 
molecules, under more “ecofriendly” reaction conditions.485-488 The reaction of compound 
3.5 with 1 mol% of bismusth(III) triflate, in dichloromethane, at reflux, afforded the 
corresponding 12-oxo-28-carboxylic acid 3.7, in 96% crude yield, after 3 hours (Scheme 
3. Oleanolic acid derivatives 
209 
 
3.1.3). Under these conditions bismuth(III) triflate is hydrolyzed, affording Brφnsted acid 
species in situ, which promote the ring opening of the 13,28β olide group, the formation 
of a carbocation at C13, and the rearrangement of the 12α-hydroxy group to a carbonyl 
group.
483
 
 
Scheme 3.1.3.
a
 Synthesis of derivatives 3.7-3.10. 
HO
O
OH
H
O
H
H
O
O
OH
H
O
H
H
AcO
O
OH
H
O
H
H
HO
O
OMe
H
O
H
H
a
b
c
d
3.5
3.7
3.8
3.9
3.10  
 
a
Reagents: (a) Bi(OTf)3, CH2Cl2, reflux; (b) Acetic anhydride, DMAP, THF, r.t.; (c) Jones 
reagent, acetone, ice; (d) CH3I, K2CO3, DMF, N2, r.t. 
 
Structural elucidation of the 12-oxo-oleanane derivatives 3.7-3.10 allowed the 
identification of carbons C12 and C28. In compound 3.7 carbon C12 is identified as a δ 
signal at 211.54 ppm, and carbon C28 as a δ 183.64 ppm (Figure 3.1.3). The correlations 
between protons H13 and H18 signals in the NOESY spectrum allowed to assign a β 
stereochemistry to these protons, in compounds 3.7-3.10, which was further confirmed by 
the ORTEP diagram of compound 3.9 (Figure 3.1.4).  
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Figure 3.1.3. 
13
C NMR spectrum of compound 3.7. 
 
 
 
Figure 3.1.4. ORTEP diagram of compound 3.9 (50% probability level, H atoms of arbitrary 
sizes). 
 
The reaction of compound 3.11 with ethyl formate and sodium methoxide allows the 
preparation of derivatives with an unsaturated exocyclic double bond in ring A (Scheme 
3.1.4).
330, 430, 431
 In compound 3.12, the signal at around δ 7.8 ppm corresponds to the 
proton in the exocyclic double bond at C2 in the 
1
H NMR spectrum. In the 
13
C NMR 
spectrum, the presence of this moiety is confirmed by the signal around δ 131 ppm. The 
signal for carbon C2 appears at around δ 123 ppm.   
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Scheme 3.1.4.
a
 Synthesis of derivatives 3.11-3.13. 
O
H
O
OMe
H
a
O
H
O
OMe
H
O
H
O
OMe
H
HO
HO
b
c
3.4
3.11
3.12
3.13
 
 
a
Reagents: (a) Jones reagent, acetone, ice; (b) Ethyl formate, benzene, NaOMe, r.t.; (c) m-CPBA 
77%, H2SO4, CH2Cl2, MeOH, ice-r.t. 
 
Compound 3.11, in the presence of m-CPBA and concentrated sulfuric acid 
(catalyst), afforded methyl 2α-hydroxy-3-oxoolean-12-en-28-oate 3.13 (Scheme 
3.1.4).
328, 489
 The presence of the α-hydroxy group was confirmed using IR, which 
presented a band at 3485 cm
-1
 corresponding to the stretching vibration of the hydroxyl 
group, as well as using NMR. In the 
1
H NMR spectrum, proton H2 presents as a double 
doublet signal at δ 4.53 ppm. The signal for carbon C2 appears at δ 69.15 ppm in the 13C 
NMR spectrum. The signals for protons H12 and H18 are according to what was 
previously described for the oleanane compounds (Figure 3.1.5).
443
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Figure 3.1.5. 
1
H NMR spectrum of compound 3.13. 
 
Mixtures of tert-butyl hydroperoxide and cobalt salts have been used for the allylic 
oxidation of ∆5 steroids.490, 491 Under these conditions, compound 3.3 affords the allylic 
oxidation of ring C (Scheme 3.1.5). The presence of the carbonyl group in ring C is 
visualized in the IR spectrum as a sharp band at 1699 cm
-1
. The presence of the carbonyl 
moiety in ring C leads to the increase in the δ signals for proton H12, and for carbons 
C12 and C13 in the 
1
H and 
13
C NMR spectra, which is in accordance with the 
literature.
443
  
 
Scheme 3.1.5.
a
 Synthesis of derivative 3.14. 
AcO
H
O
OH
H
AcO
H
O
OH
H
Oa
3.3 3.14  
 
a
Reagents: (a) t-BuOOH, Co(OAc)2.4H2O, MeCN, EtOAc, 77ºC.  
 
 
3. Oleanolic acid derivatives 
213 
 
3.2. Heterocyclic and fluorine derivatives 
3.2.1. Introduction 
 
The introduction of a heterocyclic ring(s) in the structure of triterpenoids is a 
modification that has been performed in betulinic acid and betulin, affording several 
derivatives.
433, 434, 437
 The introduction of the heterocyclic ring has to be made via the 
reaction of an alcohol or a carboxylic acid with CDI, CBMI or CDT in THF at reflux 
under inert atmosphere, giving origin to N-alkylimidazoles,
438-440
 imidazole carboxylic 
esthers (carbamates),
433, 434, 441
 or N-acylimidazoles.
442
 The formation of N-
acylimidazoles, carbamates or N-alkylimidazoles depends on the nature of the reactive 
alcohol or carboxylic acid and on the reaction conditions used. All products are formed 
by the nucleophilic attack of the alcohol to the carbonyl group of the imidazole 
reagent.
438, 440, 442
 A library of new N-acylimidazoles, carbamates and/or N-
alkylimidazoles was synthesized via the introduction of imidazole, methylimidazole or 
triazole as heterocyclic rings in several positions of oleanolic acid 3.1 and derivatives, to 
understand the influence of the heterocyclic ring on the antiproliferative activity. 
Fluorine is the least abundant halide in natural compounds and few living cells can 
metabolize it.
446, 447
 The introduction of a fluorine substituent in currently used 
pharmaceutical compounds has increased from less than 2% to around 20% since 
1970.
448, 449
 Fluorinated organic compounds can be achieved using nucleophilic, 
electrophilic and radical forms of fluorine reagents.
450
 Fluorine is a small and highly 
electronegative atom, and its presence in key positions of biologically active molecules 
can improve metabolic and chemical stability, membrane permeability and binding 
affinity.
448, 452, 455, 457
 5-Fluorouracil was the first synthetic fluorinated chemotherapeutic 
compound, and is still widely used in medicine as an anticancer agent.
448, 458, 459
 In 
addition, fluorinated compounds are often found in currently used anticancer drugs, 
including topoisomerase inhibitor gemcitabine,
492-494
 and anti-androgen agent 
flutamide.
447, 495
 This led us to develop fluorinated oleanolic acid 3.1 derivatives as an 
attempt to improve the antitumor activity further. 
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3.2.2. Results and Discussion 
3.2.2.1. Chemistry  
3.2.2.1.1.  Imidazole derivatives 
 
Imidazole oleanane derivatives 3.15-3.29 were prepared via the reaction of CDI with 
the parental compound. Compounds 3.15, 3.16, 3.19, 3.20-3.23, 3.26 and 3.28 are 
carbamates (Schemes 3.2.1-3.2.4); 3.17, 3.18, 3.24, 3.25, and 3.29 are N-acylimidazoles 
(Schemes 3.2.1 and 3.2.3), and 3.27 is an N-alkylimidazole (Scheme 3.2.4) 
In the IR spectrum, carbamate 3.15 has two bands at 1760 and 1697 cm
-1
,
 
corresponding to the carbonyl stretching vibration of the anhydride and the carboxylic 
acid, respectively. The hydroxy moiety of the carboxylic acid overlaps with the C-H 
absorptions (Figure 3.2.1). 
 
 
Figure 3.2.1. IR spectrum of compound 3.15. 
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Scheme 3.2.1.
a
 Synthesis of derivatives 3.15-3.19. 
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N
N
N
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O N
O
N
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R1 = 
R2 = OH
OH
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
3.1
3.1
3.2
3.4
3.3
3.15
3.16
3.17
3.18
3.19
a
 
 
a
Reagents: (a) CDI, THF, N2, reflux. 
 
The use of 1D and 2D NMR techniques allowed the identification of several δ 
signals in the 
1
H and 
13
C NMR spectra of compound 3.15 (Table 3.2.1). The presence of 
the imidazole group was confirmed by the visualization of three δ signals at 8.21, 7.44 
and 7.13 ppm in the 
1
H NMR spectrum, corresponding to the heterocyclic ring protons. 
The δ signal at 5.28 ppm corresponds to proton H12, which correlates with carbons C9 (δ 
47.54 ppm) and C18 (δ 40.96 ppm), allowing the assignment of the double doublet δ 
signal at 3.04 ppm to proton H18 in the 
1
H NMR spectrum (Figures 3.2.2 and 3.2.3). 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
216 
 
 
Figure 3.2.2. 
1
H NMR spectrum of compound 3.15. 
 
 
Figure 3.2.3. 
13
C NMR spectrum of compound 3.15. 
 
The δ signal at 143.80 ppm corresponds to carbon C13, as proton H18 and the 
methyl group at C27 correlate with this signal, in compound 3.15. Proton H18, in 
addition to correlating with carbon C13, correlates with carbons C12, C14, C19 and C28. 
Methyl groups at C25 and C26 correlate with carbon C9. Methyl groups at C23, C24 and 
C25 appear as a single singlet signal in the 
1H NMR spectrum at δ 0.97 ppm. Proton H3 
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correlates with carbon C2 and the carbon of the carbonyl group at the carbamate moiety, 
allowing the identification of these two signals. 
Compound 3.18 was also analyzed using 1D and 2D NMR techniques which allowed 
the attribution of several δ signals. The results are presented in Table 3.2.1.   
 
Table 3.2.1. Selected 
1
H and 
13
C NMR data from the backbone of 
compounds 3.15 and 3.18. 
R1 = 
R2 = OH
O N
N
O3.15
N
N
R1 = 
R2 =
OAc
3.18
28
3
R1
2
1
4
23 24
5
6
7
8
26
14
27
15
16
17
22
21
20
30
19
18
H
13
12
11
9
10
25
O
R2
H
29
 
Entry Position 
3.15 3.18 
δ H δ C δ H δ C 
1 3 
4.72 
(J= 15.57) 
86.94 
4.47 
(J= 15.94) 
80.79 
2 4 - 38.11 - 37.63 
3 5 - 55.22 0.79 55.26 
4 8 - 39.27 - 39.17 
5 9 - 47.54 - 47.46 
6 10 - - - 36.86 
7 12 5.28 122.21 
5.34 
(J= 7.16) 
123.13 
8 13 - 143.80 - 142.58 
9 14 - 41.60 - 41.78 
10 17 - - - 49.86 
11 18 
2.84 
(J= 10.46) 
40.96 
3.04 
(J= 18.42) 
42.51 
12 19 - 45.87 - - 
13 20 - - - 30.36 
14 25 - - 0.91 15.37 
15 26 0.77 17.05 0.66 16.66 
16 27 1.14 25.89 1.41 25.76 
17 28 - 183.23 - 174.55 
18 OCO - 148.09 - 170.97 
19 OCOCH3 - - 2.03 21.26 
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The reaction of the δ-hydroxy-γ-lactones 3.5 and 3.6 with CDI affords δ-carbamate-
γ-lactones 3.21 and 3.22, respectively. In a selective way, carbamate δ-hydroxy-γ-lactone 
3.20 can also be prepared from the reaction of CDI with the δ-hydroxy-γ-lactone 3.5 
(Scheme 3.2.2).   
 
Scheme 3.2.2.
a
 Synthesis of derivatives 3.20-3.22. 
O
H
O
OOH
O
H
O
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R2 =
N
N
O N
O
N
3.5
3.20
3.21
3.6 3.22
a
a
H
H H
H
 
 
a
Reagents: (a) CDI, THF, N2, reflux. 
 
The full characterization of carbamates 3.20-3.22 was made using IR, MS and 1D 
and 2D NMR. Compound 3.20, which has a α-hydroxyl group at C12, exhibits a broad 
band in the IR at around 3400 cm
-1
, corresponding to the hydroxyl group. The stretching 
vibration bands of the carbonyl groups in these compounds are present in the IR as sharp 
bands at around 1700 cm
-1
. The analysis of the NMR experiments for compound 3.21 
allowed the attribution of several signals in the 
1
H and 
13
C NMR spectra. Figure 3.2.4 
shows some of the HMBC correlations found for this derivative (Table 3.2.2). 
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N
N
O
N
H
H
O
H
 
 
Figure 3.2.4. Selected HMBC correlations for compound 3.21. 
 
 
Figure 3.2.5. 
1
H NMR spectrum of compound 3.22. 
 
The presence of the heterocyclic ring in compound 3.22 was confirmed by the 
presence of the δ signals at 8.12, 7.40 and 7.13 ppm in the 1H NMR spectrum, which 
correspond to the δ signals at 136.80, 116.86 and 131.33 ppm, respectively, in the 13C 
NMR spectrum (Figures 3.2.5-3.2.7). In the 
13
C NMR spectrum, the signal for the 
carbonyl group of the carbamate is present at δ 147.51 ppm, and the signal for the 
carbonyl group at C3 appears at 216.84 ppm (Figure 3.2.6).  
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Figure 3.2.6. 
13
C NMR spectrum of compound 3.22. 
 
 
Figure 3.2.7. HMQC spectrum of compound 3.22, with the correlations between protons and 
carbons of imidazole ring (red) and at position C12 (green). 
 
The identification of proton H12, with a δ signal at 5.26 ppm, allowed the 
visualization of the correlations with carbons C9, C11, C13 and the carbonyl group of the 
carbamate present at C12, with the consequent identification of these signals (Figure 
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3.2.8). Proton H12 has a higher δ signal than is usually seen for geminal protons of a 
carbamate group, due to the presence of the δ-lactone moiety (Figures 3.2.5 and 3.2.7). 
 
 
Figure 3.2.8. HMBC spectrum of compound 3.22. Correlations between proton H12 and carbonyl 
carbon, carbon C13, and carbons C9 and C11, are highlighted in red, green and blue, respectively. 
 
Other correlations were observed in the HMBC of compound 3.22, in particular 
between the methyl groups and the vicinal carbons, which allowed the identification of 
several protons and δ carbons signals. The correlation of carbon C13 allowed the 
identification of the methyl group at C27. The identification of the methyl group at C27 
allowed the recognition of the methyl group at C26, and consequently the identification 
of the methyl group at C25 (Table 3.2.2).  
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Table 3.2.2. Selected 
1
H and 
13
C NMR data of the backbone for compounds 
3.21 and 3.22. 
Entry Position 
3.21 3.22 
δ H δ C δ H δ C 
1 1 - - - 39.34 
2 2 - - - 33.64 
3 3 
4.63 
(J= 16.03) 
85.37 - 216.84 
4 4 - 38.02 - 47.15 
5 5 0.88 54.93 - 54.53 
6 7 - 33.56 - 33.16 
7 8 - 42.01 - 42.12 
8 9 - 45.22 - 44.71 
9 10 - 36.19 - 36.10 
10 11 - - - 25.51 
11 12 5.23 80.87 5.26 80.95 
12 13 - 88.49 - 88.66 
13 14 - 41.93 - 41.98 
14 15 - 27.66 - 27.79 
15 17 - 44.32 - 44.45 
16 18 - 49.86 - 50.10 
17 19 - 39.16 - 39.54 
18 20 - 31.31 - 31.44 
19 21 - - - 33.58 
20 25 - - 0.96 15.95 
21 26 1.17 18.21 1.23 18.00 
22 27 1.30 18.40 1.33 18.38 
23 28 - 178.17 - 178.29 
24 C12OCO - 147.45 - 147.51 
25 C3OCO - 148.19 - - 
 
Reaction of compounds 3.7-3.10 with CDI resulted in compounds 3.23-3.26 (Scheme 
3.2.3). Structural elucidation was made by the same means as for compounds 2.16-2.19, 
taking into consideration the substitution of the double bond with a carbonyl group in 
ring C. The carbonyl group at C12 is identified by a band in the IR spectrum at around 
1700 cm
-1
 and by a signal in the 
13C NMR spectrum at around δ 210 ppm. 
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Scheme 3.2.3.
a
 Synthesis of derivatives 3.23-3.26. 
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a
Reagents: (a) CDI, THF, N2, reflux. 
 
Compounds 3.12 and 3.13, which have a vinyl alcohol and a secondary alcohol at 
C2, respectively, react with CDI to afford N-alkylimidazole 3.27 and carbamate 3.28 
(Scheme 3.2.4). The introduction of the imidazole group was detected by the presence of 
three singlets in the 
1
H NMR spectrum with δ signals higher than 7 ppm, corresponding 
to the protons in the heterocyclic ring. Both compounds (3.27 and 3.28) have a methoxy 
group at C28, which results in a lower δ signal in the 13C NMR spectrum than that 
observed in the parental oleanolic acid 3.1. Carbamate 3.28 exhibits a signal at δ 5.70 
ppm corresponding to proton H2. The signal at δ 5.27 ppm was identified as proton H12 
(Table 3.2.3). 
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Scheme 3.2.4.
a
 Synthesis of derivatives 3.27 and 3.28. 
O
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Reagents: (a) CDI, THF, N2, reflux. 
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Figure 3.2.9. Selected HMBC correlations for compound 3.27. 
 
N-alkylimidazole 3.27, with an α,β unsaturated ketone in ring A, has several 
correlations in the HMBC spectrum that allowed the identification of various δ signals 
(Figure 3.2.9). In ring A, the proton of the exocyclic double bond correlates with carbons 
C1, C3, C2’ and C5’, which allows the attribution of the signal at δ 130.36 ppm to C3’, as 
there is no interaction with this carbon. Other correlations allow the identification of 
methyl groups at C25, C26 and C27. Methyl groups at C23 and C24, C29 and C30 were 
not distinguishable as they are geminal groups. 
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Scheme 3.2.5.
a
 Synthesis of derivative 3.29. 
AcO
H
O
OH
H
O
AcO
H
O
N
H
O
N
3.14 3.29
a
 
 
a
Reagents: (a) CDI, THF, N2, reflux. 
 
Compound 3.14, which has a carbonyl group in ring C at C11, reacts with CDI 
yielding amide 3.29. The presence of the tertiary amide is confirmed by the band at 
1654.6 cm
-1
 in the IR spectrum (Figure 3.2.10). The analysis of the 1D and 2D NMR 
spectra permitted the identification of several δ signals (Table 3.2.3).  
 
 
Figure 3.2.10. IR sectrum of compound 3.29. 
 
Carbonyl group at C11 of compound 3.29 generates a δ signal in the 13C NMR 
spectrum at 199.73 ppm, and the amide at 173.87 ppm. The correlation of proton H12 (δ 
signal at 5.69 ppm in the 
1
H NMR spectrum) with the δ signal at 61.62 ppm allowed the 
identification of this signal as carbon C9. In compound 3.29, correlations of the methyl 
group at C27 with carbons C13, C14 and C15 allowed the identification of the 
corresponding δ signals in the 13C NMR spectrum. Proton at H18 (signal at δ 3.15 ppm in 
the 
1
H NMR spectrum) correlates with carbon C19. The methyl groups at C29 and C30 
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also correlate with this signal, which allows the identification of the δ signal at 44.24 ppm 
as carbon C19.  
 
Table 3.2.3. Selected 
1
H and 
13
C NMR data from the backbone of compounds 3.27-3.29. 
Entry Position 
3.27 3.28 3.29 
δ H δ C δ H δ C δ H δ C 
1 1 - 43.01 - 45.07 - 38.71 
2 2 - 122.99 
5.70 
(J= 19.27) 
75.32 - - 
3 3 - 206.59 - 207.56 
4.47 
(J= 15.74) 
80.47 
4 4 - 45.19 - 48.68 - 37.95 
5 5 - 52.58 - 5.89 
0.75 
(J= 11.40) 
55.01 
6 7 - 31.69 - 32.11 - 32.69 
7 8 - 39.16 - 39.29 - 44.93 
8 9 - 45.46 - 47.30 2.31 61.62 
9 10 - 36.07 - 37.99 - 37.04 
10 11 - 23.63 - - - 199.73 
11 12 5.34 121.77 5.27 121.34 5.70 128.14 
12 13 - 144.02 - 144.14 - 167.21 
13 14 - 41.93 - 41.63 - 37.95 
14 15 - 27.65 - 27.52 - 27.59 
15 17 - 46.77 - 46.52 - 49.34 
16 18 
2.88 
(J= 15.94) 
41.48 
2.85 
(J= 17.20) 
41.11 
3.15 
(J= 11.90) 
42.79 
17 19 - 45.82 - - - 44.24 
18 20 - 30.69 - 30.59 - 30.32 
19 21 - - - - - - 
20 25 0.89 15.39 1.31 15.86 1.10 16.28 
21 26 0.79 16.39 0.77 16.92 0.85 18.54 
22 27 1.18 25.65 1.09 25.81 1.36 23.30 
23 28 - 178.15 - 178.08 - 173.87 
24 COCH3 3.62 51.54 3.60 51.50 - - 
25 OCO - - - 147.93 - 170.94 
26 C2CH 7.80 130.66 - - - - 
27 OCOCH3 - - - - 2.02 21.23 
28 C4’ 7.15 130.36 - - - - 
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3.2.2.1.2.  Methylimidazole derivatives 
 
The reaction of compounds 3.1-3.5 with the commercially available reagent CBMI 
affords carbamates 3.30, 3.33 and 3.34, and N-acylimidazoles 3.31 and 3.32 (Schemes 
3.2.6 and 3.2.7) with good yields. The methylimidazole group is characterized by the 
presence of two singlet signals higher than δ 6.8 ppm in the 1H NMR spectrum, 
corresponding to the protons, and a signal corresponding to the methyl group in the 
heterocyclic ring at around 2.6 ppm.  
 
Scheme 3.2.6.
a
 Synthesis of derivatives 3.30-3.33. 
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a
Reagents: (a) CBMI, THF, N2, reflux. 
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The characterization of compounds 3.30-3.34 was made via MS, IR and NMR 
experiments. Compound 3.30 was prepared via the reaction of the hydroxyl and carboxyl 
groups of oleanolic acid 3.1 with CMBI. The presence of the two methylimidazole groups 
is confirmed by the existence of four different δ signals in the 1H NMR spectrum, 
corresponding to the protons of the methylimidazole ring, and by two signals of methyl 
groups. The δ signals in the 1H NMR spectrum at 7.53, 6.88 and 2.57 ppm correspond to 
the methylimidazole ring at C3 (ring’), and the δ signals at 7.32, 6.84 and 2.63 ppm 
correspond to the methylimidazole ring at C28 (ring’’). The previous signals correspond, 
respectively, to the δ signals at 117.28, 127.19, 17.78, 117.97, 127.63 and 16.83 ppm in 
the 
13
C NMR spectrum. Other correlations were also found for compound 3.30 via 
HMBC, HMQC and COESY experiments (Table 3.2.4).   
 
Scheme 3.2.7.
a
 Synthesis of derivative 3.34. 
HO
H
O
OOH
O
H
O
OOH
N
O
3.5
a
N 3.34
HH
 
 
a
Reagents: (a) CBMI, THF, N2, reflux. 
 
Compound 3.5, when reacting with CBMI, only affords compound 3.34, in which the 
hydroxyl group at C12 did not react with CBMI, probably because of the volume of the 
CBMI reagent and the sterical impairment of this position. The presence of the hydroxyl 
group at C12 was detected in the IR spectrum by the broad band at around 3400 cm
-1
, 
which is characteristic of the hydroxyl group, and was confirmed further via NMR 
analysis.   
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Compound 3.34 exhibits a δ signal at 3.90 ppm, corresponding to proton H12. The 
proximity with the lactone moiety leads to the increase in the δ signal value when 
compared with other alcohols. The same is observed for the signal of carbon C12 (Table 
3.2.4). Proton H12 and the methyl group at C27 interact with carbon C13. The methyl 
group at C27 has several correlations in the HMBC spectrum, for example with carbons 
C14 and C15. The correlation of the methyl groups at C25 and C26 with the signal at δ 
44.67 ppm allowed the identification of this signal as carbon C9. The presence of the 
carbamate at C3 is confirmed by the correlation of methyl groups C23 and C24 with the 
carbonyl group of the carbamate. Proton H3 also correlates with this carbonyl group. 
Other correlations were observed in the 2D NMR spectra, which allowed the attribution 
of several δ signals (Figure 3.2.11, Table 3.2.4).  
 
O
H
O
O
OH
N
O
N
H
H
H
 
 
Figure 3.2.11. Selected HMBC correlations for compound 3.34. 
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Table 3.2.4. Selected 
1
H and 
13
C NMR data from the backbone of 
compounds 3.30 and 3.34. 
Entry Position 
3.30 3.34 
δ H δ C δ H δ C 
1 1 - - - 38.32 
2 3 
4.65 
(J= 16.32) 
85.89 
4.67 
(J= 16.29) 
85.77 
3 4 - 37.97 - 38.13 
4 5 - 55.26 - 55.23 
5 7 - - - 34.11 
6 8 - 39.31 - 42.26 
7 9 - 47.44 - 44.67 
8 10 - 36.87 - 36.34 
9 11 - 23.00 - - 
10 12 
5.36 
(J= 6.97) 
122.92 3.90 76.04 
11 13 - 142.96 - 90.59 
12 14 - - - 42.08 
13 15 - 41.89 - 27.99 
14 17 - 50.77 - 44.45 
15 18 
3.10 
(J= 17.28) 
42.55 - 51.10 
16 19 - 46.10 - 39.34 
17 20 - 30.35 - 31.54 
18 25 0.96 15.37 0.93 16.33 
19 26 0.73 17.16 1.16 18.55 
20 27 1.17 25.74 1.32 18.55 
21 28 - 176.73 - 179.92 
22 OCO - 149.40 - 149.37 
23 C2’ - 149.33 - 147.89 
24 C2’’ - 147.84 - - 
25 C2’CH3 2.57 17.78 2.65 16.80 
26 C2’’CH3 2.64 16.83 - - 
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The reaction of compounds 3.7-3.10 with CBMI affords oleanane-type derivatives 
3.35-3.38 (Scheme 3.2.8) in good yields. These compounds do not have the unsaturation 
in ring C, which has been replaced by a carbonyl group at C12. Therefore, the signal 
characteristic of proton H12 is not present in the 
1
H NMR spectrum of these compounds. 
However, in the 
13
C NMR spectrum, a δ signal at around 210 ppm corresponds to the 
signal of carbon C12, which is characteristic of a carbonyl group.  
 
Scheme 3.2.8.
a
 Synthesis of derivatives 3.35-3.38. 
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Reagents: (a) CBMI, THF, N2, reflux. 
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Compound 3.37 presents two carbonyl groups at carbons C3 and C12, and the 
correlations established by them allowed their identification. Proton H13 correlates with 
carbon C12, which permitted the identification of the δ signal at 210 ppm as carbon C12. 
The methyl groups at C23 and C24 correlate with carbon C3 (δ signal at 216 ppm), 
although it was not possible to distinguish them. More correlations were visualized in the 
the 2D NMR experiments that allowed the identification of other δ signals (Table 3.2.5). 
 
Table 3.2.5. Selected 
1
H and 
13
C NMR data of the backbone of compound 3.37. 
Entry Position δ 1H NMR δ 13C NMR 
1 3 - 216.50 
2 5 1.24 54.89 
3 9 
1.69 
(J= 17.78) 
49.13 
4 10 - 36.59 
5 12 - 210.14 
6 13 
2.70 
(J= 3.88) 
51.24 
7 18 
3.01 
(J= 13.12) 
32.96 
8 20 - 30.34 
9 25 0.99 15.99 
10 28 - 177.62 
11 C2’ - 149.01 
12 C2’CH3 2.60 17.72 
 
Compounds 3.12 and 3.13 react with CBMI to afford the N-alkylimidazole 3.29 and 
the carbamate 3.40, respectively (Scheme 3.2.9). Compound 3.39, which has a proton in 
the exocyclic double bond at C2 exhibits a signal in the 
1H NMR spectrum at δ 6.65 ppm, 
corresponding to this proton. Compound 3.40 exhibits a different 
1
H NMR spectrum, as 
proton H2 is present as a double doublet with a δ signal at 5.71 ppm. The δ signal is 
higher than that in other carbamates as the carbonyl group at C3 exercises influence over 
this proton (Figure 3.2.12). 
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Scheme 3.2.9.
a
 Synthesis of derivatives 3.39 and 3.40. 
O
H
O
OMe
H
O
H
O
OMe
H
R1 =
OH
R1 = O N
O
N
...................................................3.13 3.40
R1 = R1 =
..............................................3.12 3.39HO
NN
R1 R1
a
 
 
a
Reagents: (a) CBMI, THF, N2, reflux. 
 
 
Figure 3.2.12. 
1
H NMR spectrum of compound 3.40. 
 
In the 
13
C NMR spectrum, compound 3.40 exhibits δ signals at 207.87, 178.14 and 
138.92 ppm corresponding to quaternary carbons C3, C28 and the carbonyl group of 
carbamate, respectively (Figure 3.2.13). The signals corresponding to the protons and the 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
234 
 
methyl group in the methylimidazole ring were identified via HMQC experiments (Figure 
3.2.14). 
 
 
Figure 3.2.13. 
13
C NMR spectrum of compound 3.40. 
 
 
Figure 3.2.14. HMQC spectrum of compound 3.40, with the correlations between protons and 
carbons of methylimidazole ring (red), C2 (green), C12 (blue), methyl group at C28 (yellow) and 
methyl group at the methylimidazole ring (purple). 
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Figure 3.2.15. HMBC spectrum of compound 3.40. 
 
In compound 3.40, proton H5 which exhibits a δ signal at 2.38 ppm, correlates with 
carbons C2, C3, C23, C24 and C25, which allows the identification of the corresponding 
δ signals in the 13C NMR spectrum. Proton H2 correlates with the carbonyl group of the 
nearby carbamate (Figure 3.2.15). The methyl group at C27 correlates with carbons C13 
and C14, the methyl group at C26 correlates with carbons C8 and C9, the methyl group at 
C25 correlates with carbons C1, C5 and C10 (Table 3.2.6). The geminal methyl groups at 
C23 and C24, C29 and C30 were not distinguishable as they had the same magnetic 
environment. The HMBC spectrum of compound 3.40 allowed the observation of more 
correlations. 
 
Scheme 3.2.10.
a
 Synthesis of derivative 3.41. 
AcO
H
O
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H
O
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H
O
N
H
O N
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a
 
 
a
Reagents: (a) CBMI, THF, N2, reflux. 
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Compound 3.41 (Scheme 3.2.10) was characterized via IR, MS and 1D and 2D NMR 
experiments. The NMR data allowed the attribution of several δ signals (Table 3.2.6). 
 
Table 3.2.6. Selected 
1
H and 
13
C NMR data from the backbone of 
compounds 3.40 and 3.41. 
Entry Position 
3.40 3.41 
δ H δ C δ H δ C 
1 1 - 45.29 
2.81 
(J= 13.56) 
38.75 
2 2 
5.71 
(J= 18.97) 
74.97 - - 
3 3 - 207.87 
4.48 
(J= 15.60) 
80.51 
4 4 - 48.79 - 37.99 
5 5 
2.38 
(J= 17.89) 
57.07 - 55.10 
6 7 - - - 32.80 
7 8 - 39.37 - 45.06 
8 9 - 47.39 2.32 61.65 
9 10 - 38.08 - 37.07 
10 11 - - - 199.81 
11 12 5.29 121.41 5.71 128.17 
12 13 - 144.24 - 16.50 
13 14 - 41.72 - 43.56 
14 15 - 27.60 - 27.63 
15 17 - 46.60 - 50.28 
16 18 
2.87 
(J= 12.99) 
41.20 
3.20 
(J= 12.28) 
43.08 
17 19 - - - 44.53 
18 20 - 30.66 - 30.26 
19 25 1.33 15.93 1.12 16.35 
20 26 0.79 16.99 0.90 18.90 
21 27 1.12 25.88 1.37 23.24 
22 28 - 178.14 - 175.69 
23 COCH3 3.63 51.55 - - 
24 OCOCH3 - - 2.03 21.28 
25 OCO - 148.92 - 171.01 
26 C2’ - 148.06 - 149.72 
27 C2’CH3 2.62 16.69 2.55 18.22 
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3.2.2.1.3.  Triazole derivatives 
 
The reaction of oleanane type derivatives and oleanolic acid 3.1 with CDT affords N-
acyltriazoles, carbamates and N-alkyltriazoles. Compounds 3.1, 3.3 and 3.4 afforded 
carbamates 3.42 and 3.44, and N-alcyltriazole 3.43 with good yields (Scheme 3.2.11). 
The presence of the triazole ring in the oleanane structure is confirmed by the presence of 
two singlets in the 
1
H NMR spectrum, with δ signals higher than 7.8 ppm. The attribution 
of the remaining δ signals was made using the same rationale as that used for the 
imidazole and methylimidazole derivatives.  
 
Scheme 3.2.11.
a
 Synthesis of derivatives 3.42-3.44. 
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Reagents: (a) CDT, THF, N2, reflux. 
 
Compound 3.42, which has two triazole rings, exhibits four singlets in the 
1
H NMR 
spectrum, with the same number of corresponding signals being present in the 
13
C NMR 
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spectrum. The amide carbonyl group at C28 appears as a δ signal at 174.99 ppm, and the 
carbamate carbonyl group appears at 147.28 ppm, in the 
13
C NMR spectrum. The methyl 
groups at C25, C26 and C27 establish several correlations with the neighboring carbons, 
which allows the attribution of several δ signals (Table 3.2.7).  
In amide 3.43 the δ signals were also attributed based on the study of the 1D and 2D 
NMR spectra (Table 3.2.7). The δ values of proton H3 and of carbon C3 are different 
from those observed for compound 3.42, as the group at C3 changes from a carbamate to 
an acetoxy group.  
 
Table 3.2.7. Selected 
1
H and 
13
C NMR data from the backbone of 
compounds 3.42 and 3.43. 
Entry Position 
3.42 3.43 
δ H δ C δ H δ C 
1 1 - - - 38.10 
2 3 
4.79 
(J= 16.48) 
87.68 
4.48 
(J= 15.73) 
80.83 
3 4 - 38.18 - 37.65 
4 5 
0.89 
(J= 10.31) 
55.24 0.80 55.27 
5 7 - 32.40 - 32.47 
6 8 - 39.25 - 39.26 
7 9 - 47.49 - 47.50 
8 10 - 36.85 - 36.87 
9 12 5.30 122.60 5.29 122.80 
10 13 - 143.19 - 143.09 
11 14 - 41.79 - 41.68 
12 15 - 27.80 - 27.80 
13 17 - 49.97 - 49.99 
14 18 
3.20  
(J= 11.41) 
41.66 
3.19 
(J= 11.88) 
41.78 
15 19 - 45.79 - 45.78 
16 20 - 30.50 - 30.49 
17 25 0.96 15.35 0.91 15.36 
18 26 0.68 16.70 0.66 16.63 
19 27 1.17 25.90 1.15 25.89 
20 28 - 174.99 - 175.02 
21 OCOCH3 - - 2.03 21.28 
22 OCO - 147.28 - 170.98 
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Compounds 3.7-3.10 react with CDT affording compounds 3.45-3.48 (Scheme 
3.2.12). Compounds that have a 12-oxo moiety present a characteristic band in the IR 
spectrum at around 1715 cm
-1
, corresponding to the stretching vibration of the carbonyl 
group in cyclic ketones. In the 
13
C NMR spectrum, the carbonyl group at C12 has a δ 
signal around 210 ppm, carbon C13 appears at around 51 ppm, and the signal for proton 
β-H13 appears at around 2.6 ppm in the 1H NMR spectrum (Table 3.2.8). 
 
Scheme 3.2.12.
a
 Synthesis of derivatives 3.45-3.48. 
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Reagents: (a) CDT, THF, N2, reflux. 
 
Compound 3.45, which has two triazole rings, exhibits four δ signals in the 1H NMR 
spectrum corresponding to the protons of the heterocyclic rings. Other correlations are 
visible in the 2D NMR spectra of compound 3.45, which allows the attribution of various 
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δ signals, such as the methyl groups at C25, C26 and C27. Carbonyl groups of the 
carbamate and amide moieties were identified by the different δ signals at 147.22 and 
175.50 ppm, respectively (Table 3.2.8). 
 
Table 3.2.8. Selected 
1
H and 
13
C NMR data from the backbone of 
compounds 3.45 and 3.48. 
Entry Position 
3.45 3.48 
δ H δ C δ H δ C 
1 3 
4.75 
(J= 16.30) 
87.05 
4.75 
(J= 16.48) 
87.09 
2 4 - 38.21 - 38.19 
3 5 - 55.00 - 54.98 
4 8 - 41.28 - 41.16 
5 9 - 49.57 - 49.51 
6 10 - 36.75 - 36.72 
7 12 - 210.53 - 211.12 
8 13 2.70 51.45 
2.60 
(J= 3.94) 
51.71 
9 14 - 42.11 - 41.77 
10 17 - 50.34 - 47.22 
11 18 
3.26 
(J= 12.64) 
32.09 
2.76 
(J= 13.46) 
31.61 
12 20 - 30.45 - 30.54 
13 25 0.89 15.18 0.90 15.15 
14 26 0.92 16.13 0.94 23.06 
15 27 0.98 20.62 0.92 20.46 
16 28 - 175.50 - 178.23 
17 COCH3 - - 3.65 51.71 
18 OCO - 147.22 - 147.19 
 
Carbamate 3.48 has a methoxy group at C28, which was confirmed by a δ signal at 
178.23 ppm, corresponding to carbon C28. The δ signal at 147.19 ppm corresponded to 
the carbonyl of the carbamate. Proton H3 emerged as a double doublet with a δ signal at 
4.75 ppm. Carbon C3 exhibited a δ signal at 87.09 ppm in the 13C NMR spectrum. 
Correlations between H13 and C27 allowed the identification of the latter and 
consequently the identification of the δ signals of carbons C26 and C25. Other 
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correlations of these methyl groups allowed the identifications of various δ signals (Table 
3.2.8). 
 
Scheme 3.2.13.
a
 Synthesis of derivative 3.49. 
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Reagents: (a) CDT, THF, N2, reflux. 
 
Compounds 3.12 and 3.14 reacted with CDT affording amine 3.49 and amide 3.50, 
respectively (Schemes 3.2.13 and 3.2.14). The characterization by means of MS, IR, and 
1D and 2D NMR techniques of these new compounds confirmed the introduction of a 
triazole ring in the parental structure. 
 
Scheme 3.2.14.
a
 Synthesis of derivative 3.50. 
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Reagents: (a) CDT, THF, N2, reflux. 
 
3.2.2.1.4. Fluorine derivatives 
 
Fluorinated organic compounds can be achieved using nucleophilic, electrophilic and 
radical forms of fluorine reagents.
450
 The presence of fluorine in key positions of a 
biologically active molecule can improve the biological properties of the parental 
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molecule. Selectfluor, an electrophilic fluorination reagent, was used to introduce a 
fluorine atom into oleanolic acid 3.1 and derivatives. Selectfluor is a crystalline white 
solid that is stable at high temperatures, and is easy to work with because the byproducts 
are usually easily removed by an aqueous workup.
461
 Several papers describe the reaction 
of alkenes with selectfluor, usually in the presence of a nucleophilic donor.
464, 466
 The 
solvent, the temperature, and the nucleophilic donor can influence the efficiency and the 
outcome (number of isomers and byproducts) of this reaction.  
The reaction of oleanolic acid 3.1 and derivatives 3.2 and 3.3 with selectfluor in a 
mixture of two inert solvents, acetonitrile and dioxane, at 50 ºC, affords a mixture of α-
and β-fluorolactones, with α isomer being the major reaction product (Scheme 3.2.15). 
The free acid behaves like the nucleophilic donor, losing the proton and promoting 
cyclization to the carbon C13 in the oleanane backbone.   
 
Scheme 3.2.15.
a
 Synthesis of derivatives 3.51-3.56. 
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Reagents: (a) Selectfluor, acetonitrile, dioxane, 50ºC. 
 
The fluorolactone moiety is detected as a double doublet in the 
1
H NMR spectrum, 
corresponding to the proton H12, namely around δ 4.5 ppm for β-fluorolactones and δ 4.6 
ppm for α-fluorolactones (Figure 3.2.16). In the 13C NMR spectrum, the signals for 
carbons C12 and C13 are doublets. In the β isomeres their δ values are around 97 and 88 
ppm, respectively, and in the α isomeres they are around 100 and 90 ppm, respectively. 
The δ signal for carbon C28 is in the order of 179 ppm in both isomers (Figure 3.2.17).  
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Figure 3.2.16. 
1
H NMR spectrum of compound 3.52. 
 
The identification of the different isomers is based on the NOESY spectrum 
correlations of proton H12 with other groups. In flurolactone 3.51, proton H12 has a 
correlation with the methyl group at C27 and is consequently identified as the β-fluorine 
isomer. Proton H12 of flurolactone 3.52 establishes a correlation with the methyl group at 
C26, which is therefore identified as the α-fluorine isomer (Figure 3.2.18).  
 
 
Figure 3.2.17. 
13
C NMR spectrum of compound 3.52. 
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HMBC and HMQC spectra allowed the visualization of other correlations of 
fluorolactones, permitting the identification of various δ signals (Figure 3.2.19). Table 
3.2.9 shows selected attributions of δ signals to the isomers 3.51 and 3.52. 
 
 
Figure 3.2.18. Detail of the NOESY spectrum of compound 3.52. The correlation between H12 
and the methyl group at C26 is marked in red. 
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Figure 3.2.19. Selected HMBC correlations for compound 3.52. 
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Table 3.2.9. Selected 
1
H and 
13
C NMR data of the backbone of compounds 
3.51 and 3.52. 
Entry Position 
3.51 3.52 
δ H δ C δ H δ C 
1 3 
3.22 
(J= 16.11) 
78.71 
3.20 
(J= 15.99) 
78.69 
2 4 - 38.85 - 38.83 
3 5 - 55.00 - 55.77 
4 8 - 41.91 - 43.46 
5 9 - 44.65 - 
48.60 
(J= 2.63) 
6 10 - 36.40 - 37.47 
7 11 - - - 
26.28 
(J= 21.62) 
8 12 
4.56 
(J= 52.08) 
96.66 
(J= 171.56) 
4.65 
(J= 61.61) 
99.87 
(J= 179.56) 
9 13 - 
87.98 
(J= 25.90) 
- 
90.76 
(J= 7.46) 
10 14 - 41.70 - 
44.96 
(J= 18.74) 
11 17 - 44.32 - 39.31 
12 18 - 50.86 - 45.35 
13 20 - 31.47 - 30.48 
14 25 0.887 16.02 0.93 17.18 
15 26 1.11 18.28 1.13 19.18 
16 27 
1.23 
(J= 0.96) 
17.93 
(J= 8.06) 
1.21 
(J= 2.59) 
16.38 
(J= 10.91) 
17 28 - 179.35 - 178.40 
18 29 - - 0.96 33.07 
19 30 - - 0.89 23.84 
 
Deoxofluor, a thermodynamically stable nucleophilic reagent, is used for the 
fluorination of carbonyl and carboxylic functionalities.
453, 472
 The reaction of deoxofluor 
with oleanane derivatives 3.2 and 3.3 affords acyl fluorinated derivatives 3.57 and 3.58 
(Scheme 3.2.16).  
 
 
 
 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
246 
 
Scheme 3.2.16.
a
 Synthesis of derivatives 3.57 and 3.58. 
R1
H
H
OH
O
R1
H
H
F
O
R1 =
R1 =
OAc
O
R1 =
R1 =
OAc
O
3.58
3.57
3.3
3.2
a
 
 
a
Reagents: (a) Deoxofluor, THF, ice. 
 
The structural elucidation of compounds 3.57 and 3.58 was made by means of MS, 
IR and NMR. The carbonyl band stretching vibration on the IR appears around 1820 cm
-
1
, the C-F band merges with other bands and therefore it is impossible to visualize it as an 
isolated band. The acid halide moiety emerges as doublet in the 
13
C NMR spectrum, with 
a δ signal of 167 ppm and a coupling constant of 375 Hz. 
 
3.2.2.2. Biological evaluation 
 
Compounds 3.15-3.58 were evaluated for their antiproliferative activity against 
AsPC-1 pancreatic cell line, via a MTT assay (Tables 3.2.10 and 3.2.11).  
All new derivatives tested were more potent in inhibiting cell growth than oleanolic 
acid 3.1 (IC50>100). Compounds 3.15-3.19, 3.30-3.33 and 3.42-3.44, with modifications 
only at C3 and at C28, had a moderate antiproliferative activity against AsPC-1 cells, 
with IC50s between 8 and 26 μM, with the exception of methylimidazole derivatives 3.30-
3.33, with IC50s lower than 8 μM. Compound 3.30, the best compound found, had an IC50 
of 3.2 μM (Table 3.2.10). 
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Table 3.2.10. The IC50 (µM) of oleanolic acid heterocyclic derivatives to inhibit 
AsPC-1 cell growth. 
Imidazole-compd Methylimidazole-compd Triazole-compd 
Compd IC50 (μM) Compd IC50 (μM) Compd IC50 (μM) 
3.1 >100 
3.15 6.2±0.03 - - - - 
3.16 8.8±0.03 3.30 3.2±0.05 3.42 10.6±0.01 
3.17 10.6±0.04 3.31 7.4±0.04 - - 
3.18 10.1±0.12 3.32 6.9±0.06 3.43 20.6±0.72 
3.19 26.4±0.02 3.33 8.5±0.02 3.44 12.6±0.05 
3.20 9.0±0.04 3.34 5.2±0.07 - - 
3.21 3.4±0.08 - - - - 
3.22 12.0±0.06 - - - - 
3.23 4.4±0.03 3.35 5.8±0.08 3.45 10.3±0.03 
3.24 13.3±0.06 3.36 4.6±0.05 3.46 4.9±0.03 
3.25 7.9±0.02 3.37 5.5±0.03 3.47 9.1±0.02 
3.26 13.1±0.03 3.38 10.7±0.02 3.48 9.4±0.04 
3.27 0.9±0.01 3.39 0.7±0.02 3.49 1.9±0.03 
3.28 10.2±0.01 3.40 25.8±0.03 - - 
3.29 10.1±0.12 3.41 30.4±0.05 3.50 5.1±0.02 
The AsPC-1 cells were treated with the indicated compounds at varying concentrations 
for 72 h. The antiproliferative effects were determined by MTT assay and the IC50 was 
calculated. The results shown are means ± SE of three independent experiments. 
 
Compounds with a carbonyl group in ring C at position C12 or C11 exhibited an 
improvement in the antiproliferative activity for some heterocyclic derivatives. Imidazole 
derivatives 3.23, 3.25 and 3.26 exhibited better antiproliferative activity compared with 
compounds 3.16, 3.18 and 3.19, which have a double bond at C12 instead of a carbonyl 
group. The α,β unsaturated ketone moiety in ring C of compound 3.29 does not improve 
the antiproliferative activity, when compared with compound 3.18, which does not have 
Preparation and biological evaluation of novel ursane and oleanane triterpenoids 
 
248 
 
this modification. The methylimidazole derivatives 3.35-3.38 did not show an 
improvement in the antiproliferative activity when compared with compounds 3.30-3.33, 
which do not have a modification in ring C. Compound 3.41 is an exception, because the 
introduction of an α,β unsaturated ketone in ring C decreases the ability of this compound 
to inhibit cell growth.  
Hydroxy-lactones 3.20-3.22 and 3.34 have the ability to inhibit the proliferation of 
AsPC-1 cells. Compound 3.21 was the best compound found. Lactones 3.20, 3.21 and 
3.34 were better in the inhibition of cell growth of AsPC-1 pancreatic cancer cells than 
were compounds 3.19, 3.26, 3.33 or 3.38, which have a methoxy group at C28. The 
preparation of carbamates at C3 in conjugation with 13,28β-lactones improves 
significantly the antiproliferative activity of oleanane compounds.  
The presence of a Michael acceptor can increase the potency of the antiproliferative 
activity in certain compounds.
414, 444
 Oleanolic acid derivatives with modifications at C2 
were prepared with the aim of creating an electron-withdrawing moiety in ring A. 
Compounds 3.28 and 3.40, which have a carbamate at C2, did not exhibit an 
improvement of the antiproliferative activity when compared with compounds without 
modifications at C2. Compounds 3.27, 3.39 and 3.49 were the best heterocyclic oleanane 
derivatives found in the inhibition of AsPC-1 cell growth. The conjugation of an N-
alkylheterocyclic ring with an α,β unsaturated ketone in ring A affords a Michael 
acceptor moiety, which contributes to the excellent antiproliferative activity observed in 
these compounds. 
The preparation of fluorine-13,28β-lactones affords compounds 3.51-3.56. These 
compounds were able to inhibit the growth of pancreatic cancer cells, with IC50s lower 
than 10 μM, with the exception of compound 3.54. The functionally present at C3 does 
not seem to influence the antiproliferative activity. Acid fluorides 3.57 and 3.58 also 
exhibited better antiproliferative activity than that of oleanolic acid 3.1 (Table 3.2.11).  
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Table 3.2.11. The IC50 (µM) of oleanolic acid fluorine derivatives to inhibit 
AsPC-1 cell growth. 
Entry Compound AsPC-1 
1 3.51 5.8±0.02 
2 3.52 5.3±0.03 
3 3.53 8.4±0.05 
4 3.54 35.0±0.07 
5 3.55 9.0±0.03 
6 3.56 7.7±0.04 
7 3.57 8.4±0.01 
8 3.58 10.1±0.03 
The AsPC-1 cells were treated with the indicated compounds with at varying of 
concentrations for 72 h. The antiproliferative effects were determined by MTT assay 
and the IC50 was calculated. The results shown are means ± SE of three independent 
experiments. 
 
Figure 3.2.20 represents the SAR conclusions of oleanane compounds tested for their 
antiproliferative activity in AsPC-1 cells. Compounds 3.30, 3.23, 3.21, and 3.39 which 
have a ∆12 unsaturation in ring C, a carbonyl group at C12, 13,28β-lactone and 
modifications at C2, respectively, represent the most active compounds of each group. N-
alkylimidazoles 3.27, 3.39 and 3.49 represent the most active compounds in the panel of 
newly synthesized oleanane derivatives.   
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Figure 3.2.20. Structure activity relationships (SAR) among several synthetic derivatives of 
oleanolic acid 3.1. The comparison was made based on their IC50s in the inhibition of AsPC-1 cell 
growth, considering IC50 of oleanolic acid 3.1 as 100 μM. Compound 3.30 is 31- fold more potent 
than oleanolic acid 3.1. Compound 3.23 is 23-fold more potent than oleanolic acid 3.1. 
Compound 3.21 is 29- fold more potent than oleanolic acid 3.1. Compound 3.39 is 143-fold more 
potent than oleanolic acid 3.1. 
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Compounds 3.27, 3.39 and 3.49 showed the best antiproliferative activity against 
AsPC-1 cells, and were further studied for their ability to inhibit the proliferation of other 
solid tumor cell lines (Table 3.2.12). Compounds 3.27 and 3.39 exhibited IC50s lower than 
1 μM for all cell lines tested except breast cancer cells (MCF-7). Compound 3.49 was 
less active, although it presented IC50s lower than 3 μM for all studied cell lines, with the 
exception of MCF-7 tumor cells. 
 
Table 3.2.12. The IC50 (µM) of oleanolic acid heterocyclic derivatives to inhibit growth of 
pancreatic (PANC-1 and MIA PaCa 2), breast (MCF-7), prostate (PC-3), hepatic (Hep G2) 
and lung (A549) cancer cell lines. 
Compd PANC-1 MIA PaCa 2 Hep G2 MCF-7 A549 PC-3 
3.27 0.9±0.02 0.9±0.01 0.6±0.003 1.1±0.04 0.6±0.003 0.8±0.02 
3.39 1.0±0.02 0.9±0.01 0.5±0.02 2.0±0.03 0.6±0.01 0.7±0.003 
3.49 3.0±0.02 2.8±0.01 2.1±0.02 5.6±0.03 2.3±0.03 2.3±0.01 
The Panc-1, MiaPaCa 2, MCF-7, PC-3, HepG2 and A549 cells were treated with the indicated 
compounds at varying of concentrations for 72 h. The antiproliferative effects were determined by MTT 
assay and the IC50 was calculated. The results shown are means ± SE of three independent experiments. 
 
AsPC-1 pancreatic cancer cells were selected for the elucidation of the mechanism of 
action of compounds 3.27, 3.39 and 3.49. Cells treated with compounds 3.27 and 3.39 at 
0.5 μM had few modifications in the cell cycle, but at 1.5 μM an increase in the number 
of cells in the sub-G1 phase, apoptotic cells, was observed. Compound 3.49 induced cell-
cycle arrest at the G1 phase at 2 μM, and apoptosis at 4 μM (Table 3.2.13). 
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Table 3.2.13. Results of FACS analyses for AsPC-1 cells treated with compounds 3.27, 3.39 and 
3.49 for 24 h at the indicated concentrations. The results represent the percentage of the number 
of cells in the indicated phase of the cell cycle, mean ± SD of three independent experiments.  
 Control 
3.27 3.39 3.49 
0.5 μM 1.5 μM 0.5 μM 1.5 μM 2 μM 4 μM 
Sub-G1 3.6±0.2 9.9±5.1 44.5±3.8 8.4±4.5 54.1±3.0 6.1±5.0 34.6±1.8 
G1 39.9±4.2 41.9±4.0 21.7±2.9 46.6±4.2 18.8±1.3 48.9±3.8 24.3±1.3 
S 11.9±0.4  8.8±0.7 8.5±0.9 8.2±0.2 6.7±0.8 20.6±1.3 10.0±1.0 
G2/M 25.0±1.2  19.6±2.0 11.3±2.6 19.1±1.9 8.0±1.2 6.1±1.8 15.2±2.6 
 
3.2.3. Conclusions 
 
In summary, this section presented a new procedure for the preparation of 
hydroxylactones and 12-oxo oleanane heterocyclic derivatives. A series of other 
heterocyclic N-acylimidazole, carbamate and N-alkylimidazole derivatives were also 
achieved. The preparation of fluorine derivatives was made via the reaction of oleanolic 
acid 3.1 or oleanane-type compounds with selectfluor or deoxofluor. These new 
derivatives of oleanolic acid 3.1 were fully characterized using NMR, MS and IR 
techniques 
 
The new semisynthetic derivatives present a good antiproliferative profile against 
pancreatic cancer cells AsPC-1. Compounds 3.27, 3.39 and 3.49, in which we introduced 
a heterocyclic ring in conjugation with an α,β unsaturated ketone in ring A of oleanane 
backbone, were the most active ones in the inhibition of AsPC-1 cell growth. These 
compounds induce apoptosis in AsPC-1. 
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3.3. Experimental section 
3.3.1. Chemical 
 
IR spectra were recorded in JASCO FT/IR-420. 
1
H, 
13
C, DEPT-135, HMQC, 
HMBC, COESY and NOESY spectra were recorded in a Bruker Avance III 400 MHz 
spectrometer. The chemical shifts were recorded in δ (ppm) using the δ 7.26 of CHCl3 
(
1H NMR) and the δ 77.00 (13C NMR) as internal standards. Chemical shifts measures 
were given in ppm and coupling constants (J) in hertz (Hz). Low resolution mass 
spectrometry was obtained in a Finnigan Polaris QGC/MS Benchtop Ion Trap 
spectrometer with a direct insertion probe and the elemental analysis was obtained in an 
Analyzer Elemental Carlo Erba 1108 by chromatographic combustion. Melting points 
were determined using a BUCHI melting point B-540 apparatus and were uncorrected. 
For thin layer chromatography (TLC) analysis Kiesel gel 60HF254/kiesel gel 60G was 
used and FCC was performed using Kieselgel 60 (230-400 mesh, Merck). Oleanolic acid 
3.1, selectfluor, deoxofluor, bismuth triflate (Bi(OTf)3), m-CPBA, DMAP, acetic 
anhydride, ethyl formate, sodium methoxide (NaOMe), THF, dioxane, nitromethane, 
DMF, benzene, cobalt acetate, tert-butyl hydroperoxide, CDI, CBMI and CDT were 
purchased from Sigma Aldrich Co. The solvents used in the workups were purchase from 
VWR Portugal, and were of analytical grade. Potassium bicarbonate, sodium chloride, 
sodium bicarbonate, and sodium sulfite were purchased from Merck Co. All the solvents 
used in the reactions were previously purified and dried according to the literature 
procedures. 
 
3-Oxoolean-12-en-28-oic acid (3.2): 3.2 was prepared according to the literature,
241
 
from 3.1 (1 g 2.2 mmol) to give a solid (98%). mp 169.5-171.5 ºC. IR (film CHCl3): 
2945.7, 1697.1, 1460.8, 1385.6, 1276.7, 1217.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.29 
(1H s H12), 2.84 (1H dd J=11.37 H18), 2.54 (1H m J=33.61 H2), 2.37 (1H m J=15.30 
H2), 1.13 (3H s), 1.07 (3H s), 1.04 (6H d J=6.93), 0.92 (6H d J=9.91), 0.79 (3H s).
 13
C 
NMR (100 MHz CDCl3): δ 217.71 (C3), 184.28 (C28), 143.61 (C13), 122.35 (C12). EI-
MS m/z: 455.16 (5) M
+
, 410.23 (8), 248.06 (80), 203.19 (100), 190.21 (28), 175.23 (12), 
133.19 (68), 105.20 (14), 91.13 (20), 77.10 (12).  
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3β-Acetoxy-olean-12-en-28-oic acid (3.3): Preparation of 3.3 was made according 
to a previously described method,
183
 from 3.1 (100 mg 0.22 mmol), providing a solid 
(86%). mp 254.2-257.8 ºC. IR (film CHCl3): 2945.7, 1733.7, 1695.1, 1462.7, 1366.3, 
1244.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.26 (1H t J=6.88 H12), 4.49 (1H m J=15.91 
H3); 2.81 (1H dd J=17.64 H18), 2.04 (3H s OCOCH3), 1.12 (3H s), 0.99 (3H s), 0.92 (3H 
s), 0.90 (3H s), 0.86 (3H s), 0.84 (3H s), 0.74 (3H s). 
13
C NMR (100 MHz CDCl3): δ 
184.29 (C28), 171.03 (OCOCH3), 143.58 (C13), 122.52 (C12), 80.90 (C3). EI-MS m/z: 
498.28 (1) M
+
, 439.22 (6), 394.22 (5), 351.26 (3), 248.11 (64), 203.07 (100), 189.12 (22), 
175.08 (14), 133.10 (54), 91.05 (27), 79.10 (18), 67.09 (10).  
 
Methyl 3β-hydroxy-olean-12-en-28-oate (3.4): 3.4 was prepared according to the 
literature
429, 434
 from 3.1(100 mg 0.22 mmol) to give a solid (89%). mp 167.0-168.0 ºC. 
IR (film CHCl3): 3431.7, 2945.7, 1723.1, 1646.00, 1384.6, 1219.8 cm
-1
.
 1
H NMR (400 
MHz CDCl3): δ 5.27 (1H t J=7.31 H12), 3.61 (3H s COCH3), 3.20 (1H m J=15.97 H3), 
2.85 (1H dd J=18.90 H18), 1.12 (3H s), 0.97 (3H s), 0.91 (3H s), 0.89 (3H s), 0.88 (3H s), 
0.77 (3H s), 0.71 (3H s). 
13
C NMR (100 MHz CDCl3): δ 178.25 (C28), 143.74 (C13), 
122.32 (C12), 78.99 (C3). EI-MS m/z: 470.11 (6) M
+
, 453.16 (17), 411.24 (6), 377.27 
(3), 262.09 (66), 203.24 (100), 189.30 (21), 173.28 (10), 133.26 (32), 119.25 (12), 79.25 
(8). 
 
3β,12α-Dihydroxyolean-28,13β-olide (3.5): To a stirred solution of 3.1 (2 g 4.38 
mmol) in chloroform (30 mL) was added m-CPBA 77% (1.96 g 8.76 mmol) at room 
temperature. After 24 hours the reaction was evaporated to dryness, the residue was 
dissolved in ether (100 mL), the resulting mixture was washed with sodium sulphite (200 
mL) over 16 hours. The aqueous solution was extracted with ethyl acetate (3×100 mL). 
The combined extracts were washed with HCl 10% (100 mL), NaHCO3 sat (3×100 mL), 
and water (3×100 mL), dried over Na2SO4, filtered and evaporated to the dryness, and 
crystallized from acetonitrile, to afford 3.5 (94%).
483
 mp > 300.0 
o
C. IR (film CHCl3): 
3447.1, 2944.8, 1752.0, 1694.2, 1466.6, 1387.5, 1362.5, 1251.6, 1219.8 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 3.88 (1H t J=5.78 H12), 3.22 (1H m J=16.28 H3), 1.30 (3H s), 1.14 
(3H s), 0.98 (3H s), 0.98 (3H s), 0.89 (3H s), 0.87 (3H s), 0.77 (3H s).
 13
C NMR (100 
MHz CDCl3): δ 179.95 (C28), 90.60 (C13), 78.83 (C3), 76.32 (C12), 55.17, 51.10, 44.69, 
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44.55, 42.27, 42.03, 39.37, 38.88, 38.80, 36.42, 34.11, 33.94, 33.24, 31.54, 28.75, 28.01, 
27.97, 27.45, 27.20, 23.87, 21.18, 18.60, 18.51, 17.72, 16.27, 15.34. EI-MS m/z: 472.96 
(26) M
+
, 456.98 (28), 411.10 (76), 300.08 (41), 264.07 (31), 234.16 (22), 218.21 (81), 
189.24 (100), 177.29 (46), 147.17 (42), 119.12 (41), 107.13 (33), 105.13 (27), 93.13 (24), 
79.17 (19). 
 
3-Oxo-12α-hydroxyolean-28,13β-olide (3.6): To a stirred solution of 3.2 (150 mg 
0.33 mmol) in chloroform (2.5 mL), at room temperature, was added m-CPBA 77% 
(110.94 mg 0.495mmol). The workup was performed according to the same method as 
for 3.5 after 24 hours, to afford 3.6 (91%). mp 283.0-285.0 ºC. IR (film CHCl3): 3464.5, 
2950.6, 1751.1, 1701.9, 1458.9, 1386.6, 1359.6, 1218.8 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 3.89 (1H s H12), 1.31 (3H s), 1.17 (3H s), 1.08 (3H s), 1.03 (3H s), 0.97 (6H 
s), 0.89 (3H s). 
13
C NMR (100 MHz CDCl3): δ 217.79 (C3), 179.90 (C28), 90.61 (C13), 
76.05 (C12), 54.72, 51.11, 47.31, 44.66, 43.74, 42.10 (2C), 39.53, 39.38, 36.13, 34.06, 
33.96, 33.29, 33.22, 31.55, 29.09, 27.94, 27.39, 26.62, 23.83, 21.12, 21.01, 19.03, 18.36, 
18.16, 16.23. EI-MS m/z: 470.73 (70) M
+
, 452.77 (14), 424.93 (40), 408.92 (24), 234.07 
(38), 205.11 (100), 187.29 (65), 147.40 (39), 119.44 (46), 105.36 (46), 91.35 (49), 79.30 
(33). 
 
3β-Hydroxy-12-oxoolean-28-oic acid (3.7): To a stirred solution of 3.5 (3.0271 g 
6.4 mmol) at 40ºC in dichloromethane (40 mL), was added Bi(TfO)3 (41.99 mg 0.064 
mmol). After 3 hours the reaction mixture was evaporated to the dryness, and the 
resulting was diluted into water (100 mL), which was extracted with ethyl acetate (3×100 
mL). The organic phase was washed with NaHCO3 (3×100 mL) and H2O (3×100 mL), 
dried over Na2SO4, filtered and evaporated to the dryness, to afford 3.7 (96%).
483
 mp 
302.0-304.0 ºC. IR (film CHCl3): 3465.5, 2942.8, 1693.2, 1469.5, 1386.6, 1367.3, 1233.3 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 3.20 (1H dd J=15.57 H3), 2.76 (1H d J=13.35), 2.68 
(1H d J=3.77), 0.99 (6H), 0.98 (3H), 0.95 (3H), 0.91 (3H), 0.86 (3H), 0.77 (3H). 
13
C 
NMR (100 MHz CDCl3): δ 211.54 (C12), 183.64 (C28), 78.65 (C3), 55.05, 51.82, 49.73, 
47.17, 41.89, 41.27, 38.80, 38.50, 37.91, 36.96, 36.09, 34.42, 33.33, 33.04, 31.85, 31.79, 
30.61, 27.94, 27.57, 27.02, 23.10, 22.58, 20.48, 18.26, 16.41, 15.29, 15.20. EI-MS m/z: 
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471.94 (100) M
-
, 451.86 (24), 358.30 (22), 212.42 (21), 198.29 (14), 130.05 (22), 103.48 
(21), 94.11 (21), 79.97 (20), 71.62 (11), 70.44 (16), 61.40 (15). 
 
3β-Acetoxy-12-oxoolean-28-oic acid (3.8): Preparation of 3.8 was made according 
to previously described method,
183
 from 3.7 (1.5 g 3.17 mmol), providing a solid (98%). 
mp 338.0-340.0 ºC. IR (film CHCl3): 2945.7, 2866.7, 1812.8, 1729.8, 1695.1, 1469.5, 
1367.3, 1246.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 4.47 (1H dd J=15.33 H3), 2.03 (3H s 
OCOCH3), 0.98 (3H s), 0.97 (3H s), 0.94 (3H s), 0.94 (3H s), 0.90 (3H s), 0.88 (3H s), 
0.86 (3H s), 0.85 (3H s). 
13
C NMR (100 MHz CDCl3): δ 211.33 (C12), 184.01 (C28), 
170.91 (OCOCH3), 80.39 (C3), 55.10, 51.81, 49.57, 47.17, 41.80, 41.25, 38.43, 37.72, 
37.58, 36.85, 36.04, 34.39, 33.31, 33.02, 31.80, 31.70, 30.59, 27.87, 27.52, 23.36, 23.08, 
22.53, 21.22, 20.45, 18.14, 16.39, 15.24. EI-MS m/z: 515.38 (8) M
+
, 499.35 (33), 454.42 
(41), 453.47 (100), 264.31 (38), 219.44 (23), 218.41 (67), 203.4 (26), 190.5 (30), 189.47 
(49), 177.46 (32), 176.37 (22), 175.33 (29). 
 
3,12-Dioxoolean-12-en-28-oic acid (3.9): 3.9 was prepared according to the 
literature,
241
 from 3.7 (1.5 g 3.17 mmol) to give a solid (94%). mp 276.0-278.0 ºC. IR 
(film CHCl3): 2943.8, 2866.7, 1697.1, 1468.5, 1385.6, 1329.7 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 1.09 (3H s), 1.03 (6H s), 0.98 (6H s), 0.96 (3H s), 0.91 (3H s).
 13
C NMR (100 
MHz CDCl3): δ 216.75 (C3), 210.82 (C12), 183.61 (C28), 54.84, 51.85, 49.12, 47.36, 
47.14, 42.02, 41.24, 38.56 (2C), 36.65, 36.09, 34.40, 33.81, 33.30, 33.02, 31.83, 31.15, 
30.61, 27.58, 26.29, 23.08, 22.58, 21.14, 20.40, 19.52, 16.06, 14.86. EI-MS m/z: 470.31 
(9) M
+
, 456.3 (13), 455.33 (40), 410.44 (30), 409.51 (100), 264.35 (14), 218.4 (22), 205.4 
(15), 203.44 (9).  
 
Methyl 3β-hydroxy-12-oxoolean-28-oate (3.10): 3.10 was prepared according to 
the literature
429, 434
 from 3.7 (1.5 g 3.17 mmol) to give a solid (93%). mp 188.1-191.4 ºC. 
IR (film CHCl3): 3511.7, 2944.8, 2866.7, 1721.2, 1698.0, 1468.5, 1386.6, 1365.4, 1304.6, 
1240.0 cm
-1
.
 1
H NMR (400 MHz CDCl3): δ 3.67 (3H s COCH3), 3.19 (1H dd J=15.78 
H3), 2.78 (1H dt J=13.52), 2.61 (1H d J=3.96), 0.98 (3H s), 0.97 (3H s), 0.96 (3H s), 0.93 
(3H s), 0.89 (3H s), 0.84 (3H s), 0.78 (3H s). 
13
C NMR (100 MHz CDCl3): δ 211.78 
(C12), 178.37 (C28), 78.62 (C3), 55.08, 51.81, 51.77, 49.75, 47.34, 41.89, 41.23, 38.79, 
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38.51, 37.93, 36.92, 36.19, 34.46, 33.36, 32.94, 31.98, 31.80, 30.62, 27.94, 27.56, 27.05, 
23.14, 22.73, 20.54, 18.28, 16.10, 15.32, 15.18. EI-MS m/z: 487.35 (13) M
+
, 472.47 (32), 
471.48 (100), 412.70 (28), 411.68 (85), 279.63 (13), 278.39 (42), 219.66 (17), 218.5 (49), 
203.41 (16). 
 
Methyl 3-oxoolean-12-en-28-oate (3.11): 3.11 was prepared according to the 
literature,
241
 from 3.4 (600 mg 1.3 mmol) to give a solid (96%). mp 171.8-174.4 ºC. IR 
(film CHCl3): 2946.7, 1726.9, 1704.8, 1458.9, 1434.8, 1384.6, 1363.4, 1261.2 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 5.30 (1H s H12), 3.62 (3H s COCH3), 2.87 (1H dd J=17.19 
H18), 2.54 (1H m J=34.26), 2.34 (1H m J=25.88), 1.13 (3H s), 1.08 (3H s), 1.04 (6H s), 
0.92 (3H s), 0.89 (3H s), 0.77 (3H s). 
13
C NMR (100 MHz CDCl3): δ 217.67 (C3), 178.22 
(C28), 143.86 (C13), 122.12 (C12). EI-MS m/z: 469.12 (96) M
+
, 451.23 (33), 262.17 
(40), 248.21 (32), 203.32 (100), 189.33 (56), 187.35 (22), 133.26 (59), 119.25 (23), 
105.25 (18). 
 
Methyl 2-hydroxymethylene-3-oxoolean-12-en-28-oate (3.12): Preparation of 3.12 
was made according to previously described method,
330, 431
 from 3.11 (500 mg 1.1 
mmol), providing a solid (92%). mp 199.1-201.2 ºC. IR (film CHCl3): 2947.7, 1866.7, 
1726.0, 1634.4, 1585.2, 1456.0, 1386.6, 1362.5, 1256.4, 1231.3 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 14.09 (1H C2CHOH), 8.57 (1H C2CHOH), 5.33 (1H), 3.63 (3H), 2.89 (1H dd 
J=16.70), 2.27 (1H d J=14.36), 1.18 (3H s), 1.14 (3H s), 1.11 (3H s), 0.93 (3H s), 0.90 
(6H s), 0.78 (3H s).
 13
C NMR (100 MHz CDCl3): δ 190.80 (C3), 188.24 (C2CHOH), 
178.21 (C28), 143.79 (C13), 122.15 (C12), 105.73 (C2). EI-MS m/z: 496.01 (17) M
-
, 
471.95 (44), 423.35 (39), 400.67 (27), 384.14 (63), 354.76 (20), 329.69 (33), 306.67 (33), 
248.68 (100), 215.26 (18), 194.22 (35), 63.86 (22), 61.06 (19).  
 
Methyl 2α-hydroxy-3-oxoolean-12-en-28-oate (3.13): 3.13 was prepared according 
to the literature
328, 489
 from 3.11 (100 mg 0.213 mmol) to give a solid (90%). mp 116.8-
123.0 ºC. IR (film CHCl3): 3485.7, 2947.7, 1726.0, 1703.8, 1459.9, 1434.8, 1386.6, 
1363.4, 1261.2 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.28 (1H s H12), 4.53 (1H m 
J=18.93 H2), 3.62 (3H s COCH3), 2.86 (1H dd J=11.16 H18), 1.25 (3H s), 1.15 (3H s), 
1.10 (3H s), 1.09 (3H s), 0.91 (3H s), 0.88 (3H s), 0.77 (3H s). 
13
C NMR (100 MHz 
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CDCl3): δ 216.58 (C3), 178.21 (C28), 143.92 (C13), 121.84 (C12), 69.15 (C2). EI-MS 
m/z: 484.86 (60) M
+
, 468.98 (22), 425.09 (16), 262.16 (35), 249.16 (17), 218.19 (13), 
203.20 (100), 189.18 (54), 173.17 (19), 133.08 (55), 119.02 (19), 105.03 (14), 91.03 (11). 
 
3β-Acetoxy-11-oxoolean-12-en-28-oic acid (3.14): To a stirred solution of 3.3 (1 g 
2 mmol) in a mixture of acetonitrile (10 mL) and ethyl acetate (5 mL) at 77 ºC, was 
added t-butyl hydroperoxide (0.0675 mmol 7.5 mL) and the catalyst cobalt acetate tetra 
hydrate (0.72 mmol 179.208 mg). After 77 hours was added to the reaction mixture an 
aqueous solution containing Na2SO3 (200 mL), and the resulting mixture was stirred 18.5 
hours. The mixture was extracted with ethyl acetate (3×100 mL). The combined extracts 
were washed with HCl 10% (2×100 mL) and water (3×100 mL), dried over Na2SO4, 
filtered, and concentrated to afford an oil. The residue was subjected to flash column 
chromatography [hexanes-ethyl acetate from (70:30) to (40:60)] to afford 3.14 (36%). mp 
275.0-277.4 ºC. IR (film CHCl3): 2947.7, 1730.8, 1699.9, 1655.6, 1460.8, 1388.5, 
1364.4, 1245.8, 1219.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.61 (1H s H12), 4.51 (1H 
dd J=15.85 H3), 2.97 (1H d J=11.52 H18), 2.83 (1H d J=13.60), 2.03 (3H s COCH3), 
1.34 (3H s), 1.11 (3H s), 0.94 (3H s), 0.92 (3H s), 0.89 (3H s), 0.86 (6H s). 
13
C NMR 
(100 MHz CDCl3): δ 200.29 (C11), 182.85, 171.02, 168.49, 127.96, 80.57, 61.61, 55.00, 
45.00, 44.04, 43.58, 43.38, 41.33, 38.70, 37.99, 37.10, 33.59, 32.79, 32.75, 31.56, 30.61, 
28.02, 27.68, 23.53, 23.49, 23.35, 22.56, 21.25, 19.16, 17.18, 16.61, 16.24. EI-MS m/z: 
512.73 (40) M+, 302.68 (46), 261.73 (100), 256.87 (86), 216.91 (56), 188.93 (55), 174.93 
(49), 118.89 (25), 104.92 (14), 80.90 (8). 
 
3β-(1H-Imidazol-1-carbonyloxy)-olean-12-en-28-oic acid (3.15) and 28-(1H-
Imidazol-1-yl)-28-oxoolean-12-en-3β-yl-1H-imidazole-1-carboxylate (3.16): To a 
stirred solution of 3.1 (1 g 2.2 mmol) in THF (10 mL), under N2 atmosphere, at 70ºC, was 
added CDI (356.73 mg 2.2 mmol). After 41 hours the reaction mixture was diluted with 
water (60 mL), the aqueous phase was extracted with ethyl acetate (3×50 mL). The 
resulting organic phases were washed with NaCl 10% (3×50 mL), dried over Na2SO4, 
filtered and evaporated to the dryness, to afford a yellow residue. The residue was 
subjected to flash column chromatography [hexanes-ethyl acetate from (90:10) to 
(20:80)], to afford 3.16 (29%) and 3.15 (17%). 3.15: mp 216.2-218.3 ºC. IR (film 
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CHCl3): 3140.5, 2946.7, 1760.7, 1697.1, 1471.4, 1387.5, 1288.2, 1239.0 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): 8.72 (1H s Himidazole), 7.44 (1H s Himidazole), 7.13 (1H s 
Himidazole), 5.28 (1H s H12), 4.72 (1H dd J=15.57 H3), 2.84 (1H dd J=10.46 H18), 1.14 
(3H s), 0.97 (9H s), 0.93 (3H s), 0.90 (3H s), 0.77 (3H s). 
13
C NMR (100 MHz CDCl3): δ 
183.24 (C28), 148.09 (OCO), 143.80 (C13), 136.82, 129.17, 122.21 (C12), 117.28, 86.94 
(C3), 55.22 (C5), 47.54 (C9), 46.46, 45.87 (C19), 41.60 (C14), 40.96 (C18), 39.27 (C8), 
38.11 (C4), 37.91, 36.94, 33.80, 33.05, 32.47, 32.41, 30.66, 28.17, 27.67, 25.89 (C27), 
23.57, 23.41, 23.37, 22.89, 18.13, 17.05 (C26), 16.84, 15.34. EI-MS m/z: 549.84 (1) M
-
, 
302.80 (6), 247.98 (55), 202.97 (97), 190.01 (31), 175.04 (18), 133.02 (60), 105.08 (32), 
68.96 (100). 3.16: mp 237.4-241.8 ºC. IR (film CHCl3): 3134.7, 2950.6, 1757.8, 1721.2 
1525.4, 1469.5, 1388.5, 1364.4, 1319.1, 1281.5, 1240.0, 1204.3 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.36 (1H s Himidazole), 8.14 (1H s Himidazole), 7.57 (1H s Himidazole), 7.41 
(1H s Himidazole), 7.07 (2H s Himidzole), 5.36 (1H s H12), 4.69 (1H dd J=16.21 H3), 
3.06 (1H dd J=11.36), 1.17 (3H s), 0.95 (15H s), 0.69 (3H s). 
13
C NMR (100 MHz 
CDCl3): δ 174.55, 148.47, 142.69, 136.96, 130.37, 129.26, 123.01 (2C), 117.54, 117.06, 
86.30, 55.26, 49.89, 47.49, 45.82, 42.54, 41.84, 39.21, 38.08, 37.99, 36.88, 33.87, 32.82, 
32.44, 31.31, 30.39, 28.13, 27.61, 25.81, 23.79, 23.48, 23.40 (2C), 18.05, 16.82, 16.69, 
15.37. EI-MS m/z: 600.86 (4) M
+
, 488.93 (16), 393.12 (11), 298.01 (12), 255.13 (9), 
203.18 (22), 187.22 (14), 173.21 (9), 91.20 (8), 69.35 (100).  
 
3-Oxoolean-12-en-28-yl-1H-imidazole-1-carboxylate (3.17): To a stirred solution 
of 3.2 (500 mg 1.1 mmol) in THF (10 mL), under N2 atmosphere, at 70ºC, was added 
CDI (356.73 mg 2.2 mmol). The workup was performed according to the same method as 
for 3.15 after 25.5 hours. The solid was subjected to flash column chromatography 
[hexanes-ethyl acetate from (70:30) to (40:60)], to afford 3.17 (71%). mp 129.6-132.9 ºC. 
IR (film CHCl3): 2947.7, 1716.3, 1702.8, 1462.7, 1388.5, 1363.4, 1268.0, 1226.5, 1205.3 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.28 (1H s Himidazole), 7.55 (1H s Himidazole), 
7.05 (1H d J=0.93 Himidazole), 5.37 (1H t J=7.07 H12), 3.06 (1H dd J=16.90 H18), 2.32 
(1H m J=34.43 C2), 1.16 (3H s C27), 1.06 (3H s C23 or C24), 1.03 (3H s C26), 1.02 (3H 
s C23 ou C24), 0.96 (3H C29 or C30), 0.95 (3H s C29 or C30), 0.72 (3H s C25). 
13
C 
NMR (100 MHz CDCl3): δ 217.50 (C3), 174.64 (C28), 142.71 (C13), 137.01 
(Cimidazole), 129.66 (Cimidazole), 122.95 (C12), 117.44 (Cimidazole), 55.34 (C5), 
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49.83 (C17), 47.41 (C4), 46.82 (C9), 45.79 (C19), 42.59 (C18), 41.92 (C14), 39.16 (C8), 
39.13 (C1), 36.71 (C10), 34.10 (C2), 33.86, 32.81 (C29 or C30), 32.08, 31.55 (C6), 
31.27, 30.37 (C20), 27.60 (C15), 26.32 (C23 or C24), 25.72 (C27), 23.76 (C29 or C30), 
23.47 (C11), 21.42 (C23 or C24), 19.42, 16.59 (C26), 14.98 (C25). EI-MS m/z: 505.09 
(40) M
+
, 409.22 (69), 298.12 (21), 203.18 (87), 190.20 (30), 163.23 (22), 133.22 (33), 
119.22 (36), 105.20 (39), 91.21 (47), 69.17 (100).  
3β-Acetoxy-olean-12-en-28-yl-1H-imidazole-1-carboxylate (3.18): To a stirred 
solution of 3.3 (200 mg 0.4 mmol) in THF (4 mL), under N2 atmosphere, at 70ºC, was 
added CDI (129.72 mg 0.8 mmol). The workup was performed according to the same 
method as for 3.15 after 26 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (60:40)], to afford 3.18 (89%). 
mp 122.8-127.3 ºC. IR (film CHCl3): 2949.6, 1728.9, 1467.6, 1363.4, 1243.9, 1222.7, 
1202.4 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.34 (1H s Himidazole), 7.56 (1H s 
Himidazole), 7.06 (1H s Himidazole), 5.34 (1H t J=7.16 H12), 4.47 (1H dd J=15.94 H3), 
3.04 (1H dd J=18.42 H18), 2.03 (3H s OCOCH3), 1.14 (3H s C27), 0.95 (3H s C29 or 
C30), 0.94 (3H s C29 or C30), 0.91 (3H C25), 0.83 (3H s C23 or C24), 0.83 (3H s C23 or 
C24), 0.66 (3H s C26). 
13
C NMR (100 MHz CDCl3): δ 174.55 (C28), 170.97 (OCOCH3), 
142.58 (C13), 136.962 (Cimidazole), 129.22 (Cimidazole), 123.13 (C12), 117.53 
(Cimidazole), 80.79 (C3), 55.26 (C5), 49.86 (C17), 47.46 (C9), 45.76 (C19), 42.51 (C18), 
41.78 (C14), 39.17 (C8), 38.09 (C1), 37.63 (C4), 36.86 (C10), 33.84, 32.80 (C29 or C30), 
32.47, 31.54, 31.28, 30.36 (C20), 27.95 (C23 or 24), 27.57, 25.76 (C27), 23.76 (C29 or 
C30), 23.45, 23.37, 21.26 (C32), 18.05, 16.66 (C26), 16.60 (C23 or C24), 15.37 (C25). 
EI-MS m/z: 549.09 (7) M
+
, 453.19 (7), 393.23 (9), 298.09 (11), 215.16 (7), 203.11 (41), 
189.12 (30), 147.11 (19), 119.09 (33), 105.08 (40), 91.06 (47), 69.02 (100).  
 
Methyl 3β-(1H-imidazole-1-carbonyloxy)-olean-12-en-28-oate (3.19): To a stirred 
solution of 3.4 (300 mg 0.64 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, was 
added CDI (207.55 mg 1.28 mmol). The workup was performed according to the same 
method as for 3.15 after 22 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (55:45)], to afford 3.19 (82%). 
mp 220.2-221.1 ºC. IR (film CHCl3): 2947.7, 1757.8, 1726.0, 1468.5, 1388.5, 1319.1, 
1288.2, 1240.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.22 (1H s Himidazole), 7.43 (1H s 
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Himidazole), 7.11 (1H d J=0.79 Himidazol), 5.28 (1H t J=6.97 H12), 4.70 (1H dd 
J=16.54 H3), 3.61 (3H s COOCH3), 2.86 (1H dd J=17.87 H18), 1.13 (3H s), 0.96 (6H s), 
0.95 (3H s), 0.92 (3H s), 0.89 (3H s), 0.73 (3H s). 
13
C NMR (100 MHz CDCl3): δ 178.18 
(C28), 148.10 (OCO), 143.85 (C13), 136.68 (Cimidazole), 129.37 (Cimidazole), 122.03 
(C12), 117.23 (Cimidazole), 86.88 (C3), 55.21 (C5), 51.49 (COOCH3), 47.51 (C9), 46.65 
(C17), 45.81 (C19), 41.60 (C14), 41.23 (C18), 39.24 (C8), 38.08 (C4), 37.91, 36.87 
(C10), 33.80 (C21), 33.06 (C29 or C30), 32.48, 32.31, 30.65 (C20), 28.15 (C23 or C24 or 
C26), 27.64, 25.87 (C27), 23.59 (C29 or C30), 23.39 (C11), 23.36 (C2), 22.99 (C22), 
18.13, 16.83 (C23 or C24 or C26), 16.78 (C26), 15.29 (C23 or C24 or C25). EI-MS m/z: 
565.02 (5) M
+
, 452.18 (6), 393.23, 262.06 (13), 248.05 (5), 203.09 (60), 189.12 (28), 
173.15 (12), 133.12 (50), 91.09 (26), 69.05 (100).  
 
3β-(1H-Imidazole-1-carbonyloxy)-12α-hydrxyolean-28,13β-olide (3.20): To a 
stirred solution of 3.5 (500 mg 1.06 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, 
was added CDI (343.76 mg 2.12 mmol). The workup was performed according to the 
same method as for 3.15 after 6 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (60:40) to (0:100)], to afford 3.20 (13%). 
mp 278.6-280.6 ºC. IR (film CHCl3): 3480.9, 3133.8, 2951.5, 2872.5, 1759.7, 1470.5, 
1388.5, 1319.1, 1288.2, 1241.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.12 (1H s 
Himidazole), 7.40 (1H s Himidazole), 7.06 (1H s Himidazole), 4.70 (1H dd J=16.33), 
3.90 (1H s), 1.32 (3H s), 1.16 (3H s), 0.98 (6H s), 0.96 (3H s), 0.94 (3H s), 0.89 (3H s). 
13
C NMR (100 MHz CDCl3): δ 179.93, 148.48, 136.98, 130.48, 117.03, 90.59, 86.10, 
55.18, 51.08, 44.67, 44.44, 42.26, 42.07, 39.33, 38.28, 38.20, 36.33, 34.10, 33.81, 33.23, 
31.54, 28.83, 28.04, 27.97, 27.44, 23.85, 23.44, 21.15, 18.54 (3C), 17.56, 16.64, 16.33. 
EI-MS m/z: 566.26 (40) M
-
, 476.92 (12), 391.22 (100).  
 
3β,12α-Di-(1H-imidazole-1-carbonyloxy)-olean-28,13β-olide (3.21): To a stirred 
solution of 3.5 (500 mg 1.06 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, was 
added CDI (687.52 mg 4.24 mmol). The workup was performed according to the same 
method as for 3.15 after 24 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (60:40) to (15:85)], to afford 3.21 (56%). 
mp 166.9-173.4 ºC. IR (film CHCl3): 3401.8, 3128.0, 2951.5, 2878.2, 1758.8, 1470.5, 
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1390.4, 1317.1, 1289.2, 1240.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.11 (1H s 
Himidazole), 8.05 (1H s Himidazole), 7.74 (1H s Himidazole), 7.34 (1H s Himidazole), 
7.12 (1H s Himidazole), 7.00 (1H s Himidazole), 5.23 (1H s H12), 4.63 (1H dd J=16.03 
H3), 1.30 (3H s), 1.17 (3H s), 0.93 (3H s), 0.91 (3H s), 0.90 (3H s), 0.78 (3H s), 0.70 (3H 
s). 
13
C NMR (100 MHz CDCl3): δ 178.17 (C28), 148.190 (C3OCO), 147.45 (C12OCO), 
136.77 (2C Cimidazole), 131.20 (Cimidazole), 130.26 (Cimidazole), 116.86 
(Cimidazole), 116.75 (Cimidazole), 88.49 (C13), 85.37 (C3), 80.87 (C12), 54.93 (C5), 
49.86 (C18), 45.22 (C9), 44.32 (C17), 42.01 (C8), 41.93 (C14), 39.16 (C19), 38.244, 
38.02 (C4), 36.19 (C10), 33.56 (C7), 33.47, 32.92 (C29 or C30), 31.31 (C20), 27.82 (C23 
or C24 or C25), 27.66 (C15), 27.04, 25.09, 23.39 (C29 or C30), 23.10, 20.77, 18.40 
(C27), 18.21 (C26), 17.27, 16.48 (C23 or C24 or C25), 15.94 (C23 or C24 or C25). EI-
MS m/z: 660.43 (5) M
+
, 436.39 (65), 391.44 (43), 255.32 (40), 202.27 (43), 201.31 (63), 
199.28 (40), 189.3 (100), 188.28 (44), 187.33 (85), 175.38 (41), 173.36 (57), 133.33 (41), 
119.31 (50), 107.23 (40).  
 
3-Oxo-12α-(1H-imidazole-1-carbonyloxy)-olean-28,13β-olide (3.22): To a stirred 
solution of 3.6 (300 mg 0.64 mmol) in THF (4 mL), under N2 atmosphere, at 70ºC, was 
added CDI (207.55 mg 1.28 mmol). The workup was performed according to the same 
method as for 3.15 after 6.5 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (40:60)], to afford 3.22 (33 %). 
mp 263.3-269.3 ºC. IR (film CHCl3): 3128.0, 2951.5, 1776.1, 1765.5, 1702.8, 1467.6, 
1390.4, 1315.2, 1289.2, 1240.0, 1218.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.12 (1H s 
Himidazole), 7.40 (1H s Himidazole), 7.13 (1H s Himidazole), 5.26 (1H s H12), 1.33 (3H 
s C27), 1.23 (3H s C26), 1.08 (3H s C23 or C24), 1.02 (3H s C23 or C24), 0.96 (3H s 
C25), 0.82 (3H s C29 or C30), 0.74 (3H s C29 or C30). 
13
C NMR (100 MHz CDCl3): δ 
216.84 (C3), 178.29 (C28), 147.51 (OCO), 136.80 (Cimidazole), 131.33 (Cimidazole), 
116.86 (Cimidazole), 88.66 (C13), 80.95 (C12), 54.53 (C5), 50.10 (C18), 47.15 (C4), 
44.71 (C9), 44.45 (C17), 42.12 (C8), 41.98 (C14), 39.54 (C19), 39.34 (C1), 36.10 (C10), 
33.64 (C2), 33.58 (C21), 33.16 (C7), 31.44 (C20), 27.79 (C15), 27.14, 26.64 (C23 or 
C24), 25.51 (C11), 23.47 (C29 or C30), 20.95 (C23 or C24), 20.89, 18.88, 18.38 (C27), 
17.96 (C26), 15.95 (C25). EI-MS m/z: 564.75 (50) M
+
, 539.52 (37), 457.99 (28), 424.40 
(100), 314.97 (33), 272.54 (47), 146.17 (12).  
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28-(1H-Imidazol-1-yl)-12,28-dioxoolean-3β-yl-1H-imidazole-1-carboxylate 
(3.23): To a stirred solution of 3.7 (300 mg 0.63 mmol) in THF (6 mL), under N2 
atmosphere, at 70ºC, was added CDI (616.2 mg 3.8 mmol). The workup was performed 
according to the same method as for 3.15 after 19 hours. The solid was subjected to flash 
column chromatography [hexanes-ethyl acetate from (60:40) to (10:90)], to afford 3.23 
(97%). mp 165.4-166.2 ºC. IR (film CHCl3): 3132.8, 2950.6, 2866.7, 1757.8, 1699.9, 
1526.4, 1470.5, 1389.5, 1319.1, 1289.2, 1240.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 
88.30 (1H s), 8.11 (1H s), 7.59 (1H s), 7.39 (1H s), 7.06 (2H s), 4.66 (1H dd J=11.28), 
2.96 (1H dd J=12.45), 2.86 (1H s), 1.02 (3H s), 0.98 (3H s), 0.96 (9H s), 0.94 (3H s), 0.91 
(3H s). 
13
C NMR (100 MHz CDCl3): δ 210.46, 175.42, 148.44, 137.25, 136.96, 130.59, 
130.11, 117.51, 117.00, 85.64, 55.08, 50.91, 50.11, 49.67, 42.09, 41.29, 38.40, 38.13, 
37.49, 36.80, 36.04, 34.26, 33.03, 32.09, 31.60, 30.32, 29.25, 27.99, 27.64, 23.72, 23.63, 
23.27, 20.44, 18.04, 16.59, 16.14, 15.22. EI-MS m/z: 617.34 (4) M
+
, 521.44 (72), 409.45 
(76), 205.37 (100), 189.43 (75).  
 
3β-Acetoxy-12-oxoolean-28-yl-1H-imidazole-1-carboxylate (3.24): To a stirred 
solution of 3.8 (300 mg 0.58 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, was 
added CDI (188.1 mg 1.16 mmol). The workup was performed according to the same 
method as for 3.15 after 7 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (65:35) to (50:50)], to afford 3.24 (42%). 
mp 181.4-183.8 ºC. IR (film CHCl3): 3139.5, 2947.7, 2872.5, 1717.3, 1468.5, 1366.3, 
1244.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.29 (1H s), 7.57 (1H s), 7.05 (1H s), 4.44 
(1H dd J=15.75), 2.94 (1H dt J=13.08), 2.82 (1H d J=3.67), 2.01 (3H s), 1.00 (3H s), 0.95 
(3H s), 0.94 (3H s), 0.90 (3H s), 0.85 (3H s), 0.83 (6H s). 
13
C NMR (100 MHz CDCl3): δ 
210.72, 175.40, 170.82, 137.20, 129.97, 117.49, 80.29, 55.11, 50.88, 50.09, 49.65, 42.02, 
41.24, 38.36, 37.67, 37.58, 36.77, 35.98, 34.22, 32.99, 32.98, 32.05, 31.61, 30.26, 27.81, 
27.59, 23.68, 23.60, 23.30, 21.18, 20.38, 18.03, 16.36, 16.08, 15.19. EI-MS m/z: 565.24 
(8) M
+
, 469.3 (32), 205.15 (100), 189.19 (68), 187.2 (36), 107.13 (25), 69.07 (36).  
 
3,12-Dioxoolean-28-yl-1H-imidazole-1-carboxylate (3.25): To a stirred solution of 
3.9 (250 mg 0.53 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, was added CDI 
(171.9 mg 1.06 mmol). The workup was performed according to the same method as for 
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3.15 after 4 hours. The solid was subjected to flash column chromatography [hexanes-
ethyl acetate from (60:40) to (45:55)], to afford 3.25 (56%). mp 144.1-149.1 ºC. IR (film 
CHCl3): 3138.6, 2947.7, 2865.7, 1701.9, 1468.5, 1386.6, 1364.4, 1266.0, 1231.3 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 8.31 (1H s), 7.58 (1H s), 7.07 (1H s), 1.06 (3H s), 1.02 (3H 
s), 1.01 (3H s), 0.97 (6H s), 0.96 (3H s), 0.94 (3H s). 
13
C NMR (100 MHz CDCl3): δ 
216.55, 210.29, 175.37, 137.22, 129.98, 117.51, 54.92, 50.90, 50.08, 49.20, 47.35, 42.21, 
41.23, 38.56, 38.52, 36.61, 36.03, 34.23, 33.79, 33.01 (2C), 32.05, 31.07, 30.29, 27.66, 
26.17, 23.71, 23.61, 21.15, 20.32, 19.43, 15.88, 14.80. EI-MS m/z: 521.25 (5) M
+
, 425.3 
(62), 407.34 (51), 205.19 (100), 187.29 (34).  
 
Methyl 3β-(1H-imidazole-1-carbonyloxy)-12-oxoolean-28-oate (3.26): To a stirred 
solution of 3.10 (250 mg 0.514 mmol) in THF (4 mL), under N2 atmosphere, at 70ºC, was 
added CDI (166.69 mg 1.028 mmol). The workup was performed according to the same 
method as for 3.15 after 5.5 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (60:40) to (55:45)], to afford 3.26 (61%). 
mp 233.4-236.3 ºC. IR (film CHCl3): 3133.8, 2947.7, 2863.8, 1757.8, 1721.2, 1698.0, 
1468.5, 1388.5, 1318.1, 1288.2, 1240.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.10 (1H s), 
7.39 (1H s), 7.05 (1H s), 4.66 (1H dd J=16.26 H3), 3.67 (3H s COOCH3), 2.78 (1H dt 
J=13.44 H18), 2.61 (1H d J=3.72), 0.96 (12H s), 0.94 (3H s), 0.91 (3H s), 0.89 (3H s). 
13
C NMR (100 MHz CDCl3): δ 211.24, 178.30, 148.39, 136.92, 130.50, 117.00, 85.72, 
55.04, 51.77 (2C), 49.55, 47.28, 41.82, 41.20, 38.42, 38.10, 37.44, 36.76, 36.14, 34.41, 
33.33, 32.87, 31.92, 31.64, 30.59, 27.99, 27.50, 23.26, 23.10, 22.67, 20.51, 18.08, 16.59, 
16.08, 15.18. EI-MS m/z: 581.02 (8) M
+
, 218.04 (60), 175.07 (72), 119.05 (62), 107.03 
(60), 105.03 (100), 95.03 (75), 93.02 (56), 91.02 (87), 81.02 (60), 79.01 (77).  
 
Methyl 2-(1H-imidazol-1-yl)-methylene-3-oxoolean-12-en-28-oate (3.27): To a 
stirred solution of 3.12 (300 mg 0.60 mmol) in THF (5 mL), under N2 atmosphere, at 
70ºC, was added CDI (194.58 mg 1.2 mmol). The workup was performed according to 
the same method as for 3.15 after 6 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (70:30) to (55:45)], to afford 3.27 (71%). 
mp 217.2-220.0 ºC. IR (film CHCl3): 3116.4, 2948.6, 2866.7, 1725.0, 1686.4, 1607.4, 
1517.7, 1486.9, 1383.7, 1363.4, 1303.6, 1262.2, 1226.5, 1213.0 cm
-1
. 
1
H NMR (400 MHz 
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CDCl3): δ 7.79 (1H s H2’ or H5’), 7.70 (1H s C2CH), 7.22 (1H s H2’ or H5’), 7.15 (1H s 
H4’), 5.34 (1H s H12), 3.62 (3H s COOCH3), 2.88 (2H H18 and H1), 1.18 (3H s C27), 
1.172 (3H s C23 or C24), 1.128 (3H s C23 or C24), 0.935 (3H s C29 or C30), 0.907 (3H s 
C29 or C30), 0.887 (3H s C25), 0.791 (3H s C26). 
13
C NMR (100 MHz CDCl3): δ 206.59 
(C3), 178.15 (C28), 144.02 (C13), 138.47 (C2’ or C5’), 130.658 (C2CH), 130.36 (C4’), 
122.99 (C2), 121.77 (C12), 119.32 (C2’ or C5’), 52.58 (C5), 51.54 (COOCH3), 46.77 
(C17), 45.82 (C19), 45.46 (C9), 45.19 (C4), 43.01 (C1), 41.93 (C14), 41.48 (C18), 39.16 
(C8), 36.07 (C10), 33.86, 33.09 (C29 or C30), 32.28, 31.69 (C7), 30.69 (C20), 29.76 
(C23 or C24), 27.65 (C15), 25.65 (C27), 23.63 (C11), 23.58 (C29 or C30), 23.07, 22.40 
(C23 or C24), 20.29, 16.39 (C26), 15.39 (C25). EI-MS m/z: 547.4 (40) M
+
, 487.45 (51), 
298.24 (48), 285.34 (69), 203.3 (94), 133.3 (100), 69.35 (77).  
 
Methyl 2α-(1H-imidazole-1-carbonyloxy)-3-oxoolean-12-en-28-oate (3.28): To a 
stirred solution of 3.13 (300 mg 0.62 mmol) in THF (4 mL), under N2 atmosphere, at 
70ºC, was added CDI (201.1 mg 1.24 mmol). The workup was performed according to 
the same method has for 3.15 after 4 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (70:30)], to afford 2.28 (26%). 
mp 127.0-128.5 ºC. IR (film CHCl3): 3133.8, 2947.7, 2878.2, 1769.6, 1724.1, 1465.6, 
1394.3, 1318.1, 1290.1, 1240.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.12 (1H s 
Himidazole), 7.40 (1H s Himidazole), 7.04 (1H s Himidazole), 5.70 (1H dd J=19.27 H2), 
5.27 (1H s H12), 3.60 (3H s), 2.85 (1H dd J=17.20 H18), 2.37 (1H dd J=18.22), 1.31 (3H 
s), 1.15 (3H s); 1.12 (3H s), 1.09 (3H s), 0.89 (3H s), 0.87 (3H s), 0.77 (3H s). 
13
C NMR 
(100 MHz CDCl3): δ 207.56 (C3), 178.08 (C28), 147.93 (OCO), 144.14 (C13), 137.12 
(Cimidazole), 130.42 (Cimidazole), 121.34 (C12), 117.13 (Cimidazole), 75.32 (C2), 
56.89 (C5), 51.50 (COOCH3), 48.68 (C4), 47.30 (C9), 46.52 (C17), 45.67 (C19 or C21 or 
C22), 45.07 (C1), 41.63 (C14), 41.11 (C18), 39.29 (C8), 37.99 (C10), 33.69 (C19 or C21 
or C22), 32.99 (C29 or C30), 32.17, 32.11 (C7), 30.59 (C20), 27.52 (C15), 25.81 (C27), 
24.65 (C23 or C24). 23.51 (C29 or C30), 23.48 (C19 or C21 or C22), 22.83, 21.09 (C23 
or C24), 18.95, 16.92 (C26), 15.86 (C25). EI-MS m/z: 578.6 (1) M
-
, 577.99 (100), 247.25 
(30), 136.78 (37), 126.95 (33).  
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3β-Acetoxy-11-oxoolean-12-en-28-yl-1H-imidazole-1-carboxylate (3.29): To a 
stirred solution of 3.14 (145.6 mg 0.284 mmol) in THF (5 mL), under N2 atmosphere, at 
70 ºC, was added CDI (92.1 mg 0.568 mmol). The workup was performed according to 
the same method as for 3.15 after 7 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (60:40) to (20:80)], to afford 3.29 (40%). 
mp 156.6-163.0 
o
C. IR (film CHCl3): 3140.5, 2948.6, 2873.4, 1727.9, 1654.6, 1532.2, 
1465.6, 1390.4, 1365.4, 1327.8, 1305.6, 1248.7, 1209.2 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.29 (1H s Himidazole), 7.55 (1H s Himidazole), 7.05 (1H s Himidazole), 5.69 
(1H s H12), 4.47 (1H dd J=15.74 H3), 3.15 (1H d J=11.90 H18), 2.81 (1H d J=13.54), 
2.02 (3H s OCOCH3), 1.36 (3H s C27), 1.10 (3H s C25), 0.96 (3H s C29 or C23), 0.94 
(3H s C29 or C23), 0.85 (3H s C26), 0.83 (6H s C23 and C24), 0.75 (1H d J=11.40 H5).
 
13
C NMR (100 MHz CDCl3): δ 199.73 (C11), 173.87 (C28), 170.94 (OCOCH3), 167.21 
(C13), 136.91 (Cimidazole), 129.90 (Cimidazole), 128.14 (C12), 117.30 (Cimidazole), 
80.47 (C3), 61.62 (C9), 55.01 (C5), 49.34 (C17), 44.93 (C8), 44.24 (C19), 43.45 (C14), 
42.79 (C18), 38.71 (C1), 37.95 (C4), 37.04 (C10), 33.77, 32.69 (C7), 32.52 (C29 or C30), 
30.39, 30.32 (C20), 27.95 (C23 or C24), 27.59 (C15), 23.45 (2C C29 or C30), 23.30 
(C27), 23.14, 21.23 (OCOCH3), 18.54 (C26), 17.13, 16.57 (C23 or C24), 16.28 (C25). 
EI-MS m/z: 562.28 (28) M
-
, 524.55 (13), 386.82 (13), 298.10 (22), 256.64 (56), 216.63 
(100), 188.63 (77), 174.65 (73), 146.72 (72), 132.62 (33), 104.58 (45), 94.83 (38), 68.80 
(54).  
 
28-(2’Methyl-1H-imidazol-1-yl)-28-oxoolean-12-en-3β-yl-2’methyl-1H-
imidazole-1-carboxylate (3.30): To a stirred solution of 3.1 (500 mg 1.1 mmol) in THF 
(10 mL), under N2 atmosphere, at 70ºC, was added CBMI (627.69 mg 3.3 mmol). After 
94 hours the reaction mixture was diluted with water (60 mL), the aqueous phase was 
extracted with ethyl acetate (3×60 mL). The resulting organic phases were washed with 
NaCl 10% (3×60 mL), dried over Na2SO4, filtered and evaporated to the dryness, to 
afford a yellow residue. The residue was subjected to flash column chromatography 
[hexanes-ethyl acetate from (80:20) to (30:70)], to afford 3.30 (21%). mp 155.7-158.4 ºC. 
IR (film CHCl3): 3165.6, 3120.3, 2949.6, 1752.0, 1718.3, 1509.0, 1467.6, 1393.3, 1372.1, 
1294.0, 1260.3, 1214.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.53 (1H d J=1.58 H4’ or 
H5’), 7.32 (1H d J=1.73 H4’’ or H5’’), 6.88 (1H s H4’ or H5’), 6.84 (1H d J=1.58 H4’’ 
3. Oleanolic acid derivatives 
267 
 
or H5’’), 5.36 (1H t J=6.97 H12), 4.65 (1H dd J=16.32 H3), 3.10 (1H dd J=16.66 H18), 
2.64 (3H s C2’’CH3), 2.569 (3H s C2’CH3), 1.17 (3H s C27), 0.96 (3H s C25), 0.95 (6H s 
C23 or C24), 0.94 (6H s C29 or C30), 0.73 (3H s C26). 
13
C NMR (100 MHz CDCl3): δ 
176.73 (C28), 149.40 (OCO), 149.33 (C2’), 147.84 (C2’’), 142.96 (C13), 127.63 (C4’’ or 
C5’’), 127.19 (C4’ or C5’), 122.92 (C12), 117.97 (C4’’ or C5’’), 117.28 (C4’ or C5’), 
85.89 (C3), 55.26 (C5), 50.77 (C17), 47.44 (C9), 46.10 (C19), 42.55 (C18), 41.89 (C14), 
39.31 (C8), 38.03, 37.97 (C4), 36.87 (C10), 33.86, 32.77 (C30 or C29), 32.44, 31.23, 
30.35 (C30), 28.12, 27.57 (C15), 25.74 (C27), 23.83 (C23 or C24), 23.43, 23.35, 23.00 
(C11), 18.04, 17.78 (C2’CH3), 17.16 (C26), 16.96 (C29 or C30), 16.83 (C2’’CH3), 15.37 
(C25). EI-MS m/z: 629.08 (3) M
+
, 393.21 (4), 269.14 (2), 215.13 (5), 187.12 (12), 127.05 
(13), 119.11 (17), 91.08 (23), 83.09 (100).  
 
3-Oxoolean-12-en-28-yl-2’methyl-1H-imidazole-1-carboxylate (3.31): To a stirred 
solution of 3.2 (150 mg 0.33 mmol) in THF (2 mL), under N2 atmosphere, at 70ºC, was 
added CBMI (125.54 mg 0.66 mmol). The workup was performed according to the same 
method as for 3.30 after 5 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (90:10) to (40:60)], to afford 3.31 (63%). 
mp 131.9-141.4 ºC. IR (film CHCl3): 2948.6, 1703.8, 1546.6, 1510.0, 1461.8, 1384.6, 
1365.4, 1260.3, 1216.9 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.53 (1H d J=1.70 
Himidazole), 6.88 (1H d J=1.63 Himidazole), 5.37 (1H t J=7.01 H12), 3.10 (1H dd 
J=16.50 H18), 2.57 (3H s CH3imidazole), 1.16 (3H s C27), 1.10 (3H s C23 or C24), 1.04 
(3H s C26), 1.02 (3H s C23 or C24), 0.95 (3H s C29 or C30), 0.94 (3H s C29 or C30), 
0.77 (3H s C25). 
13
C NMR (100 MHz CDCl3): δ 217.48 (C3), 176.74 (C28), 149.34 
(C2’), 142.96 (C13), 127.24 (C5’), 122.92 (C12), 117.267 (C4’), 55.32 (C5), 50.78 
(C17), 47.41 (C4), 46.79 (C9), 46.09 (C19), 42.63 (C18), 42.00 (C14), 39.30 (C8), 39.14 
(C15), 36.71 (C10), 34.09 (C2), 33.87 (C6), 32.76 (C29 or C30), 32.09 (C1), 31.21 (C22 
or C16), 30.35 (C20), 27.59, 26.33 (C23 or C24), 25.65 (C27), 23.83 (C29 or C30), 23.45 
(C11), 23.02 (C22 or C16), 21.42 (C23 or C24), 19.42, 17.79 (CH3imidazole), 17.09 
(C26), 15.02 (C25). EI-MS m/z: 519.17(20) M
+
, 409.18 (89), 231.14 (25), 203.18 (70), 
175.10 (42), 145.10 (38), 119.08 (53), 105.14 (61), 95.10 (67), 91.07 (100), 81.13 (57), 
67.11 (67).  
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3β-Acetoxy-olean-12-en-28-yl-2’methyl-1H-imidazole-1-carboxylate (3.32): To a 
stirred solution of 3.3 (500 mg 1.0 mmol) in THF (10 mL), under N2 atmosphere, at 70ºC, 
was added CBMI (324.3 mg 1.7 mmol). The workup was performed according to the 
same method as for 3.30 after 47 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (40:60)], to afford 3.32 (40%). 
mp 256.8-259.4 ºC. IR (film CHCl3): 2948.6, 1729.8, 1468.5, 1384.6, 1365.4, 1243.9 
1218.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.53 (1H s Himidazole), 6.87 (1H s 
Himidazole), 5.35 (1H s H12), 4.47 (1H dd J=15.72 H3), 3.09 (1H dd J=17.32 H18), 2.57 
(3H s OCOCH3), 2.03 (3H s CH3imidazole), 1.15 (3H s C27), 0.95 (3H s C29 or C30), 
0.94 (3H s C29 or C30), 0.92 (3H s C25), 0.84 (3H s C23 or C24), 0.83 (3H s C23 or 
C24), 0.711 (3H s C26). 
13
C NMR (400 MHz CDCl3): δ 176.79 (C28), 170.98 
(OCOCH3), 149.34 (C2’), 142.90 (C13), 127.22 (Cimidazole), 123.09 (C12), 117.29 
(Cimidazole), 80.80 (C3), 55.28 (C5), 50.79 (C17), 47.46 (C9), 46.10 (C19), 42.57 (C18), 
41.89 (C14), 39.33 (C8), 38.12 (C1 or C2), 37.65 (C4), 36.88 (C10), 33.88, 32.79 (C29 or 
C30), 32.52 (C7), 31.28, 30.36 (C20), 27.97 (C23 or C24), 27.57 (C1 or C2), 25.73 (CH3 
imidazol), 23.85 (C29 or C30), 23.46, 23.36 (C11), 23.04 (C22 or C16), 21.27 (C27), 
18.07, 17.80 (OCOCH3), 17.18 (C26), 16.62 (C23 or C24), 15.41 (C25). EI-MS m/z: 
563.17 (30) M
+
, 452.20 (34), 393.23 (41), 249.04 (26), 203.12 (100), 189.18 (66), 175.18 
(19), 133.17 (27), 119.21 (36), 95.20 (34).  
 
Methyl 3β-(2’methyl-1H-imidazole-1-carbonyloxy)-olean-12-en-28-oate (3.33): 
To a stirred solution of 3.4 (500 mg 1.06 mmol) in THF (7.5 mL), under N2 atmosphere, 
at 70ºC, was added CBMI (343.76 mg 1.8 mmol). The workup was performed according 
to the same method as for 3.30 after 27 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (55:45)], to afford 3.33 (81%). 
mp 267.2-269.8 ºC. IR (film CHCl3): 2947.7, 1753.9, 1725.0, 1462.7, 1395.3, 1373.1 
1294.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.35 (1H d J=1.78 Himidazole), 6.89 (1H d 
J=1.70 Himidazole), 5.27 (1H t J=7.09 H12), 4.67 (1H dd J=16.40 H3), 3.61 (3H s 
COOCH3), 2.85 (1H dd J=18.13 H18), 2.68 (3H s CH3 imidazole), 1.13 (3H s C27), 0.96 
(3H s C26), 0.95 (3H s C23 or C24), 0.95 (3H s C23 or C24), 0.91 (3H s C29 or C30), 
0.88 (3H s C29 or C30), 0.72 (3H s C25). 
13
C NMR (100 MHz CDCl3): δ 178.20 (C28), 
149.05 (OCO), 147.91 (C2’), 143.82 (C13), 126.60 (Cimidazole), 122.02 (C12), 118.09 
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(Cimidazole), 86.45 (C3), 55.20 (C5), 51.51 (COOCH3), 47.47 (C9), 46.62 (C17), 45.78 
(C19), 41.57 (C14 or C10), 41.19 (C18), 39.19 (C14 or C10), 37.94, 37.76 (C4), 36.85 
(C8), 33.76, 33.05 (C29 or C30), 32.44 (C1), 32.28, 30.64 (C20), 28.14 (C26), 27.61 
(C2), 25.86 (C25), 23.58 (C29 or C30), 23.43, 23.33 (C11), 22.96, 18.12, 16.99 (C23 or 
C24), 16.76 (C25), 16.56 (CH3imidazole), 15.28 (C23 or C24). EI-MS m/z: 579.14 (6) 
M
+
, 452.23 (7), 317.03 (7), 262.08 (25), 215.16 (8), 203.10 (100), 189.13 (44), 173.16 
(18), 133.12 (68), 91.09 (36), 83.08 (97).  
 
3β-(2’Methyl-1H-imidazole-1-carbonyloxy)-12α-hydrxyolean-28,13β-olide 
(3.34): To a stirred solution of 3.5 (500 mg 1.06 mmol) in THF (5 mL), under N2 
atmosphere, at 70ºC, was added CBMI (302.45 mg 1.59 mmol). The workup was 
performed according to the same method as for 3.30 after 24 hours. The solid was 
subjected to flash column chromatography [hexanes-ethyl acetate from (60:40) to 
(30:70)], to afford 3.34 (49%). mp 269.2-273.1 ºC. IR (film CHCl3): 3518.5, 3172.3, 
3128.0, 2948.6, 2872.5, 1754.9, 1748.2, 1552.4, 1512.9, 1469.5, 1396.2, 1296.9, 1215.9 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.33 (1H s Himidazole), 6.84 (1H s Himidazole), 
4.67 (1H dd J=16.29 H3), 3.90 (1H s H12), 2.65 (3H s CH3imidazole), 1.32 (3H s C27), 
1.16 (3H s C26), 0.98 (6H s C23 or C24 or C29 or C30), 0.96 (3H s C23 or C24), 0.93 
(3H s C25), 0.89 (3H s C29 or C30). 
13
C NMR (100 MHz CDCl3): δ 179.92 (C28), 
149.37 (OCO), 147.89 (C2’), 127.63 (Cimidazole), 118.01 (Cimidazole), 90.59 (C13), 
85.77 (C3), 76.04 (C12), 55.23 (C5), 51.10 (C18), 44.67 (C9), 44.45 (C17), 42.26 (C8), 
42.08 (C14), 39.34 (C19), 38.32 (C1), 38.13 (C4), 36.34 (C10), 34.11 (C7), 33.82, 33.24 
(C29 or C30), 31.54 (C20), 28.85, 28.06 (C23 or C24), 27.99 (C15), 27.45, 23.86 (C29 or 
C30), 23.53, 21.16, 18.55 (2C C26), 17.58, 16.86 (C23 or C24), 16.80 (CH3imidazole), 
16.33 (C25). EI-MS m/z: 581.31 (8) M
+
, 205.19 (73), 204.17 (41), 189.23 (100), 187.24 
(54), 177.24 (57), 175.24 (50), 161.24 (42), 147.23 (53), 133.23 (40), 127.17 (48), 121.21 
(51), 119.22 (60), 109.2 (40), 107.2 (53), 105.2 (50).  
 
28-(2’Methyl-1H-imidazol-1-yl)-12,28-dioxoolean-3β-yl-2’methyl-1H-imidazole-
1-carboxylate (3.35): To a stirred solution of 3.7 (300 mg 0.63 mmol) in THF (5 mL), 
under N2 atmosphere, at 70ºC, was added CBMI (359.5 mg 1.89 mmol). The workup was 
performed according to the same method as for 3.30 after 8 hours. The solid was 
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subjected to flash column chromatography [hexanes-ethyl acetate from (50:50) to 
(10:90)], to afford 3.35 (58%). mp 170.4-179.1 ºC. IR (film CHCl3): 3168.5, 2949.6, 
2866.7, 1752.0, 1699.9, 1549.5, 1509.0, 1472.4, 1395.3, 1371.1, 1295.0, 1248.7, 1214.0 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.48 (1H s), 7.29 (1H s), 6.86 (1H s), 6.81 (1H s), 
4.60 (1H dd J=16.06), 2.99 (1H dd J=12.95), 2.60 (3H s), 2.57 (3H s), 1.00 (3H s), 0.95 
(3H s), 0.93 (6H s), 0.92 (6H s), 0.88 (3H s). 
13
C NMR (100 MHz CDCl3): δ 210.28, 
177.58, 149.26, 148.93, 147.79, 127.66, 127.54, 117.85, 117.21, 85.24, 55.00, 51.16, 
50.86, 49.51, 41.96, 41.29, 38.32, 37.96, 37.48, 36.71, 36.14, 34.17, 32.93, 32.88, 31.94, 
31.50, 30.28, 27.91, 27.56, 23.68, 23.27, 23.24, 20.31, 17.95, 17.63, 16.74, 16.65, 16.17, 
15.17. EI-MS m/z: 645.29 (1) M
+
, 205.13 (59), 189.17 (41), 187.19 (30), 127.1 (22), 
95.14 (20), 83.11 (100), 81.13 (36).  
 
3β-Acetoxy-12-oxoolean-28-yl-2’methyl-1H-imidazole-1-carboxylate (3.36): To a 
stirred solution of 3.8 (300 mg 0.58 mmol) in THF (4 mL), under N2 atmosphere, at 70ºC, 
was added CBMI (220.6 mg 1.16 mmol). The workup was performed according to the 
same method has for 3.30 after 16.5 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (60:40) to (55:45)], to afford 3.36 (65%). 
mp 157.5-164.6 ºC. IR (film CHCl3): 2946.7, 2866.7, 1724.1, 1715.4, 1706.7, 1471.4, 
1384.6, 1366.3, 1246.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.48 (1H s), 6.87 (1H s), 
4.43 (1H dd J=15.79), 3.00 (1H d J=13.08), 2.65 (1H d J=3.83), 2.58 (3H s), 2.01 (3H s), 
1.01 (3H s), 0.94 (3H s), 0.93 (6H s), 0.85 (3H s), 0.82 (6H s). 
13
C NMR (100 MHz 
CDCl3): δ 210.58, 177.65, 170.81, 148.95, 127.59, 117.24, 80.25, 55.07, 51.21, 50.90, 
49.56, 41.95, 41.31, 38.36, 37.66, 37.59, 36.74, 36.16, 34.21, 32.97, 32.90, 31.99, 31.58, 
30.31, 27.79, 27.57, 23.71, 23.29 (2C), 21.18, 20.32, 18.00, 17.68, 16.34, 16.18, 15.22. 
EI-MS m/z: 579.05 (3) M
+
, 205.01 (100), 189.05 (67), 187.07 (37), 107.02 (20), 82.99 
(24), 80.99 (24).  
 
3,12-Diooxoolean-12-en-28-yl-2’methyl-1H-imidazole-1-carboxylate (3.37): To a 
stirred solution of 3.9 (350 mg 0.74 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, 
was added CBMI (416.6 mg 1.48 mmol). The workup was performed according to the 
same method as for 3.30 after 4 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (60:40) to (40:60)], to afford 3.37 (44%). 
3. Oleanolic acid derivatives 
271 
 
mp 164.5-165.0 ºC. IR (film CHCl3): 3122.2, 2947.7, 2866.7, 1702.8, 1509.0, 1471.4, 
1384.6, 1365.4, 1284.4, 1248.7, 1212.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.49 (1H s), 
6.89 (1H d J=0.72), 3.01 (1H dd J=13.12 H18), 2.70 (1H d J=3.88), 2.60 (3H s 
CH3imidazole), 1.06 (3H s C23 or C24), 1.02 (6H s C23 or C24, C29 or C30), 0.99 (3H s 
C25), 0.99 (6H s C26 and C27), 0.93 (3H s C29 or C30). 
13
C NMR (100 MHz CDCl3): δ 
216.50 (C3), 210.14 (C11), 177.62 (C28), 149.01 (Cimidazole), 127.64 (Cimidazole), 
117.26 (Cimidazole), 54.89 (C5), 51.24 (C13), 50.90, 49.13 (C9), 47.35, 42.16 (C14 or 
C8), 41.31 (C14 or C8), 38.59, 38.54, 36.59 (C10), 36.22, 34.22, 33.78, 32.96 (2C C29 or 
C30 and C18), 31.99, 31.05, 30.34 (C20), 27.67, 26.16 (C23 ou C24), 23.73 (C23 or C24 
or C29 or C30), 23.36, 21.14 (C23 or C24 or C29 or C30), 20.26 (C27 or C26), 19.40, 
17.72 (CH3imidazole), 15.99 (C25), 14.83 (C26 or C27). EI-MS m/z: 535.29 (8) M
+
, 
426.33 (28), 425.35 (86), 407.42 (58), 205.34 (100), 187.43 (30).  
 
Methyl 3β-(2’methyl-1H-imidazole-1-carbonyloxy)-12-oxoolean-28-oate (3.38): 
To a stirred solution of 3.10 (325 mg 0.67 mmol) in THF (5 mL), under N2 atmosphere, 
at 70ºC, was added CBMI (254.88 mg 1.34 mmol). The workup was performed according 
to the same method as for 3.30 after 8 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (60:40) to (45:55)], to afford 3.38 (48%). 
mp 215.6-217.6 ºC. IR (film CHCl3): 3116.4, 2946.7, 2878.2, 1753.0, 1721.2, 1698.0, 
1509.0, 1466.6, 1397.2, 1372.1, 1295.0, 1239.0 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.31 
(1H d J=0.85 Himidazole), 6.84 (1H s Himidazole), 4.63 (1H dd J=16.26 H3), 3.67 (3H 
s), 2.78 (1H dd J=13.24), 2.63 (3H s), 0.96 (12H s), 0.94 (3H s), 0.90 (3H s), 0.89 (3H s). 
13
C NMR (100 MHz CDCl3): δ 211.25, 178.31, 149.31, 147.86, 127.67, 117.93, 85.43, 
55.10, 51.78, 51.77, 49.57, 47.29, 41.84, 41.21, 38.43, 38.04, 37.52, 36.79, 36.16, 34.42, 
33.33, 32.88, 31.94, 31.66, 30.60, 28.01, 27.52, 23.34, 23.11, 22.69, 20.52, 18.11, 16.81, 
16.75, 16.09, 15.18. EI-MS m/z: 595.30 (7) M
+
, 579.33 (32), 519.37 (33), 218.2 (46), 
175.21 (66), 105.19 (36), 95.19 (36), 83.16 (100), 81.17 (41).  
 
Methyl 2-(2’methyl-1H-imidazol-1-yl)-methylene-3-oxoolean-12-en-28-oate 
(3.39): To a stirred solution of 3.12 (300 mg 0.60 mmol) in THF (4 mL), under N2 
atmosphere, at 70ºC, was added CBMI (228.25 mg 1.2 mmol). The workup was 
performed according to the same method as for 3.30 after 6.5 hours. The solid was 
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subjected to flash column chromatography [hexanes-ethyl acetate from (60:40) to 
(50:50)], to afford 3.39 (75%). mp 212.1-215.3 ºC. IR (film CHCl3): 3162.7, 3122.2, 
2948.6, 2866.7, 1724.1, 1685.5, 1605.5, 1540.9, 1504.2, 1461.8, 1411.6, 1383.7, 1244.8 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 7.65 (1H s), 7.12 (1H s), 6.98 (1H s), 5.33 (1H s), 
3.62 (3H s), 2.46 (3H s), 1.17 (3H s), 1.16 (3H s), 1.14 (3H s), 0.92 (3H s), 0.90 (3H s), 
0.87 (3H s), 0.78 (3H s). 
13
C NMR (100 MHz CDCl3): δ 206.63, 178.15, 147.31, 144.01, 
130.25, 128.29, 123.68, 121.81, 118.12, 52.73, 51.54, 46.76, 45.84, 45.44, 45.28, 42.34, 
41.92, 41.47, 39.16, 36.13, 33.83, 33.06, 32.26, 31.73, 30.67, 29.66, 27.64, 25.64, 23.57 
(2C), 23.06, 22.52, 20.24, 16.42, 15.25, 13.57. EI-MS m/z: 561.48 (40) M
+
, 560.34 (44), 
545.44 (45), 501.51 (42), 312.17 (47), 299.35 (67), 203.18 (98), 133.19 (100), 119.18 
(59), 105.2 (62), 91.13 (47), 83.16 (95), 81.13 (41), 79.12 (43).  
 
Methyl 2α-(2’methyl-1H-imidazole-1-carbonyloxy)-3-oxoolean-12-en-28-oate 
(3.40): To a stirred solution of 3.13 (400 mg 0.825 mmol) in THF (10 mL), under N2 
atmosphere, at 70ºC, was added CBMI (313.85 mg 1.65 mmol). The workup was 
performed according to the same method as for 3.30 after 6 hours. The solid was 
subjected to flash column chromatography [hexanes-ethyl acetate from (80:20) to 
(45:55)], to afford 3.40 (58%). mp 170.4-179.1 ºC. IR (film CHCl3): 2947.7, 2878.2, 
1761.7, 1724.1, 1554.3, 1508.1, 1457.0, 1395.3, 1297.9 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 6.85 (1H s Himidazole), 5.71 (1H dd J=18.97 H2), 5.29 (1H s H12), 3.63 (3H 
s), 2.87 (1H dd J=12.99), 2.62 (3H s), 2.38 (1H dd J=17.89), 1.33 (3H s), 1.18 (3H s), 
1.14 (3H s), 1.12 (3H s), 0.92 (3H s), 0.89 (3H s), 0.93 (3H s). 
13
C NMR (100 MHz 
CDCl3): δ 207.87 (C3), 178.14 (C28), 148.92 (C2OCO), 148.06 (C2’), 144.24 (C13), 
127.41 (Cimidazole), 118.16 (Cimidazole), 74.97 (C2), 57.07 (C5), 51.55 (COOCH3), 
48.79 (C4), 47.39 (C9), 46.60 (C17), 45.77, 45.29 (C1), 41.72 (C14), 41.20 (C18), 39.37 
(C8), 38.08 (C10), 33.76, 33.05 (C29 or C30), 32.24, 32.21 (C7), 30.66 (C20), 27.60 
(C15), 25.88 (C27), 24.71 (C23 or C24), 23.57 (2C C29 or C30), 22.91, 21.15 (C23 or 
C24), 19.02, 16.99 (C26); 16.69 (CH3imidazole), 15.93 (C25). EI-MS m/z: 592.31 (7) M
-
, 547.50 (5), 330.73 (6), 282.50 (8), 268.66 (23), 24.7 (17), 214.72 (100), 188.82 (71), 
14.90 (27), 132.87 (67), 118.90 (52), 90.86 (62).  
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3β-Acetoxy-11-oxoolean-12-en-28-yl-2’-methyl-1H-imidazole-1-carboxylate 
(3.41): To a stirred solution of 3.14 (148.8 mg 0.29 mmol) in THF (2.5 mL), under N2 
atmosphere, at 70ºC, was added CBMI (110.32 mg 0.58 mmol). The workup was 
performed according to the same method as for 3.30 after 5 hours. The solid was 
subjected to flash column chromatography [hexanes-ethyl acetate from (70:30) to 
(35:65)], to afford 3.41 (30%). mp 244.3-247.6 
o
C. IR (film CHCl3): 3175.2, 2948.6, 
1805.1, 1727.9, 1656.6, 1551.5, 1466.6, 1389.5, 1366.3, 1321.0, 1248.7 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 7.52 (1H s Himidazole), 6.90 (1H s Himidazole), 5.71 (1H s H12), 
4.48 (1H dd J=15.60 H3), 3.20 (1H dd J=12.28), 2.81 (1H dd J=13.57), 2.55 (3H s), 2.03 
(3H s), 1.37 (3H s), 1.12 (3H s), 0.96 (6H d J=2.09), 0.90 (3H s), 0.84 (6H s).
 13
C NMR 
(100 MHz CDCl3): δ 199.81 (C11), 175.69 (C28), 171.00 (OCOCH3), 167.50 (C13), 
149.72 (C2’), 128.17 (C12), 127.78 (Cimidazole), 117.03 (Cimidazole), 80.51 (C3), 
61.61 (C9), 55.06 (C5), 50.28 (C17), 45.06 (C8), 44.53 (C19), 43.56 (C14), 43.08 (C18), 
38.75 (C1), 37.99 (C4), 37.07 (C10), 33.83 (C21 or C22), 32.80 (C7), 32.54 (C29 or 
C30), 30.33, 30.26 (C20), 27.99 (C23 or C24), 27.63 (C15), 23.59 (C29 or C30), 23.49 
(C21 or C22), 23.24 (C27), 22.64, 21.28 (OCOCH3), 18.90 (C26), 18.22 (CH3imidazole), 
17.16, 16.61 (C23 or C24), 16.35 (C25). EI-MS m/z: 576.70 (4) M
+
, 496.59 (5), 466.79 
(7), 406.79 (12), 362.73 (5), 298.97 (5), 280.99 (100), 257.34 (5), 217.24 (14), 189.35 
(17), 175.36 (13), 105.32 (10), 91.43 (16), 83.39 (100).  
 
28-(4H-Triazol-4-yl)-28-oxoolean-12-en-3β-yl-4H-triazole-4-carboxylate (3.42): 
To a stirred solution of 3.1 (350 mg 0.77 mmol) in THF (4 mL), under N2 atmosphere, at 
70ºC, was added CDT (758.28 mg 4.62 mmol). After 7 hours the reaction mixture was 
diluted with water (60 mL), the aqueous phase was extracted with ethyl acetate (3×50 
mL). The resulting organic phases were washed with NaCl 10% (3×50 mL), dried over 
Na2SO4, filtered and evaporated to the dryness, to afford a yellow residue. The residue 
was subjected to flash column chromatography [hexanes-ethyl acetate from (80:20) to 
(55:45)], to afford 3.42 (86%). mp 158.8-167.9 ºC. IR (film CHCl3): 3133.8, 2949.6, 
1782.9, 1762.6, 1735.6, 1511.0, 1466.6, 1405.9, 1359.6, 1349.9, 1279.5, 1226.5 cm
-1
. 
1
H 
NMR (400 MHz CDCl3): δ 8.85 (1H s Htriazole), 8.77 (1H s Htriazole), 8.06 (1H s 
Htriazole), 7.99 (1H s Htriazol), 5.30 (1H s H12), 4.79 (1H t J=16.48 H3), 3.20 (1H d 
J=11.41 H18), 2.51 (1H d J=13.49), 1.17 (3H s C27), 0.99 (6H s C23 or C24), 0.97 (3H s 
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C29 or C30), 0.96 (3H s C25), 0.94 (3H s C29 or C30), 0.89 (1H d J=10.32 H5), 0.68 
(3H s C26). 
13
C NMR (100 MHz CDCl3): δ 174.99 (C28), 153.57 (Ctriazole), 152.28 
(Ctriazole), 147.28 (OCO), 145.29 (2C Ctriazole), 143.19 (C13), 122.60 (C12), 87.68 
(C3), 55.20 (C5), 49.97 (C17), 47.49 (C9), 45.79 (C19), 41.79 (C14), 41.66 (C18), 39.25 
(C8), 38.18 (C4), 37.97, 36.85 (C10), 33.76, 32.93 (C29 or C30), 32.40 (C7), 30.50 
(C20), 30.02, 28.11 (C29 or C30), 27.80 (C15), 25.90 (C27), 23.73 (C23 or C24), 23.38 
(2C), 21.86, 18.07, 16.77 (C23 or C24), 16.70 (C26), 15.35 (C25). EI-MS m/z: 602.36 
(24) M
-
, 589.36 (47), 588.21 (47), 486.83 (56), 312.49 (48), 282.43 (26), 270 (100), 
248.06 (42), 186.25 (49), 156.89 (91), 87.94 (54), 58.16 (51).  
 
3β-Acetoxy-olean-12-en-28-yl-4H-triazole-4-carboxylate (3.43): To a stirred 
solution of 3.3 (200 mg 0.4 mmol) in THF (4 mL), under N2 atmosphere, at 70ºC, was 
added CDT (196.96 mg 1.2 mmol). The workup was performed according to the same 
method as for 3.42 after 6 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (80:20) to (75:25)], to afford 3.43 (90%). 
mp 195.2-198.7 ºC. IR (film CHCl3): 3133.8, 2948.6, 1732.7, 1511.0, 1465.6, 1361.5, 
1246.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.84 (1H s Htriazole), 7.97 (1H s Htriazole), 
5.29 (1H s H12), 4.48 (1H t J=15.73 H3), 3.19 (1H d J=11.88 H18), 2.50 (1H d J=13.51), 
2.03 (3H s), 1.15 (3H s), 0.98 (3H s), 0.94 (3H s), 0.91 (3H s), 0.84 (3H s), 0.83 (3H s), 
0.80 (1H s H5), 0.66 (3H s). 
13
C NMR (100 MHz CDCl3): δ 175.02 (C28), 170.98 
(OCOCH3), 152.25 (Ctriazole), 145.28 (Ctriazole), 143.09 (C13), 122.80 (C12), 80.83 
(C3), 55.27 (C5), 49.99 (C18), 47.50 (C9), 45.78 (C19), 41.78 (C18), 41.68 (C14), 39.26 
(C8), 38.10 (C1), 37.65 (C4), 36.87 (C10), 33.78, 32.93 (C29 or C30), 32.47 (C7), 30.49 
(C20), 30.04, 27.99 (C24 or C23), 27.80 (C15), 25.89 (C27), 23.74 (C29 or C30), 23.47, 
23.38, 21.89, 21.28 (OCOCH3), 18.11, 16.71 (C23 or C24), 16.63 (C26), 15.36 (C25). EI-
MS m/z: 549.01 (72) M
+
, 507.26 (32), 487.65 (77), 486.61 (53), 431.43 (43), 375.45 (23), 
294.67 (37), 172.68 (100), 84.56 (46).  
 
Methyl 3β-(4H-triazole-4-carbonyloxy)-olean-12-en-28-oate (3.44): To a stirred 
solution of 3.4 (500 mg 1.062 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, was 
added CDT (348.6 mg 2.124 mmol). The workup was performed according to the same 
method as for 3.42 after 5 hours. The solid was subjected to flash column 
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chromatography [hexanes-ethyl acetate from (80:20) to (60:40)], to afford 3.44 (84%). 
mp 259.4-260.4 ºC. IR (film CHCl3): 3118.3, 2946.7, 1758.8, 1725.0, 1514.8, 1469.5, 
1407.8, 1384.6, 1281.5, 1267.0, 1228.5, 1202.4 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.77 
(1H s Htriazole), 8.06 (1H s Htriazole), 5.28 (1H s H12), 4.80 (1H t J=16.38 H3), 3.62 
(3H s), 2.86 (1H dd J=10.92 H18), 1.13 (3H s), 1.0 (3H s), 0.98 (3H s), 0.97 (3H s), 0.89 
(3H s), 0.73 (3H s). 
13
C NMR (100 MHz CDCl3): δ 178.20, 153.56, 147.27, 145.29, 
143.85, 122.04, 87.76, 55.21, 51.50, 47.52, 46.66, 45.82, 41.61, 41.24, 39.25, 38.19, 
37.95, 36.88, 33.81, 33.07, 32.49, 32.31, 30.66, 28.12, 27.64, 25.87, 23.60, 23.39, 23.37, 
23.00, 18.15, 16.78 (2C), 15.32. EI-MS m/z: 567.21 (49) M
+
, 565.09 (98), 557.85 (50), 
492.9 (60), 198.98 (53), 194.61 (52), 186.57 (100), 174.59 (50), 166.34 (48), 144.78 (46), 
101.54 (51), 92.7 (48), 60.51 (48), 56.93 (58).  
 
28-(4H-Triazol-4-yl)-12,28-dioxoolean-3β-yl-4H-triazole-4-carboxylate (3.45): 
To a stirred solution of 3.7 (500 mg 1.1 mmol) in THF (5 mL), under N2 atmosphere, at 
70ºC, was added CDT (722.17 mg 4.4 mmol). The workup was performed according to 
the same method as for 3.42 after 7 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (60:40) to (45:55)], to afford 3.45 (75%). 
mp 169.2-180.7 ºC. IR (film CHCl3): 3138.6, 2947.7, 2865.7, 1762.6, 1725.0, 1698.0, 
1512.9, 1471.4, 1406.8, 1360.5, 1346.1, 1279.5, 1222.7, 1202.4 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.91 (1H s), 8.76 (1H s), 8.04 (1H s), 7.99 (1H s), 4.76 (1H dd J=16.30 H3), 
3.26 (1H dd J=12.64 H18), 2.70 (1H d J=2.49 H13) 1.04 (3H s C29 or C30), 0.98 (6H s 
C23 or C24 and C27), 0.97 (3H s C23 or C24), 0.92 (6H s C29 or C30 and C26), 0.89 
(3H s C25). 
13
C NMR (100 MHz CDCl3): δ 210.53 (C12), 175.50 (C28), 153.55 
(Ctriazole), 152.48 (Ctriazole), 147.22 (OCO), 145.48 (Ctriazole), 145.30 (Ctriazole), 
87.05 (C3), 55.00 (C5), 51.45 (C13), 50.34 (C17), 49.57 (C9), 42.11 (C14), 41.28 (C8), 
38.36, 38.21 (C4), 37.44, 36.75 (C10), 36.09, 34.28, 33.17 (C29 or C30), 32.09 (C18), 
31.55, 30.85, 30.45 (C20), 27.94 (C23 or C24), 27.65, 23.33 (C29 or C30), 23.21, 22.07, 
20.62 (C27), 18.02, 16.50 (C23 or C24), 16.13 (C26), 15.18 (C25). EI-MS m/z: 618.59 
(1) M
+
, 521.34 (45), 408.39 (50), 218.19 (100), 205.22 (75), 204.22 (84), 189.33 (57).  
 
3β-Acetoxy-12-oxoolean-28-yl-4H-triazole-4-carboxylate (3.46): To a stirred 
solution of 3.8 (300 mg 0.58 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, was 
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added CDT (285.6 mg 1.74 mmol). The workup was performed according to the same 
method as for 3.42 after 8 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (70:30) to (60:40)], to afford 3.46 (68%). 
mp 171.5-177.4 ºC. IR (film CHCl3): 3133.8, 2945.7, 2872.5, 1726.9, 1699.0, 1511.0, 
1466.6, 1359.6, 1274.7, 1245.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.91 (1H s 
Htriazole), 8.00 (1H s Htriazole), 4.45 (1H dd J=15.81 H3), 3.26 (1H d J=12.84 H18), 
2.69 (1H d J=2.85), 2.02 (3H s), 1.05 (3H s), 0.97 (3H s), 0.93 (3H s), 0.90 (3H s), 0.84 
(3H s), 0.83 (6H s). 
13
C NMR (100 MHz CDCl3): δ 210.89, 175.56, 170.83, 153.48, 
145.50, 80.33, 55.12, 51.49, 50.39, 49.62, 42.12, 41.30, 38.41, 37.70, 37.59, 36.79, 36.10, 
34.32, 33.19, 32.11, 31.64, 30.89, 30.47, 27.84, 27.67, 23.37, 23.33, 22.12, 21.20, 20.64, 
18.08, 16.39, 16.14, 15.20. EI-MS m/z: 566.09 (1) M
+
, 218.25 (76), 205.35 (100), 204.4 
(97), 190.44 (35), 189.31 (58), 176.39 (28), 121.57 (30), 107.18 (27), 105.3 (26).  
 
3,12-Dioxoolean-28-yl-1H-triazole-1-carboxylate (3.47): To a stirred solution of 
3.9 (250 mg 0.53 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, was added CDT 
(261 mg 1.59 mmol). The workup was performed according to the same method as for 
3.42 after 8 hours. The solid was subjected to flash column chromatography [hexanes-
ethyl acetate from (70:30) to (60:40)], to afford 3.47 (66%). mp 113.4-114.0 ºC. IR (film 
CHCl3): 3128.0, 2944.8, 2866.7, 1724.1, 1700.9, 1511.0, 1457.9, 1385.6, 1345.1, 1274.7 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 8.92 (1H s), 8.00 (1H s), 3.28 (1H dd J=13.00), 2.73 
(1H d J=3.31), 1.06 (3H s), 1.05 (3H s), 1.02 (3H s), 0.98 (3H s), 0.96 (6H s), 0.93 (3H 
s). 
13
C NMR (100 MHz CDCl3): δ 216.54, 210.39, 175.52, 152.52, 145.51, 54.89, 51.50, 
50.35, 49.16, 47.34, 42.28, 41.27, 38.54 (2C), 36.59, 36.13, 34.30, 33.79, 33.18, 32.13, 
31.06, 30.87, 30.47, 27.72, 26.19, 23.35, 22.11, 21.15, 20.55, 19.45, 15.90, 14.78. EI-MS 
m/z: 522.16 (3) M
+
, 218.18 (92), 205.25 (100), 204.29, (85), 189.32 (32), 105.27 (30).  
 
Methyl 3β-(4H-triazole-4-carbonyloxy)-12-oxoolean-28-oate (3.48): To a stirred 
solution of 3.10 (300 mg 0.62 mmol) in THF (5 mL), under N2 atmosphere, at 70ºC, was 
added CDT (305.28 mg 1.86 mmol). The workup was performed according to the same 
method as for 3.42 after 6 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (70:30) to (55:45)], to afford 3.48 (72%). 
mp 162.6-164.2 ºC. IR (film CHCl3): 3133.8, 2948.6, 2866.7, 1763.6, 1720.2, 1698.0, 
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1510.0, 1468.5, 1405.9, 1299.8, 1281.5, 1222.7, 1202.4 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.76 (1H s), 8.03 (1H s), 4.75 (1H s J=16.48 H3), 3.65 (3H s COOCH3), 2.76 
(1H dt J=13.46 H18), 2.60 (1H d J=3.94 H13), 0.99 (3H s C23 or C24), 0.97 (3H s C23 
or C24), 0.95 (3H s C29 or C30), 0.94 (3H s C26), 0.92 (3H s C27), 0.90 (3H s C25), 
0.87 (3H s C29 or C30). 
13
C NMR (100 MHz CDCl3): δ 211.12 (C12), 178.23 (C28), 
153.51 (Ctriazole), 147.19 (OCO), 145.28 (Ctriazole), 87.09 (C3), 54.98 (C5), 51.71 
(C13 and COOCH3), 49.51 (C9), 47.22 (C17), 41.77 (C14), 41.16 (C8), 38.36, 38.19 
(C4), 37.42, 36.72 (C10), 36.10, 34.36, 33.29 (C29 or C30), 32.82, 31.88, 31.61 (C18), 
30.54 (C20), 27.93 (C23 or C24), 27.46, 23.21, 23.06 (C26), 22.63, 20.46 (C27), 18.04, 
16.49 (C23 or C24), 16.04 (C29 or C30), 15.15 (C25). EI-MS m/z: 582.29 (4) M
+
, 278.25 
(45), 219.38 (31), 218.39 (100), 203.36 (35), 176.38 (31), 175.33 (34), 70.51 (33).  
 
Methyl 2-(4H-triazol-4-yl)-methylene-3-oxoolean-12-en-28-oate (3.49): To a 
stirred solution of 3.12 (300 mg 0.60 mmol) in THF (5 mL), under N2 atmosphere, at 
70ºC, was added CDT (295.47 mg 1.8 mmol). The workup was performed according to 
the same method as for 3.42 after 24 hours. The solid was subjected to flash column 
chromatography [hexanes-ethyl acetate from (70:30) to (60:40)], to afford 3.49 (56%). 
mp 151.7-159.4 ºC. IR (film CHCl3): 3122.2, 2948.6, 1863.8, 1722.1, 1686.4, 1616.1, 
1510.0, 1458.9, 1410.7, 1382.7, 1362.5, 1299.8, 1281.5 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.34 (1H s), 8.06 (1H s), 7.77 (1H s), 5.36 (1H s H12), 3.621 (3H s COOCH3), 
3.36 (1H d J=17.60), 2.90 (1H dd J=16.86), 2.37 (1H d J=17.67), 1.18 (6H s), 1.12 (3H 
s), 0.93 (3H s), 0.90 (3H s), 0.88 (3H s), 0.79 (3H s). 
13
C NMR (100 MHz CDCl3): δ 
207.17, 178.18, 152.81, 145.82, 143.76, 128.22, 125.51, 122.12, 52.73, 51.53, 46.79, 
45.84, 45.29, 45.21, 43.24, 41.93, 41.51, 39.12, 35.78, 33.86, 33.07, 32.29, 31.72, 30.67, 
29.70, 27.66, 25.63, 23.64, 23.58, 23.10, 22.41, 20.31, 16.40, 15.49. EI-MS m/z: 548.40 
(12) M
+
, 299.25 (21), 203.23 (100), 202.28 (23), 19.33 (34), 173.3 (20), 134.21 (26), 
133.29 (63), 119.23 (23), 105.35 (22).  
 
3β-Acetoxy-11-oxoolean-12-en-28-yl-4H-triazole-1-carboxylate (3.50): To a 
stirred solution of 3.14 (210.6 mg 0.41 mmol) in THF (4 mL), under N2 atmosphere, at 70 
ºC, was added CDT (134.6 mg 0.82 mmol). The workup was performed according to the 
same method as for 3.42 after 8 hours. The solid was subjected to flash column 
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chromatography [hexanes-ethyl acetate from (80:20) to (65:35)], to afford 3.50 (25%). 
mp 138.9-145.5 
o
C. IR (film CHCl3): 3141.5, 2950.6, 2875.3, 1730.8, 1659.5, 1513.9, 
1466.6, 1389.5, 1362.5, 1349.9, 1275.7, 1247.7, 1210.1 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 8.87 (1H s Htriazole), 8.02 (1H s Htriazole), 5.68 (1H s H12), 4.50 (1H dd 
J=16.16), 3.26 (1H d J=11.74), 2.82 (1H d J=13.65), 2.70 (1H d J=14.14), 2.04 (3H s 
OCOCH3), 1.39 (3H s), 1.12 (3H s), 0.97 (6H s), 0.85 (9H s).
 13
C NMR (100 MHz 
CDCl3): δ 199.88, 174.39, 170.98, 167.63, 152.66, 128.15, 80.57, 61.74, 55.09, 49.64, 
45.02, 44.29, 43.59, 42.13, 38.79, 38.03, 37.12, 33.71, 32.77, 32.70, 30.43, 29.25, 28.03, 
27.97, 23.54 (2C), 23.49, 23.47, 21.53, 21.27, 18.74, 17.24, 16.64, 16.28. EI-MS m/z: 
563.22 (75) M
-
, 507.95 (44), 465.45 (100), 400.79 (78), 364.26 (34), 246.05 (26), 148.31 
(34), 129.76 (40), 92.67 (26).  
 
3β-Ol-12β-fluor-olean-13,28β-olide (3.51) and 3β-ol-12α-fluor-olean-13,28β-olide 
(3.52): To a stirred solution of 3.1 (100 mg 0.22 mmol) in acetonitrile (3 mL) and 
dioxane (3 mL) at 50ºC was added selectfluor (155.9 mg 0.44 mmol). After 4 hours the 
reaction mixture was diluted with water (50 mL), the aqueous phase was extracted with 
ether (3×50 mL). The resulting organic phases were washed with NaCl 10% (3×50 mL), 
dried over Na2SO4, filtered and evaporated to the dryness, to afford a solid. The solid was 
subjected to flash column chromatography [hexanes-ethyl acetate from (90:10) to 
(65:35)], to afford 3.51 (25%) and 3.52 (33%). 3.51: mp 280.8-285.0 ºC. IR (film 
CHCl3): 3323.7, 2945.7, 1772.3, 1467.6, 1390.4, 1222.7 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 4.56 (1H dt J=52.08 H12), 3.22 (1H dd J=16.11 H3), 1.23 (3H d J=0.96 C27), 
1.11 (1H s C26), 0.99 (3H s C23 or C24 or C29 or C30), 0.98 (3H s C23 or C24 or C29 
or C30), 0.89 (3H s C29 or C30), 0.87 (3H s C25), 0.77 (3H s C23 or C24). 
13
C NMR 
(100 MHz CDCl3): δ 179.35 (C28), 96.66 (J=171.56 C12), 87.98 (J=25.90 C13), 78.71 
(C3), 55.00 (C5), 50.86 (C18), 44.65 (C9), 44.32 (C17), 41.91 (C8), 41.70 (C14), 38.85 
(C4), 38.53 (2C), 36.40 (C10), 34.07, 33.51, 33.18 (C29 or C30 or C24 or C23), 31.47 
(C20), 27.96 (C23 or C24 or C29 or C30), 27.45, 27.35, 27.15, 25.68 (J=21.39), 23.75 
(C29 or C30), 21.05, 18.28 (C26), 17.93 (J=8.06 C27), 17.66, 16.02 (C25), 15.33 (C23 or 
C24). EI-MS m/z: 475.20 (5) M
+
, 457.20 (8), 437.17 (12), 231.10 (22), 207.13 (30), 
201.14 (56), 145.20 (32), 133.19 (45), 119.20 (100), 91.19 (52), 79.19 (45), 67.15 (31). 
3.52: mp 278.9-279.6 ºC. IR (film CHCl3): 3323.7, 2945.7, 1734.7, 1467.6, 1387.5, 
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1362.5, 1260.3 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 4.65 (1H dq J=61.61 H12), 3.20 (1H 
dd J=15.99 H3), 1.21 (3H d J=2.59 C27), 1.122 (3H s C26), 0.96 (6H s), 0.93 (3H s C29 
or C30), 0.88 (3H s C25), 0.78 (3H s C23 or C24). 
13
C NMR (100 MHz CDCl3): δ 178.40 
(C28), 99.89 (J=179.56 C12), 90.76 (J=7.46 C13), 78.69 (C3), 55.769 (C5), 48.60 
(J=2.63 C9), 45.351 (C18), 44.96 (J=18.74 C14), 43.46 (C8), 39.31 (C17), 38.83 (C4), 
38.68, 37.60, 37.47 (C10), 36.91, 33.43, 33.07 (C29), 30.48 (C20), 27.77 (C23 or C24), 
27.15, 26.70, 26.28 (J=21.62), 24.83, 23.84 (C30), 21.84, 19.22, 19.18 (C26), 17.18 
(C25), 16.38 (J=10.91 C27), 15.14 (C23 or C24). EI-MS m/z: 475.21 (6) M
+
, 455.19 (9), 
203.18 (22), 201.17 (34), 189.20 (100), 187.22 (60), 159.24 (32), 145.24 (43), 119.22 
(52), 107.20 (44), 91.23 (39), 79.21 (33), 67.22 (25).  
 
3-Oxo-12β-fluor-urs-13,28β-olide (3.53) and 3-oxo-12α-fluor-urs-13,28β-olide 
(3.54): To a stirred solution of 3.2 (100 mg 0.22 mmol) in acetonitrile (3 mL) and 
dioxane (1 mL) at 50ºC was added selectfluor (155.9 mg 0.44 mmol). The workup was 
performed according to the same method as for 3.51 and 3.52 after 2.5 hours. The 
obtained solid was subjected to flash column chromatography [hexanes-ethyl acetate 
from (90:10) to (70:30)], to afford 3.53 (21%) and 3.54 (35%). 3.53: mp 264.9-269.9 ºC. 
IR (film CHCl3): 2933.2, 1782.9, 1699.9, 1455.0, 1384.6, 1363.4 cm
-1
. 
1
H NMR (400 
MHz CDCl3): δ 4.57 (1H dt J=46.51 H12), 2.48 (2H m J=65.47 H2), 1.24 (3H s C27), 
1.16 (3H s C26), 1.09 (3H s C23 or C24), 1.04 (3H s C23 or C24), 0.98 (6H s C25 and 
C29 or C30), 0.90 (3H s C29 or C30). 
13
C NMR (100 MHz CDCl3): δ 217.28 (C3), 
179.18 (C28), 96.40 (J=171.78 C12), 87.90 (J=26.01 C13), 54.68 (C5), 50.94 (C18), 
47.30 (C4), 44.31 (C17), 43.96 (C9), 41.83 (C14 and C8), 39.29, 38.58 (J=3.54), 36.14 
(C10), 34.07, 33.90, 33.17 (C25 or C29 or C30), 32.92, 31.49 (C20), 27.48, 27.34, 26.60 
(C23 or C24), 26.05 (J=21.28), 23.72 (C29 or C30), 21.07, 21.04, 18.99, 17.95 (C26), 
17.77 (J=8,024 C27), 15.95 (C25 or C29 or C30). EI-MS m/z: 473.17 (24) M
+
, 453.14 
(20), 231.11 (22), 205.11 (45), 201.15 (62), 187.15 (66), 163.18 (47), 145.19 (43), 119.19 
(100), 105.18 (48), 91.18 (59), 79.15 (41), 77.14 (34). 3.54: mp 264.8-270.1 ºC. IR (film 
CHCl3): 2945.7, 1737.6, 1703.8, 1458.9, 1384.6, 1256.4 cm
-1
. 
1
H NMR (400 MHz 
CDCl3): δ 4.63 (1H dq J=60.64 H12), 2.49 (2H m J=62.71 H2), 1.21 (3H d J=3.08 C27), 
1.15 (3H s C26), 1.07 (3H s C23 or C24), 1.04 (3H s C23 or C24), 1.00 (3H d J=0.45 
C25), 0.96 (3H s C29 or C30), 0.88 (3H s C29 or C30). 
13
C NMR (100 MHz CDCl3): δ 
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216.92 (C3), 178.19 (C28), 100.12 (J=180.18 C12), 90.54 (J=6.92 C13), 54.77, 47.75 
(J=1.62), 47.17 (C4), 45.97, 44.99 (J=19.05 C14), 43.29 (C8), 39.35 (C17), 39.20, 37.04 
(C10), 36.84, 36.74, 33.63, 33.33, 33.09 (C29 or C30), 30.52 (C20), 26.71, 26.60 (C23 or 
C24), 26.53 (J=21.02), 24.46, 23.82 (C29 or C30), 21.52, 20.60 (C23 or C24), 20.52, 
18.48 (C26), 16.71 (C25), 16.37 (J=12.31 C27). EI-MS m/z: 473.17 (16) M
+
, 453.14 
(22), 247.10 (9), 187.20 (20), 165.18 (24), 145.21 (37), 133.17 (36), 120.20 (100), 105.22 
(39), 91.15 (37), 79.14 (29), 67.13 (23).  
 
3β-Acetoxy-12β-fluor-olean-13,28β-olide (3.55) and 3β-acetoxy-12α-fluor-olean-
13,28β-olide (3.56): To a stirred solution of 3.3 (200 mg 0.4 mmol) in nitrometane (3 
mL) and dioxane (2 mL) at 50ºC was added selectfluor (283.41 mg 0.8 mmol). The 
workup was performed according to the same method as for 3.51 and 3.52 after 4 hours. 
The obtained solid was subjected to flash column chromatography [hexanes-ethyl acetate 
from (90:10) to (70:30)], to afford 3.55 (26%) and 3.56 (20%). 3.55: mp 327.1-329.5 ºC. 
IR (film CHCl3): 2946.7, 1776.1, 1227.9, 1467.6, 1388.5, 1368.3, 1246.8 cm
-1
. 
1
H NMR 
(400 MHz CDCl3): δ 4.54 (2H m J=56.95 H12 and H3), 2.04 (3H s OCOCH3), 1.22 (3H 
d J=0.90), 1.11 (3H s), 0.98 (3H s), 0.89 (6H s), 0.86 (3H s), 0.85 (3H s). 
13
C NMR (100 
MHz CDCl3): δ 179.30 (C28), 170.90 (OCOCH3), 96.52 (J=171.84 C12), 87.94 (J=25.89 
C13), 80.54 (C3), 55.08 (C5), 50.84 (C18), 44.58 (C9), 44.29 (C17), 41.92, 41.69 (C14), 
38.51 (J=3.51), 38.22, 37.77, 36.31, 34.07, 33.45, 33.16 (C29 or C30), 31.46, 27.88 (C23 
or C24), 27.43, 27.35, 25.70 (J=21.45), 23.74, 23.46, 21.25 (OCOCH3), 21.04, 18.29 
(C26), 17.90 (J=8.16 C27), 17.53, 16.43 (C29 or C30), 16.08 (C25). EI-MS m/z: 517.21 
(3) M
+
, 496.23 (10), 246.11 (58), 201.27 (76), 189.29 (100), 159.23 (35), 119.17 (58), 
107.17 (31), 91.20 (27), 79.21 (22). 3.56: mp 309.4-309.9 ºC. IR (film CHCl3): 2942.8, 
1741.4, 1726.9, 1467.6, 1388.5, 1363.4, 1249.7 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 4.65 
(1H dq J=61.02 H12), 4.47 (1H dd J=16.03 H3), 2.04 (3H s OCOCH3), 1.21 (3H d 
J=1.63), 1.13 (3H s), 0.96 (6H s), 0.88 (3H s), 0.86 (3H s), 0.84 (3H s). 
13
C NMR (100 
MHz CDCl3): δ 178.39 (C28), 170.93 (OCOCH3), 99.63 (J=179.65 C12), 90.71 (J=7.54 
C13), 80.45, 55.89, 48.57 (J=2.46), 45.24, 44.97 (J=18.69 C14), 43.47 (C8), 39.31 (C17), 
38.37, 37.77, 37.42 (C10), 37.56, 36.93, 33.44, 33.06 (C25 or C29 or C30), 30.47 (C20), 
27.72 (C23 or C24), 26.70, 26.27 (J=21.58), 24.92 (J=1.31), 23.84 (C29 or C30), 23.42, 
21.89, 21.25 (OCOCH3), 19.20 (C26), 19.08, 17.26 (C25 or C29 C30), 16.36 (J=10.73 
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C27), 16.24 (C23 or C24). EI-MS m/z: 517.18 (11) M
+
, 497.11 (19), 437.17 (43), 247.09 
(19), 203.17 (24), 201.17 (44), 189.18 (100), 187.20 (82), 145.25 (62), 119.24 (76), 
107.22 (65), 91.23 (57), 79.24 (47), 67.24 (35).  
 
Fluor-3oxoolean-28-oate (3.57): To a mixture of 3.2 (200 mg 0.44 mmol) and THF 
(2 mL) was added deoxofluor 50% dropwise (0.39 mL 0.88 mmol), in an ice bath. The 
temperature was allowed to rise up until the room temperature. After 0.5 hours was added 
dropwise, to the reaction mixture, NaHCO3 (10 mL). After been stirred for 30 minutes the 
mixture was extracted with ether (3×50 mL). The combined extract was washed with 
NaHCO3 (3×60 mL) and water (3×60 mL), dried over Na2SO4, filtered and evaporated to 
the dryness, to afford a yellow solid. The residue was subjected to flash column 
chromatography [hexanes-ethyl acetate from (95:5) to (85:15)], to afford 3.57 (73%). mp 
245.7-249.7 ºC. IR (film CHCl3): 2948.6, 1828.2, 1703.8, 1460.8, 1385.6, 1365.4, 1224.6 
cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.37 (1H s H12), 2.77 (1H dd J=16.97 H18), 2.55 
(1H m J=34.31), 2.36 (1H m J=25.84), 1.16 (3H), 1.08 (3H), 1.06 (3H), 1.04 (3H), 0.94 
(3H), 0.92 (3H), 0.85 (3H). 
13
C NMR (100 MHz CDCl3): δ 217.491 (C3), 167.32 
(J=375.78 C28), 142.27 (C13), 123.46 (C12), 55.37, 47.43, 46.81, 45.43, 41.94, 41.49, 
39.31, 39.20, 36.74, 34.13, 33.39, 32.88, 32.28, 30.98, 30.56, 27.83, 26.42, 25.58, 23.51, 
23.41, 22.85, 21.47, 19.56, 16.82, 15.04. EI-MS m/z: 455.44 (38) M
+
, 437.48 (60), 
407.51 (80), 248.66 (35), 105.86 (53), 103.85 (84), 89.85 (100), 77.89 (55).  
 
Fluor-3β-acetoxy-olean-28-oate (3.58): To a stirred solution of 3.3 (100 mg 0.2 
mmol) in THF (2 mL) deoxofluor 50% dropwise (0.3 mL 0.8 mmol), in an ice bath. The 
temperature was allowed to rise up until the room temperature. The workup was 
performed according to the same method as for 57 after 0.5 hours. The obtained solid was 
subjected to flash column chromatography [hexanes-ethyl acetate from (95:5) to (90:10)], 
to afford 3.58 (89%). mp 248.7-252.8 ºC. IR (film CHCl3): 2946.7, 1829.2, 1733.7, 
1463.7, 1368.3, 1245.8, 1219.8 cm
-1
. 
1
H NMR (400 MHz CDCl3): δ 5.35 (1H t J=7.33 
H12), 4.49 (1H dd J=16.02 H3), 2.76 (1H dd J=18.53 H18), 2.04 (3H s), 1.14 (3H s), 
0.94 (3H d J=0.40), 0.93 (3H s), 0.92 (3H s), 0.87 (3H s), 0.80 (3H s). 
13
C NMR (100 
MHz CDCl3): δ 170.99 (OCOCH3), 167.37 (J=375.91 C28), 142.21 (C13), 123.60 (C12), 
80.86 (C3), 55.31, 47.57, 47.48, 47.19, 45.44, 41.80, 41.41, 39.32, 38.17, 37.68, 36.91, 
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33.39, 32.88, 32.68, 31.01, 30.56, 28.03, 27.82, 23.51, 23.43, 22.85, 21.28, 18.19, 16.88, 
16.66, 15.41. EI-MS m/z: 498.57 (9) M
-2
, 440.68 (73), 391.86 (97), 249.78 (100), 221.87 
(89), 189.89 (85), 174.81 (43), 146.69 (33), 132.65 (40), 118.62 (25).  
 
3.3.2. Biological activity assays 
 
1. Reagents. MTT powder and DMSO were obtained from Sigma Aldrich Co (St. 
Luis, MO). The compounds tested for biological activity were dissolved in DMSO for 
stock solutions, stored at -80ºC. The working solutions were prepared in medium.   
 
2. Cell culture. Cancer cells AsPC-1, MIA PaCa 2, PANC-1, PC-3, Hep G2 and 
A549 were cultured in RPMI 1640 supplemented with 10% of FBS. MCF-7 cells were 
cultured in DMEM supplemented with 5% FBS and 1mg/mL insulin. 
 
3. Determination of cell growth inhibition. AsPC-1, MIA PaCa 2, PANC-1, MCF-
7, PC-3, Hep G2 and A549 cells were plated with 1.0×10
3
 cells/well in 96-well plates in 
100 μl medium. The tested compounds with variant concentrations in 100 μl were added 
after 24 h after seeding and the cells were continued to culture for 3 days. Fifty μl of 
MTT (0.5 mg/ml) was added to each well and incubated for 4 h. Supernatant was 
removed and the formazan precipitated was dissolved in DMSO (100 μl). The density of 
absorbance was measured at 570 nm on a multiple plate reader. Concentrations that 
inhibited cell growth by 50% (IC50) were determined by nonlinear regression with 
GraphPad Prism software version 5.0 (GraphPad Software, Inc., San Diego, CA). 
 
4. Cell cycle analysis. Cell cycle was assessed by flow cytometry using a 
fluorescence activated cell sorter (FACS). AsPC-1 cells were treated with diverse 
concentrations of compounds 3.27, 3.39 and 3.49 for 24 h, and then fixed with ice-cold 
70% ethanol at a density of 1 x 10
6
 cells/mL. The cells were treated with PI/RNase 
solution according to the manufactures protocol. DNA content was quantitated by a flow 
cytometry (Becton Dickinson, San Jose, CA) with an excitation wavelength of 488 nm 
and an emission wavelength of 625 nm. 
 
  
 
 
4.  
Concluding remarks  
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Cancer is still a disease with poor prognosis and for which few chemotherapeutic 
options are available. In addition, most of the drugs currently in clinical use have severe 
side effects. Natural products have been and still are the most reliable source of 
antitumoral drugs. Triterpenoids are natural products widely explored for their biological 
activities. Ursolic and oleanolic acids, two pentacyclic triterpenoids, are well known for 
their anticancer properties; however, their use in clinical settings is restricted, mainly due 
to pharmacokinetic problems. Therefore, new semisynthetic derivatives are needed to 
overcome the present problems. 
 
The literature is abundant with examples of semisynthetic derivatives of ursolic and 
oleanolic acids. Oleanolic acid derivative CDDO-Me 1.108 entered clinical trials, but 
these were suspended because of the cytotoxicity of this compound. Despite all the new 
ursolic and oleanolic acid derivatives already produced, new derivatives are stil needed to 
overcome the flaws of the previously synthezised molecules.  
 
In this work we accomplished the synthesis and structural elucidation of several 
ursane and oleanane derivatives. Most of them had a better antiproliferative profile than 
the parental compound. In addition, we unveiled some of the mechanisms responsible for 
the anticancer activity of these novel compounds. 
 
Chapter 2 describes the successful synthesis of new ursolic acid derivatives with 
heterocyclic ring(s) placed in carbons C2, C3 and C28, or/and a fluorolactone moiety. 
These compounds were characterized efficiently, with the identification of characteristic 
bands in the IR and δ signals in the NMR. The presence of a heterocyclic ring was 
visualized by the presence of δ signals at around 7 ppm in the 1H NMR spectrum. The 
presence of the β-fluorolactone moiety is characterized by the double doublet of proton 
H12 with a δ signal between 4-6 ppm, and by doublets of carbons C12 and C13 in the 13C 
NMR spectrum.  
The new ursane compounds were tested for their ability to inhibit the proliferation of 
AsPC-1 cancer cells, and several compounds were found to have a better antiproliferative 
activity than the parental compound (ursolic acid 2.1). Based on SAR, compounds with 
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modifications in ring A, by the presence of an α,β unsaturated ketone, were the best 
compounds found to inhibit cell growth.  
The anticancer mechanism of N-alkyltriazole 2.57 and fluorolactone 2.72, the best 
antiproliferative ursane compounds found, was tested. Compound 2.57 induced apoptosis 
in AsPC-1 cells via the upregulation of NOXA and p21
waf1
 as a consequence of the 
induction of p53. Compound 2.72 induces cell-cycle arrest at the G1 phase with an 
increase of p21
waf1
, and at higher concentrations it induces apoptosis with upregulation of 
NOXA and downregulation of c-FLIP.  
These findings shed new light on the mechanism of action of these novel ursane 
derivatives, which are new prototypes for exploring the ursane backbone as a starting 
point for better chemotherapeutic drugs.  
 
Chapter 3 explores new chemical modifications of oleanolic acid 3.1 and derivatives; 
the new compounds were fully characterized by IR, MS and NMR. The modifications 
performed in the oleanane-type compounds were mainly in carbons C2, C3, C12 and 
C28, with the synthesis of new heterocyclic and fluorine derivatives, the identification of 
the chemical modifications was made in the same way as for ursane derivatives.  
The novel oleanane compounds were tested for their antiproliferative activity in the 
AsPC-1 pancreatic cancer cell line and the SAR designed. Through the SAR findings 
oleanane compounds with a α,β unsaturated ketone moiety in ring A were establish to be 
the most active, and were also studied for their inhibitory activity against other solid 
tumor cell lines, an demonstrated to have IC50s lower than 5 μM. 
Compounds 3.27 and 3.39 induced apoptosis at 1.5 μM in AsPC-1 cells treated for 
24 hours. Compound 3.49 was less active than compounds 3.27 and 3.39 in the induction 
of apoptosis, although it induced cell cycle arrest at the G1 phase at 2 μM in AsPC-1 
pancreatic cancer cells.  
New oleanane derivatives represent a novel series of compounds with the ability to 
inhibit cell growth via the induction of apoptosis, and represent new starting points for 
the development of new chemotherapeutic drugs for the treatment of solid tumors. 
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In summary the use of novel synthetic procedures in this work led to the synthesis of 
new ursane and olenane heterocyclic and fluorine derivatives, which were successfully 
characterized using IR, MS and 1D and 2D NMR. 
The antiproliferative activity was determined for these new compounds, as well as 
SAR. The best compounds were the ones bearing an α,β unsaturated ketone moiety in 
ring A. The antitumor mechanisms of action of the best compounds were determined via 
the study of the cell cycle alterations, as well as cell cycle and apoptosis-related protein 
modifications. Some of the new semisynthetic compounds induced cell cycle arrest at the 
G1 phase, and all tested compounds induced apoptosis. These alterations were related 
with alterations at the level of proteins that regulate cell cycle and apoptosis. 
 
Ursane and oleanane-type triterpenoids look promising as leads for the development 
of new drugs and there is still much to learn from the production of novel semisynthetic 
derivatives, as well as the continuous study of their anticancer activities. 
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